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82.- Introducción
La anorexia es el primer obstáculo que puede tener el paciente urémico
para asegurar una ingesta dietética adecuada. Aunque el síntoma se asocia a la
misma uremia, especialmente cuando ésta es extrema, puede ser muy frecuente
y sobre todo persistente. Los reconocidos efectos nocivos de la malnutrición
justifican toda profundización en este tema.
2.1.- Fisiología normal de la conducta alimentaría.
El ciclo hambre-saciedad es controlado por un sistema complejo y
heterogéneo de autorregulación que incluye el tracto gastrointestinal, el hígado,
los nutrientes circulantes, los depósitos de grasa, el metabolismo celular y el
sistema de transmisión del mensaje (sistema nervioso periférico) al sistema
nervioso central (SNC) (1-4). En el SNC existe un centro llamado del hambre que
está localizado en el hipotálamo lateral y otro centro, el de la saciedad, situado
en el hipotálamo ventromedial. Otras áreas del cerebro como el núcleo
paraventricular, las áreas tegmentales ventrales, la amígdala, el globus pallidus y
el área postrema están también implicadas en el control del apetito (3).
Fases que regulan el ciclo hambre-saciedad.
A.- La fase gástrica empieza cuando el alimento llega al estómago
produciendo distensión de sus paredes, con la consiguiente sensación de
plenitud. Posteriormente, los nutrientes inducen liberación de péptidos GI con
efecto saciante: Colecistoquinina (CCK), gastrina, somatostatina y bombesina.
La CCK es uno de los pépticos más importantes en la regulación del apetito,
atribuyéndosele un doble efecto saciante, uno central y otro periférico (control
periférico del apetito) (5). En esta fase, el tipo de alimento ingerido tiene
importancia, ya que por ejemplo, la ingesta de hidratos de carbono produce
9saciedad para los mismos pero no para las proteínas (6). El mensaje es
finalmente llevado al SNC por el nervio vago, concluyendo la fase gástrica.
B.- La siguiente es la fase post-absortiva. Para explicar esta fase existen
varias teorías que asocian el efecto de los nutrientes y sus formas de reserva
corporal con la regulación del apetito (teorías lipostática, glucostática y
aminostática) (7). El descubrimiento de la leptina confirma estas ideas. Esta
hormona segregada por los adipocitos, cuyo nivel plasmático refleja las reservas
grasas corporales, inhibe el apetito mediante lo que podría considerarse un feed-
back negativo de mantenimiento del peso corporal (8). Recientemente se ha
postulado que el mensaje de la depleción nutritiva viene dado por la tasa de
utilización-producción celular de energía a partir de los alimentos (9). Smith GB
et al (10), plantearon que el control alimenticio podría venir de signos endógenos
producidos en el intestino como consecuencia de la absorción alimenticia. En
cualquier caso, la presencia de cualquier tipo de metabolito de los alimentos en
la sangre (aminoácidos, glucosa, ácidos grasos, lipoproteínas) son capaces de
inhibir el apetito (11).
C.- La fase hepática. Varios estudios implican receptores vagales y
hepáticos en el control del ciclo hambre-saciedad. La concentración de ATP
(adenil-trifosfato) en los hepatocitos es un fuerte estímulo para regular la
sensación de hambre (12, 13).
D.- La fase central de regulación del apetito incluye neuropeptidos
(Neuropéptido Y o NPY y CCK) y neurotransmisores (serotonina), capaces de
inhibir o estimular el apetito a través de mensajes que son captados por el SNP
(7). La concentración intracerebral o sanguínea de algunos aminoácidos
precursores de la síntesis de neurotransmisores, juegan un papel importante en
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esta fase de control del apetito. Por ejemplo el triptofano es el sustrato para la
síntesis de serotonina. La serotonina es el principal regulador central del apetito,
de tal manera que niveles elevados de esta inducen saciedad central (14, 15).
2.2.- Medición del impulso a comer, escala análoga visual (EAV) y
otras escalas.
Para definir los trastornos en el hábito alimentario es necesario evaluar
aspectos biológicos, sociales y culturales. Existen algunas encuestas que
evalúan el impulso a comer. Algunas de estas han sido utilizadas en pacientes
en diálisis, tal es el caso de la escala analógica visual (EAV), que fue utilizada
por primera vez en pacientes en diálisis peritoneal y transplantados por la Dra.
Hylander B, et al (16). Otra encuesta utilizada en la misma población es la
utilizada por Wright MJ, et al (17) en pacientes en hemodiálisis. En este caso
nosotros seleccionamos la EAV con el fin de validarla para nuestra población y
para patologías concretas como la anorexia o bulimia-obesidad en el estado
uremico. La EAV consiste en 5 preguntas que deben responderse antes y
después de comer. Las preguntas son: deseo de comer, hambre, sensación de
vacío y plenitud, cantidad de comida que comería y placer de comer en ese
momento.
Otro aspecto poco estudiado en los pacientes en diálisis son las
preferencias y rechazos alimenticios. Tradicionalmente se sabe que los
pacientes uremicos muestran una tendencia universal a consumir carbohidratos
y rechazo a carnes rojas, comparado con la población normal. Estos aspectos
fueron evaluados a través de la encuesta de preferencias alimenticias utilizada
por Dobell E, et al (18). En contraposición, la ingesta de carnes blancas fue
menos problemática. Los pacientes urémicos también muestran una marcada
11
atracción por los cítricos y sabores fuertes en general. Las preferencias y
rechazos alimenticios han sido relacionados a la predominancia de algunos
pépticos moduladores del apetito. Niveles elevados de CCK (un poderoso
anorexigeno) son asociados con saciedad temprana a carbohidratos, y NPY (un
orexigeno) con repetidas ingesta alimenticia. En la población en diálisis, la
asociación entre estos péptidos y los trastornos en la preferencia o rechazo a
alimentos tampoco ha sido estudiada.
2.3.- Hipótesis propuestas para la anorexia y malnutrición en
pacientes en diálisis.
Hablar de los trastornos en el apetito en la uremia resulta difícil por la
ausencia de estudios específicos y la dificultad intrínseca para medir un síntoma
tan subjetivo, multifactorial y contaminado por la propia enfermedad (16). Sin
embargo, el área es de enorme interés por la elevada morbi-mortalidad asociada
a malnutrición (19, 20).
Un factor importante propuesto para la génesis de la anorexia del paciente
en diálisis es la dosis de diálisis (21, 22). Existe la idea de que la acumulación de
una o varias sustancias tóxicas de peso molecular intermedio, sean las
responsables de la anorexia urémica (hipótesis de las medianas moléculas) (23).
Bergström et al (24), aislaron una mediana molécula del ultrafiltrado de pacientes
en hemodiálisis (HD) capaz de suprimir el apetito. Sin embargo, estas sustancias
no han sido plenamente identificadas, estudiadas y reconocidas por otros grupos
a pesar del paso de mucho tiempo. Además es demasiado frecuente la
existencia de pacientes con buenos índices de diálisis que presentan anorexia y
malnutrición. La hipótesis de los "picos" de toxicidad sugiere que los pacientes
en HD están expuestos a picos de urea y medianas moléculas durante los
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periodos interdiálisis, que les suprimen el apetito (25). Sin embargo, no explica la
anorexia de los pacientes en diálisis peritoneal (DP), en los que dichos picos no
se producen. La ausencia de función renal residual es frecuente en los pacientes
con anorexia en diálisis (26-28), apoyando la idea que la acumulación de
productos tóxicos no aclarados adecuadamente por las distintas formas de
diálisis, podrían ser la causa de la ausencia de apetito. En los pacientes en DP el
suministro constante de glucosa por el peritoneo supone un freno al apetito, ya
que los niveles séricos de glucosa son el primer inhibidor del apeptito conocido
(2, 3). Nosotros hemos calculado que el suministro de glucosa peritoneal en
nuestros pacientes puede rondar entre 400 y 1200 kcal/día. Lo que condiciona
además hiperinsulinismo, dislipemias y major riego cardiovascular (17, 18, 28).
Otra hipótesis que explica la toxicidad de la uremia y de forma particular la
génesis de la malnutrición y la falta de apetito, es el síndrome MIA (malnutrición,
inflamación y ateroescleroisis) (29). El MIA se basa en la retención por falta de
excreción renal o hiperproducción de moléculas pro-inflamatorias con acción
caquetizante como el factor de necrosis tumoral-alfa (TNF-) y la interleuquina-6
(IL-6). La hiperproducción se realizaría por órganos inflamados, enfermos, el
peritoneo o por el estimulo constante que produce el contacto de
polimorfonucleares de la sangre, con las membranas de hemodiálisis (30).
Finalmente, este exceso de moléculas pro-inflamatorias produciría inhibición del
apetito actuando directamente sobre el hipotálamo, inhibición del la motilidad del
tracto gastro-intestinal (TGI), inhibición de la síntesis hepática de albúmina y
caquexia muscular actuando en la vía de las ubiquin-proteasas (31). Sin
embargo, podemos mencionar al menos dos críticas que cuestionan el MIA:
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1.- En animales de experimentación la administración de TNF- recombínate
produce tolerancia y sus efectos caquetizantes desaparecen entre 1 y 12 días
después de su administración (32).
2.- De la misma manera en que se retienen molecular pro-inflamatorias, se
retienen también moléculas anti-inflamatorias. ¿Cual sería la resultante de este
desequilibrio?. Seria necesario analizar estas últimas moléculas y definir su
papel en el MIA (33).
Ante esta situación en 1995, empezamos a estudiar los aspectos
biológicos del ciclo hambre-saciedad en pacientes en diálisis. Fue así como
planteamos la hipótesis del desorden en el triptofano-serotonina para explicar
la falta de apetito en los pacientes en diálisis (34). Esta hipótesis plantea que
existe un exceso de triptofano libre que atraviesa la barrera hemato-encefálica.
Este triptofano que es el sustrato para la síntesis de serotonina, induciéndose
así anorexia. El exceso de triptofano libre en el líquido cefalorraquídeo se
produciría por una disminución en los amino ácidos ramificados de cadena
corta (BCCA), que a su vez están disminuidos por condiciones propias del
estado uremico, como niveles elevados de citoquinas pro-inflamatorias,
peptidos gastrointestinales, CCK, ghrelina, leptina, insulina, catecolaminas,
acidosis, sobrehidratación y niveles bajos de NO (anexos I, fig.1).
La última hipótesis ha sido propuesta en 2005 por Cheung W et al (35),
quienes encontraron un desorden en el receptor del gen de la melanocortina-4
(MC4-R). Este receptor se encuentra justo al final de la cascada del ciclo
hambre-saciedad y su sobre-expresión disminuye el apetito. En los pacientes
uremicos hay un trastorno en la habilidad para regular dicho receptor.
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3.- Hipótesis y Objetivos
La observación de pacientes en diálisis que sufrían una dramática falta de
apetito a pesar de mostrar criterios de diálisis adecuada junto con la ausencia
de otros factores que puedieran explicarla, nos impulso a formular la hipótesis
de que otros elementos biológicos y metabólicos tuvieran una mayor relevancia
en la regulación del apetito.
De esta manera nuestros objetivos fueron:
1.- Definir y validar una unidad de medida del impulso a comer para conseguir
de forma clara un diagnostica de anorexia y/o bulimia-obesidad
2.- Caracterizar y establecer factores de riesgo para sufrir falta de apetito en
pacientes en diálisis
3.- Identificar el papel de sustancias biológicamente activas retenidas o
hiperproducidas (citoquinas, peptidos…etc) en pacientes en diálisis en la
regulación del apetito y en otras complicaciones como las cardiovasculares
implicadas en la patogenia del síndrome MIA (malnutrición, inflamación y
ateroesclerosis).
4.- Estudiar las interacciones entre trastornos del metabolismo hidrocarbonado,
medido a través de marcadores en suero y expresión genética en tejido
adiposo abdominal, con los trastornos en la regulación del apetito en pacientes
en diálisis y con el síndrome MIA.
5.- Investigar el efecto del acetato de megestrol y del infliximab (anti-TNF-)
sobre el apetito y el estado nutricional de pacientes en diálisis.
6.- Todo ello, con el objetivo final de proporcionar argumentos que puedan
sustentar como confluente la hipótesis de que la via del triptofano-serotonina en
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hipotálamo unifica y es la que mejor explica el conjunto del entramado de
factores reguladores del apetito conocidos hasta la actualidad.
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4.- Pacientes y Métodos
Los pacientes renales incluidos en las diferentes partes del estudio son
detallados en cada uno de los capitulos de resultados. En nuestra relación
profesional con ellos siempre ha primado la preocupación por su estado en
gereral y por la regulación de su apetito en particular. Para ello, hemos
explicado en cada ocasión y a cada paciente el propósito de la investigación
realizada, contando siempre con su complicidad. El objetivo constante ha sido
contar con ellos para profundizar en conceptos tratados hasta ahora un tanto
superficial y simplísticamente. Y el último objetivo fue modificar con
conocimiento el abordaje del problema nutricional que tan negativamente
afecta a los pacientes renales en diálisis.
Todos los materiales y métodos utilizados en esta tesis se describen en
los apartados correspondientes de cada uno de los capítulos de resultados.
17
5.- Resultados
Capitulo 5.1. Estimación del impulso para comer. La inflamación y su
influencia.
“La infección por helicobacter pylori: una nueva causa de anorexia en
pacientes en diálisis peritoneal”.
Aguilera A, Codoceo R, Bajo MA, Díez JJ, Del Peso G, Pavone M, Ortíz J,
Váldez J, Cirugeda A, Fernandez-Perpen A, Sánchez-Tomero JA, Selgas R
Perit Dial Int 2001; 21 (S3): S152-156.
* Este trabajo responde a los objetivos 1 y 2.
* Trabajo ganador de los premios:
1.- Ganador al mejor trabajo de investigación (best abstract-research).
International peritoneal dialysis congress. Montreal. Canada. Junio 2001
2.- Ganador del Premio a la investigación en Nefrología clínica,
(Fundación Iñigo Alvarez de Toledo. Premio Reina Sofía de la
investigación). Septiembre 2002.
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La infección por helicobacter pylori: una nueva causa de anorexia en
pacientes en diálisis peritoneal.
La infección por helicobacter pylori (HP) ha sido frecuentemente
encontrada en pacientes en diálisis. Las infecciones crónicas inducen
sobreproducción de sustancias pro-inflamatorias. La inflamación ha sido
asociada con caquexia y anorexia. En este estudio exploramos la relación entre
la infección por HP anorexia y malnutrición en pacientes en diálisis peritoneal
(DP).
Pacientes y métodos. El estudio incluyo 48 pacientes clínicamente
estables en DP que fueron divididos en 4 grupos: HP (+) con anorexia (grupo I,
n=12); HP (+) sin anorexia (grupo II, n=4), HP (-) con anorexia (grupo III, n=5),
y HP (-) sin anorexia (grupo IV, n=27). La infección por HP fue diagnosticada
por el test del aliento. Anorexia fue evaluada usando una entrevista personal y
una escala de motivación a comer o escala análoga visual (EAV). La EAV
incluyo 5 preguntas que deben responderse antes y después de comer. Las
preguntas son: deseo de comer, hambre, sensación de vacío y plenitud,
cantidad de comida que comería y placer de comer. También determinamos
marcadores bioquímicos de nutrición e inflamación.
Resultados. El grupo I mostró basalmente un bajo escore para el deseo
de comer, hambre, sensación de vacío y plenitud futura consumición y el placer
de comer. Ellos también mostraron bajo nº de linfocitos, prealbumina,
transferrina, albúmina sérica, nPCR y función renal residual. Además, el mismo
grupo mostró niveles elevados de proteína-C- reactiva (PCR) y más sensación
de plenitud que el resto de los pacientes. En la serie total, encontramos una
correlación linear estadísticamente significativa entre marcadores nutricionales
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y EAV: albúmina con el deseo de comer antes de tomar la comida (r=0.38,
p<0.05), y prelabumina con la misma variable (r=0.41, p<0.05) y negativa con
la sensación de hambre después de comer (r=-0.35, p<0.05). Correlaciones
negativas fueron encontradas entre la albúmina y la sensación de plenitud
antes de comer (r=-0.45, p<0.01), y la misma variable con la prealbumina (r=-
0.39, p<0.05). Una correlación negativa también observada entre PCR y
albúmina (r=-0.35, p<0.05), y la misma variable con la prealbumina (r=-0.36,
p<0.05). De manera similar, la PCR muestra una correlación negativa con el
deseo de comer antes de comer (r=-0.38, p<0.05) y el deseo de comer
después de comer (r=-00.45, p<0.01). Después de la erradicación del HP, el
grupo I mostró una mejoría muy importante del estado nutricional y de la EAV
en casi todas las preguntas. Simultáneamente, la PCR disminuyo. Muy
importantes diferencias fueron encontradas antes y después de la erradicación
del HP, nº de linfocitos (1105 ± 259.4 vs. 1330.8 ± 316 células/mm3, p<0.05),
nPCR (0.9 ± 0.16, vs. 1.07 ± 0.3 g/kg/día, p<0.05), prealbúmina (26.7 ± 6.5 vs.
33.9 ± 5.6 mg/dL, p<0.01), albúmina (3.48 ± 0.3 vs. 3.67 ± 0.35 g/dL, p<0.05),
PCR (1.16 ± 1.14 vs. 0.88 ± 1.2 mg/dL, p=0.054), deseo de comer antes de
comer (56.6 ± 6.8 vs. 72.2 ± 4, p<0.001), deseo de comer después de comer
(5.4 ± 2.6 vs. 12.3 ± 2, p<0.01), hambre antes de comer (55.4 ± 5.4 vs. 73.1 ±
4.6, p<0.001), hambre después de comer (5.8 ± 2.9 vs. 11 ± 4, p<0.01),
sensación de plenitud antes de comer (36.6 ± 10.3 vs. 18.7 ± 8.8, p<0.001),
deseo de consumición futura (5 ± 4.7 vs. 17.5 ± 18, p<0.05), y en el placer de
comer (61 ± 5.3 vs. 74.1 ± 4.1, p<0.001).
Conclusión. La infección por HP se asocia con anorexia, inflamación y
malnutrición en pacientes en DP. La erradicación del HP mejoro
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significativamente este síndrome. La función renal residual tiene un efecto
protector sobre la preservación de apetito mas que la dosis de diálisis. El
presente estudio soporta la hipótesis de la participación de la inflamación en la
patogénesis de la malnutrición en pacientes en DP.
21
Capitulo 5.2. Péptidos reguladores del apetito y el impulso a comer
“Niveles plasmáticos de ghrelina y apetito en pacientes en diálisis
peritoneal”.
Aguilera A, Cirugeda A, Amair R, Sansone G, Codoceo R, Bajo MA, del Peso
G, Díez JJ, Sánchez-Tomero JA, Selgas R.
Adv Perit Dial 2004; 20: 194-199.
* Este trabajo responde a los objetivos 1 y 2.
* Trabajo presentado como comunicación oral en varios congresos
internacionales: USA, Bélgica y Canada.
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Niveles plasmáticos de ghrelina y apetito en pacientes en diálisis
peritoneal.
Anorexia asociada a malnutrición es una complicación severa que
aumenta la mortalidad en pacientes en diálisis peritoneal (DP). La ghrelina es
una hormona orexigena recientemente descubierta con acción sobre el cerebro y
estómago. Analizamos la posible relación entre ghrelina y la regulación del
apetito en 42 pacientes en DP, además de otros orexigenos como el
neuropeptido Y (NPY) y el óxido nítrico en forma de nitrato (NO3), y
anorexigenos como la CCK, leptina, péptido insulina trópico dependiente de la
glucosa (GIP) y el factor de necrosis tumoral alfa (TNF-). Todos fueron
determinados en plasma. La motivación a comer fue evaluada usado la escala
análoga visual (EAV). Los pacientes fueron divididos en 3 grupos, pacientes
con anorexia (n=12), obesidad asociada a alta ingesta (n=12) y los que no
presentaban desordenes en la conducta alimenticia (n=18). Incluimos también
10 sujetos voluntarios sanos. Le media de niveles de ghrelina fue alta (3618.6 ±
1533 mg/mL), con 36 pacientes mostrando valores arriba del rango normal
(<2600 mg/mL). Los pacientes con anorexia presentaron mas baja ghrelina, y
NPY acompañado de niveles mas altos de péptido-C, CCK, interleuquina-1 (IL-
1), TNF- y GIP, que el resto de los pacientes. Estos mismos pacientes
también presentaron saciedad temprana, bajo deseo y placer al comer medida
por EAV y una baja ingesta medida por una encuesta dietética.
Encontramos una correlación positiva entre ghrelina y albúmina (r=0.43,
p<0.05), prealbúmina (r=0.51, p<0.05), transferrina (r=0.4, p<0.05), hormona
del crecimiento (GH) (r=0.66, p<0.01), NO3 (r=0.36, p<0.05) y motivación a
comer (VAS). Al mismo tiempo, encontramos una relación negativa entre
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ghrelina y GIP (r=-0.42, p<0.05), insulina (r=-0.42, p<0.05), leptina (r=-0.45,
p<0.05) y CCr: (r=-0.33, p=0.08, NS). La ghrelina no presento relación con el
Kt/V o con CCK y citoquinas.
Conclusión: La ghrelina esta elevada en pacientes en DP. Pacientes
uremicos con anorexia mostraron niveles relativamente bajos de ghrelina que
los obesos o los que no tenía trastornos del apetito. El papel de la ghrelina en
la modulación del apetito esta alterada en pacientes uremicos en DP, este
desorden es posiblemente asociado a desordenes en el metabolismo de
insulina y GH.
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Capitulo 5.3. Selectividad del apetito y peptidos regualdores
“Trastorno en la conducta alimenticia en la uremia: una cuestión de
balance en la regulación del apetito”.
Aguilera A, Codoceo R, Bajo MA, Iglesias P, Díez JJ, Barril G, Sigarran C,
Alvarez V, Celdilla O, Fernández-Perpen A, Montero A, Selgas R.
Semin Dial 2004; 17: 44-52.
* Este trabajo responde a los objetivos 1, 2, 3 y 6. Aunque es básicamente
una revisión con formulación de hipótesis también contiene resultados
originales.
* Trabajo presentado como comunicación oral en varios congresos
internacionales: USA y UK. Conferencista invitado al 9th world conference of
clinical nutrition (9º congreso mundial de nutrición). Londres, Junio 24-26, 2002.
Conferencia: “uremic anorexia, pathophysiology and management”
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Trastorno en la conducta alimenticia en la uremia: una cuestión de balance
en la regulación del apetito.
Los trastornos en el apetito son una complicación frecuente del síndrome
urémico que puede contribuir a malnutrición en pacientes en diálisis. Los datos
que sugieren que la anorexia urémica puede ocurrir con y sin acumulo de grasa
abdominal y visceral a pesar de una baja ingesta. Esta forma de obesidad (con
baja ingesta y malnutrición) es más común en pacientes diálisis que obesidades
con elevada ingesta. Este trabajo revisa el conocimiento actual sobre los
mecanismos responsables de regular el apetito en condiciones normal es y en el
estado urémico. La anorexia en pacientes en diálisis ha sido históricamente
considerada como un signo de toxicidad de la uremia debido a una diálisis
inadecuada, tal como lo interpretan las hipótesis de las medianas moléculas,
KT/V o la de los picos y otras. Nosotros proponemos la hipótesis del triptofano
serotonina, basado en que la uremia induce un desorden en el perfil de amino
ácidos, con baja concentración de amino ácidos largos neutros y principalmente
ramificados de cadena corta con un nivel elevado de triptofano. Esto condiciona
una elevada tasa de triptofano capaz de cruzar la barrera hemato-encefálica y
sintetizar serotonina, el mayor inhibidor del apetito. La inflamación puede
también juega un rol en la génesis de la anorexia y malnutrición. Por ejemplo,
infecciones silentes por helicobacter pylori pueden ser la fuente de citoquinas
con acción caquetizante. Su erradicación mejora el apetito y la malnutrición.
La evaluación del apetito debe considerar aspectos sociales y culturales. Los
pacientes ureicos muestran una tendencia universal a carbohidratos y rechazo a
carne roja comparado con la población normal medida a través de la encuesta
de preferencias alimenticias utilizada por Dobell E, et al (SD53). En
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contraposición la ingesta de carnes blancas fue menos problemática. Los
pacientes urémicos también tuvieron una marcada atracción por los cítricos y
sabores fuertes en general. Las preferencias y rechazos alimenticios han sido
relacionados a la predominancia de algunos peptidos moduladores del apetito.
Niveles elevados de CCK (anorexigeno) son asociados con saciedad temprana
a carbohidratos, y neuropeptido Y (orexigeno) con repetidas ingesta alimenticia.
En pacientes urémicos pueden contribuir al acumulo de grasa abdominal sin
aumento del apetito, el estado hiperinsulinico, la leptina, IGF-I, ácidos grasos,
desordenes en los receptores a de la insulina, lipoprotein-lipasa, la proteina-2
mitocondrial desacoplada y receptores -adrenergicos. Esta obesidad con
elevado indice de masa corporal (BMI) es frecuente y falsamente asociado a un
adecuado estado nutricional.
Para evaluar el impulso a comer, nosotros utilizamos la escala análoga
visual (EAV) (Hill J, et al), en 52 pacientes en diálisis en comparación con 104
voluntarios sanos de de los cuales 10 fueron incluidos en este estudio. Estos
fueron contrastados con la población estudiada. Fuimos capaces de establecer
los criterios diagnósticos de la anorexia uremica:
1.- EAV antes de comer < 60 mm, con al menos 4 horas de ayuno.
2.- El otro criterio fue baja ingesta alimenticia medida por una encuesta dietética
< 30 kcal/kg/día.
3.- criterios de malnutrición definidos por los DOQI (SD64)
Por el contrario, obesidad con elevada ingesta fue definida de acuerdo con los
siguientes criterios:
1.- EAV > 60 mm
2.- alto BMI definido de acuerdo con la OMS.
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3.- ingesta alimenticia elevada medida por una encuesta dietética >35
kcal/kg/día.
Finalmente, la regulación del apetito en la uremia es altamente compleja. Los
desordenes en el tejido adiposo, en el tracto gastrointestinal y en los
neuropeptidos, las sustancias retenidas o hiperproducidas como las moléculas
pro inflamatorias y sus productos finales, así como cambios en el sistema
nervioso juegan un rol en el control inadecuado del apetito en el estado uremico.
La anorexia urémica puede ser explicada por un estado hiperserotoninergico
derivado de una alta concentración de triptofano y bajos niveles de amino ácidos
ramificados de cadena corta.
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Capitulo 5.4. Inflamación, peptidos, apetito y estado nutricional.
“Niveles plasmáticos de anorexigenos (TNF-, colecistoquinina) y
orexigeno (neuropeptido Y) en pacientes en diálisis: su relación con
parámetros nutricionales”.
Aguilera A, Selgas R, Codoceo R, Picorline M, García P, Picornell M, Diaz C,
Sanchez C, Bajo MA.
Nephrol Dial Transp 13: 1476-1483, 1998.
* Este trabajo responde a los objetivos 1 y 4
* Es el primer estudio en poner de manifiesto la asociación entre factores
inflamatorios y trastornos del apetito en pacientes en diálisis. El Síndrome
MIA fue publicado 2 año mas tarde.
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Niveles plasmáticos de anorexigenos (TNF-, colecistoquinina) y
orexigeno (neuropeptido Y) en pacientes en diálisis: su relación con
parámetros nutricionales.
La malnutrición en pacientes en diálisis ha sido definitivamente
relacionada a una elevada mortalidad. Pérdida persistente del apetito es uno de
los síntomas mas frecuentes encontrados en estos pacientes. Varias sustancias
producen anorexia y desordenes en el ciclo hambre-saciedad en varias
enfermedades.
El objetivo de este estudio fue identificar el papel que juegan sustancias
anorexigenas (TNF- y CCK) y orexigenas (NPY) en la génesis de la anorexia y
malnutrición en 55 pacientes clínicamente estables en diálisis peritoneal.
Resultados. Niveles plasmáticos elevados de TNF- fueron encontrados
en 41/42 pacientes (97.6%), media (70.5 ± 32.3 pg/ml). Pacientes con anorexia
(n=11) o con anorexia acompañada de nauseas y vómitos (n=5) tenían los
niveles más altos de TNF- que aquellos que no tenían síntomas (75.9 ± 34 vs.
52.1 ± 24.5 pg/ml, p<0.05). Ocho pacientes diagnosticados de enfermedad
ácido péptica mostraron los niveles más altos de TNF- (87.2 ± 24.3 pg/ml) que
30 pacientes sin enfermedad ácido péptica (63.6 ± 30.5 pg/ml, p<0.05). TNF-
mostró una correlación negativa, estadísticamente significativa con la proteína
transportadora del retinol (RBP) (r=-0.37, p<0.05), y el pH venoso (r=-0.4, n=42,
p<0.01); así mismo, niveles de TNF- > 65 pg/ml estaban inversamente
relacionados con transferían, colesterol, urea, y CCK. Pacientes con
prealbumina < 30 mg/dL, BMI < 30 kg/m2, nPCR <1.1 g/kg/día y KT/V de urea
< 2.2 mostraron niveles elevados de TNF-. Aquellos pacientes quienes han
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estado en esta modalidad de tratamiento por largo tiempo también mostraron
los niveles más elevados de TNF-.
En relación a la CCK, fueron encontrados los niveles elevados en 38 de 45
pacientes (84%), media 45.9 ± 32.3 pg/ml. No encontramos diferencia en los
niveles de CCK entre pacientes que sufren anorexia vs. los que presentan
apetito normal. En relación a la asociación entre CCK y el estado nutricional,
encontramos una asociación directa entre CCK y albúmina, fibronectina,
triglicéridos, ácido fólico, y nPCR en no diabéticos). Aunque CCK muestra en
efecto anorexigeno, esta asociación directa con marcadores nutricionales
puede deberse a una estimulación anormal del feed-back de la CCK-glucosa
vía tripsina debido a la absorción peritoneal constante de glucosa. Esto podría
sugerir que la CCK puede ser un marcador nutricional temprano (ingesta).
Los niveles plasmáticos de NPY fueron normales en 33 pacientes, altos en 6 y
bajos en 11. Los pacientes con anorexia presentaron niveles más bajos de
NPY que el resto. NPY < 50 pg/ml fue positivamente asociado con transferrina,
prealbúmina, RBP, nPCR y KT/V de urea.
Encontramos una correlación negativa entre NPY y TNF- (r=-0.42, n=41,
p<0.01). No hubo relación significativa entre la función renal residual y los
niveles en suero de estos 3 peptidos.
Conclusión: nuestros datos sugieren que los niveles elevados de TNF-
y bajos de NPY están asociados a anorexia. Niveles plasmáticos elevado de
TNF-, bajos de CCK y NPY están relacionados con pobre estado nutricional.
Estudios futuros sobre estas sustancias circulantes son requeridos.
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Capitulo 5.5. Inflamación, nutrición y riesgo cardiovascular.
“El factor de necrosis tumoral alpha como una toxina urémica: su
correlación con neuropatía, hipertrofia ventricular izquierda, anemia,
hipertrigliceridemia en pacientes en diálisis peritoneal”.
Espinoza M, Aguilera A, Auxiliadora Bajo M, Codoceo R, Caravaca E,
Cirugeda A, del Peso G, Hevia C, Selgas R.
Adv perit Dial 1999; 15: 82-86.
* Este trabajo responde al objetivos 3, 4
* Plantea la posibilidad de utilizar medicamentos anti-TNF como tratamiento
de la malnutrición y enfermedad vascular en pacientes en diálisis. Este trabajo
ha sido presentado en varios congresos nacionales e internacionales
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El factor de necrosis tumoral alpha como una toxina urémica: su
correlación con neuropatía, hipertrofia ventricular izquierda, anemia,
hipertrigliceridemia en pacientes en diálisis peritoneal.
El factor de necrosis tumoral alpha (TNF-) es habitualmente excretado
por los riñones. En pacientes en diálisis, este se acumula. TNF- ha sido
implicado en la patogénesis de la malnutrición, neuropatía diabética y resistencia
a la eritropoyetina.
Estudiamos los niveles plasmáticos de TNF- en 49 pacientes
clínicamente estables en diálisis peritoneal (DP), con el objetivo de correlacionar
estos niveles con la presencia y severidad de la neuropatía periférica,
miocardiopatía hipertrófica, y anemia. Medimos el KTV de urea la función renal
residual (FRR), marcadores nutricionales y realizamos una bioquímica general.
La media de TNF- fue (67 ± 32 pg/mL, rango 18.1-156.3 pg/mL, normal: 3-20).
No encontramos correlación entre TNF- y KTV, pero si encontramos correlación
entre TNF- y FRR medida por CCr (1.5 ± 1.7 vs. 3.9 ± 2.6 mL/min, p<0.01). Los
niveles de TNF- fueron mas altos en los pacientes con HVI (70.4 ± 32 vs. 38.5 ±
20.8 pg/mL, p<0.05). Los pacientes con HVI severa presentarón la mas baja
FRR. Encontramos una relación estadísticamente significativa entre los niveles
de TNF- y la dosis de EPO (r=0.41, p<0.05). Los pacientes con
hipertrigliceridemia tomando hipolipemiantes orales mostraron una correlación
positiva con el nivel de triglicéridos (r=0.7, n=14, p<0.05).estos datos sugieren
que el acumulo de TNF- pueden contribuir al desarrollo y mantenimiento de
complicaciones neurologicas, hematologicas y cardícas del síndrome uremico.
La perdida de la función renal residual condiciona un aumento de los niveles de
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TNF-. Estos datos dan y añaden soporte a la idea de que el TNF- puede ser
considerado como una toxina urémica.
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Capitulo 5.6. Inflamación, nutrición y disfunción endotelial.
5.6.1.- “El síndrome malnutrición-inflamación se asocia con disfunción
endotelial in pacientes en diálisis peritoneal”.
Aguilera A, Sanchez-Tomero JA, Bajo MA, Ruiz-Caravaca ML, Alvarez V, del
Peso G, Herranz A, Cuesta MV, Castro MJ, Selgas R.
Adv Perit Dial. 2003;19:240-5
* Este trabajo responde a los objetivos 3, 4
* Plantea una asociación definitiva entre inflamación sistemica, disfunción
endotelial y malnutrición. En definitiva entre los diferentes componentes del
síndrome MIA. Refuerza además la posibilidad de utilizar medicamentos anti-
TNF como tratamiento de la enfermedad vascular en pacientes en diálisis.
* Este trabajo ha sido presentado en varios congresos nacionales e
internacionales
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El síndrome malnutrición-inflamación se asocia con disfunción endotelial
in pacientes en diálisis peritoneal.
La disfunción endotelial con ateroesclerosis es una complicación
reconocida de los pacientes uremicos. La hipoalbuminemia de los pacientes en
diálisis peritoneal (DP) puede inducir estados de hipercoagulabilidad y un
estado pro-aterogenico. En el presente estudio investigamos el papel jugado
por el síndrome malnutrición-inflamación sobre marcadores de función
endotelial en pacientes en DP. Medimos, marcadores nutricionales la tasa
[normalizada de metabolismo proteico (nPCR), albumina, prealbumina, factor
de crecimiento de insulina tipo I (IGF-I), transferrina y colesterol], marcadores
de daño y función endotelial [activador del plasminogeno tisular (tPA),
trombomodulina (TM), von Willebrand factor (vWF) y NO3 como representante
del oxido nitrico (NO)], marcadores del estado de coagulabilidad [fibrinogeno y
activador del inhibidor del plasminogeno 1 (PAI-1)], marcadores de inflamación
[factor de necrosis alfa (TNF-) y proteina-C-reactiva (PCR)], y otros factores
asociados a daño endotelial [lipoproteina(a) [Lp(a)] y homocisteina (Hcy)].
Realizamos una prueba de función endotelial consistente en una prueba de
oclusión venosa (OV) por 10 minutos. Los pacientes fueron divididos en 4
grupos de acuerdo con un score ateroesclerotico clínico (SAC).
Estudiamos 45 pacientes estables en DP. Basalmente, encontramos una
correlación negativa entre albúmina y edad (r= -0.54, p<0.05), albúmina y vwF
post-OV (r=-0.54, p<0.05), y albúmina con TM (r=-0.36, p<0.05), los cuales son
marcadores de daño endotelial y factores pro-trombóticos. Una correlación
positiva fue encontrada entre albúmina y NO3 post-VO (r= 0.48, p<0.05),
indicando una alta capacidad vasodilatadora. PCR y TNF- mostraron una
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correlación linear positiva (r=0.5, p<0.01). Similarmente, TNF- mostró una
correlación linear positiva con marcadores de riego CV como el fibrinógeno
(r=0.79, p<0.01), PAI (r=0.44, p<0.05), y Hcy (r=0.37, p<0.05). CCr mostró una
correlación negativa con TM (r=-0.36, p<0.05). Los pacientes con albúmina < 4
g/dL mostraron una bajo tPA-ratio, bajo NO3, y alta PCR, TNF- y Lp(a) que
aquellos con albúmina > 4 g/dL [tPA ratio: 2.1 ± 1.56 (n = 29) vs. 2.6 ± 2.3 (n =
16), p < 0.05; NO3: 47 ± 27 g/mL vs. 69 ± 33 micrograms/mL, p < 0.05; CRP:
1.8 ± 3 mg/dL vs. 1.1 ± 1.6 mg/dL, p < 0.05; TNF alpha: 44.4 ± 16 pg/mL vs.
36.6 ± 21.4 pg/mL, p < 0.05; Lp(a): 55 ± 39 mg/dL vs. 33 ± 21 mg/dL, p < 0.05].
Los pacientes con peor SAC mostraron niveles elevados de Hcy y baja
albúmina. No encontramos relación entre la dosis de diálisis y la función
endotelial.
En conclusión, el síndrome malnutrición-inflamación puede contribuir al
síndrome de disfunción endotelial y, consecuentemente a procesos pro-
trombóticos y pro-aterogénicos en pacientes en DP.
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5.6.2.- “La inflamación sistémica induce disfunción endotelial en
pacientes tratados con diálisis peritoneal”.
Abelardo Aguilera, Eddy Velásquez, María A Bajo, Maria L Ruiz-Caravaca,
Mario Pavone, Victoria Martínez, Gloria del Peso, Angel Herranz, Maria V.
Cuesta, Manuel López-Cabrera, Rafael Selgas.
* Este trabajo responde al objetivos 3, 4
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La inflamación sistémica induce disfunción endotelial en pacientes
tratados con diálisis peritoneal.
La disfunción endotelial (DE) asociada a ateroesclerosis es una
complicación frecuente de los pacientes uremicos. Recientemente se ha
sugerido la importancia de la inflamación en la fisiopatología de la DE. El objetivo
de este estudio es analizar el papel jugado por la inflamación sistemica como
iniciador de la DE en pacientes en diálisis peritoneal (DP).
Métodos. Todos los pacientes de nuestra unidad de DP fueron seguidos
durante 15 meses. Medimos, marcadores nutricionales, inflamatorios (proteína-
C-reactiva (PCR), TNF- y la molécula de adhesión vascular tipo-I (VCAM) y de
función endotelial, de forma basal y al aparecer un proceso inflamatorio sistémico
(IS). 17 pacientes fueron finalmente incluidos debido a que presentaron elevación
de la PCR asociado a varias etiologías (4 sufrieron infección silente por HP, 4
infecciones respiratorias superiores, 2 sobre crecimiento bacteriano intestinal y
causas desconocidas en 7). Estos fueron comparados con un grupo control (GC)
con 12 pacientes que no sufrieron IS.
Realizamos un test de oclusión venosa (VOT) para estimular el endotelio
induciendo isquemia y ectasis durante 10 minutos con el esfigmomanómetro
insuflado (brazo derecho). Las muestras de sangre fueron tomadas antes y
después del VOT. La capacidad fibrinolitica endotelial fue medida a través del
activador del plasminogeno tisular (tPA) y el inhibidor del activador (PAI). Los
marcadores de daño endotelial medidos fueron el von Willebrand factor (vWF),
la trombomodulina (TM), y el oxido nítrico (NO). Los marcadores de riego
cardiovascular (CV), fibrinogeno, lipoproteína(a) y homocisteina (Hcy). Los
marcadores VCAM-1, factor de crecimiento vascular (VEGF), factor de
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transformación tipo  (TGF-) y factor de crecimiento derivado de las plaquetas
(PDGF). Después de un tiempo variable de seguimiento en los pacientes
estudiados la PCR y el TNF- aumento.
Resultados. Después de sufrir IS encontramos una disminución en la albúmina,
tPA-ratio (post VOT/pre-VOT) y NO3-ratio. PAI, TM, Lp(a) y TGF- aumento.
Encontramos una correlación positive entre Hcy y PDGF, sugiriendo a pro-
aterogenico. GC no sufrió ninguna modificación.
Conclusión: En pacientes en DP la IS induce DE medida a través
marcadores de daño endotelial. La elevación de citoquinas proinflamatorias
esta estrechamente relacionada con elevación de mediadores pro-cogulantes y
pro-ateroescleroticos en plasma.
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5.6.3.- “La erradicación de Helicobacter pylori mejora la malnutrición, la
inflamación y la arterisoclerosis en pacientes en diálsis peritoneal”.
Abelardo Aguilera, Rafael Selgas, Rosa Codoceo, M. Auxiliadora Bajo, Juan
J. Diéz, Pedro Iglesias, Rosa Martin, Olga Celadilla, Maria J Castro, Camen
Mansilla, Agustin Montero.
* Este trabajo responde al objetivos 3, 4 y fue ganador de los premios:
1.- Ganador al mejor trabajo de investigación (best abstract-research).
International peritoneal dialysis congress. Montreal. Canada. Junio 2001
2.- Ganador del Premio a la investigación en Nefrología clínica,
(Fundación Iñigo Álvarez de Toledo. Premio Reina Sofía de la
investigación). Septiembre 2002.
* Este estudio estable una relación causa-efecto entre la presencia de una
infección crónica silente con gran producción de citoquinas y el síndrome MIA.
La erradicación del HP resulta en una mejoría sustancial de los marcadores del
MIA. Resalta además la importancia de la función renal residual como factor
protector, mas que la dosis de diálisis.
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La erradicación de Helicobacter pylori mejora la malnutrición, la
inflamación y la arterisoclerosis en pacientes en diálsis peritoneal
La infección por Helicobacter pylori (HP) ha sido detectada
frecuentemente en pacientes en diálisis. Las infecciones crónicas inducen
producción de citoquinas las cuales son aclaradas pobremente por insuficiencia
renal. Estas citoquinas tienen efectos sistémicos y catabólicos.
Estudiamos el efecto de la infección y erradicación del HP sobre los niveles
séricos de citoquinas, estado nutricional y sobre marcadores de función
endotelial (FE) en pacientes en diálisis peritoneal (DP).
Métodos. La infección por HP fue diagnosticad a través de test del aliento.
Medimos, pre y post erradicación de HP, marcadores nutricionales, bioquímicos,
ingesta alimenticia diaria y moduladores del apetito (orexigenos neuropeptido-Y,
NPY, anorexigeno colecistiquinina, CCK). Secreción ácida en él estomago:
pepsinogeno-I y II, y marcadores inflamatorios: proteina-C reactiva (CRP),
niveles plasmáticos de TNF- y IL-6. Y marcadores de función endotelial que
fueron tomados pre- y post-oclusión venosa (VOT), se toma la tensión arterial
(TA), se calculo la TA media (TAM), se insuflo el esfignomanametro a la TA en el
brazo derecho durante 10 minutos y se tomaron muestras de sangre antes y
después del VOT. El activador tisular del plasminogeno (tPA), NO3
(representando el oxido nítrico) y el activador del inhibidor del plasminogeno tipo-
I (PAI).
Cuarenta y ocho pacientes en diálisis peritoneal clínicamente estables
fueron divididos en 4 grupos de acuerdo a la presencia de infección por HP e
ingesta alimenticia. Grupo I HP (+) y baja ingesta (<30 kcal/ kg/día, DOQI guías)
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n=12. Grupo II, HP (+) e ingesta alimenticia normal, n=4. Grupo III, HP (-) y baja
ingesta n=5. Grupo IV, HP (-) e ingesta normal n=27.
Valores de TNF-, grupo I: 125  85* pg/ml, grupo-II: 70.5  25, grupo III: 60.5 
10*, y grupo IV 43.4  5.4*, * <0.05. Con relación a la IL-6: grupo I: 34.2  18*
pg/ml. G 3.4  7*, *<0.05. Grupo III: 11.1  7.9*, *<0.05 y grupo IV 1.02  0.65 *, *
<0.05. La función renal residual fue significativamente mas alta en el grupo IV
(4.8  1.6* ml/min) que el grupo I (2.7  2.3*, p<0.05). Después de la erradicación
del HP en el grupo-I mejoro nutricional y bioquímicamente con aumento del NPY.
Los marcadores inflamatorios y de secreción ácida disminuyeron. La función
endotelial también mejoro. El grupo control con 10 voluntarios no renales
infectados por HP, experimentaron una leve mejoría en marcadores
nutricionales, después de la erradicación del HP que se asocio además con
mejoría en parámetros inflamatorios y el los marcadores de secreción ácida del
estomago.
Conclusión: La infección por HP induce sobre producción de citoquinas,
que se asocia a malnutricición, inflamación sistémica y ateroesclerosis en
pacientes en DP. La erradicación del HP normalizo la secreción ácida del
estomago, disminuyo la inflamación y mejoro el estado nutricional y la disfunción
endotelial.
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Capitulo 5.7.- Tejido adiposo, estado nutricional y riego cardiovascular.
“La leptina como marcador nutricional y de riesgo cardiovascular en
pacientes en diálisis peritoneal”.
Aguilera A, Bajo MA, Rebollo F, Díez JJ, Roca A, Díaz C, Paiva A, Codoceo R,
Selgas R.
Adv Perit Dial 2002; 18: 212-217.
* Este trabajo responde a los objetivos 3, 4
* Este trabajo ha sido presentado en varios congresos nacionales e
internacionales
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La leptina como marcador nutricional y de riesgo cardiovascular en
pacientes en diálisis peritoneal.
Anorexia y malnutrición proteica, ocasionalmente asociado con obesidad
son frecuentemente encontrados en pacientes en diálisis peritoneal (DP).
Ambos son reconocidos factores de riesgo cardiovascular (CV), de morbilidad y
mortalidad. La leptina es producida por lo adipositos y regula la masa grasa
induciendo saciedad central. La leptina se acumula en ele estado urémico.
Nosotros analizamos la relación entre los niveles plasmáticos de leptina, estado
nutricional, obesidad, factores de riesgo CV y aterosclerosis en pacientes en
DP. La leptina fue determinada usando un anticuerpo policlonal (RIA. Linco
Research, St. Louis, MO, USA). El rango normal fue de 1-7.8 ng/mL.
Estudiamos 38 pacientes en DP. La media de leptina plasmática fue:
59.1 ± 57.5 ng/mL (elevado en 32 pacientes). Las mujeres (n=21) presentaron
niveles más elevados de leptina que los hombres (80.4 ± 60 vs. 32.3 ± 43.3
ng/mL, p<0.01), a pesar que ambos grupos tenían igual BMI. Encontramos una
correlación directa estadísticamente significativa entre leptina y BMI (r=0.7,
p<0.01) y el pliegue tricipital (r=0.77, p<0.01). Los niveles de leptina y él
aclaración de Cr no mostraron correlación. Independientemente del BMI,
niveles elevados de leptina fueron asociados con parámetros de riesgo CV
(estudios Framingham) incluyendo, triglicéridos < 150 (n=29) vs. >150 mg/dL
(44.2 ± 53.2 vs. 80 ± 58.4 ng/mL, p<0.05), colesterol <250 (n=28) vs. >250
mg/dL (50 ± 55.6 vs. 84.7 ± 57.7 mg/dL, p<0.05), y con la presencia o ausencia
de hipertrofia ventricular izquierda (HVI) (68.8 ± 60, n=30, vs. 29.5 ± 23.7, n=5,
p<0.05). Los pacientes fueron clasificados en 2 grupos de acuerdo al escore
ateroesclerotico clínico (EAC). Diecinueve pacientes mostraron alto EAC y altos
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niveles de leptina que el resto (82.4 ± 65.7 vs. 35.8 ± 36.6 ng/mL, p<0.05).
Doce pacientes con anorexia presentaron bajos noveles de leptina que
aquellos con apetito normal (19.2 ± 15.8 vs. 91.3 ± 58.8 ng/mL, p<0.001). en
no-obesos (BMI < 25 y CCr < 3 mL/min, n=14), la leptina presento una
correlación estadística, directa significativa con marcadores nutricionales
incluyendo la albúmina (r=0.63, p<0.05), transferrina (r=0.4, p<0.05), colesterol
(r=0.65, p<0.05) y triglicéridos (r=0.6, p<0.05). Finalmente, los niveles
plasmáticos de leptina estaban notablemente elevados en la población en DP,
indicando un aumento en la producción posiblemente por hiperinsulinismo
crónico, retención urémica o ambas. A través de un análisis multivariante
confirmamos la asociación entre leptina y sexo, leptina y BMI, y leptina >40
ng/mL y sexo e HVI. Todos estas características sugieren que los niveles
plasmáticos de leptina pueden ser considerados como marcador de riego CV y
de ingesta de alimentos en pacientes no obesos sin inflamación.
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Capitulo 5.8.- Eje anabolizante y uremia
“Modulación colinergica de la respuesta de la hormona del crecimiento a
la hormona liberadora de la hormona del crecimiento en pacientes
uremicos en diálisis peritoneal”.
Diez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
Clin Endocrinol 2000; 53(5):587-93
* Este trabajo responde a los objetivos 3 y 4
* Este trabajo ha sido presentado en varios congresos nacionales e
internacionales
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Modulación colinergica de la respuesta de la hormona del crecimiento a la
hormona liberadora de la hormona del crecimiento en pacientes uremicos
en diálisis peritoneal.
Los neurotransmisores colinergicos hipotalamicos juegan el mayor papel
en la regulación de la secreción de hormona del crecimiento (GH).
Piridostignina, un inhibidor de la colinesterasa, es capaz de disminuir el tono
samatostatinergico hipotalamico y liberar GH en sujetos normales. El bloqueo
de los receptores muscarinicos con pirenzepina bloquea la liberación de GH en
varias condiciones clínicas. Sin embargo, hay poca información disponible
sobre el papel jugado por la vía colinergica central en la regulación de la GH en
pacientes uremicos.
Objetivo: nuestro objetivo fue medir la respuesta de la GH a la hormona
liberadora de GH después de pretratar con piridostigmina y pirenzepina en un
grupo de pacientes uremicos en diálisis peritoneal (DP).
La respuesta de la GH de los pacientes tratados con eritropoyetina
recombinante humana (EPO) se comparo con pacientes sin este tratamiento.
Diseño: investigamos 14 hombres en DP y 9 voluntarios sanos. Todos los
sujetos fueron sometidos a 3 test endocrinologicos. Cada sugeto recibio
hormona liberadora de GH (100 g, IV en bolus al minuto “o”). 16 minutos
después de la inyección de hormona liberadora de GH fue dado un placebo
oral, pyridostigmine (120 mg), ó pirencepina (100 mg)
Determinaciones: las muestras de GH fueron colectadas a -60, 0, 15, 30, 45, 60
y 90 minutos. La respuesta hormonal secretoria fue estudiada en función al
tiempo (área bajo la curva, ABC) y a tiempos independientes (valores pico).
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Resultados: basalmente, la concentración de GH fue similar en los
pacientes que en los controles. La respuesta de la GH a placebo mas hormona
liberadora de GH fue también comparable (pico 26.6 ± 3.8 vs. 33.2 ± 4.4 mU/l,
ABC 28.2 ± 3.4 vs. 27.8 ± 4.6 mU/h/l). La administración de piridostignina
indujo una potenciación significativa de la respuesta de la GH a su hormana
liberadora que también fue comparable en pacientes (pico 43.2 ± 5.2 mU/l,
ABC 47.6 ± 6.0 mU/h/l; P < 0.01), que en controles (pico 79.2 ± 8.6 mU/l, ABC
78.0 ± 9.4 mU/h/l; P < 0.01). Sin embargo, el incremento en el pico de GH y
ABC fue significativo, más alto en controles que en los pacientes.
La administración de pirenzepina indujo una abolición de la GH después de
estimulación con su hormona liberadora, en pacientes (pico 5.4 ± 2.6 mU/l,
ABC 6.0 ± 2.4 mU/h/l; P < 0.01) y en voluntarios sanos (pico 3.8 ± 0.6 mU/l,
ABC 4.0 ± 0.4 mU/h/l; P < 0.05).
La respuesta a la piridostignina mas hormona liberadora de GH y pirenzepina
mas la misma fue similar en pacientes con terapia crónica con EPO y sin ella.
Conclusion: nuestros resultados suguieren que la regulación colinergica
de la liberación de GH esta preserva en la unremia y en pacientews en DP. El
incremento significativamente bajo en la respuesta a la GH por su hormona
liberadora (piridostignina), sugiere que la estimulación del tono colinergico es
atenuado en pacientes en relación a los controles. La terapia a largo plazo con
EPO no parece afectar la respuesta de la GH a su estimulación o bloqueo.
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Capitulo 5.9.- Tejido adiposo y peptidos reguladores del apetito.
“Las alteraciones en la liberación de los péptidos moduladores del apetito
explican los trastornos en la conducta alimenticia de los pacientes en
diálisis peritoneal”.
Aguilera A, Codoceo R, Bajo MA, Caravaca E, Diez JJ, Jara MC, del Peso G,
Herranz A, Grande C, Selgas R. En vías de publicación.
* Este trabajo responde al objetivo 4.
* Plantea una interesante conección entre el tejido graso, la expresión genetica
de adipoquinas, resistencia hidrocarbonada, factores inflamatorios y los
trastornos en la liberación de peptidos moduladores del apetito.
* He sido presentado en varios congresos nacionales e internacionales como
comunicación oral.
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Las alteraciones en la liberación de los péptidos moduladores del apetito
explican los trastornos en la conducta alimenticia de los pacientes en
diálisis peritoneal
La malnutrición es una complicación frecuente en paciente en diálisis
peritoneal (DP), los trastornos del apetito conducen a malnutrición
especialmente la anorexia, y la obesidad a malnutrición de tipo protéico. Este
estudio analiza los trastornos en la conducta alimenticia de 42 pacientes en DP,
12 anoréxicos, 12 obesos, 18 sin trastornos del apetito y 10 controles sanos. El
impulso a comer se analizo con la escala análoga visual (EAV), los pacientes
anoréxicos presentaron mayor valores en el score de saciedad antes y después
de comer, menor deseo y placer al comer. El neuropéptido Y (NPY) el más
poderoso orexígeno conocido y la colecistoquinina (CCK) (un potente
anorexígeno), se correlaciono con este impulso. Los anoréxicos presentaron
niveles mas altos de factores anorexígenos (insulina, glucosa, péptido C, CCK,
IL-1, TNF- y péptido inhibidor gástrico (GIP)), y niveles relativamente bajos de
NPY. Por el contrario, los obesos presentaron niveles mas altos de NPY y
bajos de anorexígenos. También encontramos desordenes en la liberación de
péptidos tras estimulo alimenticio. Los anoréxicos presentaron un "pico" de
CCK temprano y muy elevado, lo que explicaría la saciedad temprana que
sufren estos pacientes en la EAV. Además la curva del NPY es los anoréxicos
fue plana y descendió a niveles mas bajos de los basales 90 minutos después
de comer, agravando la falta de apetito tardío. Los obesos presentaron dos
"picos" de NPY, uno temprano (30 minutos) y otro tardío (90 minutos), que
explica las ingestas abundantes y reiteradas. La curva de la insulina fue
completamente paralela a la del NPY, mostrando el efecto de la insulina sobre
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este péptido. La IL-1 se correlaciono con la insulina y el GIP, ambos son
estimulantes de la insulina. La IL-1 ejerce su efecto anorexígeno vía CCK. Los
uremicos sufren un sufren un síndrome de intolerancia hidrocarbonada con
hiperinsulinemia. Este síndrome puede alterar el equilibrio normal de los
pépticos moduladores del apetito, dando origen a trastornos en la conducta
alimenticia. La leptina participo como anorexígeno solo de forma basal. El NO3
como forma de determinar el oxido nítrico (NO) también fue determinado.
Todos los pacientes en DP presentaron un descenso de los mismos 30 minutos
después de comer. Todos los pacientes uremicos presentaron un rebote a los
90 minutos, elevando sus niveles, especialmente los obesos. Los controles
disminuyeron efectivamente la curva de ghrelina después de comer.
Muestras de grasa abdominal fueron obtenidas durante la colocación de
catéteres de DP o cirugías electivas. De tal manera que obtuvimos 5 muestras
del grupo I, 6 del grupo II, 4 del grupo III y 4 del grupo control.
Determinamos la expresión génica de leptina, adiponectina y TNF- por
PCR cuantitativa. Todos los uremicos presentaron una sobre-expresión de
TNF-, la más elevada en los anoréxicos, seguido por los obesos y los
uremicos asintomático. Un patrón inverso fue encontrado cuando se analizo la
leptina y la adiponectina, donde los niveles más bajos fueron encontrados en
los uremicos. En relación a la adiponectina los niveles mas bajos se
encontraron en los obesos.
Finalmente: la conducta alimenticia en pacientes en DP es modulada al
menos en parte, por pépticos con acción central y periférica que elevados de
forma basal se liberan de anómalamente. Esto es debido a la retención renal
que estos pépticos sufren, a la interacción de los mismos entre sí, a la
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retención y sobre producción de sustancia que normalmente se producen en
pequeñas cantidades (toxinas urémicas), y a la intolerancia hidrocarbonada del
urémico que parece jugar un papel clave en la liberación de los péptidos.
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Capitulo 5.10.- Intervenciones sobre el apetito y la inflamación
“Tratamiento de la anorexia y malnutrición con acetato de megestrol en
pacientes en diálisis peritoneal”.
Costero O, Bajo MA, del Peso G, Gil F, Aguilera A, Ros S, Hevia C, Selgas R.
Adv Perit Dial. 2004;20:209-12
* Este trabajo responde al objetivo 5.
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Tratamiento de la anorexia y malnutrición con acetato de megestrol en
pacientes en diálisis peritoneal.
La anorexia y malnutrición son complicaciones comunes y poderosos
predoctores de mortalidad y morbilidad en pacientes en diálisis peritoneal (DP).
El acetato de megestrol (AM) es un progestageno que ha demostrado que
aumenta el apetito y el peso en pacientes con cáncer o síndrome de
inmunodeficiencia adquirido. Con el objetivo de determinar si el AM puede
beneficiar pacientes en DP, nosotros tratamos 32 pacientes con 160 mg diarios.
El periodo de tratamiento fue 5.93 ± 5.12 meses (rango 1-23 meses). En el
68.8% de los pacientes, mejoró el apetito. La ganancia de peso fue
estadísticamente al 3er mes (la media del peso inicial 66.5 ± 11.4 kg, a los 3
meses fue 68 ± 10.4 kg; p<0.05). Observamos un incremento no significativo de
la albúmina sérica al 3er mes (inicial 3.44 ± 0.27 g/L, al tercer mes 3.54 ± 0.27,
p=0.45). No observamos efectos secundarios. Nuestra experiencia sugiere que
el tratamiento con 160 mg de AM diario en pacientes en DP indujo un aumento
del apetito, albúmina sérica, y ganancia de peso en muchos pacientes, sin
efectos secundarios.
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6.- Discusión.
A lo largo de estos años pretendimos desarrollar una línea continua de
investigación en los trastornos del apetito en los pacientes en diálisis, bajo la
concienciación de que el primer paso para obtener un estado nutricional
adecuado es tener una ingesta apropiada de alimentos. De tal manera, que
nuestro primer objetivo fue establecer los factores de riesgo para presentar
anorexia uremica y en el otro extremo, obesidad con bulimia. Fue así como en
nuestros primeros trabajos determinamos que para sufrir anorexia uremica eran
factores de riesgo, presentar anuria, largo tiempo en diálisis, enfermedades
crónicas potencialmente caquetizantes como insuficiencia cardiaca o
enfermedades hepáticas, infecciones de repetición y la cantidad de
medicamentos ingeridos a lo largo del día. El sexo femenino y la dosis de diálisis
se quedaron al borde de la significación estadística (resultados capitulo del I al
IV). Con relación a la dosis de diálisis, a pesar que tradicionalmente la anorexia
ha sido considerada como un signo de toxicidad de la uremia (CANUSA) (36), en
el análisis estadístico pesó más la función renal residual. Resultados recientes
de otros autores (37) refuerzan nuestras conclusiones.
Como factores de riesgo para sufrir obesidad/bulimia en pacientes en
diálisis encontramos que la diabetes mellitus, el hiperinsulinismo basal, el peso
elevado al entrar en diálisis, el sedentarismo y el tipo de diálisis (diálisis
peritoneal) fueron determinantes para sufrir obesidad. De forma interesante,
encontramos que el sufrir o haber sufrido hiperparatiroidismo secundario se
asoció ligeramente a obesidad central. Este último hecho puede ser debido a
una desregulación de los genes que regulan la distribución de grasa en el cuerpo
(resultados capitulo 5.3).
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De acuerdo con nuestra información esta es la primera vez que se
establecen los factores de riesgo para sufrir trastornos de la conducta alimenticia
en pacientes en diálisis. Además la importancia del apetito en esta población no
ha sido reconocida hasta hace dos años (38).
Nuestro siguiente objetivo fue encontrar y validar una encuesta que nos
sirviera para valorar y definir la intensidad del apetito en la población en diálisis.
En este caso, utilizamos la escala análoga visual (EAV) publicada por Hill J, et al
(39). Una de las razones por las que seleccionamos esta encuesta es porque
existian validaciones previas en pacientes en diálisis, aunque no en nuestra
población (16, 40, 41). Este instrumento fue de gran utilidad ya que resulta difícil
evaluar un síntoma tan subjetivo como es el apetito, en especial si
consideramos que involucra aspectos biológicos, sociales, culturales y
religiosos. En el estado uremico la situación es aun más compleja ya que a los
moduladores normales se añaden sustancias que se encuentran alteradas,
bien por retención uremica o por trastornos en su liberación (33). A través de
los diferentes estudios que realizamos, tanto transversales como seguimientos
cortos, fuimos capaces de establecer los criterios para definir la anorexia
uremica en nuestra población (resultados capitulo 5.3):
1.- EAV antes de comer < 60 mm, con al menos 4 horas de ayuno.
2.- Baja ingesta alimenticia medida por una encuesta dietética < 30 kcal/kg/día.
3.- Criterios de malnutrición definidos por los DOQI (42).
La obesidad con elevada ingesta fue definida de acuerdo con los
siguientes criterios:
1.- EAV > 60 mm
2.- Alto BMI definido de acuerdo con la OMS.
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3.- Ingesta alimenticia elevada medida por una encuesta dietética >35
kcal/kg/día.
En este estudio (Capitulo 5.3) evaluamos la conducta alimenticia de 52
pacientes en diálisis y la comparamos con 104 voluntarios sanos comparables
con la población estudiada. En otros estudios que utilizamos la EAV incluimos 48
y 42 pacientes en diálisis respectivamente (resultados capitulo 5.1 y 5.2).
Sin embargo, existen otros instrumentos que se han utilizado con el
mismo fin en pacientes en diálisis, como la “visual analog ratings”, utilizada por
Wright M et al. (17, 43).
Nuestro tercer objetivo fue indentificar el papel de algunas sustancias
biológicamente activas que podrían retenerse o hiperproducirse en pacientes
en diálisis, lo que podría deberse a ineficiencia de los métodos actuales de
diálisis para eliminar moléculas con capacidad de dismunuir el apetito. Como
ocurre con las citoquinas pro-inflamatorias que se liberan en grandes
cantidades después que los polimorfonucleares entran en contacto con las
membranas de diálisis.
La primera sustancia que investigamos fue el TNF- por su reconocido
efecto caquectizante y anorexigeno. Efectivamente, encontramos niveles
elevados de esta citoquina en el 99% de los pacientes, sin asociación con la
dosis de diálisis pero si con la función renal residual (resultados capitulo 5.4).
Niveles plasmáticos elevados de TNF- se asociaron a anorexia, malnutrición,
anemia, caquexia muscular, hipertrigliceridemia, neuropatía uremica, hipertrofia
ventricular izquierda y disfunción endotelial (resultados capitulo 5.5, 5.6.1, 5.7).
En 1998, sugerimos la existencia de un grupo de complicaciones paralelas al
estado de la uremia que se asociaban al TNF-, proponiendo que el TNF-
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fuera incluido en la lista de tóxinas uremicas (resultados capitulo 5.5). Esto
rompía la definición tradicional de toxina uremica propuesta por Bergström y
Furst (44), ya que el TNF- no se eliminaba por los métodos de diálisis, sino
que por el contrario, se hiperproducia. Mas tarde, en el año 2000 otros autores
definieron este síndrome con el nombre de “síndrome MIA, o malnutrición,
inflamación arteriosclerosis” (29).
El MIA junta sabiamente la acumulación de citoquinas pro-inflamatorias
que inducen caquexia y ateroesclerosis, explicando el elevado riesgo
cardiovascular que presentan los pacientes en diálisis. En este sentido nos
planteamos cómo afectaría la inflamación sistémica al primer evento que ocurre
antes de iniciarse el proceso de ateroesclerosis. Es decir, su efecto sobre la
disfunción endotelial. Fue así como encontramos que los pacientes que sufrían
un MIA-2, presentaban una tendencia a la trombosis mediada por niveles bajos
de tPA (el más poderoso fibronolitico) y altos de PAI (factor protrombotico),
aumento en marcadores de daño endotelial como la trombomodulina (marcador
de células endoteliales muertas) y del NO (vasodilatador) (resultados capitulo
VI). En un seguimiento prospectivo (15 meses) de pacientes en diálisis que
desarrollaron una inflamación sistémica demostramos dicha asociación causal
(Capitulo 5.6.2).
Nuestros resultados y los de otros grupos con relación al síndrome
malnutrición inflamación, nos hay llevado a plantear un ensayo clínico
utilizando un anticuerpo monoclonal anti-TNF- (infliximab) para tratar
determinados pacientes en diálisis que sufren caquexia uremica. Este estudio
debe completar el grupo de trabajos que durante estos años hemos
desarrollado.
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Pero no solo nos interesó el efecto deletéreo del TNF-, si no los
factores que condicionaban su hiperproducción. En este sentido encontramos
que pacientes que padecían infecciones crónicas silentes como la infección por
Helicobacter pylori (HP) sufrían anorexia y niveles plasmáticos más altos de
TNF-. Erradicamos el HP y los pacientes recuperaron al apetito, el estado
nutricional y mejoraron la función endotelial (resultados capítulos 5.1 y 5.6.3).
Esta mejoría se asoció a elevación de niveles plasmaticos de NPY y a
descenso de los de TNF- . Este hecho nos sugirió que otros procesos como
prótesis vasculares y cualquier órgano enfermo e inflamado era potencialmente
productor de TNF-, como es el caso de pacientes con cardiopatías o
hepatopatías. Sin embargo, en este mismo estudio encontramos un grupo de
pacientes que sufrían anorexia y niveles de TNF- similares al resto. Por ello
investigamos la asociación entre anorexia y péptidos de diferente origen con
acción sobre el ciclo hambre-saciedad. Uno de los más poderosos
anorexigenos es la CCK, pero no encontramos diferencias en los pacientes
estudiados (resultado capitulo 5.4). Otros anorexigenos como el péptido-C, GIP
e IL-1 estaban elevados. Los orexigenos, el NPY y la ghrelina estaban
relativamente bajos en pacientes anoréxicos. Finalmente, encontramos
resultados variables en los niveles de ghrelina, leptina y NO medido como NO3
(resultados capitulo 5.2 y 5.7).
Con relación al papel de la ghrelina en la modulación del apetito en
pacientes en diálisis, investigamos los factores que influían en su liberación
como la GH y la insulina. Nuestros resultados en este capitulo, y algunas
observaciones previas (45), nos sugirieron que podria existir un trastorno en la
liberación de la GH y que repercutiría en la liberación de ghrelina.
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Efectivamente, encontramos una respuesta disminuida a la liberación de GH
inducida por su hormona liberadora (GHRH), que fue experimentalmente
estimulada por piridostigmina. Esto es indicativo de una atenuación de la
regulación colinergica de la GH en el estado uremico (resultado capitulo 5.8).
En esta misma línea exploramos la influencia del metabolismo de la
insulina, de péptidos gastrointestinales, de citoquinas pro-inflamatorias y
adipocitoquinas derivadas de la masa grasa, sobre los trastornos en la
conducta alimenticia en pacientes en diálisis. Encontramos que en general
todos los pacientes presentaban curvas lentas de liberación de insulina,
glucagón y péptido-C después de un estímulo alimenticio estándar. Con el
mismo patrón, los pacientes anoréxicos, obesos, los uremicos sin trastornos del
apetito y los controles presentaron curvas completamente distintas. Así mismo,
la CCK, NPY, GIP, NO3 y ghrelina, presentaron patrones distintos pero
paralelos a sus respectivas curvas de insulina. La Leptina, TNF- y la IL-6
participaron como orexigenos solo en fase basal. Sabemos que la insulina
participa en la modulación de la liberación de estos péptidos, y que la insulina
es modulada por la resistencia hidrocarbonada en células periféricas.
Investigamos la expresión genética de leptina, TNF- y adiponectina en
muestras de grasa abdominal de pacientes a los que se les sometió a cirugías
electivas, colocación o re-emplazo de catéteres de DP. Encontramos, una
sobre-expresión de TNF- en todos los uremicos, mas marcada en anoréxicos
y en segundo lugar en obesos. Con relación a la leptina los uremicos
presentaban una baja expresión mas marcada en obesos, lo que podría ser
producto de los niveles sericos elevados de leptina. Una situación similar
ocurrió con la adiponectina. Este patrón es el inductor de resistencia a la
61
insulina, la insulina regula muchos péptidos con acción sobre el apetito y por
tanto podemos concluir que el tejido graso es un protagonista importante en la
dis-regulación del apetito en el estado uremico (resultados capitulo 5.9).
Las alteraciones en la liberación de estos péptidos pueden ser también
responsables de las preferencias y aversiones alimenticias que presentan los
pacientes en diálisis. Es así como los niveles elevados de CCK o NPY producen
saciedad preferentemente para hidratos de carbono (46, 47). Nosotros no
encontramos asociación entre los niveles de estos péptidos y las preferencias
alimenticias, pero la muestra seleccionada fue pequeña y nuestro objetivo en el
trabajo (resultados capitulo 5.3) era valorar las preferencias alimenticias de
nuestros pacientes con una encuesta validada para la población no renal. Esta
es una area pendiente de estudio, ya que nuestros pacientes presentaron
rechazo a carnes rojas, intermedio para carnes blancas y preferencia por
hidratos de carbono y sabores intensos, posiblemente para neutralizar el sabor
metálico o amargo asociado a la uremia.
Una de las últimas fases de nuestro estudio fue aplicar nuestros
resultados a un eventual tratamiento para la anorexia y malnutrición en diálisis
(33). En este sentido administramos acetato de megestrol 160 mg/día por
tiempo variable a 32 pacientes en diálisis peritoneal. Encontramos una
ganancia importante de peso al 3er mes y la albúmina plasmática aumentó al
borde de la significación estadistica (resultado capitulo 5.10). Actualmente
estamos analizando los resultados de un ensayo clínico a doble ciego,
comparado con placebo. Uno de los resultados más interesantes es el aumento
en sangre de NPY y descenso del TNF- que se queda en el borde de la
significancia estadística. Así mismo algunos resultados preliminares podrían
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indicar que el acetato de megestrol aumenta la expresión genética de forma
dosis dependiente de NPY en cultivo de una línea neuronal inmortal (anexo II).
En este mismo sentido, tenemos en marcha un ensayo clínico utilizando
infliximab como anti-TNF- a pacientes malnutridos en diálisis. Hasta el
momento se ha sido incluido un solo paciente. Lo mas relevante es que ha
experimentado una elevación dramatica en los niveles de albúmina y sobre
todo una mejoría muy significativa en la calidad de vida medida por el SF36.
Finalmente, y a medida que profundizamos en los mecanismos que
controlan el apetito y sus alteraciones en el estado uremico, hemos propuesto
la hipótesis del triptofano-serotonina (34), que conjunta todas las alteraciones
conocidas encontradas por nosotros y otros grupos en una sola. Esta se basa
en la elevada concentración del aminoácido triptofano en el liquido cefalo-
raquídeo secundaria a una disminución en los BCCA secundaria a niveles
elevados de TNF-, CCK, leptina, ghrelina, insulina, acidosis, sobrecarga
hídrica, deficiencia de NO-sintetaza (NOS) y de la enzima triptófano-
hidroxilasa. Los niveles elevados de triptofano producen un síndrome
hiperserotoninergico-like y como resultante anorexia severa y persistente
(anexos I, fig. 1). Este trastorno no se corrige con diálisis y podría entrar dentro
de la definición de la toxicidad de la uremia o bien llamarle síndrome
metabólico-toxico de la uremia.
Aunque esta hipótesis no ha sido probada, ha recibido un importante
soporte cientifico por la investigación de otros grupos (48-51). Demostrar esta
hipótesis es parte de nuestro trabajo para próximos años. Además,
investigaciones muy recientes indican que la ghrelina, un poderoso orexigeno
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de muy reciente descubrimiento muestra un feed-back negativo con la
serotonina cerebral (52).
7.- Conclusiones.
I.- Es necesario incorporar a la práctica clínica diaria una escala para
medir el apetito en pacientes en diálisis como la escala analógica visual.
II.- La infección por Helicobacter pylori se asocia con anorexia,
inflamación y malnutrición en pacientes en diálisis peritoneal. La erradicación
del HP mejora significativamente este síndrome.
III.- La función renal residual tiene un efecto protector sobre la
preservación de apetito, mas importante que la dosis de diálisis.
IV.- La conducta alimenticia en pacientes en DP es modulada por
peptidos con acción central y periférica que estan elevados de forma basal y
que se liberan anormalmente. Esto es debido a la retención renal de estos
peptidos, a la interacción de los mismos entre sí, a la retención y
sobreproducción de sustancias que normalmente se producen en pequeñas
cantidades (toxinas urémicas) como el TNF-, a desordenes en la liberación de
hormona del crecimiento y a la intolerancia hidrocarbonada del urémico, que
juega un papel clave en la liberación de los péptidos.
V.- La adipocitoquinas producidas por el tejido adiposo y la resistencia
hidrocarbonada secundaria a estas sustancias tienen un papel predominante en
la regulación del apetito en pacientes en diálisis.
VI.- Los niveles plasmáticos de leptina pueden ser considerados como
marcador de riesgo cardiovascular y de ingesta de alimentos en pacientes no
obesos sin inflamación.
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VII.- La inflamación sistemica debido a la alta producción y acumulación
de citoquinas proinflamatorias, inicia la disfunción endotelial y
consecuentemente favorece procesos pro-trombóticos y pro-aterogénicos en
pacientes en diálisis. Esto nos lleva a concluir lo importante que es erradicar
infecciones crónicas silentes como el helicobacter pylory, accesos (prótesis de
vasculares) infectadas. En general cualquier órgano enfermo es capaz de
producir estas caquexinas.
VIII.- El acetato de megestrol mejora considerablemente el apetito y el
estado nutricional posiblemente estimulando el NPY que es el más poderoso
orexigeno conocido.
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Leyenda de la Figura 1. Hipótesis del triptofano serotonina. Patogénesis de la
anorexia uremica y su tratamiento. CCK: colecistoquinina, IL-1: interleuquina-1.
TNF-: factor de necrosis tumoral alfa. TRP: triptofano. BCAA: aminoácidos
ramificados de cadena corta. NO: óxido nítrico. NPY: neuropeptido Y. NOS:
oxido nítrico sintetiza. nNOS: NO-sintetiza neural. ADMA: dimetil arginina L-
asimétrica sintetaza. CSF: fluido cerebro espinal. TRH: triptofan hidroxilasa.
MSH: hormona estimulante de la melanocortina-alfa. AgRP: proteina
relacionada a agouti. MC4-Rs: receptor 4 de la melanocortina. Tratamiento de la
anorexia uremica los números significan el sitio especifico donde se puede actual
desde el punto de vista terapéutico. (1): CCK antagonistas. (2): medicamentos
anti-TNF- (anticuerpos específicos, acetato de megestrol, talidomida, otros). (3):
aumento del NPY. (4): ihnibidor del transporte del triptofano a través de la
membrane hemato-encefálica (BCCA) (5): bloqueando el receptor de MC4-Rs.
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8.2.- Anexos II.
-actina
Dosis acetato de megestrol (nM) C 10 30 50 100
Fig. 2
Legenda de la figura 2. Wester blot. Las neuronas inmortales (SHSY.5Y),
fueron lisadas (RIPA buffer). El extracto proteico fue guardado en congelación a -
80 ºC. Para WB las proteínas fueron transferidas a una membrana de
nitrocelulosa, que posteriormente fue bloqueada. Finalmente, se utilizó un
anticuerpo primario y otro secundaria (anti-NPY humano). Para corregir la
cantidad de proteína se utilizo la -actina. El acetato de megestrol fue diluido en
DMSO obteneiendo una concentración final major de 1 en 1 millon, los que no
nos abligo a utilizar un grupo control con DMSO. La concentraciones molares del
AM fuerón calculadas de acuerdo al peso molecular.
.
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¤¤
¤¤
¤ Objective: Helicobacter pylori (HP) infection has fre-
quently been found in dialysis patients. Chronic infections
induce overproduction of pro-inflammatory substances.
Inflammation has been associated with cachexia and an-
orexia. We explored the relationship between HP infec-
tion, anorexia, and malnutrition in peritoneal dialysis (PD)
patients.
¤¤
¤¤
¤ Patients and Methods: The study included 48 clinically
stable PD patients divided into four groups: HP+ with an-
orexia (group I, n = 12); HP+ without anorexia (group II,
n = 4); HP– with anorexia (group III, n = 5); and HP– with-
out anorexia (group IV, n = 27). Infection with HP was di-
agnosed by breath test. Anorexia was evaluated using a
personal interview and an eating motivation scale (VAS).
The VAS included five questions that are answered be-
fore and after eating. The questions concern desire to eat,
hunger, feeling of fullness, prospective consumption, and
palatability. Biochemical markers of nutrition and inflam-
mation were also determined.
¤¤
¤¤
¤ Results: At baseline, group I showed lower scores for
desire to eat, hunger sensation, prospective consump-
tion, and palatability. They also showed lower lymphocyte
counts, prealbumin, transferrin, serum albumin, normal-
ized equivalent of protein–nitrogen appearance (nPNA),
and residual renal function (RRF). In addition, the same
group showed higher levels of C-reactive protein (CRP)
and more sensation of fullness than the remaining groups.
In the entire series, we found significant linear correla-
tions between the following markers of nutrition and cer-
tain questions on the VAS: albumin with before-lunch
desire to eat (r = 0.38, p < 0.05), and prealbumin with be-
fore-lunch hunger (r = 0.41, p < 0.05) and after-lunch hun-
ger (r = –0.35, p < 0.05). Negative linear correlations were
found between albumin and fullness before lunch (r =
–0.45, p < 0.01), and between prealbumin and before-lunch
desire to eat (r = –0.39, p < 0.05). Negative linear correla-
tions were also seen between CRP and albumin (r = –0.35,
p < 0.05) and between CRP and prealbumin (r = –0.36, p <
0.05). Similarly, CRP showed a negative correlation with
before-lunch desire to eat (r = –0.38, p < 0.05) and after-
lunch desire to eat (r = –0.45, p < 0.01). After HP eradica-
tion, group I showed a significant increase in markers of
nutrition and in VAS scores for almost all questions.
Simultaneously, they showed a decrease in CRP level. Sig-
nificant differences were also found in lymphocyte count
(1105 ± 259.4 cells/mm3 vs 1330.8 ± 316 cells/mm3, p <
0.05), nPNA (0.9 ± 0.16 g/kg/day vs 1.07 ± 0.3 g/kg/day, p <
0.05), prealbumin (26.7 ± 6.5 mg/dL vs 33.9 ± 56.6 mg/dL,
p < 0.01), albumin (3.48 ± 0.3 g/dL vs 3.67 ± 0.35 g/dL, p <
0.05), CRP (1.16 ± 1.14 mg/dL vs 0.88 ± 1.2 mg/dL, p <
0.054), before-lunch desire to eat (56.6 ± 6.8 vs 72.2 ± 4,
p < 0.001), after-lunch desire to eat (5.4 ± 2.6 vs 12.3 ± 2,
p < 0.01), hunger before lunch (55.4 ± 5.4 vs 73.1 ± 4.6,
p < 0.001), hunger after lunch (5.8 ± 2.9 vs 11 ± 4, p < 0.01),
fullness before lunch (36.6 ± 10.3 vs 18.7 ± 8.8, p < 0.001),
consumption after lunch (5 ± 4.7 vs 17.5 ± 18, p < 0.05),
and palatability (61 ± 5.3 vs 74.1 ± 4.1, p < 0.001).
¤¤
¤¤
¤ Conclusion: Infection with HP is associated with anor-
exia, inflammation, and malnutrition in PD patients. Eradi-
cation of HP significantly improves this syndrome.
Residual renal function seem to have a protective effect
on appetite preservation. The present study supports the
hypothesis of the involvement of inflammation in the
pathogenesis of malnutrition in PD patients.
KEY WORDS: Uremic anorexia; Helicobacter py-
lori; inflammation; malnutrition.
Anorexia is a symptom frequently associated withuremic toxicity. It is also a cause of malnutrition
in dialysis patients. Malnutrition is associated with
high morbidity and mortality in dialysis patients (1).
Factors implicated in the pathogenesis of uremic an-
orexia include retention of substances with anorexi-
genic effects (satietins), a decrease in orexigenic
substances, inflammation, and disorders in factors
that usually modulate the hunger–satiety cycle—for
example, amino acid levels and underdialysis, among
others (2,3).
The role of inflammation has recently been empha-
sized as a key point in the genesis of uremic cachexia
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[hypothesis of malnutrition, inflammation, and ath-
erosclerosis (MIA syndrome)] (4). One of the markers
of the inflammatory process is C-reactive protein
(CRP), which is associated with an increased risk of
cardiovascular disease in healthy and uremic subjects.
Increased levels of CRP appear to reflect the
overgeneration of pro-inflammatory cytokines
[interleukin-1 (IL-1), interleukin-6 (IL-6), tumor ne-
crosis alpha (TNFa )] (4,5), all of which are able to
inhibit appetite at the hypothalamus (6). In conse-
quence, acute or chronic infections are recognized as
being responsible for inflammation cycles that induce
production of substances with anorectic and cachec-
tic action (2).
Infection with Helicobacter pylori (HP) is a silent
infectious process that has been related to anorexia
in the normal population (7). Some authors have re-
ported an increased prevalence of HP infection among
dialysis patients (8). The hypothesis of the present
study was that chronic infection by HP in uremic sub-
jects may be a cause of anorexia. Eradicating the in-
fection should lead to an improvement in appetite.
PATIENTS AND METHODS
We studied 48 peritoneal dialysis (PD) patients, 24
on continuous ambulatory peritoneal dialysis (CAPD)
and 24 on APD (22 men and 26 women), ranging in
age from 22 years to 79 years (mean: 56.9 ± 14 years).
The mean time on PD was 17.5 ± 13.2 months (range:
3 – 63 months). No active acute or chronic disorders
were present in the patients in the 3 months before
the study. Patients with recognized endothelial dis-
ease (vasculitis, scleroderma, malignant hyperten-
sion), active systemic disease, or immunosuppression
were excluded. The causes of renal failure in the study
patients were glomerulonephritis (9 cases), diabetes
(8 cases), chronic pyelonephritis (10 cases), polycys-
tic kidney disease (6 cases), nephrosclerosis (10 cases),
unknown etiology (4 cases), and other (1 case).
We assigned each patient to one of four groups ac-
cording to the presence of anorexia and HP infection:
HP+ with anorexia (group I, n = 12); HP+ without an-
orexia (group II, n = 4); HP– with anorexia (group III,
n = 5); and HP– without anorexia (group IV, n = 27).
The study had two phases, including two analyti-
cal determinations and two breath tests: one at
baseline and one after HP eradication in the positive
cases. The therapeutic regime was omeprazole (40 mg
daily), clarithromycin (1 g daily), amoxicillin (1 g
daily), and clavulanic acid (250 mg daily) for 10 days.
DETERMINATION OF PARAMETERS
Infection with HP was diagnosed by breath test
(Tau-Kit: Isomed SL, Madrid, Spain). This method is
based on an oral intake of 100 mg of 13C urea. In the
presence of HP, urease hydrolyzes the 13C urea, re-
leasing 13CO2, which is detected by mass spirometry
in a breath sample. Patients in a fasting condition
take half a glass of a citric solution (200 mL). After
10 minutes, the baseline breath sample (exhalation)
is obtained. A solution of Tau-Kit plus water is imme-
diately ingested, and 309 minutes later, the second
breath sample is obtained. Diagnosis of HP infection
by breath test is a recognized method with high sen-
sitivity and specificity. It is currently the diagnostic
method of choice (9).
Dialysis adequacy was assessed by weekly urea
Kt/V and normalized equivalent of protein–nitrogen
appearance (nPNA) (10).
For markers of nutrition, we measured serum al-
bumin, transferrin, prealbumin, cholesterol, triglyc-
erides, ferritin, and iron. Serum albumin was
determined by a colorimetric method (Hitachi 704
analyzer: Hitachi, Madrid, Spain). Transferrin and
prealbumin were measured by immunonephelometry
(Boehringer nephelometer: Terminal SA, Madrid,
Spain); cholesterol, by a colorimetric method; triglyc-
erides, using the Hitachi 704; ferritin and iron, using
the Hitachi 911 analyzer (Hitachi, Madrid, Spain).
Anorexia was evaluated by personal interview and
an eating motivation scale [visual analog scale (VAS)]
(11). The VAS included five questions to be answered
before and after eating. The question dealt with de-
sire to eat, hunger, feeling of fullness, prospective con-
sumption, and palatability. Answers were given using
a horizontal scale (0 – 100 mm). The scale score has
no normal value; each subject is a personal control.
However, a normal degree of before-lunch desire to
eat generally ranges from 65 mm to 75 mm (11).
As a marker of inflammation, we measured CRP
by immunonephelometry [ELISA Vectastain ABC kit:
Vector Laboratories, Burlingame, CA, U.S.A. (normal
range: <0.5 mg/dL)].
STATISTICAL ANALYSIS
Results are given as median and range. Compari-
sons between groups were performed using a non-
parametric test, the Mann–Whitney rank-sum U-test.
Spearman regression analysis and the Student t-test
were used for paired and non paired data. A p value
less than 0.05 was considered statistically significant.
RESULTS
Table 1 shows the differences among the four
groups at baseline. Patients from group I (HP+ with
anorexia) showed a lower lymphocyte count and
lower prealbumin, transferrin, serum albumin,
nPNA, and creatinine clearance than did the remain-
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TABLE 1
Differences in General Parameters for the Four Groups at Baseline
Parameter Group I Group II Group III Group IV
Hemoglobin (g/dL) 11.4±0.9 11.8±0.5 10.4±1.4 11.4±0.9
Lymphocyte count (cells/mm3) 1105±259a,b 1225±230 1350±62a 1525±184b
Prealbumin (mg/dL) 26.7±6.4c,d 32.7±9.9c 31.7±0.5 36.1± 2.5d
Transferrin (mg/dL) 177.6±27f,g 242±15f 210±47.7 233.4±35g
Cholesterol (mg/dL) 202±45 227±15.8 193±8.8 215±37
Serum albumin (g/dL) 3.4±0.25h,i 3.7±0.13 3.7±0.3h 3.9±0.15i
Serum creatinine (mg/dL) 7.7±2.3j 7.78±1.3 6.3±1.4 6±0.5j
nPNA (g/kg/day) 0.9±0.16k 1.03±0.1 0.89±0.14 1.08±0.1k
Weekly Kt/V 2±0.3l 2.1±0.19 2.1±0.24 2.21±0.11l
CRP (mg/dL) 1.16±1.14m 0.7±0.23 0.9±0.6 0.6±0.23m
CCr (mL/min) 2.7±2.3
n 4.7±1.2 2.8±0.9 4.8±1.6n
nPNA = normalized equivalent of protein–nitrogen appearance; CRP = C-reactive protein; CCr = creatinine clearance.
a – n Groups in which the differences were statistically significant (p < 0.05).
TABLE 2
Differences in Eating Motivation Between the Groups at Baseline Using a Visual Analog Scale (mm)
Parameters Group I Group II Group III Group IV
Desire to eat
Before lunch 56.6±6.8a,b 74±4.1a 61.2±4.5 74.5±6b
After lunch 5.4±2.6c 7±2.7 7.5±2.9 9±4c
Hunger
Before lunch 55.4±5.4d,e 72±4d 61±2.5 73.7±5e
After lunch 5.8±2.9f 10±6 8.7±2.5f 8±4.8
Fullness
Before lunch 36.6±10.3g 15±5g 32.5±3 14.7±6
After lunch 85±26 73±4.4 91.2±8.5 80.3±21.5
Prospective consumption
Before lunch 57.9±5h 72±5.7h 61.2±4.8 70±5.9
After lunch 5±4.7i,j 13±6.7i 5±5.7 10.7±3.9j
Palatability 61±5.3k,l 75±3.5k 61±12.5 74.9±4l
a – l Groups in which the differences were statistically significant (p < 0.05).
ing groups. The group I patients also showed higher
CRP levels. These findings suggest a unique situa-
tion of the HP-infected patients with respect to the
other groups.
Table 2 shows the differences in the VAS at
baseline. Group I patients (HP+ with anorexia) again
showed significantly lower values in desire to eat,
hunger, sensation of fullness, prospective consump-
tion, and palatability—all indicating the poor state
of their appetite.
In all patients studied (n = 48), we found signifi-
cant linear correlations between the various mark-
ers of nutrition. Serum albumin correlated with
prealbumin (r = 0.43, p < 0.01) and cholesterol (r =
0.38, p < 0.05); nPNA correlated with prealbumin (r =
0.35, p < 0.05). A linear correlation was also seen be-
tween markers of nutrition and VAS values: albumin
with before-lunch desire to eat (r = 0.38, p < 0.05),
and prealbumin with hunger before lunch (r = 0.4,
p < 0.05) and hunger after lunch (r = –0.35, p < 0.05).
A negative linear correlation appeared between al-
bumin and fullness before lunch (r = –0.45, p < 0.01)
and between prealbumin and before-lunch desire to
eat (r = –0.39, p < 0.05).
A negative linear correlation was seen between
CRP and albumin (r = –0.35, p < 0.05), prealbumin
(r = –0.36, p < 0.05), before-lunch desire to eat (r =
–0.38, p < 0.05), and after-lunch desire to eat (r =
–0.45, p < 0.01).
Table 3 shows the changes in the markers of nu-
trition, CRP, and VAS scores in the infected patients
with anorexia before and after HP eradication. A sig-
nificant increase was observed in almost all markers
of nutrition, together with a simultaneous decrease
in CRP. The VAS parameters also showed significant
and unequivocal improvement.
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TABLE 3
Changes in Helicobacter pylori (HP)–Infected Patients After HP Eradication
Parameters Pre-treatment Post-treatment p Value
Lymphocyte count (cells/mm3) 1105±259.4 1330.8±316 <0.05
nPNA (g/kg/day) 0.9±0.16 1.07±0.3 <0.05
Prealbumin (mg/dL) 26.7±6.5 33.9±56.6 <0.01
Albumin (g/dL) 3.48±0.3 3.67±0.35 <0.05
CRP (mg/dL) 1.16±1.14 0.88±1.2 =0.054
Desire to eat
Before lunch 56.6±6.8 72.2±4 <0.001
After lunch 5.4±2.6 12.3±2 <0.01
Hunger
Before lunch 55.4±5.4 73.1±4.6 <0.001
After lunch 5.8±2.9 11±4 <0.01
Fullness
Before lunch 36.6±10.3 18.7±8.8 <0.001
After lunch 85±26 73±14.6 NS
Prospective consumption
Before lunch 57.9±5 66±18 NS
After lunch 5±4.7 17.5±18 <0.05
Palatability 61±5.3 74.1±4.1 <0.001
nPNA = normalized equivalent of protein–nitrogen appearance; CRP = C-reactive protein.
The four patients from group II (HP+ without an-
orexia) showed no changes in their markers of nutri-
tion. The values before and after HP eradication were
these: lymphocyte count [1225.8 ± 230.7 cells/mm3 vs
1381 ± 297.8 cells/mm3, nonsignificant (NS)],
prealbumin (32.9 ± 10 mg/dL vs 33.8 ± 5.6 mg/dL,
NS), transferrin (242 ± 15 mg/dL vs 256.8 ±
19.6 mg/dL, NS), albumin (3.7 ± 0.13 g/dL vs 3.9 ±
0.3 g/dL, p < 0.01), before-lunch desire to eat (74 ±
4.1 vs 75 ± 5, NS) and after-lunch desire to eat (7 ±
2.7 vs 6 ± 3.1, NS), hunger before lunch (72 ± 4.4 vs
73 ± 2.7, NS) and hunger after lunch (10 ± 6.1 vs 8 ±
2.7, NS), fullness before lunch (15 ± 5 vs 20 ± 3, NS)
and fullness after lunch (10 ± 6.1 vs 8 ± 2.7, NS), pro-
spective consumption before lunch (72 ± 5.7 vs 73 ±
5, NS) and prospective consumption after lunch (13 ±
6.7 vs 11 ± 4.2, NS), and palatability (75 ± 3.5 vs 74 ±
2.2, NS). Levels of CRP showed a nonsignificant de-
crease (0.7 ± 0.23 mg/dL vs 0.6 ± 0.3 mg/dL, NS).
Because groups III and IV (both HP–) underwent
no medical intervention, the results of their second
analysis are not shown.
DISCUSSION
The most important finding of the present study is
that it provides the first clinical support for the hy-
pothesis linking inflammation and malnutrition (via
anorexia) in PD patients suffering a chronic, symp-
tomatic (anorexia), but silent infection caused by
Helicobacter pylori. The distinct behavior differences
between the two infected groups suggests that the
presence of anorexia in this infection is quite relevant.
Only those patients with coexisting anorexia and HP
infection showed significant changes in appetite and
nutrition after eradication of the infection (Table 3).
We used three approaches to evaluate anorexia,
inflammation, and malnutrition. The VAS (11) ap-
peared to be a good instrument for dialysis patients
with appetite disorders. In the present study, it was
able to establish differences in diverse situations of
anorexia. The correlation between the VAS data and
the markers of nutrition supports the VAS measure-
ments.
The results shown in Table 2 reveal important dif-
ferences in eating behavior. Patients with existing
anorexia who were also infected with HP (group I)
showed lower desire, hunger, prospective consump-
tion, and palatability than did the other groups. The
inverse relationships between CRP, VAS, and mark-
ers of nutrition also support the link between anor-
exia and inflammation.
The pathogenesis of uremic anorexia nevertheless
appears to be more complex than being caused exclu-
sively by inflammation. In the present study, a group
of patients with no inflammatory signs (group III)
suffered anorexia. In this regard, we recently pub-
lished a hypothesis concerning other anorexia-induc-
ing mechanisms, such as gastrointestinal
hormones (3).
Residual renal function (RRF) has been considered
to protect dialysis patients from morbidity and mor-
tality (12). In this sense, RRF appears more impor-
tant than weekly peritoneal urea Kt/V in appetite
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preservation among our patients (Table I). Group IV,
in effect, showed the best health conditions (no in-
flammation, best nutrition status, and highest RRF).
The important contribution of RRF has been sug-
gested previously by others (12,13). Residual renal
function may protect infected patients from cytokine
accumulation; patients with no RRF may suffer the
effects of similar cytokine production more intensively.
This hypothesis concurs with the recognized sensi-
tivity of uremic patients to infectious insult, in terms
of general well-being, appetite, and food intake. The
renal inability to eliminate cytokine excess would
prolong the effects of the insult on heart, gastrointes-
tinal tract, liver, and blood vessels through the accu-
mulated mediators (14–16). The fact that HP infection
has been associated with hyperproduction of cytokines
in non uremic patients (17,18) supports that idea.
Our findings point to the importance of diagnosis
and early treatment of HP infection in dialysis pa-
tients, especially when they show anorexia and signs
of malnutrition. Treatment of HP infection after an
appropriate diagnosis should precede other ap-
proaches such as anabolics, orexigen drugs, or dietary
supplements.
CONCLUSION
Infection with HP is associated with anorexia, in-
flammation, and malnutrition in PD patients. Eradi-
cation of the HP infection significantly improves the
entire syndrome. Residual renal function may have
an overarching role in appetite preservation, espe-
cially in infected patients. Our findings give concrete
support to the hypothesis of inflammation as a cause
of malnutrition in dialysis patients.
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Advances in Peritoneal Dialysis, Vol. 20, 2004
Anorexia-associated malnutrition is a severe compli-
cation that increases mortality in peritoneal dialysis
(PD) patients. Ghrelin is a recently-discovered
orexigenic hormone with actions in brain and stom-
ach. We analyzed, in 42 PD patients, the possible re-
lationship between ghrelin and appetite regulation
with regard to other orexigens [neuropeptide Y (NPY),
NO3] and anorexigens [cholecystokinin (CCK),
leptin, glucose-dependent insulinotropic peptide
(GIP), tumor necrosis factor alpha (TNFα)]. All
orexigens and anorexigens were determined in
plasma. Eating motivation was evaluated using a vi-
sual analog scale (VAS). The patients were divided
into three groups: those with anorexia (n = 12), those
with obesity associated with high intake (n = 12), and
those with no eating behavior disorders (n = 18). A
control group of 10 healthy volunteers was also
evaluated.
Mean plasma levels of ghrelin were high
(3618.6 ± 1533 pg/mL), with 36 patients showing
values above the normal range (<2600 pg/mL). Pa-
tients with anorexia had lower ghrelin and NPY lev-
els and higher peptide-C, CCK, interleukin-1 (IL-1),
TNFα, and GIP levels than did the other patients.
Patients with anorexia also had an early satiety score
and low desire and pleasure in eating on the VAS and
diet survey. We observed significant positive linear
correlations between ghrelin and albumin (r = 0.43,
p < 0.05), prealbumin (r = 0.51, p < 0.05), transfer-
rin (r = 0.4, p < 0.05), growth hormone (r = 0.66,
p < 0.01), NO3 (r = 0.36, p < 0.05), and eating moti-
vation (VAS). At the same time, negative relationships
were observed between blood ghrelin and GIP (r =
–0.42, p < 0.05), insulin (r = –0.4, p < 0.05), leptin
(r = –0.45, p < 0.05), and creatinine clearance [r =
–0.33, p = 0.08 (nonsignificant)]. Ghrelin levels were
not related to Kt/V or to levels of CCK and cytokines.
Ghrelin plasma levels are elevated in PD patients.
Uremic patients with anorexia show relatively lower
ghrelin plasma levels than the levels seen in obese
patients or in patients with normal appetite. The role
of ghrelin in appetite modulation is altered in uremic
PD patients, and that alteration is possibly associ-
ated with disorders in insulin and growth hormone
metabolism.
Key words
Eating behavior disorders, malnutrition, inflammation,
ghrelin
Introduction
The deleterious effects of malnutrition in dialysis pa-
tients are well recognized. Malnutrition is a common
factor in the two major causes of death during dialy-
sis: cardiovascular disease and infection (1). Anor-
exia is frequently associated with uremia and
represents the first step in malnutrition (2). Uremic
status complicates appetite regulation because it pro-
vokes disorders in adipose tissue, the gastrointestinal
system, neuropeptide protection and retention, inflam-
mation, and the central nervous system. We have sug-
gested the possibility that, in uremic patients, a true
imbalance exists between anorexigenic and orexigenic
mediators (3)—a misbalance that favors the appear-
ance of anorexia.
Ghrelin is a novel 28-amino-acid octanoylated
peptide that has been identified in stomach as an
endogenous ligand for the growth hormone (GH)
secretagogue receptor. Ghrelin is a powerful
orexigen in fasting conditions; and, because its
postprandial cycle is inverse to the glucose and
insulin curves, it has satiating properties. Ghrelin
influences eating consumption by increasing the
desired meal size, and the peptide has been associ-
ated with bulimia–anorexia in non uremic patients
(4). Recently, it has been suggested that renal re-
tention may significantly elevate ghrelin plasma
levels in patients with renal failure (5). Our hy-
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pothesis derives from the contradiction between
elevated ghrelin levels and the strong tendency to
anorexia in uremic patients. In the present study,
we analyzed the relationship between ghrelin
plasma levels, other appetite regulators, and mark-
ers of nutrition in peritoneal dialysis (PD) patients.
Patients and methods
We studied 42 clinically stable PD patients [20 on
continuous ambulatory PD (CAPD), 22 on auto-
mated PD (APD)]. The 22 male and 26 female pa-
tients ranged in age from 22 years to 79 years
(mean: 56.9 ± 14 years). Their mean period on PD
was 17.5 ± 13.2 months (range: 3 – 63 months).
Causes of renal failure were nephrosclerosis
(10 cases), glomerulonephritis (8 cases), diabetes
(7 cases), chronic pyelonephritis (6 cases), poly-
cystic kidney disease (5 cases), unknown (4 cases),
and others (2 cases).
We used a visual analog scale (VAS) adapted from
Hill and Blundell [see (6)] to evaluate eating motiva-
tion. The VAS includes 5 questions about desire, hun-
ger, sense of fullness, prospective consumption, and
palatability to be answered before and after eating.
Answers are marked on a horizontal scale (0 –
100 mm).
Anorexia was defined as low eating motivation
(personal interview and VAS < 60 mm), low food in-
take [normalized protein equivalent of nitrogen ap-
pearance (nPNA) < 1.1 g/kg/day, daily dietary
assessment < 30 kcal/kg], and low values for markers
of nutrition [Dialysis Outcomes Quality Initiative
clinical practice guideline for nutrition (7)].
Obesity with high food intake was considered
when the patient’s body mass index (BMI) measured
25 – 30 kg/m2 [grade I, World Health Organization
(WHO) criteria (8)], 30 – 40 kg/m2 (WHO grade II),
or >40 kg/m2 (WHO grade III); when eating motiva-
tion was high (VAS > 60 mm); and when daily food
intake (6) or bulimic criteria [Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (9)]
was high.
Normal eating behavior was considered in the
absence of anorexia (VAS) and bulimia, with a nor-
mal BMI (18.5 – 25 kg/m2) and normal values for
markers of nutrition (7).
Using those definitions, we divided the study pa-
tients into 3 groups: those with anorexia (n = 12), those
with obesity (n = 12) and high food intake, and those
without eating behavior disorders (n = 18). We also
studied a control group of 10 healthy volunteers
(6 men, 4 women).
For all patients and controls, we determined these
parameters:
• Dialysis adequacy:
• Kt/V urea and nPNA
• Markers of nutrition:
• Long-term: plasma creatinine, albumin, choles-
terol (colorimetric method, Hitachi 704:
Boehringer Mannheim, Mannheim, Germany),
and transferrin (immunonephelometry, Behring
Nephelometer: Behringwerte AG, Marbus,
Germany)
• Medium-term: short, half-life plasma proteins
such as prealbumin and retinoid-binding pro-
tein [RBP (immunonephelometry, Behring
Nephelometer)], serum GH [immunoenzymatic
assay, AIA 1200: Tosoh Corporation, Tokyo,
Japan; maximum intra-assay and inter-assay
coefficients of variation, 5.4% and 3.3% respec-
tively; sensitivity, 0.1 ng/mL (normal,
<5 ng/mL)]
• Short-term: urea nitrogen, serum phosphate, and
serum potassium. Mean daily dietary intake was
determined from individual 24-hour food
records during a 3-day period (including 1 week-
end day). Daily calories and intake of carbohy-
drates, lipids, and protein were calculated for
each patient using commercially available com-
puter software [Wander (1990): Sandoz
Nutrición, Barcelona, Spain].
• Plasma or serum peptide appetite modulators
(radioimmunoassay):
• Glucose (hexoquinase reaction: Boehringer
Mannheim; normal fasting levels, 90 –
120 mg/dL)
• Insulin (Sorin: Biomedica, Saluggia, Italy; sen-
sitivity, 3 mIU/mL; intra-assay and inter-assay
coefficients of variation, 6.6% and 6.2%
respectively)
• Glucose-dependent insulinotropic peptide [GIP
(Peninsula Laboratories, Belmont, CA, U.S.A.);
normal range, 35 – 52 pg/mL]
• Cholecystokinin [CCK, 26–33 unsulfated frag-
ment (Peninsula Laboratories); normal value,
12 – 20 pg/mL], which shows anorexigenic
action
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• Leptin (Linco Research, St. Louis, MO, U.S.A.;
sensitivity, 0.5 ng/mL; linearity, 100 µg/L;
normal range, 3 – 7.8 ng/mL), which has an an-
orexigenic effect
• Neuropeptide Y [NPY (Peninsula Laboratories);
normal range, 220 – 370 pg/mL], a powerful
orexigen
• Ghrelin (RIA, 125-Ighrelin: Linco Research;
sensitivity, 100 pg/mL; normal range in our
10 healthy volunteers, 900 – 2500 pg/mL), which
shows anorexigenic action
• NO [measured as serum NO3, a final metabo-
lite of NO, by capillary electrophoresis; normal
range, 90 – 110 µmol/L (10)], a powerful
orexigen
• Cytokines with recognized action on the hun-
ger–satiety cycle: tumor necrosis factor alpha
[TNFα (ELISA, Medigenix Easia kit: Biosource
Europe SA, Nivelles, Belgium); normal, 3 –
20 pg/mL] and interleukin-1 [IL-1 (ELISA,
Medigenix Easia kit); normal, <15 pg/mL]
Statistical analysis
Results are given as medians and ranges. Compari-
sons between study groups were performed using a
nonparametric test, the Mann–Whitney rank sum
U-test. Spearman regression analysis and the Student
t-test were used for paired and unpaired data. A
p value less than 0.05 was considered statistically
significant.
Results
Table I shows the demographic and hematologic char-
acteristics of the patients at baseline. Patients with
anorexia were older and showed lower nPNA, albu-
min, prealbumin, RBP, and daily food intake. They
also showed higher plasma levels of TNFα and IL-1
than were seen in the other groups. Relatively higher
plasma levels of anorexigens (CCK, TNFα) and lower
levels of orexigenic substances (NPY, ghrelin) were
present in the group with anorexia. The contrary was
observed in the obese group. Table I also shows a clear
difference in ghrelin plasma levels between the dialy-
sis patients and the healthy controls.
Table II shows the data from the VAS. Before and
after eating, patients with anorexia scored differently
than the other patients, confirming poor appetite in
the anorectic group. Patients with obesity presented
the opposite eating attitude.
Table III shows significant linear correlations be-
tween VAS scores and plasma levels of CCK, NPY,
ghrelin, leptin, TNFα, and NO3. Those results effec-
tively confirm the associations between anorexia and
CCK, leptin, and TNFα. On the other hand, NPY,
ghrelin, and NO3 were associated with higher eating
desire.
In PD patients, ghrelin plasma levels were 3618.6 ±
1533 pg/mL as compared with 2084 ± 533.3 pg/mL in
healthy controls, p < 0.01. Most patients (n = 36)
showed values above the normal range.
We found significant positive linear correlations
between ghrelin and some nutritional markers: albu-
min (r = 0.43, p < 0.05), prealbumin (r = 0.51, p <
0.05), transferrin (r = 0.4, p < 0.05), GH (r = 0.66,
p < 0.01), and NO3 (r = 0.36, p < 0.05). Ghrelin also
showed negative correlations with GIP (r = –0.42, p <
0.05), insulin (r = –0.4, p < 0.05), leptin (r = –0.45,
p < 0.05), and creatinine clearance (r = –0.33, p = 0.08,
NS). Ghrelin was not significantly related to Kt/V
urea, CCK, or cytokine levels.
Levels of NPY showed a negative linear correla-
tion with IL-1 (r = –0.52, p < 0.05) and TNFα (r =
–0.51, p < 0.05), and TNFα and IL-1 showed a posi-
tive linear correlation (r = 0.85, p < 0.005). Levels of
IL-1 and CCK also showed a positive linear correla-
tion (r = 0.45, p < 0.05), as did levels of IL-1 and GIP
(r = 0.46, p < 0.05).
Discussion
Eating behavior is a complex phenomenon with socio-
cultural and biologic influences, and eating is compli-
cated by the resulting profound metabolic alterations
and retention of catabolic end-products (3,4).
Dialysis patients have a strong tendency toward
anorexia. They retain substances with anorectic ac-
tion such as CCK, leptin, corticotropin-releasing hor-
mone, insulin, glucagons, TNFα, IL-1, GIP, lack of
NO, C-peptide, α-melanocyte-stimulating hormone
(α-MSH), and free tryptophan (11). All of those agents
promote the transfer of high concentrations of free
tryptophan into cells—most especially in the hypo-
thalamus—resulting in increased serotonin production
and loss of appetite [tryptophan–serotonin hypothesis
(12)].
Ghrelin, a novel 28-amino-acid polypeptide with
GH secretagogue action, increases food intake, fat
accumulation, body weight, gastric acid secretion, and
stomach motility; it also reduces blood pressure, im-
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proving cardiac function (5,13). The high ghrelin
plasma levels we found in PD patients correlate nega-
tively with residual renal function (RRF), indicating
that RRF is responsible at least in part for ghrelin ac-
cumulation. Our findings also confirm findings by
Yoshimoto A et al. (5).
Importantly, dialysis dose (Kt/V) does not seem to
play an important role in uremic ghrelin accumulation,
supporting the idea that RRF is more important than
dialysis dose in preserving appetite in uremia (11,14).
We found a close association between fasting ghrelin
plasma levels and eating motivation as measured by
VAS (Table III). We also found a positive relationship
between fasting ghrelin plasma levels and markers of
nutrition. Moreover, patients with anorexia showed
relatively lower values of ghrelin than did obese
patients or patients with normal appetite (Table I). The
anabolic effect of ghrelin is the result of its stimulation
TABLE I Demographics and biochemical and nutrition markers in the study groups
Patients
Anorexic Obese Normal appetite Controls
(A) (O) (N) (C) p Value
Age (years) 66.4±10 56.3±7.1 49.7±14 31±3.7 A vs. N, <0.05
O vs. C, <0.05
N vs. C,<0.05
A vs. C, <0.001
PD duration (months) 36.8±32.3 23±11.5 45.5±46.7 — NS
CCr (mL/min) 0.5±0.45 1.42±1.01 1.38±1.39 101±7 A/O/N vs. C, <0.001
Daily nPNA (g/kg) 0.87±0.21 1.1±0.25 1.14±0.11 A vs. N, <0.05
Weekly Kt/V urea 2±0.25 1.98±0.33 2.17±0.33 NS
Cholesterol (mg/dL) 174±57.4 211±55.6 188±56 184±30 NS
Albumin (g/dL) 3.7±0.08 4±0.2 3.9±0.4 5±0.4 A vs. O/C, <0.05
Transferrin (mg/dL) 209±36 262±47 205±50.7 303±57.2 NS
Prealbumin (mg/dL) 26±7 31±2.9 31±7.5 34±3 A vs. O/C, <0.05
Retinol protein binding (mg/dL) 8.4±3 11.5±3 13±2 5.3±1.2 A vs. O/N, <0.05
Lymphocytes/mm3 1298±444 1452±613 1727±480 1877±592 NS
Growth hormone (ng/mL) 3.4±3.8 4±4.8 2.2±1.4 1.7±1.7 NS
Diet survey (kcal/day) 1277±467.4 2320±179.4 2006±351 2089±339 A vs. O, <0.01
A vs. N/C, <0.05
Fat (kcal/day) 60.4±28.9 102±23.2 98±22 74.7±15 A vs. O/N, <0.05
O vs. C, <0.05
Protein (kcal/day) 63±18 85.7±16.6 83.8±13.7 74.5±21.8 A vs. O, <0.05
Carbohydrates (kcal/day) 98±41 227±71 155.5±27 248.8±67.2 A vs. O/N/C, <0.01
Glucose (mg/dL) 93±33 101±40 105±69 81±5 A vs. N/C, <0.05
O vs. C, <0.05
Insulin (mIU/mL) 34±24 41.3±50.7 13.8±4.9 12.4±3.2 A vs. N/C, <0.05
O vs. C, <0.05
GIP (pg/mL) 101.2±22 111.8±28 132.6±25 47.1±7.3 A/O/N vs. C, <0.01
Cholecystokinin (pg/mL) 25.8±3.7 19.9±4.1 21.6±8 10.9±1.8 A vs. O, <0.05
N vs. C, <0.05
Leptin (ng/mL) 44.5±45 110±45 35±28 11.8±8 A vs. O, <0.01
O vs. N, <0.01
N vs. C, <0.01
Neuropeptide Y (pg/mL) 369±260 463.5±61.6 433.7±61 320.5±48 A vs. O/N/C, <0.05
Ghrelin (pg/mL) 3646±958.6 4486±1614.8 4289±1161 2084±533.3 A/O/N vs. C, <0.05
NO3 (µmol/L) 175±60 190±35.9 152±26.6 92.7±7.5 A vs. C, <0.001
N vs. C, <0.001
O vs. C, <0.05
TNFα (pg/mL) 121±43.8 40±11.6 38.2±16 18±4 A vs. O/N, <0.01
IL-1 (pg/mL) 6.12±0.8 2.1±0.43 2.2±1.34 1±0.8 A vs. O/N, <0.001
PD = peritoneal dialysis; NS = nonsignificant; CCr = creatinine clearance; nPNA = normalized equivalent of protein nitrogen
appearance; GIP = glucose-dependent insulinotropic peptide; TNFα = tumor necrosis alpha; IL-1 = interleukin-1.
Aguilera et al.
198
of appetite by an unknown mechanism and stimulation
of GH–anabolic action (15).
We have successfully used recombinant GH (rGH)
to treat malnourished patients on dialysis (16). Nota-
bly, treatment with rGH was associated with a dra-
matic reduction in plasma levels of leptin and in insulin
resistance, supporting the possibility of a direct effect
on ghrelin (17). Our present results—a positive asso-
ciation between ghrelin and GH, and a negative asso-
ciation between ghrelin and leptin and insulin—sup-
port that idea.
Importantly, we found no association between
ghrelin and proinflammatory cytokines, which would
be the result of independent ghrelin–GH anabolic
mechanisms. Moreover, GH release is altered in end-
stage renal disease (18), and cytokines may be one of
the mechanisms implicated in that alteration (19).
We could consider ghrelin accumulation to be
positive. Moreover, RRF may play a crucial role as a
TABLE III Relationship between visual analog scale values and plasma levels of appetite peptide regulators
CCK NPY Ghrelin Leptin TNFα NO3
Desire to eat before lunch 0.6 b –0.4 a –0.4 a 0.54 b
Desire to eat after lunch 0.46 a –0.38 a 0.4 a
Hunger before lunch –0.41 a 0.66 b –0.6 b –0.65 b 0.56 b
Hunger after lunch 0.55 b
Fullness after lunch –0.46 a –0.4 a –0.6 b
Prospective consumption before lunch 0.48 a 0.7 b –0.34 a –0.48 a 0.5 b
Prospective consumption after lunch –0.43 a
Palatability –0.5 a 0.6 b –0.4 a 0.38 a
a p < 0.05.
b p < 0.01.
CCK = cholecystokinin; NPY = neuropeptide Y; TNFα = tumor necrosis factor alpha.
TABLE II Motivation to eat, measured by the visual analog scale a
Patients
Anorexic Obese Normal appetite Controls
(A) (O) (N) (C) p Value
Desire to eat before lunch 60±6.1 76.6±6 67.8±6.9 72.8±3.9 A vs. O/C, <0.01
Desire to eat after lunch 8.6±2.2 21.6±4 13.2±5 13.5±8.5 A vs. O, <0.05
Hunger before lunch 60±6.1 78.3±6 68.6±4.7 74.3±4.5 A vs. O/N, <0.001
A vs. C, <0.01
O vs. N, <0.01
Hunger before lunch 8±4.4 21.6±4 12.8±5.5 17.1±4.8 A vs. O/C, <0.01
Fullness before lunch 28±8.4 18.8±2.5 12.5±4.2 11.8±4.1 A vs. N/C, <0.01
Fullness after lunch 81±5.4 59.1±19.6 77±5.6 77±5.6 A vs. O, <0.05
O vs. C, <0.05
Prospective consumption before lunch 59±5.5 78.3±4 71.4±3.7 75.7±4.5 A vs. O/N/C, <0.001
O vs. N, <0.01
Prospective consumption before lunch 6±2.2 25±5.4 12.3±2.7 13.5±4.7 A vs. O, <0.001
A vs. N/C, <0.01
O vs. N, <0.01
Palatability 60±7 75±5.4 71.4±4.7 74.3±5.3 A vs. O/N/C, <0.01
Hunger 2 hours before lunch 34±5.4 58.3±2.6 45±8.6 45.7±5.3 A vs. O/C, <0.01
A vs. N, < 0.05
O vs. N/C, <0.01
Satiety 2 hours after lunch 60±0 39. 2±6.6 40.7±17.4 40±0 A vs. O/C, <0.001
A vs. N, < 0.05
a The visual analog scale is measured on the horizontal, with a maximum value of 100 mm.
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protective factor against anorexia. Because ghrelin
depends on GH release for its anabolic effect, and
because uremia alters that cycle, with a resulting re-
tention of many anorexigenic molecules, the final re-
sult is anorexia.
Conclusions
Ghrelin plasma levels are elevated in PD patients.
Uremic patients with anorexia show relatively lower
ghrelin plasma levels than the levels seen in obese
patients or in patients with normal appetite. The dis-
ordered insulin and GH metabolism in PD patients
probably affects the role of ghrelin modulation in ap-
petite control.
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ABSTRACT
 
Eating and appetite disorders are frequent complications of the
uremic syndrome which contribute to malnutrition in dialysis
patients. The data suggest that uremic anorexia may occur with
or without abdominal and visceral fat accumulation despite a
lower food intake. This form of obesity (i.e., with low food
intake and malnutrition) is more common in dialysis patients
than obesity with high food intake. This article reviews the
current knowledge regarding mechanisms responsible for
appetite regulation in normal conditions and in uremic patients.
Anorexia in dialysis patients has been historically considered as
a sign of uremic toxicity due to ‘‘inadequate’’ dialysis as judged
by uncertain means (‘‘middle molecule’’ accumulation, 
 
Kt / V
 
,
‘‘peak-concentration hypothesis,’’ and others). We propose the
tryptophan-serotonin hypothesis, based on a uremia-induced
disorder in patients’ amino acid profile—low concentrations of
large neutral and branched-chain amino acids with high
tryptophan levels. A high rate of tryptophan transport across
the blood-brain barrier increases the synthesis of serotonin, a
major appetite inhibitor. Inflammation may also play a role in
the genesis of anorexia and malnutrition. For example, silent
infection with 
 
Helicobacter pylori
 
 may be a source of cytokines
with cachectic action; its eradication improves appetite and
nutrition. The evaluation of appetite should take into account
cultural and social aspects. Uremic patients showed a universal
trend to carbohydrate preference and red meat refusal
compared to healthy people. In contrast, white meat was less
problematic. Uremic patients also have a remarkable attraction
for citrics and strong flavors in general. Eating preferences or
refusals have been related to the predominance of some appetite
peptide modulators. High levels of cholecystokinin (CCK) (a
powerful anorexigen) are associated with early satiety for
carbohydrates and neuropeptide Y (NPY) (an orexigen) with
repeated food intake. Obesity and elevated body mass index
often falsely suggest a good nutritional status. In uremic
patients (a hyperinsulinemia state), disorders in the regulation
of fat distribution (insulin, leptin, insulin-like growth factor
[IGF]-1, fatty acids, and disorders in receptors for insulin,
lipoprotein lipase, mitochondrial uncoupling protein-2, and
 
β
 
3
 
-adrenoreceptors) may cause abdominal fat accumulation
without an increase in appetite. Finally, appetite regulation in
uremia is highly complex. Disorders in adipose tissue, gas-
trointestinal and neuropeptides, retained or hyperproduced
inflammatory end products, and central nervous system changes
may all play a role. Uremic anorexia may be explained by a
hypothalamic hyperserotoninergic state derived from a high
concentration of tryptophan and low branched-chain amino acids.
 
There is no doubt about the deleterious effects of
malnutrition in dialysis patients. Malnutrition is a
common factor in the two major causes of death,
cardiovascular and infectious diseases, among uremic
patients (1). There is a substantial body of literature on
the pathophysiology of malnutrition in end-stage renal
disease (ESRD) and there is general agreement on the
subject’s complexity. No effective standard therapeutic
measures have been derived from our knowledge base.
One reason for this could be the lack of alternatives to the
basic need for an adequate eating behavior, a sine qua
non to achieving an adequate nutritional status (2).
Eating behavior is a complex phenomenon that results
from sociocultural and biologic components, complica-
ted in uremic patients by the retention of catabolism
products and profound metabolic alterations (3,4).
Evaluating eating behavior disorders (EBDs) in nonu-
remic patients utilizes well-defined diagnostic criteria (5).
However, these criteria have not been validated in
dialysis patients. As a consequence, tools to assess
nutrition in ESRD patients lack validated scales to define
appetite disorders in terms of quality and intensity.
Our group has been interested in studying this
unexplored field since 1995 in the belief that the first
requirement of adequate nutrition is an appropriate
appetite. We have studied the EBDs of many dialysis
patients and will, in this article, review current knowledge
about mechanisms responsible for appetite regulation,
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propose a classification of EBDs in dialysis patients, and
suggest new therapeutic approaches for the loss of
appetite.
 
Normal Appetite Control Regulation
 
Appetite is regulated by a heterogeneous feedback
system that includes various signals derived from the
gastrointestinal tract and liver, circulating nutrients, fat
reserves and cell products (leptin, resistin), and the
central nervous system (CNS). Inputs from the peri-
pheral nervous system, including the vagus nerve and
gastric receptors, are also important. Signals are integ-
rated in the CNS, inducing hunger or satiety. The hypo-
thalamus contains the feeding (hunger) center (lateral
hypothalamus), which has dopaminergic predominance,
and the satiety center (ventromedial hypothalamus),
which has serotoninergic and adrenergic neurotransmitter
predominance (6). High concentrations of serotonin
cause satiety.
There are four phases responsible for regulating food
intake:
The gastric phase starts when a meal reaches the
stomach by stimulating satiety signals. Meal volume
induces distention and stimulates baroreceptors; meal
composition (protein and carbohydrates) stimulates
cholecystokinin (CCK) release by duodenal cells which
inhibits gastric motility. Central satiety (CNS) via the
vagus nerve is induced by both signals (7).
In the postabsorptive phase, satiety is induced by
metabolic end products, such as glucose, amino acids,
and fatty acids (6–8). Their absolute and relative plasma
concentrations regulate the hunger sensation. It is known
that the equilibrium between tryptophan and branched-
chain amino acids (BCAA) in plasma and cerebrospinal
fluid plays a major role in the hunger-satiety cycle (6–8).
At the same time, circulating nutrients and metabolic end
products regulate appetite by inducing gastrointestinal
peptide release (CCK, glucagon, and insulin) (9).
Liver vagal glucoreceptors have a physiologic role in
appetite regulation. Their activation by glucose increases
intracellular adenosine triphosphate (ATP) concentration,
which stimulates the vagus nerve and inhibits appetite
(10). Hepatocytes are sensitive to abnormal stimuli (such
as cytokines) that diminish glucose and protein synthesis,
exaggerating satiety and favoring cachexia (11).
Peripheral signals are integrated in the CNS (central
phase), stimulating the activation of peptides and
neurotransmitters. Two principal peptides, CCK and
neuropeptide Y (NPY), are involved in appetite
control: CCK as an anorexigen (9) and NPY as the
most potent appetite stimulant known (12). In abnor-
mal conditions, excess plasma cytokine levels (tumor
necrosis factor [TNF]-
 
α
 
 and interleukin [IL]-1) entering
the CNS increase serotonin and induce satiety (13,14).
Nine TNF-
 
α
 
 molecular fragments have been isolated,
each one with different actions. The 69–100 fragment
has suppressive effects on food intake (15). IL-1 may
also contribute to the anorexigenic effect of CCK and
TNF-
 
α
 
 by stimulating tryptophan and serotonin
(16,17).
Cerebrospinal fluid amino acids are also implicated in
peripheral and central appetite control. Centrally amino
acids can act as neurotransmitters or precursors of
neurotransmitters inducing hunger or satiety (18). The
final product of these stimuli, catecholamines and
serotonin, represent the ultimate mediators in the
hypothalamic regulation of feeding. Catecholamine
synthesis is influenced by brain levels of its precursor,
tyrosine, while serotonin is locally synthesized from its
precursor, tryptophan. Increasing brain serotonin activ-
ity is highly important in appetite reduction. Tryptophan
concentration in cerebrospinal fluid is determined by
BCAA plasma concentration, which compete with
tryptophan for brain entry (18,19). Therefore two factors
play a pivotal role, the concentration of free tryptophan
(not bound to albumin) (FTRP) and the molar ratio
between FTRP and BCAA.
Nitric oxide (NO), an endothelium-released factor
synthesized from L-arginine by a specific synthase
(NOS), also participates in hunger-satiety control.
Interesting observations have demonstrated an interac-
tion between brain NO levels and serotonin synthesis
(20). Brain NO inactivates brain tryptophan hydroxylase
(TPH), decreasing brain tryptophan and subsequently
serotonin and catecholamine levels (21).
On the other hand, high brain leptin and a low NPY
concentration stimulate a recently described appetite
suppression pathway, the menocortin pathway. By stimu-
lating 
 
α
 
-melanocyte-stimulating hormone (
 
α
 
-MSH)
and inhibiting a powerful central orexigen, the agouti-
related protein (AgRP), this pathway has been demon-
strated to induce an important reduction in food intake
(22).
With this summary in mind, we can now review
appetite regulation in uremia.
 
Appetite Regulation in Uremia
 
Even under normal conditions, appetite regulation is a
very complex phenomenon; the uremic status produces a
still greater degree of complexity. In uremia, multiple
factors that are present cause a variety of EBDs. These
factors include disorders in adipose tissue, gastrointes-
tinal and neuropeptides, and the central nervous system
(Fig. 1). Table 1 lists the neuropeptides implicated in
food intake regulation. Table 2 shows the potential
causes of EBDs in dialysis patients.
 
Anorexigen/Orexigen Imbalance
 
Dialysis patients have higher than normal CCK
plasma levels, possibly due to renal retention or hyper-
production (23,24), while NPY plasma levels are normal
or low in anorexic peritoneal dialysis (PD) patients.
Recent studies have shown that CCK increases hypotha-
lamic serotoninergic activity (via tryptophan pathway),
an effect that NPY usually blocks, inducing hunger (18).
In uremia, the balance of these interactions favors an
anorexic effect (Fig. 2).
Accumulation of endogenous NO inhibitor, asym-
metrical dimethyl-L-arginine (ADMA), has been
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described in uremic patients (25). Experimentally the
administration of L-NAME (NO inhibitor) increases
blood pressure and brain serotonin concentration,
induces gastric distention, and increases and facilitates
oxidation of L-arginine to ornithine (20).
Leptin, produced by adipocytes, regulates body fat
mass through a central satiety effect. Hyperleptinemia
has been described in uremia, possibly due to uremic
retention, hyperproduction, or both (26). It has been
suggested that leptin might be involved in malnutrition
in dialysis patients. Leptin induces appetite suppression
by reducing hypothalamic NPY levels by increasing
sympathetic activity and hyperinsulinemia (27).
Consistent with this hypothesis is the sympathetic
hyperactivity (i.e., dopamine, norepinephrine, serotonin)
described in uremic patients (28). Moreover, in rats, the
injection of leptin decreases brain neural nitric oxide
synthase (nNOS), thyrotropin-releasing hormone, and
corticotropin-releasing hormone (CRF) mRNA in
paraventricular and supraoptic nuclei, with the conse-
quent increase in diencephalic serotonin content (29).
In HD patients, high plasma levels of another import-
ant central anorexigen, 
 
α
 
-MSH (30), have recently been
described.
 
Particular Characteristics in Dialysis Patients
 
In PD, the use of glucose or amino acid dialysate
makes patients particularly sensitive to the influence
of appetite regulation mechanisms. The peritoneum
provides a rapid way for these elements to reach the
bloodstream (7,8). Furthermore, abdominal distention
induced by peritoneal fluid and high osmolality may
cause food intake disregulation (31). However, an
increase in intragastric pressure has not been demon-
strated in these patients (32).
Fig. 1. EBDs result from abnormalities in gastrointestinal peptides,
adipose tissue, or central nervous system appetite modulators.
TABLE 1. Neuropeptides implicated in food intake control
Molecules
Regulated by 
adiposity signals
Situation in 
uremic patients
Orexigen
NPY Down-regulation Variable (23,63,70)
AgRP Down-regulation Not studied
MCH Down-regulation Not studied
Hypocretin 1 and 2 Down-regulation Not studied
Galacin ? Not studied
Norepinephrine ? Not studied
Ghrelin ? Elevated (*)
Anorexigenic
α-MSH Up-regulation Elevated (30)
CRH Up-regulation Normal or elevated (63)
TRH Up-regulation Not studied
CART Up-regulation Not studied
IL-1β Up-regulation Elevated (14,23,63)
TNF-α Up-regulation Elevated (14,23)
Urocortin ? Not studied
Glucagon-like peptide 1 ? Not studied
Oxytocin ? Not studied
Neurotensin ? Not studied
Serotonin ? Elevated (39,41–43)
CCK ? Elevated (23,24)
PYY ? Not studied
Ghrelin ? Elevateda
NPY, neuropeptide Y (we found relatively low NPY values in anor-
ectic PD patients); AgRP, agouti-related protein; MCH, melanin-
concentrating hormone; α-MSH, α-melanocyte-stimulating hormone;
CRH, corticotropin-releasing hormone; TRH, thyrotropin-releasing
hormone; CART, cocaine and amphetamine-related transcript; CCK,
cholecystokinin; PYY, polypeptide YY.
aUnpublished data by our group.
 
TABLE 2. Causes of EBDs in uremic patients
 
Taste abnormalities
Acuity
Metal flavor
Dry mouth
Gastric phase
Disturbances in peripheral and autonomic nervous system 
(axonal vagus nerve degeneration)
GIT motility disorders associated with peptide, TNF-
 
α
 
 or 
uremia per se, and diabetic gastropathy
Abdominal discomfort in PD patients
Gastric distention associated to NO deficiency (accumulation 
of ADMA)
Postabsorptive phase
PD solution based on glucose or amino acids 
(peritoneal absorption)
Inappropriate diets (rich in carbohydrates)
Hepatic phase
Disorders in metabolic hepatic glucose (increase in 
glycogenolysis and decrease in gluconeogenesis)
High cytokine plasma levels decreasing hepatic ATP 
production
Central (brain) phase
High plasma levels of satietins: peptide (CCK, glucagon, 
insulin, leptin, cortisol release factor, pancreatic 
polypeptide, leptin, 
 
α
 
-MSH), cytokines (TNF-
 
α
 
 and IL-1), 
lower zinc, and possibly NPY
 
a
 
Lower NO synthesis (accumulation of ADMA)
High FTRP producing an increase in serotonin synthesis by 
NO deficiency
Imbalance in brain amino acids (high FTRP:BCAA ratio)
Fat store metabolism
Insulin resistance (leptin, resistin, fatty acids, TNF-
 
α
 
) 
which induces abnormal regulation of intracerebral NPY
Other causes: low doses if dialysis, infections, medications, 
depression, poverty, alcohol abuse, rigorous diet before 
starting dialysis
GIT, gastrointestinal tract; TNF-
 
α
 
, tumor necrosis factors 
 
α
 
;
PD, peritoneal dialysis; NO, nitric oxide; ATP, adenosine tri-
phosphate; CCK, cholecystokinin; 
 
α
 
-MSH, 
 
α
 
-melanocyte-stimulating
hormone; IL-1, interleukin 1; NPY, neuropeptide Y; FTRP, free
tryptophan; BCAA, branched-chain amino acids.
 
a
 
Another group found high plasma levels (70). In our study (23),
NPY was normal in 80% of the cases; relatively low values were
found in anorectic PD patients.
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Peripheral and autonomic nervous system dysfunction
with axonal vagus nerve degeneration is a scantily
studied complication of uremia (33). It has the potential
to inhibit gastrointestinal motility with an adverse effect
on appetite.
 
Dialysis Dose
 
Many studies have shown a strong correlation
between 
 
Kt/V
 
urea
 
 and daily protein intake, though
residual renal function may be more important for
appetite than dialysis dose (34). These correlations
suggest that one or more molecules that inhibit appetite
accumulate in dialysis patients. However, the clinical
correlation between dialysis dose and the presence of
EBDs is poor (35–38). Therefore it is impossible to
account for the EBDs of uremia exclusively through low
doses of dialysis.
 
Amino Acid Profile Disorders in Uremia
 
Brain serotonin overproduction may be the final
common pathway involved in the genesis of EBDs in
dialysis patients (36). Serotonin is the final element in
hunger genesis; low levels induce hunger, while with
increased levels satiety appears (18,19,21,39,40). In
uremic patients, high plasma and brain levels of
tryptophan, the amino acid precursor of serotonin, have
been repeatedly reported. Increases in plasma aromatic
amino acid concentration (including tryptophan) and
reductions in neutral amino acids (consequently increas-
ing the FTRP/BCAA ratio) have also been reported in
this population (40–43) as well as in cirrhotic patients
(44). The high plasma and intracerebral concentration of
FTRP and, as a consequence, serotonin, increase the
serotonin/dopamine ratio. In uremia, this phenomenon
is perpetuated by numerous factors including high
concentrations of IL-1, TNF-
 
α
 
, CCK, leptin, catecho-
lamines, insulin, interdialysis fluid overload releasing
cytokines, metabolic acidosis, and low levels of NO
induced by high ADMA concentrations (Fig. 3).
These disturbances probably induce a poor response
to peripheral appetite-stimulating signals. The clinically
variable expression of uremic anorexia could be the result
of different combinations of changes in amino acid
profiles and peripheral appetite modulators (CCK,
NPY, leptin, cytokines, and NO). Consistent with our
tryptophan/serotonin disorders hypothesis, Hiroshige
et al. (45) gave BCAA to malnourished HD patients and
observed an improvement in appetite and nutritional
status.
 
Inflammation
 
Tumor necrosis factor 
 
α
 
 and IL-1, elevated in the
plasma of dialysis patients with anorexia and malnutri-
tion (23), interfere with the mechanism regulating the
plasma tryptophan pool. Inflammatory molecules oxid-
ize BCAA, increasing FTRP, which in turn facilitates
tryptophan entry into the brain and serotonin produc-
tion (13,18,46). TNF-
 
α
 
 also decreases gastrointestinal
motility, another potential mechanism inducing anorexia
(47). At the same time, TNF-
 
α
 
 decreases NOS levels
(through selective destabilization of mRNA transcrip-
tion) and increases sympathetic activity inducing anor-
exia (48). Thus uremic NO deficiency could be another
cause of anorexia via inactivation of brain TPH (21).
Another interesting hypothesis proposed by Stevinkel
et al. (49), the malnutrition, inflammation, and athero-
sclerosis (MIA) hypothesis, suggests that anorexia results
from inflammation. They propose two specific forms of
malnutrition: MIA type I with normal or low serum
albumin, usually absent comorbidity and inflammatory
markers, low food intake, normal resting energy expen-
diture (REE), increased oxidative stress, and decreased
Fig. 2. Imbalance between anorexigen versus orexigen sub-
stances in uremia status. CCK, cholecystokinin; CRF, corticotropin-
releasing hormone; TNF-α, tumor necrosis factor α; IL-1, interleukin
1; GIP, gastric inhibitory peptide; NO, nitric oxide; FTRP, free
tryptophan; NPY, neuropeptide Y; gherlin: elevated (Aguilera et al.,
unpublished data).
Fig. 3. Tryptophan/serotonin disorder hypothesis. CCK, cholecysto-
kinin; IL-1, interleukin 1; TNF-α, tumor necrosis factor α; TRP,
tryptophan; LNAA, large neutral amino acids; BCAA, branched-
chain amino acids; NO, nitric oxide; NPY, neuropeptide Y; NOS,
nitric oxide synthase; nNOS, neural nitric synthase; ADMA, asym-
metric dimethyl-L-arginine; CSF, cerebrospinal fluid; TRH, tryptophan
hydroxylase; α-MSH, melanocyte-stimulating hormone; AgRP (hypocretin),
agouti-related protein.
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protein catabolism; it is potentially reversible with
dialysis and nutritional support. Type II is associated
with low albumin, high comorbidity and inflammatory
markers, low or normal food intake, elevated REE,
markedly elevated oxidative stress, and increased protein
catabolism; it is not reversible with dialysis or nutritional
support.
Our observation that elevated cytokine levels are
associated with anorexia and malnutrition in PD patients
is consistent with the MIA hypothesis (23). Moreover,
TNF-
 
α
 
 can inhibit hepatic albumin gene expression
(contributing to dialysis protein malnutrition) and
induce systemic acidosis and muscle mass wasting with
structural protein breakdown (22,50,51). Also support-
ing the MIA hypothesis are our findings in a group of PD
patients suffering from anorexia and 
 
Helicobacter pylori
 
infection (52). These patients showed high plasma
cytokine levels and low anorexigen substances and
residual renal function (RRF). After 
 
H. pylori
 
 eradica-
tion, appetite improved, orexigen and biochemical
nutritional markers increased, and cytokine levels
decreased. Another group of patients having 
 
H. pylori
 
infection without anorexia appeared to be protected
from the cachectic actions of cytokines by their RRF.
 
Evaluation of EBDs in Dialysis Patients
 
The evaluation of appetite should take into account
cultural and social considerations, such as food prefer-
ences, gender, and habits. To quantify appetite, ques-
tionnaires utilizing scales on eating motivation and diet
can be utilized. The appetite of dialysis patients has been
of little interest to those studying appetite in general, as
well as those studying nutrition in ESRD patients. For
these reasons we felt prompted to explore the area of
appetite in dialysis patients.
 
Eating Preference and Refusal 
in Dialysis Patients
 
By diet survey, we studied eating preferences and food
intake in 48 PD patients and 36 healthy subjects from our
region, matched for age and gender (Aguilera A, et al.,
unpublished data). Dialysis patients showed a universal
trend toward carbohydrate preference and red meat
refusal (veal, lamb, pork) relative to healthy people.
White meat (poultry, turkey, fish) was better accepted
among patients. They confessed to a marked attraction
to citrics and strong flavors in general. Similar findings
have been reported by Dobell et al. (53). Other authors
(54) have demonstrated taste abnormalities (including
bitter impairment in PD patients and a salty taste in HD
patients) associated with EBDs.
Taste is an important factor that regulates food
preference and the amount of food eaten (55). In several
EBDs, taste disorders and meal flavors have been
identified as risk factors for decreasing food intake and
changing food preferences (56,57). The influence of taste
abnormalities on EBDs in uremic patients has not been
studied. We have seen that in patients with a clearly
insufficient dialysis dose (typically with uremic halitosis),
taste abnormalities (acuity, metal flavor, and dry mouth)
undoubtedly play a role in the quantity of food consumed.
Some eating preferences have been related to serum
levels of peptide appetite modulators. In particular, high
CCK levels are associated with early satiety for carbo-
hydrates (58). Little information is available on modu-
lators of protein intake. Furthermore, none of these links
have been considered in dialysis patients.
 
Eating Motivation
 
Eating motivation can be evaluated through an eating
motivation scale (visual analog scale [VAS]) (59) that has
been validated for dialysis patients (31,60,61). The VAS
includes five questions which are answered at least 4
hours before (in fasting conditions) and immediately
after eating. It measures desire, hunger and fullness,
prospective consumption, and palatability. The results
are measured on a scale from 0 to 100, added, and divided
by five, giving a score. Values greater than 60 (before
eating) are considered normal in a healthy population
(52,59). The VAS has successfully been used in uremic
patients (31,60,61). Wright et al. (62) recently published
another model to evaluate appetite disorders in HD
patients.
Table 3 shows the results of the VAS in different
groups of dialysis patients suffering from EBDs. Moti-
vation to eat was significantly lower in patients with
uremic anorexia than in asymptomatic or obese patients.
Obese patients show the highest eating motivation value,
the highest food intake, and the highest early and later
peaks of NPY (explaining hunger sensation). Our data
on the VAS have been validated by the significant
correlation between greater values of the scale and higher
NPY (range 0.51 to 0.55) and lower CCK (range 
 
−
 
0.43 to
 
−
 
0.66) plasma levels. Notably the metabolic disorder
caused by CCK- and NPY-releasing abnormalities in
uremic status is not expected to be correct by the current
renal replacement therapies.
 
Diet Survey
 
We have determined mean daily dietary intake from
individual 24-hour food records over a 3-day period in
68 patients on PD and 54 on HD. Daily calorie, carbo-
hydrate, lipid, and protein intakes were calculated for
each patient using a commercially available computer
software (Wander; Sandoz Nutrición, Barcelona, Spain).
Types of macronutrients ingested and the most frequent
(preferred) macronutrients were estimated by expert
personnel. In general, PD patients showed a lower
daily food intake (kcal/day) than those on HD
(1867.6 
 
±
 
 332.3 versus 2173 
 
±
 
 297, 
 
p
 
 < 0.05). How-
ever, when we included glucose absorbed by peritoneum,
PD patients showed a higher caloric intake than those on
HD (2380.6 
 
±
 
 274 kcal/day, 
 
p
 
 < 0.05). These differ-
ences were mainly based on carbohydrate intake: PD
patients (245.5 
 
±
 
 43.9) versus HD patients (186 
 
±
 
 38
kcal/day) (
 
p
 
 < 0.05). The protein intake was also
significantly lower in PD versus HD patients (77.5 
 
±
 
 16.1
versus 89.3 
 
±
 
 12, 
 
p
 
 < 0.05). Our results highlight the
negative effect of peritoneal glucose absorption, inducing
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satiety and inhibiting protein intake. Table 3 shows the
daily food intake in patients with EBDs on PD. Anorexic
patients showed a severe lack of eating motivation and
the lowest food and protein intake.
We have had good results using these instruments
in different studies (52; Aguilera A, et al., unpublished
data).
 
Biochemical Appetite Modulation in Uremia
 
The list of factors influencing appetite in uremia
(Fig. 2) show a clear trend to ‘‘incline the balance’’ toward
anorexia. The high plasma levels of several anorexigen
substances including CCK, insulin, glucagon, leptin,
anti-NO activity, cytokines, tryptophan-serotonin, and
others (14,23,27,30,39,43,48) probably cannot be com-
pensated for by high plasma levels of ghrelin (Aguilera
A, et al., unpublished data) and the normal or low NPY
plasma levels (23). However, there is quite a substantial
disparity among patients in their loss of appetite.
This observation led us to perform a study (62; Agui-
lera A, et al., unpublished data) to examine appetite
modulators in dialysis patients. We divided our patients
into three groups: anorectics, obese with a tendency to
bulimia, and patients without EBDs. We determined
serum appetite modulator substances at baseline and
30, 60, and 90 minutes after a standard food stimulus
(Fresubin; Fresenius, Spain; with 750 cc, 750 kcal, 17 g
of carbohydrate, 7.5 g of protein, 5.8 g of fat, and 79 ml
of water). Eating motivation was evaluated by the VAS
(59). Healthy controls showed an early peak of NPY,
with hunger persisting 60 minutes after food stimuli. In
contrast, patients with anorexia showed a higher satiety
before and after eating, and a low desire for and pleasure
from eating. At baseline, anorectic patients showed high
levels of C-peptide, CCK, IL-1, TNF-
 
α
 
, and gastric
inhibitory peptide (GIP). These anorexigens showed an
early peak that remained elevated during the observation
period. NPY levels were low without an early peak after
eating. In fact, the NPY stimulation curve was flat, with
levels decreasing to values lower than baseline at 90
minutes in association with less appetite. The early plasma
peak of CCK may explain the early satiety of these
patients, also demonstrated by the VAS (63). The obese
group showed higher baseline NPY levels, lower levels
of anorexigens, and a prolonged hunger sensation meas-
ured by VAS compared with uremics not suffering from
EBDs and with anorectic patients (63).
Hyperleptinemia and low nitrate (NO
 
3
 
) values are also
anorexigen agents. According to our results, leptin is an
anorexigen only at baseline, not after food intake. NO
 
3
 
was lower in all studied patients relative to controls (63;
Aguilera A, et al., unpublished data).
The change in NPY and insulin levels after food intake
were parallel in all patients, but in obese patients they
were accompanied by a premature and prolonged hunger
sensation. The high insulin levels reflect the carbohydrate
intolerance in uremia (and in some cases, obesity). We
postulate that the abnormal secretion of NPY in obese
patients may be conditioned by peripheral insulin
resistance (63).
 
Proposal for Classification of EBDs in Uremic 
Patients
Uremic Anorexia
 
Diagnostic Criteria for Anorexia.
 
In previous
studies we have defined anorexia as low eating motiva-
tion (personal interview and VAS < 60) (52,63), low
food intake (daily dietary assessment < 30 kcal/kg/
day), and low nutritional markers (64).
 
Classification Depending on the Period of 
Appearance.
 
Early anorexia appears in the first
months of dialysis. It is generally associated with a low
dialysis dose or, on some occasions, with systemic
inflammation. The treatment required is an increase in
the dialysis dose, nutritional support, and identification
and treatment of any inflammatory disorders. Late
anorexia generally appears in patients who have received
long-term dialysis. These patients are often anuric and
may have other complications of uremia. Any inflamed
organ (including anuric kidneys) may be a source
of cytokines with anorexigen and cachectic actions; thus
TABLE 3. Eating motivation measured through the VAS in PD patients suffering from EBDs
VAS
Anorectic 
(n = 12)
Obese 
(n = 12)
Asymptomatic 
(n = 18)
Controls 
(n = 10) p
Diet survey (kcal /day) 1277 ± 467.4 (a,b,c) 2320 ± 179.4 (a) 2006 ± 351 (b) 2089 ± 339 (c) (a) < 0.01, (b,c) < 0.05
Proteins (kcal /day) 63 ± 18 (d)  85.7 ± 16.6 (d)  83.8 ± 13.7  74.5 ± 21.8 (d) < 0.05
Desire to eat before lunch 60 ± 6.1 (e,f )  76.6 ± 6 (e)  67.8 ± 6.9  72.8 ± 3.9 (f ) (e,f ) < 0.01
Desire to eat after lunch  8.6 ± 2.2 (g)  21.6 ± 4 (g)  13.2 ± 5  13.5 ± 8.5 (g) < 0.05
Hunger before lunch   60 ± 6.1 (h,i,j)  78.3 ± 6 (h)  68.6 ± 4.7 (i)  74.3 ± 4.5 (c,j) (h) < 0.001, (i,j) < 0.01
Hunger after lunch     8 ± 4.4 (k,l)  21.6 ± 4 (k)  12.8 ± 5.5  17.1 ± 4.8 (l) (k,l) < 0.01
Fullness before lunch   28 ± 8.4 (m,n)  18.8 ± 2.5  12.5 ± 4.2 (m)  11.8 ± 4.1 (n) (m,n) < 0.01
Fullness after lunch   81 ± 5.4 (o)  59.1 ± 19.6 (o,p)     77 ± 5.6     77 ± 5.6 (p) (o,p) < 0.05
Prospective consumption 
before lunch
  59 ± 5.5 (q,r)  78.3 ± 4 (s)  71.4 ± 3.7 (q,s)  75.7 ± 4.5 (r) (q,r) < 0.001, (s) < 0.01
Prospective consumption 
after lunch
6 ± 2.2 (t,u,v)   25 ± 5.4 (t,w)  12.3 ± 2.7 (u,w)  13.5 ± 4.7 (v) (t) < 0.001, (u,v) < 0.01
Palatability 60 ± 7 (x,y,z)   75 ± 5.4 (x)  71.4 ± 4.7 (y)  74.3 ± 5.3 (z) (x,y,z) < 0.01
VAS is measured on a horizontal scale with a maximum value of 100.
(a–x): statistical differences (read in horizontal).
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it is necessary to rule out silent and chronic infections.
The treatment should include anorexigen agents such as
megestrol acetate, anabolic agents such as nandrolone
decanoate (mainly in men more than 55 years old) (65) and
recombinant human growth hormone (hGHr), potential
anticytokine agents (antibodies, anti-TNF-α, thalidomide),
and nutritional support. Steroidal and nonsteroidal anti-
inflammatory drugs are anecdotally suggested.
Classification Based on Levels of Cata-
bolism. The first classification is associated with
hypercatabolism, severe malnutrition, high levels of
inflammatory markers, urea and oxidative stress,
increased REE, and metabolic acidosis. It is nonrevers-
ible with dialysis or nutritional support and represents
the type II MIA syndrome. Recently the administration
of pentoxifylline, an anti-TNF-α agent, decreased whole-
body proteolysis in uremic patients (66).
The second classification has no associated hyper-
catabolism, with normal or low serum albumin, uncom-
mon comorbidity, absence of inflammatory markers, low
food intake, normal REE, increased oxidative stress, and
decreased protein catabolism. It is potentially reversible
with dialysis and nutritional support, and represents the
type I MIA syndrome.
Classification Depending on Persistence.
Cyclic anorexia appears sporadically and requires that
acute dental, respiratory, urinary (especially in anuric
patients), old vascular graft, and gastrointestinal infections
be sought. Treatment consists of eradicating any focus of
infection.
Persistent anorexia, usually in long-term dialysis
patients, may be associated with chronic infections
(dental, H. pylori carrier, old vascular access, urinary)
and chronic rejected kidney. It is also important to
consider neoplasia as an etiology. The treatment should
or may include orexigens (megestrol acetate), anabolic
agents (nandrolone decanoate), anticytokine agents (66),
and anti-inflammatory drugs, including steroids; nutri-
tional support as well is required.
Early Satiety
While generally associated with anorexia, it is occa-
sionally an isolated symptom present in patients who do
not meet the full criteria for the diagnosis of anorexia.
Patients show normal eating motivation, but they suffer
satiety after eating a small quantity of food. In our study
of these patients we detected an early (30 minutes after
food stimuli) CCK plasma peak, very different from
healthy controls in whom this peak does not appear. This
finding suggests the potential value of using CCK
inhibitors (proglumide, loxiglumide) prior to mealtime
(67).
Obesity with Malnutrition
Obesity with malnutrition is generally associated with
protein malnutrition (Kwashiorkor-like syndrome) and
is a consequence of high carbohydrate and low protein
intake. It occurs more frequently in PD patients and type
II diabetics, with insulin resistance, dyslipidemia, and
high cardiovascular risk.
Clinically it is characterized by a high body mass
index (BMI). According to the World Health Organiza-
tion (WHO) criteria (68), obesity grade I characterized
by a BMI of 25–30 kg/m2, grade II 30–40 kg/m2, and
grade III greater than 40 kg/m2, low or normal eating
motivation (VAS > 60, low or normal quantities of daily
food intake (by diet survey), and frequently DSM-IV
criteria (69).
In this group of patients, obesity and a high BMI
falsely suggest a good nutritional status. In normal
conditions, abdominal visceral fat accumulation and
female fat distribution are regulated by plasma levels of
sexual hormones, insulin, insulin-like growth factor
(IGF)-1, leptin, fatty acids, as well as disorders in insulin
receptors and the β3-adrenoreceptor system (70,71).
With hyperinsulinemia, abnormalities in insulin recep-
tors, high fatty acids, TNF-α, and leptin plasma levels
produce a vicious circle with more carbohydrate intol-
erance and more insulin production, resulting in a
decrease in the abdominal insulin-lipolytic capacity,
and as a consequence, abdominal obesity (72).
In uremic patients, the mechanisms responsible
for regulating the fat distribution are dysfunctional
(26,28,73–76). For example, there is a uremic-acquired
gene disorder in leptin and a mitochondrial uncoupling
protein called UCP2 that is responsible for fat accumu-
lation in PD patients (77). In HD patients the fat
accumulation in the first year of HD is associated with
malnutrition (78). We speculate that abdominal fat
accumulation in dialysis patients without increased
appetite might be explained through both uremic
hyperinsulinism, hyperparathyroidism (decreasing the
fat-lipoprotein lipase [LPL] activity) (76,79,80) and
acquired fat gene disorders (leptin, β3-adrenoreceptors,
UCP2, LPL, and transforming growth factor [TGF]-β)
(73,75,77,81,82) (Fig. 4).
On the other hand, we have found (63; Aguilera A,
et al., unpublished data) that on some occasions obesity
Fig. 4. Hypothesis about the influence of uremic hyperinsulinism and
the pathogenesis of central obesity with malnutrition. R-HPT, renal
hyperparathyroidism; UCP2, mitochondrial uncoupling protein; LPL,
lipoprotein lipase.
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in dialysis patients may be associated with high food
intake (equivalent to bulimia).We have found plasma
levels of NPY to be high at baseline, with two peaks after
food stimuli. Since insulin is responsible for regulating
NPY release, insulin resistance and large fat stores in
obese patients play an important role in appetite regula-
tion in these patients (Table 1), as has been suggested in
other circumstances (22).
In conclusion, we would like to propose that adipose
tissue is the protagonist in appetite changes induced by
uremia. Uremic carbohydrate intolerance (represented
by elevated plasma insulin levels and mediated by
increased levels of TNF-α, free fatty acids, leptin, and
other molecules of adipose origin) induces different
EBDs. The regulation of the normal set point for
appetite, a result of the equilibrium between central and
peripheral stimuli (peptides, neurotransmitters), is bro-
ken. The variability in these factors in dialysis patients
account for their different EBDs. Uremic anorexia may
be explained by a hypothalamic hyperserotoninergic
state resulting from a high concentration of tryptophan,
peripheral stimuli, and a low levels of branched-chain
amino acids.
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Abstract nPCR in non diabetic patients). Although CCK has a
recognized anorectic effect, this direct associationBackground. Malnutrition has definitely been related
to mortality among dialysis patients. Persistent loss of might be because of an abnormal stimulation of
CCK–glucose feedback (trypsin) due to continuousappetite is one of the major symptoms found in these
patients. It is also well recognized that several sub- peritoneal glucose absorption. This suggests that CCK
could be an immediate food intake marker in PDstances produce anorexia or disorders of the hunger–
satiety cycle in several diseases. The aim of this study patients.
The NPY plasma levels were normal in 33 patients,was to identify the role of anorexigen substances
(TNF-a and cholecystokinin or CCK ) and an orexigen high in 6 and low in 11. Patients with anorexia showed
lower NPY levels than those without. NPY valuessubstance (neuropeptide Y or NPY ) in anorexia and
malnutrition among 55 clinically stable peritoneal dia- greater than 50 pg/ml were directly associated with
higher transferrin, prealbumin, RBP, nPCR and urealysis (PD) patients.
Results. High TNF-a plasma levels were found in KT/V values. Importantly, a negative linear correlation
between NPY and TNF-a was found (r=−0.42, n=41 of 42 patients (97.6%) with a mean of
70.5±32.3 pg/ml. Patients with anorexia (n=11) or 41, P<0.01).
There was no significant relationship between resid-anorexia with nausea or vomiting (n=5) had higher
TNF-a values than patients without these symptoms ual renal clearance and the serum levels of the three
peptides.(75.9±34 vs 52.1±24.5 pg/ml, P<0.05). Eight
patients with a prior diagnosis of acid pylori disease Conclusion. In conclusion, our data suggest that high
TNF-a and low NPY serum levels are associated withshowed higher TNF-a values (87.2±24.3) than 30
unaffected patients (63.6±30.5, P<0.05). TNF-a anorexia. High TNF-a, low CCK and low NPY serum
levels are also related to a poor nutritional status.showed a significant negative linear correlation with
retinol binding protein (RBP) (r=−0.37, n=34, Further research on these circulating substances is
required.P<0.05), and venous pH (r=−0.4, n=42, P<0.01);
also, TNF-a values higher than 65 pg/ml were inversely
associated with transferrin, cholesterol, blood urea Key words: nutrition; peritoneal dialysis; uremic anor-
exia; TNF-a; cholecystokinin; neuropeptide Y; acidosisnitrogen (BUN) and CCK. Patients with prealbumin
levels lower than 30 mg/dl, a BMI lower than 30 kg/m2,
nPCR lower than 1.1 g/kg/day and urea KT/V lower
than 2.2 showed higher serum TNF-a levels. Patients
Introductionwho had been on CAPD treatment for longer periods
showed higher TNF-a values.
High plasma CCK levels were found in 38 of 45 Protein–energy malnutrition has been demonstrated in
patients (84%), mean 45.9±32.3 pg/ml. Patients with 20–40% of patients on maintenance dialysis [1,2].
anorexia had no difference in CCK values compared Malnutrition has definitely been related to high mor-
with those without. A direct association was found bidity and mortality both in hemodialysis (HD) [3]
between CCK levels and some nutritional markers and peritoneal dialysis (PD) patients [4,5].
(albumin, fibronectin, triglycerides, folic acid and Several factors have been associated with a poor
nutritional status: decreased nutrient intake (anorexia,
prescribed diets, sociocultural and economic factors,Correspondence and offprint requests to: Dr R. Selgas, Servicio de
depression and sleep disturbances), decreased nutrientNefrologia, Hospital Universitario La Paz, Castellana 261,
E-28046-Madrid, Spain. utilization, nutrient loss, altered hormonal and enzym-
© 1998 European Renal Association–European Dialysis and Transplant Association
Nutritional parameters in PD patients 1477
(5.4%). The mean period on PD was 30.3±34.8, (1–179)atic function and increased metabolic demand [6 ].
months.Anorexia is possibly one of the most important causes
Anorexia, assessed by an interview with the patient guidedof malnutrition in the uremic state [7]. It is considered
through a 3-day food intake survey, was present in 16a sign of uremic intoxication, associated with dysgeu-
patients, isolated in 11 and associated with nausea/vomitingsia, nausea and vomiting; these are used as clinical in 5. Twenty patients were asymptomatic and 19 referred to
indicators for initiating dialysis and also for inadequate mild occasional gastrointestinal (GI ) symptoms (dyspepsia,
dialysis [8]. However, it is frequent to find patients sporadic abdominal pain, nausea or vomiting and pyrosis).
with adequate dialysis criteria who nevertheless show Forty-three patients (78.2%) had never been diagnosed with
malnutrition associated with persistent and severe GI disease. Of the remainder, eight had been previously
diagnosed with acid pylori disease, two with hiatus herniaanorexia. Although the exact cause of anorexia is
and two with spastic colon and diverticulosis.unknown, several factors have been suggested includ-
Peritoneal ultrafiltration capacity was considered normaling: uremic toxicity, insufficient dialysis, deficient diets,
in 43 patients (800±200 ml/day, using a combination of 1.36gastropathy in diabetics, infection, drugs, psychosocial
and 2.27% dextrose), high in 7 (using most of their bags withand economical factors and, in particular in PD
dextrose 1.36%) and low in 5 patients (requiring at least 25%patients, with abdominal discomfort and glucose of the daily bags with dextrose 3.86%).
absorption through the peritoneal membrane [8].
Several endogenous substances have been related to
satiety–hunger cycle disorders. TNF-a and cholecysto-
kinin (CCK) have been recognized as having an anor- Methods
exigen effect under different conditions. TNF-a is
associated with anorexia in wasting syndromes [9],
For reasons outside our control, not all determinations wereanorexia nervosa [10], rheumatoid cachexia [11] and performed in all patients. Throughout the paper, we expressly
cancer [12]. In dialysis patients, studies on the effects indicate the exact figures for each analysis.
of TNF-a almost never include this recognized con- The following parameters were determined:
sequence [13,14]. (1) Dialysis adequacy: urea KT/V and nPCR (normalized
CCK is an intestinal peptide released by duodenal protein catabolic rate) [5].
(2) Long-term nutritional markers: plasma creatinine,cells in the presence of carbohydrates in intestinal
albumin, cholesterol (colorimetric method, Hitachi 704) andlumen. It has a satiety effect through central and
transferrin by the immunonephelometric method (Boehringperipheral action [15,16 ]. CCK has been implicated in
Nephelometer-Terminal S.A., Spain). Plasma levels of vit-anorexia nervosa [15,16 ], cancer [17], senile [18] and
amin B12 and folic acid (radioimmunoassay), ferritin andalcoholic anorexia [19]. CCK has renal clearance, iron (Hitachi 911) and triglycerides (Hitachi 704). Short- totherefore ESRD patients have high plasma levels medium-term nutritional markers (short half-life proteins)
[20–23]. include plasma prealbumin, retinol-binding protein (RBP),
Neuropeptide Y (NPY ) is the most potent orexigen fibronectin, antithrombin III (AT III ), ceruloplasmin and a-
known in relation to the pathogenesis of obesity [24], 1-antitrypsin analyzed by immunonephelometric methods.
even diabetic obesity [25]. To our knowledge, NPY NPCR, urea nitrogen, phosphorus and potassium were also
considered representative of short-term food intake markers.plasma levels have not been related to uraemic hunger-
Body mass index (weight in kg/height2 in m) was the nutri-–satiety processes.
tional anthropometric method used to evaluate severe obesityThe ultimate aim of this cross-sectional study was
(BMI30).to identify the role played by orexigen–anorexigen
(3) Hunger–satiety cycle parameters (anorexigen–orexigensubstances in uremic anorexia, hunger–satiety regula-
substances).tion and poor nutritional status.
TNF-a plasma levels
Patients Five milliliters of plasma were drawn. Plasma TNF-a was
measured using the enzyme-amplified sensitive immunoassay
(ELISA) performed on micro-titer plates. It is based on theWe studied 55 clinically stable peritoneal dialysis (PD)
patients, 47 on continuous ambulatory peritoneal dialysis oligoclonal system, in which several monoclonal antibodies
are used. The minimum detectable concentration is estimated(CAPD) and 8 on automatic peritoneal dialysis (APD) (2
continuous cycler-assisted peritoneal dialysis (CCPD) and 6 to be 3 pg/ml and is defined as the TNF-a concentration
corresponding to the mean of 20 replicates of the zeronocturnal peritoneal dialysis (NPD)), 21 male and 34 female,
ranging in age from 22 to 86 years (mean 51±14.2). No standard ±2 standard deviations. It is specific as TNF-a
ELISA does not cross-react with TNF-b, IL-1, IL-2 andacute disorders were present during the 2 months prior to
the study. Patients who suffered intestinal, pancreatic and IFN-a, b or c. Normal values ranged from 3 to 20 pg/ml
(Easia Medgenix Diagnostics S.A. Belgium).chronic liver diseases, active infections, neoplasms and
chronic obstructive lung disease were not included. The Fifteen of the 16 anorectic patients, 13 of the 20 asympto-
matic patients and 14 of the 19 with mild GI symptoms hadcauses of chronic renal failure were glomerulonephritis in 12
cases (21.8%), diabetes in 11 (20%), chronic pyelonephritis TNF-a levels determined (42 patients). TNF-a determination
was performed on 30 of the 43 patients without previous GIin 7 (12.7%), polycystic kidney disease in 7 (12.7%),
nephrosclerosis in 7 (12.7%), unknown etiology in 4 (7.2%), disease and on the 12 patients with this antecedent, 8 were
diagnosed with acid pylori disease.systemic diseases in 4 (7.3%) and congenital diseases in 3
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Cholecystokinin (CCK) levels of cholesterol, vitamin B12, ferritin, RBP andfibronectin are all over the normal range. There was
The 26–33 unsulfated fragment was determined (Peninsula no association between anorexia and peritoneal ultra-
Laboratories, Inc.) with an IC50 of 35 pg/100 ml. Specificity filtration capacity or peritoneal glucose load.to CCK 26–33, CCK 33 with a percentage cross-reactivity
100%. Values considered normal were 12–20 pg/ml. CCK
TNF-a plasma levelsdetermination was performed in 15 of the 16 anorectic
patients, 15 of the 20 asymptomatic patients and 15 of the High TNF-a levels were detected in 41 of 42 patients19 patients with other GI symptoms (45 patients). CCK was
(97.6%), with a mean of 70.5±32.3 (18.1–156.3 pg/ml )also studied in 33 of the 43 patients without prior GI
(Figure 1). PD duration was longer in patients withdiagnoses and in 12 with antecedents.
TNF-a levels greater than 65 pg/ml (45.8±42.4 months
in 22 patients vs 23.3±27.2 months in the 20 patients
Neuropeptide Y (NPY) with levels less than 65 pg/ml, P<0.05).
Patients with anorexia or anorexia with nausea orThe method used was radioimmunoassay (Peninsula
vomiting showed higher plasma TNF-a levels thanLaboratories, Inc.). The IC50 was 23 pg/100 ml (normal values patients without GI symptoms (75.9±34, n=15 vswere 20–80 pg/ml ). NPY was determined in 50 of the 55
52.1±24.5 pg/ml, n=13; P<0.05). Non-anorecticpatients studied: 14 of the 16 anorectic patients, 19 of the 20
patients suffering other GI symptoms also had higherasymptomatic and 17 of the 19 patients with other GI
symptoms. NPY was also studied in 38 of 43 patients without levels of TNF-a than asymptomatic patients (81.7±
prior GI diagnoses and in 12 with antecedents. 31.5, n=14 vs 52.1±24.5 pg/ml; n=13, P<0.05).
The statistical study was performed by Student’s t and Higher plasma TNF-a levels were found in eight
Mann–Whitney tests and linear regression analysis. When patients previously diagnosed with acid pylori disease,
linear regression analysis gave no statistically significant (87.2±24.3, n=8) compared with patients without GI
results, a stratified analysis for different values of the three disease (63.6±30.5 pg/ml, n=30, P<0.05).target variables was performed. The appropriate comparative
Table 2 shows the statistically significant differencestest was then applied. The values are expressed as mean±1
for several nutritional parameters according to TNF-SD.
a levels greater and less than 65 pg/ml.
A significant negative linear correlation appeared
between TNF-a and plasma RBP levels (r=−0.37,Results
n=34, P<0.05). A similar situation was observed
between TNF-a and venous pH (r=−0.4, n=42,Table 1 shows the general analytical data, short-,
P<0.01). We found no statistically significant relation-medium-and long-term nutritional markers. Mean
ship between plasma TNF-a levels and the age of the
patients, renal creatinine clearance, plasma albumin,
Table 1. General analytical parameters and short-, medium- and triglycerides, AT III, fibronectin, vitamin B12, foliclong-term nutritional markers in PD patients acid, P, K, creatinine or ferritin.
Parameter Mean±SD n Normal range
Cholecystokinin (CCK) plasma levels
Hemoglobin (g/dl ) 11±1.4 55 10–15 High plasma CCK levels were found in 38 of
Urea (mg/l ) 146.1±38 55 variable
45 patients, mean 45.94±32.28 (3.8–131.5 pg/ml )Potassium (mEq/l ) 4.4±0.7 55 3.5–4.5
Calcium (mg/dl ) 9.5±0.9 55 8.5–10.5
Phosphorus (mg/dl ) 5.5±1.5 55 3.5–6.5
Urea KT/V 2.2±0.5 55 1.8
nPCR (g/kg/day) 1±0.2 55 1
RBP (mg/dl ) 11.1±3.8* 38 3–6
Fibronectin (mg/dl ) 40±15.1* 41 25–40
Prealbumin (mg/dl ) 32.7±9.8 44 10–40
Antithrombin III (%) 100±15.1 38 90–120
Ceruloplasmin (mg/dl ) 26.5±5.5 44 15–60
a-1-antitrypsin (mg/dl ) 248.7±67.6 45 150–350
Venous pH 7.34±0.04 50 7.3–7.4
Cr. Clearance (ml/min) 2.14±2.26 55 variable
Creatinine (mg/dl )† 9.4±2.2 55 variable
Albumin (g/dl )† 3.8±0.5 55 3.5–5
Triglycerides (mg/dl ) 160.6±90 55 40–170
Cholesterol (mg/dl )† 226.2±46.8* 55 90–200
Vitamin B12 (pg/ml ) 785.2±339.4* 52 150–750Folic acid (ng/ml ) 7.5±3.7 52 2–10
Iron (mg/dl ) 63.7±24.2 55 59–145
Ferritin (ng/ml ) 253.1±213.4* 55 50–250
Transferrin (mg/dl )† 255.2±48.1 55 209–389
Fig. 1. TNF-a and cholecystokinin (CCK) mean and individual
plasma levels in this series. Normal range for TNF-a and CCK,*Different from normal range.
†Long-term nutritional markers. 3–20 and 12–20 pg/ml, respectively.
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Table 2. TNF-a plasma levels and nutritional markers levels of 39.9±29.4 (n=25), whereas patients with
plasma albumin levels greater than 3.9 g/dl showed
Marker TNF-a Mean±SD n P levels of 57.5±34.6 pg/ml (n=17, P<0.05). Table 2
(pg/ml ) shows that TNF-a levels greater than 65 pg/ml are
associated with significantly lower CCK levels.
RBP <65 13±4.67 13 <0.05 We found no statistically significant relationship
(mg/dl ) 65 9.6±2.6 21 between CCK and peritoneal glucose load, renal creati-
Transferrin <65 268±52.3 20 <0.05
nine clearance, cholesterol, AT III, transferrin, serum(mg/dl ) 65 236.4±40.1 22
iron and urea KT/V. However, we found higher CCKIron <65 70.8±25.5 20 <0.05
(mg/dl ) 65 54.9±18.9 22 levels in patients with KT/V greater than 2.1
Cholesterol <65 242.4±44.4 20 <0.05 (38.6±22.9, n=23) compared with those with values
(mg/dl ) 65 213.6±41.8 22 less than 2.1 (53.6±39, n=22, P<0.1, within the limitBlood urea <65 158.6±32.7 20 <0.05
of statistical significance).(mg/dl ) 65 131.7±38.3 22
CCK <65 55.5±34.1 20 <0.05
(pg/ml ) 65 36.4±30 22
Neuropeptide Y plasma levelsPrealbumin
<30 (mg/dl ) 91.7±35.8 13 <0.05 Lower than normal NPY plasma values were found in30 62.9±27.9 22
11 patients (22%), normal values in 33 patients (66%)BMIa
and high values in 6 patients (12%). Patients with<30 (kg/m2) 76.5±35 29 <0.001
30 46.1±10 5 anorexia showed lower NPY values (43.2±27.5 pg/ml,
nPCR (g/kg/day) n=14) than patients without anorexia (64.9±25.5, n=
<1.1 79.3±32.6 26 <0.05 19 P<0.05). Patients with GI symptoms also showed1.1 56.1±27 16
lower values (42.8±25.3, n=17) than those withoutUrea KT/V
<2.2 78.3±32.9 27 <0.05 GI symptoms (64.9±25.5, n=19, P<0.05). Patients
2.2 56.3±26.6 15 with prior GI disease showed no significant differences
with respect to non-diagnosed patients.
aNon-diabetic patients. Table 4 shows the relationship between NPY values
and nutritional markers. A direct linear relationship
appeared between NPY and RBP levels (r=0.27, n=(Fig. 1). CCK serum levels showed no relationship
37, P<0.05). The six patients (one diabetic) with NPYwith CAPD duration.
values greater than 80 pg/ml had a shorter PD termAnorectic patients showed no significant differences
(9±10.52 months) than the patients with NPY lessin CCK values compared with asymptomatic patients
than 80 pg/ml (34.1±36.7 months, n=44, P<0.01:(46±36.5, n=15 vs 42±27.7, n=15, n.s.). A similar
nine were diabetics). These differences were maintainedsituation was observed in non-anorectic patients
for non-diabetic patients.suffering other GI symptoms (50±33.7, n=15, vs
The NPY plasma levels had a significant inverse42±27.7, n=15, n.s.) and in patients with prior dia-
correlation with plasma TNF-a levels (r=−0.42, n=gnoses of acid pylori disease (30.5±23.9, n=8, vs
41, P<0.01, Figure 2). The mean plasma TNF-a level48.4±32.6, n=33, n.s.).
was also significantly lower in patients with NPY levelsTable 3 shows the relationship between CCK plasma
greater than 80 pg/ml (33.5±8.9, n=4) compared withlevels and nutritional markers. Patients with plasma
patients with levels lower than 80 pg/ml (74.4±31.9,albumin levels less than 3.9 g/dl showed CCK plasma
n=37, P<0.001). We found no association between
Table 3. Cholecystokinin plasma levels and nutritional markers
Table 4. Neuropeptide Y plasma levels and nutritional markers
Marker CCK Mean±SD n P
(pg/ml ) Marker NPY Mean±SD n P
(pg/ml )
Albumin <34 3.66±0.5 21 <0.05
(g/dl ) 34 3.97±0.4 24 Transferrin <50 238.4±46.9 23 <0.05
(mg/dl ) 50 268.4±48.6 27Fibronectin <30 38.4±13.6 12 <0.05
(mg/dl ) 30 50.1±13.9 22 Prealbumin <50 31.1±10 23 <0.05
(mg/dl ) 50 37±6.9 18Triglycerides <30 148.5±39.8 17 <0.05
(mg/dl ) 30 166.2±65.1 28 RBP <50 9.8±3.3 20 <0.05
(mg/dl ) 50 12.6±4 17Folic acid <30 5.6±1.9 17 <0.01
(ng/ml ) 30 8.6±4.6 26 nPCR <50 0.96±0.17 23 <0.05
(g/kg/day) 50 1.11±0.2 27nPCR (g/kg/day)a
<1.1 36.7±28.6 22 <0.05 KT/V <45 2.03±0.24 18 <0.05
45 2.34±0.57 321.1 56.4±34.3 14
a-1-antitrypsin BMI (kg/m2)a
<30 46.6±27.1 32 <0.05<350 (mg/dl ) 42.6±25.1 32 <0.1
350 102±46.3 4 30 70.6±23.4 8
aFor non-diabetic patients. aNon-diabetic patients.
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Fig. 2. Linear regression analysis: significant inverse correlation between TNF-a and neuropeptide Y plasma levels (r=−0.41, n=
41, P<0.01).
NPY values and renal creatinine clearance, plasma indirect relationships between nutritional parameters
and the circulating levels of these substances.albumin, CCK, AT III, fibronectin, ceruloplasmin, a-
1-antitrypsin, cholesterol, triglycerides, P, K, BUN, TNF-a, is responsible for cachectic and anorectic
effects in wasting syndrome [9–12,29]. Under experi-glucose concentration in dialysate and peritoneal ultra-
filtration capacity. mental conditions, TNF-a administered by the peri-
Finally, Table 5 shows a summary of nutritional and pheral or intracerebral route decreases food intake
dialysis parameters in anorectic and asymptomatic through effects on the hunger center [29,30]. Nine
patients. Notable statistically significant differences are fragments have been isolated, each with different
found in age, PD duration (months), serum albumin, actions. The 69–100 fragment has suppressive effects
AT-III, TNF-a, NPY, nPCR and urea KT/V, this last on food intake [30].
only the case of non-diabetic patients. We found high TNF-a plasma levels in 97.6% of our
patients. Patients with anorexia showed higher levels
than those without. Several reports [13,31] have found
Discussion increased TNF-a plasma levels in non-dialyzed and
PD patients. However, McKenna et al. [32] did not
find high TNF-a production in cultured CAPD patientAnorexia is one of the most frequent symptoms in
mononuclear cells. Methodological differences (plasmadialysis patients. Several factors have been related to
levels instead of biological activity) may in part explainanorexia: middle molecular weight molecule retention
these discrepancies. TNF-a increased synthesis by cells[7,26,27], uremic toxicity [28], metabolic and biochem-
damaged by hypertension, atherosclerosis, cardiomy-ical disorders and abnormalities in cell composition
opathy [33], liver diseases [34] and uremia [13,14,31]and metabolism [20]. The results of the present study
have been shown. Chronic elevated TNF-a levels areconcur with the idea that several plasma substances
more important than acute increments for anorexia(TNF-a, cholecystokinin and neuropeptide Y ), related
induction, this is likely to be due to the short TNF-ato the hunger–anorexia cycle, might also be of impor-
tance in PD patients. This is suggested by direct and half-life (27 min). Plasma concentration peaks are less
Table 5. Differences between anorectic and asymptomatic patients
Parameter Anorectic Asymptomatic
Mean±SD n Mean±SD n P
Age (years) 55.1±15.9 16 45±13.7 20 <0.05
PD duration (months) 42.2±30.8 16 15.4±27.8 20 <0.01
Phosphorus (mg/dl ) 4.8±1.3 16 5.7±1.5 20 <0.1
Albumin (g/dl ) 3.5±0.6 16 3.9±0.3 20 <0.05
Prealbumin (mg/dl ) 28.2±13.3 13 35.2±5.8 15 <0.1
Antithrombin-III (%) 89.5±14.7 11 104.7±12.5 17 <0.01
TNF-a (pg/ml ) 75.9±34 15 52.1±24.5 13 <0.05
NPY (pg/ml ) 43.2±27.4 14 64.9±25.5 19 <0.05
nPCR (g/kg/day) 0.91±0.15 16 1.06±0.2 20 <0.05
Urea KT/V 2±0.32 16 2.3±0.54 20 <0.1
Urea KT/Va 1.91±0.24 12 2.37±0.55 17 <0.01
Cr. Clearance (ml/min) 0.78±1.2 16 3.29±2.2 20 <0.001
aNon-diabetic patients.
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important than stable brain concentrations. Chronic obese patients (BMI<30 kg/m2). A similar observa-
administration of low doses of recombinant-murine- tion was found by Chollet-Martin et al. [43]. A direct
TNF-a causes persistent anorexia [35]. TNF-a might lipolytic effect of TNF-a has been demonstrated [29].
operate in this way in PD patients. TNF-a induced an increase in serum triglycerides over
Long-term PD patients showed higher TNF-a a 10-day period [29], but no significant relation
plasma levels. This relationship has been found in HD between these parameters was found (r=0.22, n.s.).
patients by Herbelin et al. [14]. Although PD patients Another factor involved in dialysis malnutrition is
do not suffer stimulation by HD membranes, a decrease acidosis [44]. Metabolic acidosis is an effect of R-m-
in renal clearance and an increase of synthesis by other TNF-a long-term administration [29,35]. The inverse
conditions [13,14,31–34,36 ] may explain these data. correlation between TNF-a and blood pH (r=−0.4,
Our results show that lower TNF-a values are associ- n=42, P<0.01) agrees with this finding. Acidosis
ated with urea KT/V values greater than 2.2, whereas increases muscle proteolysis in rats via the ubiquitin–
no relationship with residual renal function is demon- proteasome pathway [45]. Other conditions associated
strated, suggesting that dialysis efficacy plays a role in with inflammation, and presumably high TNF-a
TNF-a elimination. values, exhibit catabolism by activating the same
Another TNF-a source is GI tract [37,38]. Our system of protein degradation as acidosis [46 ]. We
patients with prior acid pylori disease had higher TNF- cannot rule out that high TNF-a plasma levels could
a plasma levels. TNF-a may be produced by intestinal represent a chronic inflammatory state as it has been
cells in inflammatory bowel disease [37] and anti-TNF- found in haemodialysis, although not in PD patients,
a monoclonal antibodies have been used for relapse to be related with malnutrition [32,47]. TNF-a seems
treatment in Chron’s disease [38]. Patients with pyloric therefore to contribute to acidosis and malnutrition in
ulcer associated with Helicobacter pylori infection have PD patients.
high TNF-a, IL-1-b and IL-8 production by antral CCK is a GI peptide released by duodenal cells in
mucosa cells [39]. the intestinal lumen in response to protein, fat, acid
If we recognize an anorexigenic effect of TNF-a in and calcium intakes. It stimulates gall bladder contrac-
PD patients, we should demonstrate that the high tion and pancreatic enzyme secretion and inhibits
levels found influence nutritional markers. The negative gastric emptying. Through peripheral and brain recep-
correlation between TNF-a and short-half life plasma tors, CCK causes anorexia by a satiety effect [15–19].
proteins rules out the existence of an increase in acute High CCK plasma levels were found in 84% of our
phase reactants. Plasma albumin, transferrin, choles- patients. The decrease in CCK-33 the fragment renal
terol and creatinine are representative of long-term clearance [21,23] and its longer half-life, 10× that ofnutritional parameters. TNF-a showed a negative rela- CCK-8, may explain this feature [22]. In our patients,tionship with transferrin and cholesterol; transferrin is anorexia showed no relationship with CCK plasmaa marker of energy status and low levels of cholesterol levels. The influence of other factors on CCK release,have been related to mortality [1,2]. However, we
such as peritoneal glucose absorption could explainfound a non-significant tendency in the relationship
this apparent contradiction. Plasma glucose is a nega-between TNF-a and plasma albumin. TNF-a inhibits
tive factor in the feedback of CCK release by exocrinehepatic albumin synthesis in rats, possibly by direct
pancreatic stimulation (trypsin) [48]. In addition, a-inhibition of gene expression [40]. Peritoneal or renal
1-glycoprotein composed of hexoses such as glucose,protein losses and the slower albumin synthesis rate
mannose or galactose, and amino acids have a satietythan that of prealbumin or RBP, may modify this
effect per se [20]. Some studies of anorexia nervosarelationship.
indicate that peak CCK plasma levels, stimulated byPrealbumin, RBP, AT III, fibronectin, ceruloplasmin
food intake, occurred earlier than in normal subjectsand lymphocyte count are medium-term nutritional
(30 min vs 60 min). This finding suggests that highmarkers. There was a statistically significant negative
initial CCK plasma rise may contribute to the abnor-linear correlation between TNF-a plasma levels and
mal perception of satiety [49]. Although we did notRBP. TNF-a values also showed an inverse association
investigate the CCK cycle, the high levels of plasmawith prealbumin levels greater and lower than
CCK and the continuous peritoneal glucose absorption30 mg/dl. Prealbumin and RBP have proved useful in
could induce a loss of the normal CCK–glucose feed-the recognition of moderate and severe malnutrition
back function in PD patients.in PD patients [6 ].
With respect to CCK and nutritional markers, lowerWe also found a negative association between TNF-
CCK plasma levels were associated with malnutritiona levels and early food intake markers (nPCR and
data. The difference was observed with CCK valuesurea nitrogen). An important factor in the genesis of
lower and higher than 30 pg/ml. Plasma albumindialysis anorexia is underdialysis. Several authors have
showed a direct association with CCK levels; levelsobserved transitory improvements of appetite after
greater than 3.9 g/dl were associated with CCK levelsincreasing dialysis dosage [41,42]. According to our
greater than 30 pg/ml. However, as albumin bindsdata, lower urea KT/V values are associated with
CCK, this association could be explained [50]. Theanorexia in non-diabetics and high TNF-a plasma
remaining nutritional parameters (Table 3) were alsolevels (Tables 2 and 5).
Obese patients showed lower TNF-a levels than non- positively correlated with CCK. These features may
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of mortality in patients undergoing hemodialysis. N Engl J Medindicate that CCK plasma levels are a food intake
1993; 329: 1001–1006marker in PD patients.
4. Teehan B, Schleifer C, Brown J, Sigler M, Raimound J. Uremic
Neuropeptide Y (NPY ) belongs to the pancreatic kinetic analysis and clinical outcome on CAPD: A five year
polypeptide family and is involved in drinking and longitudinal study. Adv Perit Dial 1991; 6: 181–185
5. Selgas R, Bajo MA, Fernandez-Reyes MJ, Bosque E, Lopez-eating [51,52] control and in intestinal motility and
Revuelta K, Jimenez J, Borrego F, De Alvaro F. An analysis ofsecretion [48]. It is the most potent orexigen known
adequacy in a selected population on CAPD for over 3 years:to be related to the pathogenesis of obesity [24]. the influence of urea and creatinine kinetics. Nephrol Dial
Thirty-four percent of our patients showed abnormal Transplant 1993; 8: 1244–1253
NPY plasma values (22% lower and 12% higher than 6. Chertow GM, Bullard A, Lazarus JM. Nutrition and dialysis
prescription. Am J Nephrol 1996; 16: 79–89normal ). In uremic patients, the state of NPY plasma
7. Blumenkrantz MJ. Nutrition. In: Daugirdas JT, Ing T, eds.levels is poorly known. Factors related to NPY release
Handbook of dialysis, 2nd edn. Little Brown Edit, Boston,were excluded in our population (inadequate hydration 1995; 284–302
state, no fasting or insulin use, which was postponed 8. Bergstrom J. Appetite in CAPD patients. Perit Dial Int 1996;
16: S181–S184to after sampling in diabetics) [25]. NPY values were
9. Beutler B, Cerami A. Cachectin and tumor necrosis factor arenot related to peritoneal ultrafiltration capacity or
two sides of the same biological coin. Nature 1986; 320: 584–588glucose concentration in PD fluid. An increase in NPY
10. Vaisman N, Hahn T. Tumor necrosis factor alpha and anorexia.
plasma levels has also been reported during hemodia- Cause or effect? Metabolism 1991; 40: 720–723
lysis sessions associated with fluid removal [52] but 11. Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson
H-B, Dinarello CA, Rosenberg IA. Rheumatoid cachexia. J Clinthis factor did not contribute in our patients. Since
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12. Knapp ML, Al-Sheibani-S, Riches PG, Hanham JW, Philipsnic area and kidney are important sources of NPY RH. Hormonal factors associated weight loss in patients with
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Midpeliq Reduces Glucose
LoadNoritomo Itami, Yaushige Tsuji, Yoshio Katsuki, Seiji Ohira
From: Nikko Memorial Hospital, Hokkaido, Japan.
The rate of technique failure is still high in Japan for
peritoneal dialysis (PD) patients. Of the dropouts who
have been treated with PD for more than 6 years, about
half suffer from ultrafiltration failure. That condition
is supposedly related to the bioincompatible aspects
of conventional acidic PD solutions.
In 2001, a neutral-pH, lactate-buffered PD solu-
tion with low glucose degradation products (GDPs),
Midpeliq (Terumo Corporation, Tokyo, Japan), was
developed and began to be used in Japan. After switch-
ing 3 patients from conventional acidic PD solution
to Midpeliq, we observed that 2 patients could then
use lower-glucose PD solutions.
Case 1 was a 42-year-old woman with a 10-year
history of PD. In February 2001, she was switched
from Peritoliq (Terumo) to Midpeliq. One month later,
she complained of dizziness, and her blood pressure
was found to be down to 96/60 mmHg. Post-change
fluid removal increased to 1,481 mL from 1,238 mL
(p < 0.02). Before the solution switch, this patient
exchanged 4 times daily, using 2 L of 2.5% Peritoliq
each time. From 3 months after the solution switch,
she exchanged 3 times daily using 2 L of 2.5%
Midpeliq and 1 time daily using 2 L of 1.35%
Midpeliq. Fluid volume removal stayed almost the
same.
Case 2 was a 52-year-old man with a 9-year his-
tory of PD. In June 2002, he was switched from
Dianeal 4 (Baxter Healthcare, Tokyo, Japan) to
Midpeliq. After the change, his daily drainage vol-
ume increased from approximately 1,500 mL to
2,000 mL. He began to use 2 L of 1.35% Midpeliq
4 times daily instead of 2 L of 1.5% Dianeal 3 times
daily and 2 L of 2.5% Dianeal 1 time daily. At 1 month
after the solution switch, his drainage volume was still
approximately 1,500 mL daily.
Our observations suggest that new, neutral-pH PD
solutions such as Midpeliq might reduce the glucose
load in addition to having low GDPs and fewer toxic
effects on the peritoneum.
Key words
Glucose load, neutral peritoneal dialysis solution
Introduction
The rate of technique failure is still high in Japan for
peritoneal dialysis (PD) patients. Of the dropouts who
have been treated with PD for more than 6 years, about
half suffer from ultrafiltration failure (1). That condi-
tion is supposedly related to the bioincompatible as-
pects of conventional acidic PD solutions. Aspects of
PD solutions that have been considered responsible
for bioincompatibility are low pH, high glucose con-
centration, high osmolality, high lactate concentration,
and presence of glucose degradation products (GDPs).
To correct those drawbacks, a neutral-pH, lactate-buff-
ered, double-chamber technology with a reduced
amount of GDPs, Midpeliq (Terumo Corporation,
Tokyo, Japan; Figure 1), was developed in 2001 and
began to be used in Japan. In many trials and experi-
ences, neutral-pH, lactate-buffered, low-GDP PD so-
lutions—including Midpeliq—have been reported to
have beneficial effects on PD patients.
Given the low pH and high GDPs of many PD
solutions, much concern has developed regarding
glucotoxicity on the peritoneal membrane, because
glucose is supposed to be the principal cause of peri-
toneal membrane damage in long-term PD patients
(2). To reduce the deleterious effects of glucose load
on the peritoneal membrane, the use of non glucose-
based PD solutions has been proposed (3). Little at-
tention has been drawn to the effects of neutral-pH,
lactate-buffered, glucose-based PD solutions with low
GDPs (such as Midpeliq) on reducing the glucose load.
After switching 3 patients from conventional acidic
PD solution to Midpeliq, we observed 2 patients who
were able to use lower-glucose PD solutions. In the
present article, we want to emphasize the reduction in
glucose load offered by neutral-pH solutions, so that
that aspect of treatment won’t be forgotten. In Japan,
production of conventional acidic PD solutions has
been discontinued. Those solutions are being replaced
by neutral-pH, lactate-buffered, glucose-based PD
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FIGURE 1 Composition of, and levels of glucose degradation products (GDPs) in, Midpeliq.
FIGURE 2 Ultrafiltration volumes before and after a switch to
Midpeliq in case 1.
solutions, and, as a result, studies like ours will cease
to appear.
Patients and methods
Case 1
Case 1 was a 42-year-old woman with a 10-year his-
tory of PD. In February 2001, she was switched from
Peritoliq (Terumo) to Midpeliq. One month later, this
patient complained of dizziness. Her blood pressure
had dropped to 90/60 mmHg. The symptoms were
thought to be related to dehydration, caused by too
much fluid removal. She recovered after fluid re-
placement. After the solution switch, her fluid re-
moval had actually increased to 1,481 mL from
1,238 mL (p < 0.001). When her body weight de-
creased, she was advised to use reduced-glucose PD
solutions. From 3 months after the switch, she ex-
changed 3 times daily using 2 L of 0.5% Midpeliq
and 1 time daily using 2 L of 1.35% Midpeliq. Her
fluid removal remained at about the same volume as
that seen when she exchanged 4 times daily using
2 L of 2.5% glucose Midpeliq (Figure 2). Blood
chemistry showed no significant change, including
no change in serum albumin concentration. The
4-hour dialysate-to-plasma creatinine (D/P Cr) at
1 month before the switch was 0.55; at 6 months after
the switch, it was 0.59.
Itami et al.
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FIGURE 3 Ultrafiltration volumes before and after a switch to
Midpeliq in case 2.
Case 2
Case 2 was a 52-year-old man with a 9-year history
of PD. In June 2002, he was switched from Dianeal
PD-4 (Baxter Healthcare, Tokyo, Japan) to Midpeliq.
After the change, his daily drainage volume increased
significantly to 2,037 mL from 1,550 mL. He began
to use 2 L of 1.35% Midpeliq 4 times daily instead of
2 L of 1.5% Midpeliq 3 times daily and of 2 L of 2.5%
Midpeliq 1 time daily (Figure 3). At 1 month after the
solution switch, his daily drainage volume was still
approximately 1,640 mL. Blood chemistry showed no
significant change, although a downward trend in
serum total cholesterol and serum triglycerides was
noted. His 4-hour D/P Cr at 2 months before the switch
was 0.49; 4 months after the switch, it was 0.51.
Discussion
Neutral-pH, lactate-buffered, and reduced-GDP PD
solution was developed to prevent PD dropout owing
to ultrafiltration failure. More patients on PD using
the novel neutral solution are expected to continue
PD longer than before. The less deleterious effects of
the new solution on the peritoneal membrane are
thought to be related to neutral pH and low concen-
trations of GDPs. Although similar observations have
not been reported previously, our observations sug-
gest that the reduction in glucose seen with neutral-
pH, lactate-buffered, glucose-based PD solutions with
low GDPs (such as Midpeliq) might have additional
effects on keeping peritoneal membrane function
stable.
Following the correction of acidic pH and the pres-
ence of GDPs in PD solutions, more attention has fo-
cused on the glucotoxicity of PD solution for the
peritoneal membrane (2). Holmes and Shockley (3)
proposed to reduce the deleterious effects of glucose
load on the peritoneal membrane by using non glu-
cose-based PD solutions. Davies et al. (4) observed
that higher peritoneal glucose exposure caused
changes in peritoneal solute transport with time on
PD. That finding suggested that using reduced-glu-
cose PD solution would make it possible to prolong
peritoneal membrane structure and function.
Our observations suggest that a reduction in glu-
cose load is made possible by the increased ultrafil-
tration volume seen after a change to Midpeliq. The
reason why Midpeliq resulted in increased ultrafiltra-
tion volume as compared with conventional acidic PD
solutions is still unclear. The question of whether new
neutral-pH PD solutions cause increased ultrafiltra-
tion volume after a change from conventional acidic
PD solutions is still not settled. Coles et al. (5) did
not confirm that the use of neutral-pH fluid was asso-
ciated with increased ultrafiltration. On the other hand,
Tranæus (6) noticed that ultrafiltration increased sig-
nificantly from baseline (150 mL for the total 6-month
treatment period) in patients using bicarbonate/lac-
tate–based PD solution. We also observed an incre-
ment in ultrafiltration after a switch to Midpeliq in
2 patients. However, Tranæus did not report that the
new, neutral-pH PD solutions lead to a reduced glu-
cose load owing to the use of lower-glucose PD solu-
tions. That difference between our observations and
his might be attributable to the use of a different, neu-
tral PD solution or to other, unknown factors. We need
further study to clarify the reasons for the increase in
ultrafiltration and the ability to reduce the glucose load
after a change from conventional acidic PD solution
to Midpeliq.
Conclusions
Our observations suggest that new, neutral-pH PD
solutions such as Midpeliq might enable a reduction
in glucose load, in addition to having lower GDPs
and fewer toxic effects on the peritoneum.
Addendum
After a change to Midpeliq, a 3rd patient showed in-
creased drainage volume, but no decrease in glucose
load. At the time of writing (starting from December
2002), that patient has been using 2 L of 1.35%
Midpeliq 3 times daily and 2 L of 2.5% Midpeliq
1 time daily instead of 2 L of 1.35% Midpeliq 2 times
daily and 2 L of 2.5% Midpeliq 2 times daily.
Midpeliq Reduces Glucose Load
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Endothelial dysfunction with atherosclerosis is a rec-
ognized complication of uremic patients. The hypoal-
buminemia of peritoneal dialysis (PD) patients can
induce a hypercoagulable and atherogenic state. In
this study, we investigated the role played by malnu-
trition–inflammation syndrome on endothelial func-
tion markers in PD patients.
We measured markers of nutrition [normalized
protein catabolic rate (nPCR), albumin, prealbumin,
insulin-like growth factor 1 (IGF-1), transferrin, and
cholesterol], markers of endothelial damage and func-
tion [tissue-type plasminogen activator (tPA),
thrombomodulin (TM), von Willebrand factor (vWF),
and NO
3
 (representing NO)], markers of a coagulable
state [fibrinogen and plasminogen activator inhibi-
tor 1 (PAI-1)], markers of inflammation [tumor ne-
crosis factor α (TNFα) and C-reactive protein (CRP)],
and other endothelial injury factors {lipoprotein(a)
[Lp(a)] and homocysteine}. We also performed an
endothelial stimulation test consisting of right-arm
venous occlusion (VO) for 10 minutes. The patients
were divided into four groups according to their clini-
cal atherosclerotic score (CAS).
We studied 45 clinically stable PD patients. At
baseline, statistically significant negative linear cor-
relations were found between albumin and age (r =
–0.54, p < 0.05), albumin and vWF post-VO (r =
–0.54, p < 0.05), and albumin and TM (r = –0.36,
p < 0.05), which are endothelial damage markers and
prothrombotic factors. A positive linear correlation
was seen between albumin and NO
3
 post-VO (r = 0.48,
p < 0.05), indicating a high vasodilatation capacity.
C-Reactive protein and TNFα showed a positive lin-
ear correlation (r = 0.5, p < 0.01). Similarly, TNFα
showed a positive linear correlation with cardiovas-
cular risk markers such as fibrinogen (r = 0.79, p <
0.01), PAI-1 (r = 0.44, p < 0.05), and homocysteine
(r = 0.37, p < 0.05). Creatinine clearance showed a
negative linear correlation with TM (r = –0.36, p <
0.05). Patients with albumin < 4 g/dL showed a lower
tPA ratio, lower NO
3
, and a higher CRP, TNFα, and
Lp(a) than did patients with albumin > 4 g/dL [tPA
ratio: 2.1 ± 1.56 (n = 29) vs. 2.6 ± 2.3 (n = 16), p <
0.05; NO
3
: 47 ± 27 µg/mL vs. 69 ± 33 µg/mL, p <
0.05; CRP: 1.8 ± 3 mg/dL vs. 1.1 ± 1.6 mg/dL, p <
0.05; TNFα: 44.4 ± 16 pg/mL vs. 36.6 ± 21.4 pg/mL,
p < 0.05; Lp(a): 55 ± 39 mg/dL vs. 33 ± 21 mg/dL,
p < 0.05]. Patients with a worse CAS showed higher
homocysteine levels and lower albumin values. Those
relationships were maintained in both periods of the
study. We found no relationships between dialysis dose
and endothelial function markers. In conclusion, mal-
nutrition–inflammation syndrome may contribute to
endothelial dysfunction and, consequently, to
prothrombotic and proatherogenic processes in PD
patients.
Key words
Inflammation, malnutrition, endothelial dysfunction,
cardiovascular risk
Introduction
Malnutrition and cardiovascular complications are the
main causes of morbidity and mortality in dialysis
patients (1). Recently, both processes have been sug-
gested to possibly be part of one large, complex path-
way: malnutrition, inflammation, and atherosclerosis
(MIA) syndrome (2). The syndrome adds to the tradi-
tional cardiovascular (CV) risk factors (hypertension,
Malnutrition–Inflammation
Syndrome Is Associated
with Endothelial
Dysfunction in Peritoneal
Dialysis Patients
Abelardo Aguilera,1 José A. Sánchez–Tomero,1 María A.
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dyslipidemia, smoking, obesity, and sedentary
lifestyle), with inflammation playing a crucial part in
MIA pathogenesis.
Endothelial dysfunction is possibly the starting and
common element of early atherosclerosis (3). It also
is a prominent feature of uremic status (4), and owing
to protein malnutrition, it may induce procoagulant
events (5). Procoagulant status is recognized as being
proatherosclerotic (3–5).
Recently, a strong relationship has been described
between inflammation and endothelial dysfunction in
renal (6) and non renal patients (7). Experimentally,
intermittent inflammatory episodes have been sug-
gested to induce impairment of endothelium-depen-
dent vascular relaxation (8). Moreover, an
epidemiologic association between C-reactive protein
(CRP) and CV events has been accepted (7). Impor-
tant support for the inflammation hypothesis has been
provided by the association between endothelial dys-
function and chronic, silent infection by Chlamydia
pneumoniae, several viruses, or Helicobacter pylori
(9). Furthermore, we found an association between
Helicobacter pylori infection and malnutrition through
anorexia in peritoneal dialysis (PD) patients (10). The
eradication of Helicobacter pylori reduced plasma
levels of cytokines [interleukin 1 (IL-1) and tumor
necrosis factor α (TNFα)] and improved nutrition
status.
Our aim was to establish the association between
endothelial dysfunction, malnutrition, and inflamma-
tion, considering that endothelial dysfunction is the
initial phenomenon in the atherosclerosis pathway.
Patients and methods
We studied 45 clinically stable PD patients, 20 men
and 25 women with an age range of 25 – 86 years
(mean: 55 ± 13.2 years). The mean period on PD was
29.3 ± 28 months (range: 1 – 120 months). No ac-
tive disorders were present during the 3 months be-
fore the study. Patients with recognized endothelial
and active systemic diseases, and those with immu-
nosuppression, were excluded. We also excluded
patients treated with recombinant human erythropoi-
etin, owing to the potential effect of that drug on endo-
thelium (11).
In the 45 patients, the causes of renal failure were
diabetes (n = 11), nephrosclerosis (n = 7), glomerulo-
nephritis (n = 6), polycystic kidney disease (n = 6),
tubulointerstitial disease (n = 6), unknown (n = 6),
systemic disease (n = 2), and congenital disease
(n = 1). Thirty-eight patients had been diagnosed with
hypertension. For medical treatment, 7 patients were
receiving angiotensin converting-enzyme inhibitors;
4 were using calcium channel blockers; 7 were using
other drugs; and 15 were receiving various drug com-
binations. Hypertension was controlled by ultrafiltra-
tion in 5 patients. By echocardiogram, we found
17 patients with mild left ventricular hypertrophy
(LVH), 16 with moderate LVH, and 5 with severe LVH
(Penn convention). No LVH was apparent in 7 pa-
tients. Eight patients used acetylsalicylic acid, and
three, pentoxifylline. Five patients were active smok-
ers; 13 had a past history of smoking; and 27 had never
smoked.
We measured these parameters:
• Dialysis adequacy, by weekly Kt/V urea and nor-
malized equivalent of protein nitrogen appearance
(nPNA)
• Nutrition, by the markers albumin, by the colori-
metric method; cholesterol (Hitachi 704:
Boehringer Mannheim, Mannheim, Germany);
transferrin, prealbumin, and retinol binding pro-
tein, by the immunonephelometric method
(Behring Nephelometer Terminal SA: Behring-
werte AG, Marbus, Germany); and insulin-like
growth factor 1 (IGF-1), by radioimmunoassay
after acid–ethanol extraction (Nichols Institute
Diagnostics, San Juan Capistrano, CA, U.S.A.).
Maximal intra-assay and inter-assay coefficients
of variation were 2.9% and 11.4%, respectively.
The IGF-1 sensitivity was 12.9 ng/mL.
• Inflammation, by the markers CRP {by the
immunonephelometric method [ELISA (Vectastin:
Vector Laboratories, Burlingame, CA, U.S.A.)]}
and TNFα (Easia: Medgenix Diagnostics SA,
Fleurus, Belgium)
• Endothelial function, by venous occlusion test
(VOT), an endothelial stimulation test consisting
of a right-arm venous occlusion {stasis was
achieved for 10 minutes by applying a sphygmo-
manometer cuff inflated to a pressure midway
between the systolic and diastolic values [mean
arterial pressure = ( systolic pressure + diastolic
pressure ) / 2]}; by endothelial factors associated
with endothelial fibrinolytic capacity [tissue-type
plasminogen activator (tPA)] pre-VOT and post-
VOT; by endothelial damage markers [von
Aguilera et al.
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Willebrand factor (vWF), thrombomodulin (TM)];
and by relaxation factor NO (measured as NO
3
concentration) pre-VOT and post-VOT (12)
• Coagulation and CV risk status, by the markers
fibrinogen [inflammatory and procoagulant
marker (by thrombin time method as described by
Clauss)], lipoprotein(a) {Lp(a) [by sandwich-type
enzyme-linked immunoassay (TintElize: Biopool,
Umea, Sweden)]}, and homocysteine (by high-
pressure liquid chromatography)
Blood samples were drawn in resting and fasting
conditions, between 9:00 h and 11:00 h, and were
collected into Vacutainer tubes (Becton–Dickinson,
Mountain View, CA, U.S.A.) containing 0.129 mol/L
sodium citrate. The samples were centrifuged and
tested immediately or stored at –70°C until assayed.
Plasma antigenic to tPA was determined by ELISA
(Coaliza: Chromogenix AB, Mölndal, Sweden); vWF
by Asserachrom (Boehringer Mannheim, Meylan,
France); TM by Asserachrom (Diagnostica Stago,
Asnières, France); and NO
3
 by capillary electrophore-
sis (11). A clinical atherosclerotic score (CAS: I – IV)
was applied to all patients, defining the highest risk
as CAS IV (13). Of the 45 patients, 14 were CAS I,
17 were CAS II, 4 were CAS III, and 10 were CAS IV.
Statistical analysis
Results are given as means and ranges. Comparisons
between groups were performed using the Mann–
Whitney rank sum U-test. Also, we used the Student
t-test for paired and unpaired data.
Results
Table I shows the overall data for the series. We found
high plasma levels of inflammatory markers (CRP,
TNFα), low values for markers of nutrition (albumin,
prealbumin, IGF-1, nPNA), and high plasma levels
of endothelial damage markers (vWF, TM). We also
found low plasma levels of fibrinolytic markers (tPA)
and high plasma levels of other CV risk markers
[Lp(a), homocysteine]. Statistically significant inverse
linear correlations were found between albumin and
age (r = –0.54, p < 0.05), albumin and vWF post-VOT
(r = –0.54, p < 0.05), and albumin and TM (r = –0.36,
p < 0.05). Albumin also showed a positive linear cor-
relation with NO
3
 post-VOT (r = 0.48, p < 0.05) and
a negative correlation with tPA ratio (r = –0.33, p <
0.05).
The inflammatory markers CRP and TNFα
showed a positive linear correlation (r = 0.5, p < 0.01).
Similarly, TNFα showed a positive linear correlation
with CV risk markers such as fibrinogen (r = 0.79,
p < 0.01), PAI-1 (r = 0.44, p < 0.05), and homocys-
teine (r = 0.37, p < 0.05). Finally, TNFα showed a
negative relationship with serum albumin (r = –0.4,
p < 0.05).
Table II shows the status of all of those markers
according to the malnutrition pattern defined by the
Dialysis Outcomes Quality Initiative guidelines (14).
Malnourished patients showed elevated markers of
inflammation and of endothelial dysfunction as com-
pared with patients whose albumin was higher than
4 g/dL. Those differences were not due to differences
in residual renal function, age, arterial pressure, time
MIA Syndrome and Endothelial Dysfunction in PD
TABLE I Overall data
Parameter Mean±SD Normal range
Hemoglobin (g/dL) 10.3±1.9 10–12
Systolic BP (mmHg) 138±17.7 <135
Diastolic BP (mmHg) 74±9.2 <85
CRP (mg/dL) 1.34±2.15 0.5
TNFα (pg/mL) 38.12±20 <20
Creatinine (mg/dL) 9.73±2.7 Variablea
Albumin (g/dL) 3.73±0.47 >4
Prealbumin (mg/dL) 31.4±11.3 >30
IGF-1 (ng/mL) 254±155.5 54–450
Transferrin (mg/dL) 259.8±58 210–390
Cholesterol (mg/dL) 212.5±38.8 150–220
Weekly Kt/V urea 2.21±0.46 >2
Daily nPNA (g/kg) 1.06±0.27 >1.1
PAI-1 (ng/mL) 9.9±7.41 <10
tPA pre-VOT (ng/mL) 8±4.15 1–12
tPA post-VOT (ng/mL) 17.32±11.2 Variable
tPA ratio 2.16±2.7 >2
vWF pre-VOT (%) 221.6±45.6 60–150
TM pre-VOT (mg/dL) 292.9±108.9 14–55
NO
3
 pre-VOT (µmol/L) 53.9±30.7 40–60
NO
3
 post-VOT (µmol/L) 54±30.4 Variable
NO
3
 ratio 0.99±1 Variable
Fibrinogen (mg/dL) 468±106.6 150–350
Lipoprotein(a) (mg/dL) 47.6±35.4 <20
Homocysteine (mmol/L) 37.6±11 5–10
a For dialysis patients.
SD = standard deviation; BP = blood pressure; CRP = C-reactive
protein; TNFα = tumor necrosis factor α; IGF-1 = insulin-like
growth factor type 1; nPNA = normalized equivalent of protein
nitrogen appearance; PAI-1 = plasminogen activation inhibitor
type 1; tPA = tissue-type plasminogen activator; VOT = venous
occlusion test; vWF = von Willebrand factor; TM =
thrombomodulin.
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on dialysis, or adequacy parameters. However, CAS
was a distinguishing parameter, revealing that higher
values were associated with other CV risk factors such
as homocysteine level: CAS I versus CAS II (32.9 ±
8.2 mmol/L vs. 39.9 ± 12.5 mmol/L, p < 0.05), CAS II
versus CAS IV (39.9 ± 12.5 mmol/L vs. 43.2 ±
13.7 mmol/L, p < 0.05), and CAS III versus CAS IV
[42.4 ± 13.5 mmol/L vs. 43.2 ± 13.7 mmol/L, p =
nonsignificant (NS)].
Discussion
Endothelium is an active barrier between vessel and
bloodstream with several important roles, but its lo-
cation makes evaluating its functional integrity diffi-
cult. Still, several markers have been proposed,
including vasoactive dilatation and constriction ca-
pacity evaluated by plasma levels of NO and
endothelin I, and fibrinolytic capacity estimated by
PAI-1 and tPA. Endothelial repair capacity is estimated
by cell turnover markers [vWF and TM (11)].
The markers chosen for the present research con-
firm the existence, in PD patients, of endothelial dys-
function characterized by low fibrinolytic capacity,
disorders in endothelial vasoactive function, and el-
evated plasma markers of endothelial injury (Table I).
All of those features were associated with data com-
patible with inflammatory and malnourished status
(Table II).
Endothelial fibrinolytic system
Fibrinolysis is regulated by plasma concentrations of
PAI-1 and tPA, which have opposing action. Both
regulate plasmin concentration, which activates the
coagulation final pathway. In normal conditions, when
fibrinolysis is activated, tPA transforms plasminogen
into plasmin. Plasmin is degraded in the liver by
PAI-1 (5).
The endothelium-derived fibrinolytic glycoprotein
tPA is released by exercise, VOT, and stimulation with
desmopressin. After stimulation (VOT > 2), tPA val-
ues indicate adequate fibrinolytic capacity (4,11,15).
Patients with severe atherosclerosis or unstable an-
gina have been demonstrated to show low tPA after
stimulation (16). Uremia per se is associated with tPA
disturbances for unknown causes (4,5,11). Recently,
we found that treatment with recombinant human
erythropoietin (rHuEPO) in PD patients is associated
with a dramatic decrease in tPA post-VOT, theoreti-
cally worsening the uremic prothrombotic status (11).
Importantly, in the present research, we found a
clear association between elevated pro-inflammatory
molecules, malnutrition, and a decrease in tPA. In vivo
TABLE II Markers of malnutrition–inflammation syndrome and of endothelial function
Albumin (<4 g/dL) Albumin (⊕4 g/dL)
Parameter (n=29) (n=16) p Value
CRP (mg/dL) 1.8±3 1.1±1.6 <0.05
TNFα (pg/mL) 44.4±16 36.6±21.4 <0.05
Age (years) 59.4±12.48 51.2±11.6 0.054 (NS)
Time on PD (months) 27.4±30.7 35±28.1 NS
Weekly Kt/V urea 2.29±0.55 2.13±0.27 NS
Daily nPNA (mg/kg) 1.3±0.2 1.42±0.4 0.06 (NS)
CCr (mg/dL) 1.9±2 1.67±2.17 NS
Prealbumin (mg/dL) 27.8±9.2 41±11.3 <0.001
PAI-1 (ng/mL) 8.7±3.8 12.6±12 NS
tPA ratio 2.1±1.56 2.6±2.3 <0.05
NO
3
 post-VOT (µmol/L) 46.9±27 68.9±33 <0.05
vWF pre-VOT (%) 245.2±77 220±33 0.061 (NS)
Lipoprotein(a) (mg/dL) 54.7±39 32.7±20.6 <0.05
Fibrinogen (mg/dL) 469.4±136 467±209 NS
Homocysteine (mmol/L) 37.3±12.5 38.4±7.7 NS
TM pre-VOT (mg/dL) 281.8±104 316±119.4 NS
CAS (I/II/III/IV) (7/13a/3/6) (7/4a/1/4) a <0.05
CRP = C-reactive protein; TNFα = tumor necrosis factor α; PD = peritoneal dialysis; nPNA = normalized equivalent of protein nitrogen
appearance; CCr = creatinine clearance; PAI-1 = plasminogen activation inhibitor type 1; tPA = tissue-type plasminogen activator; VOT =
venous occlusion test; vWF = von Willebrand factor; TM = thrombomodulin; CAS = clinical atherosclerotic score.
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and in vitro, cytokines (IL-1 and TNFα) have been
demonstrated to stimulate endothelium, inducing a
profound alteration in fibrinolytic capacity mediated
by PAI-1 (5,6,17). In the present research, we found
no significant differences in PAI-1, indicating that
other mechanisms such as alteration in protein hepatic
metabolism might be determining PAI-1 levels. In
patients with malnutrition and inflammation, liver
protein metabolism disorders have been described
(15). Relative to tPA, stimulation of cultured human
umbilical vein endothelial cells with IL-1 and TNFα
reduces tPA synthesis (18), reducing endothelial fi-
brinolytic capacity. Because tPA can be considered a
pro-inflammatory molecule (15), pre-VOT or post-
VOT elevation of tPA may result in a reduction in the
tPA ratio, inducing procoagulant phenomena.
Endothelial turnover and response to injury
After endothelial damage, vWF is released, stimulat-
ing platelet aggregation (11). High levels of vWF have
been found in various types of endothelial damage.
Von Willebrand factor is considered a true CV risk
factor because it promotes thrombosis (5,15,17). In
dialysis patients, elevated plasma levels of vWF have
been described (11,15,17). Kidneys do not remove
vWF; lack of renal excretion therefore does not affect
its level in plasma (11). Von Willebrand factor is also
an acute-phase reactant; it is increased by cytokines
(15). Our results confirm that high TNFα plasma lev-
els are associated with high vWF levels [245.2% ±
77% vs. 220% ± 33%, p = 0.061 (NS); Table II]. Defi-
nitely, those differences are strong indicators of endo-
thelial damage. In uremia, other factors such as
activation of platelets by hemodialysis filters contrib-
ute to high vWF levels (15,19).
The structural protein TM is released from the
membrane of endothelial cells in injury conditions;
its level represents the quantity of dead cells (15,17).
Because TM is normally excreted by the kidneys, high
plasma levels are found in uremia (11,20). The TM
released into plasma activates protein C to inhibit fi-
brin formation (17). We found no differences in TM
plasma levels between patients with and without in-
flammation. Inflammatory mediators, proteolysis, and
oxidation are well known to induce downregulation
of TM (5,15). However, in cultured cells, stimulation
with high (near-lethal) doses of TNFα induces an in-
crease in TM, representing endothelial injury (5,15).
Another potential impact of inflammation on protein C
occurs through the loss of protein S function and C4b-
binding protein, which worsen procoagulant status
(15).
The most potent vasodilator, NO, is synthesized
by endothelial cells. It inhibits platelet adhesion, re-
lease of mitogenic factors, and proliferation of muscle
vessel cells (12). Deficient NO production with early
atherosclerosis has been frequently reported (21,22).
Administration of recombinant TNFα depressed endo-
thelium-dependent relaxation. Moreover, in cultured
endothelial cells, TNFα administration reduced the
half-life of the mRNA that encodes for NO synthase
(23). We found that the endothelial response to VOT
(elevating NO levels) was lower in the group of pa-
tients with inflammation and malnutrition (Table II).
Another possible explanation for the difference is the
low level of arginine in malnourished patients, given
that arginine is the substrate to NO synthesis.
Lipoprotein(a) and homocysteine are recognized
CV risk factors that are frequently elevated in dialy-
sis patients (5,9). Inflammation causes an increase in
the hepatic synthesis of acute-phase reactants.
Lipoprotein(a) is one of the proteins that induce a
procoagulant status (24). We found no differences
between patients in plasma levels of homocysteine
(Table II), possibly because inflammation is not a risk
factor for homocysteine elevation (5,13,25).
The various in vivo and in vitro effects associated
with TNFα make us think that TNFα is the inductor
molecule in endothelial dysfunction. Supporting that
idea is the fact that IL-6 infusion in a healthy popula-
tion is not associated with impaired endothelial func-
tion (8). Moreover, infusion of albumin only partially
corrects endothelial dysfunction (1). Therefore, we
speculate that a sole molecule, TNFα, may be respon-
sible for the multiple parts of MIA syndrome.
Conclusions
The presence of inflammation is associated with mal-
nutrition, endothelial dysfunction, and procoagulant
and proatherosclerotic status in PD patients.
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The aim of the present study was to establish a rela-
tionship between serum haptoglobin (HTG) concen-
tration, peritoneal dialysis (PD) adequacy, and
nutrition status in PD patients with and without dia-
betes. We measured serum concentrations of HTG, al-
bumin, iron, and cholesterol; platelet count;
transferrin saturation (TSAT); weekly Kt/V; and total
weekly creatinine clearance (CCr) in 60 patients with
and without diabetes who were being treated with
continuous ambulatory PD or automated PD. The
mean serum HTG concentration in PD patients with-
out diabetes (2.5 ± 1.2 g/L) was elevated and differed
significantly from that in PD patients with diabetes
(2.0 ± 1.1 g/L). In patients without diabetes the cor-
relation of serum HTG concentration with serum al-
bumin level was r = –0.330 (p < 0.030), with platelet
count was r = 0.320 (p < 0.040), with serum iron con-
centration was r = –0.450 (p < 0.002), with TSAT was
r = –0.4200 (p < 0.005), and with age was r = 0.337
(p = 0.003). No such relationships were seen in pa-
tients with diabetes. In both subgroups, no dependence
was seen between serum HTG concentration and
weekly Kt/V, total weekly CCr, or serum cholesterol
concentration.
Serum HTG concentration in PD patients without
diabetes may be a valid inflammatory marker. The HTG
serum level displays a significant statistical dependence
on age, platelet count, and markers of nutrition such
as serum albumin level, iron, and TSAT. It does not
depend on markers of dialysis adequacy (weekly Kt/V,
total weekly CCr) or on serum cholesterol concentra-
tion. The serum HTG concentration in PD patients with
diabetes is lower than that in patients without diabe-
tes, and it is not related to examined factors of inflam-
mation, nutrition, or adequacy of dialysis.
Key words
Haptoglobin, diabetes, adequacy of dialysis, nutrition
status
Introduction
End-stage renal disease (ESRD) is characterized by a
high mortality rate (1), higher levels of pro-inflam-
matory cytokines, and increased oxidative stress (2),
all of which also are connected with malnutrition and
atherosclerosis (3). Inflammation predicts poor out-
come in ESRD. The acute-phase response may also
be related to oxidative stress and progressive vascu-
lar injury and consequently may contribute to cardio-
vascular disease (CVD).
Haptoglobin (HTG) is a hemoglobin (Hb)–bind-
ing protein. Hemoglobin is released during erythro-
cyte disintegration. The Hb-HTG complex is rapidly
removed from the circulation. Intravascular hemoly-
sis increases the release of Hb, which in turn reduces
serum HTG concentration. During acute hemolysis,
HTG is totally consumed.
As a Hb-binding protein, HTG provides protec-
tion against the oxidative stress (4) that plays an im-
portant role in the development of diabetic vascular
complications (5). But haptoglobin is also an acute-
phase protein that can rise in response to inflammation.
The aim of the present investigation was to find
any relationship between serum HTG concentration,
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adequacy of peritoneal dialysis (PD), and the nutri-
tion status of PD patients with and without diabetes.
Patients and methods
The 60 patients (36 men, 24 women) in our study had
been on dialysis (54 on continuous ambulatory PD, 6
on automated PD) for a mean of 17 months (median:
12 months; range: 0.5 – 66 months). The age range of
the patients was 18 – 77 years (mean: 53 years). We
divided this group of patients into two subgroups:
those with diabetes [n = 17; mean age: 54 ± 14 years;
treated with PD through 2 – 66 months (median:
11 months)] and those without diabetes [n = 43; mean
age: 55 ± 15 years; treated with PD through 0.5 –
65 months (median: 14 months)].
Serum concentration of HTG was determined by
immunonephelometry (Behring Nephelometer Ana-
lyzer: Behringwerte AG, Marbus, Germany). The fol-
lowing parameters were simultaneously measured:
serum albumin level, platelet count, serum iron con-
centration, transferrin saturation (TSAT), weekly Kt/V,
total weekly creatinine clearance (CCr), and serum
cholesterol concentration. Statistical analysis of the
data [computation of the mean, standard deviation
(SD), variance, kurtosis, and median; comparison of
the observed distribution of variables against the nor-
mal distribution; statistical significance tests for evalu-
ating the discrepancy of the observed data from the
respective theoretical distributions] was performed
using Statistica, version 6.0 (StatSoft, Tulsa, OK,
U.S.A.).
Results
The reference range of serum HTG concentration is
0.3 – 2.0 g/L. This “normal range” was seen in only
25 patients. The mean HTG concentration for the en-
tire group (2.4 ± 1.2 g/L) was above the norm. The
distribution of serum HTG concentration was not nor-
mal in the group of patients under investigation (Fig-
ure 1 histogram; chi-square test: χ2 =14.14; df = 5;
kurtosis = 0.38). Figure 2, in which histograms for
both subgroups are presented (that is, for patients with
and without diabetes), clarifies that finding. The
mean ± SD serum HTG concentration measured 2.0 ±
1.1 g/L (with diabetes) and 2.5 ± 1.2 g/L (without dia-
betes). Figure 3 shows the difference between the
medians of the two subgroups. That difference is sta-
tistically significant. Table I gives the results of the
four nonparametric tests and their significance levels.
Additionally, in the subgroup of patients without
diabetes, significant statistical dependencies
(Spearman test) were noted between HTG concentra-
tion and age, serum albumin level, platelet count,
serum iron concentration, and TSAT (Figures 4 – 8).
Table II shows the Spearman coefficients (r) and sig-
nificance levels. Such dependences were not obtained
in the subgroup of patients with diabetes.
Discussion
In ESRD patients, CVD mortality is 10 – 20 times
higher than in the general population (6). Addition-
ally, 30% – 50% of ESRD patients, including PD pa-
tients, have elevated serum levels of C-reactive protein
Sucharzewska–Tomczak et al.
FIGURE 1 Histogram of the serum haptoglobin (HTG) concentra-
tion (g/L) in the entire group of examined patients.
FIGURE 2 Histogram of the serum haptoglobin (HTG) concentra-
tion (g/L) in the subgroups of patients with and without diabetes.
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(7). A relationship between inflammation, oxidative
stress, and higher frequency of CVD is suggested in
ESRD patients (7,8).
Some recent reports have pointed to the existence
of relationships between inflammation-sensitive
plasma proteins (ISPs: fibrinogen, α1-antitrypsin,
HTG, ceruloplasmin, orosomucoid) and systolic blood
pressure (SBP) or incidence of stroke (9). The depen-
dencies were established in a large cohort of healthy
men with a long follow-up. The authors concluded
that high ISP levels are associated with elevated SBP
and increased risk of stroke. The same authors noted
that hypercholesterolemia, which increases the cho-
lesterol-related incidence of CVD, is associated with
high plasma levels of ISPs (10). Other authors have
examined certain acute-phase proteins (amyloid A,
Haptoglobin, Adequacy, and Nutrition Status in PD
FIGURE 3 Median and range of the serum haptoglobin (HTG) con-
centration (g/L) in patients with and without diabetes.
TABLE I Results of nonparametric tests rejecting the hypothesis
that no difference exists between mean serum haptoglobin con-
centrations in patients with and without diabetes on the given sig-
nificance level p
Wald–Wolfowitz test p=0.040
Kolmogorov-Smirnov test p<0.050
Mann–Whitney U-test p=0.092
Kruskal–Wallis test p<0.010
FIGURE 4 Serum haptoglobin (HTG) concentration (g/L) versus
age (years) in patients without diabetes.
FIGURE 5 Serum haptoglobin (HTG) concentration (g/L) versus
serum albumin concentration (g/dL) in patients without diabetes.
FIGURE 6 Serum haptoglobin (HTG) concentration (g/L) versus
platelet (PLT) count (g/L) in patients without diabetes.
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serum C-reactive protein, plasma fibrinogen, and
serum HTG) as markers for coronary heart disease
(CHD) in a middle-aged male population. In their
conclusion, those authors preferred serum C-reactive
protein as a first-class acute-phase reactant for detec-
tion of CHD (11).
In serum, HTG is a marker of inflammation and
an antioxidant factor (4). In the present study, signifi-
cant differences were seen in the HTG serum level of
patients with and without diabetes. Further study is
needed to explain the reasons for that state of affairs.
In patients with diabetes, an increase in oxidative stress
seems to be responsible for the lower serum concen-
trations of HTG and its behavior (atypical for an in-
flammatory factor, not being correlated with other
markers of inflammation and nutrition).
Conclusions
1. Serum HTG concentration in PD patients without
diabetes is elevated and may be a typical inflam-
matory marker.
2. Serum HTG concentration in PD patients without
diabetes displays a significant statistical depen-
dence on age and other markers of inflammation
and nutrition such as serum albumin level, plate-
let count, serum iron concentration, and TSAT.
3. Serum HTG concentration in PD patients with dia-
betes is lower than in patients without diabetes
and is unrelated to the inflammation and nutrition
factors mentioned in point 2.
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2Background. Endothelial dysfunction (ED) with atherosclerosis is a recognized
complication of uremic patients. The importance of inflammation in the ED
pathophysiology has recently been proposed. The aim of this study was to analyze the
role played by inflammation as starter of ED in peritoneal dialysis (PD) patients.
Methods. During 15 months, all the patients from our PD unit were followed-
up. We determined Nutritional, inflammatory (C-reactive protein (CRP), TNF- and
Vascular cell adhesion molecule-1 (VCAM)) and endothelial function markers at
baseline and during systemic inflammation (SI). Seventeen patients were finally
included due to elevation of CRP by various etiologies (four suffered silent infection by
Helicobacter pylori, four upper respiratory infections and two intestinal bacterial over-
growth ). They were compared with a control group (CG) with 12 PD patients who did
not suffer SI.
A venous oclusion test (VOT) was performed to stimulate the endothelium by
inducing a stasis in the right arm. Endothelial fibrinolytic capacity: tissue-type
plasminogen activator (t-PA) and plaminogen activator inhibitor (PAI). Endothelial
damage markers: von Willebrand factor (vWF), thrombomodulin (TM), and nitric oxide
(NO). Cardiovascular (CV) risk markers: fibrinogen, Lipoprotein(a) and homocysteine
(Hcy). Growth factors: VCAM-1, vascular endothelial growth factor (VEGF),
transforming growth factor- (TGF-) and platelet-derived growth factor (PDGF). After
variable of follow-up time, C-RP and TNF- plasma levels increased.
Results. We found a decrease in albumin, tPA ratio (post VOT/pre-VOT) and
NO3-ratio. PAI, TM, Lp(a) and TGF- Increase. A positive linear correlation between
Hcy and PDGF was found, suggesting a pro-atherogenic environment. CG did not suffer
modifications in no studied parameters.
3Conclusion: In PD patients, systemic inflammation induces endothelial
dysfunction estimated by elevation of endothelial damage markers. Pro-inflammatory
cytokines are deeply associated to elevation of procogulable and proatherosclerotic
mediators in plasma.
Key Words: Systemic Inflammation. Endothelial Dysfunction. Cardiovascular
Risk. Peritoneal Dialysis. MIA syndrome.
Introduction
Endothelial dysfunction (ED) is a common element in atherosclerosis and
hypertension and is considered an independent cardiovascular (CV) risk factor (1). It is
also a prominent feature of uremic status and protein malnutrition (2, 3). ED
intrinsically may induce procoagulant events (4). Procoagulant status is recognized as a
atherosclerosis promoter (1, 3-5).
On the basis that malnutrition and cardiovascular complications are the main
cause of morbidity and mortality in dialysis patients (2), it has recently been suggested
that malnutrition and accelerated atherosclerosis might be part of the same complex
syndrome, the so-called MIA (malnutrition, inflammation and atherosclerosis)
syndrome. MIA syndrome (5) adds to the traditional CV risk factors (hypertension,
dyslipemia, smoking, obesity and sedentary), the inflammation as a central and crucial
part (6). Although a lot of information exists as to the relationship between
inflammation, ED, atherosclerosis and CV complications in renal (6) and non-renal
patients (7), the exact point in the pathogenesis of MIA syndrome remains undefined.
Several questions that need response include whether inflammation is the key and
starting factor responsible for stimulating factors implicated in atherosclerosis cascade,
whether inflammation is a cause or consequence and whether inflammation is a silent
constant or cyclic process.
4The aim of the present study was to define the role played by inflammation as
starting factor for ED, subsequent malnutrition and CV risk, convincing to constitute a
sole syndrome in peritoneal dialysis (PD) patients.
Patients and Methods
During 15 months, we followed-up all patients from our PD unit (n= 68, 17
initiating dialysis) to periodically determine inflammatory, endothelial function and
nutritional markers. All the parameters considered in this study at baseline and when
inflammatory markers showed elevation. Therefore, the sole inclusion criteria was the
elevation of C-reactive protein (CRP) from its baseline level or enhanced over the
normal range, with elevation of one proinflammatory cytokine, along the study. Every
month we also measured inflammatory markers, and if they suffered elevation, we
immediately included the patient and measured endothelial function markers. We
excluded patients with recognized active systemic diseases (systemic lupus, vasculitis or
other active immune disease), as well as those with immunosuppression. We also
excluded patients who started r-HuEPO by its potential effect on endothelium (8).
However, eleven patients using regularly r-HuEPO (range 9-34 months) were admitted.
Study design: Seventeen patients, who suffered elevation of CRP and TNF-
after variable periods of time (1-15 months), were finally selected. Twelve were males
and ten women, with an age range of 25–78 years (53  11.2). We performed a baseline
determination and follow-up of the patients determining periodically every month the C-
RP (figure 1). The timing of the second determinations was just after C-RP showed
elevation.
In regard to study group, the mean period on PD was 28.7  27 months (range 1-
117). The causes of renal failure were nephrosclerosis in five, diabetes in five,
glomerulonephritis in three, polycystic kidney disease in two, tubulointerstitial disease
5in one and unknown origin in one case. Eleven patients had been diagnosed of
hypertension. As medical treatment, five were receiving angiotensin-converting enzyme
(ACE) inhibitors, two calcium channel blockers, and six other drugs or different
combinations. By echocardiogram eleven patients showed mild left ventricular
hyperthrophy (LVH) (Penn convention criteria), five moderate LVH and five severe;
four patients did not show LVH. Five used aspirin and three pentoxifillin. Active
smoking was present in four patients and past history of smoking in seven.
We defined systemic inflammation (SI) as the elevation of CRP and one of the
high sensibility inflammatory markers, TNF- and vascular cell adhesion molecule-1 or
VCAM-1 (9, 10).
We studied the possible cause for systemic inflammation (SI), including
anamnesis, laboratory and image-diagnosis tests addressed by clinical data. As a
consequence, we have diagnosed in four patients silent infection by Helicobacter pylori
(breath test), four patients upper viral respiratory infections, and two intestinal bacterial
over-growth (breath test). We were not able to establish the cause for increment of
inflammatory markers in the remaining patients. The different studied parameters before
and after suffering SI were contrasted, being the patients the control of themselves.
We also included a control group with 12 patients who did not suffer elevation
of inflammatory markers. The different studied parameters were determined at baseline
and between 1 and 3 months later (figure 1).
We determined the follow parameters:
Dialysis adequacy was assessed by weekly urea Kt/V and nPNA.
Peritoneal membrane transport. Urea and creatinine mass transfer coefficients (urea-
MTC and Cr-MTC) were measured using standard method (11). Ultrafiltration (UF)
capacity was calculated by a peritoneal exchange of 4 h using 3.86% glucose.
6Nutritional markers included serum albumin (colorimetric method), cholesterol
(Hitachi 704), transferrin and prealbumin by immunonephelometric methods (Boehring,
Nephelometer terminal SA.: Behringwerte AG, Magnus Germany).
Inflammatory markers were C-reactive protein (CRP) by immunonephelometric
method (ELISA, Vectastin: vector laboratories, Burlingame, CA, USA.), tumor necrosis
factor alpha (TNF-) (Easia: Medgenix Diagnostics SA., Fleurus, Belgium) and
VCAM-1 (Human Quantikine, R & D systems, MN, USA).
Venous oclusion test (VOT) was performed to stimulate endothelium, by inducing a
stasis in the rightarm during 10 minutes applying a sphygmomanometer cuff inflated to
a pressure midway between systolic and diastolic values mean arterial pressure =
(systolic pressure + diastolic pressure)/2 (8).
Endothelial factors associated with endothelial fibrinolytic capacity included tissue-
type plasminogen activator (t-PA) pre-VOT and post-VOT, (ELISA-plasma-t-PA
antigenic coaliza t-PA: chromogenix, Mölndal, Sweden), and PAI (plasminogen
activator inhibitor) levels determined by a commercial monoclonal ELISA (Tintelize,
PAI Biopool, Umea, Sweden). We also calculated t-PA ratio (t-PA post-VOT/pre-
VOT).
Endothelial damage markers were von Willebrand factor (vWF) (asserachrom vWF:
Boehringer Mannheim, Meylan, France), Trombomodulin (Asserachrom TM:
Diagnostica Stago, Asnières, France), endothelial relaxing factor nitric oxide (NO)
measured as nitrate (NO3) concentration pre-VOT and post VOT by capillary
electrophoresis. We also calculated NO3-ratio: (post-VOT/pre-VOT).
Growth factors included vascular endothelial growth factor (VEGF), transforming
growth factor- (TGF-) and platelet-derived growth factor (PDGF), all determined by
ELISA commercial kits (Human Quantikine, R & D systems, MN, USA).
7Other cardiovascular risk markers included serum or plasma levels of fibrinogen
(inflammatory and pro-coagulant marker) (thrombin time method described by Clauss),
lipoprotein-a (Lp(a)) (sandwich-type enzyme-linked immunoassay, TintElize Lp(a);
Biopool, Umea Swede), and homocysteine (Hcy) (high pressure liquid chromatography).
Blood samples were drawn in resting and fasting conditions, between 09:00h and
11:00h and collected into vacutainer tubes (Becton Dickinson) containing 0.129 mmol
of sodium citrate. The samples were centrifuged and tested immediately or stored at –
70ºC until assayed.
Statistic analysis. Results are given as mean ( SD) and range. Comparisons
between groups were performed using “t” student tests for paired and non-paired data,
and simple liner regression analysis was performed to investigate the relationship
between all endothelial function and inflammatory markers. A “p” value less than 0.05
was considered statistically significant.
Results
The 17 selected patients showed Hb 11  0.56 g/dL, systolic blood pressure
(SBP) 130  18 mmHg, diastolic blood pressure (DBP) 80  11.1 mmHg, cholesterol
200.1  38 mg/dL, transferrin 220  36 mg/dL. Table I, shows the baseline data and the
changes suffered by patients prior and during SI. A relatively elevated plasma levels of
inflammatory markers (CRP and TNF-) were found, C-RP 1.19  2.38 mg/dL (range
0.3-5.2), (normal range 0.1-0.6), and TNF- 38  12.9 pg/ml (normal 2-20). These
markers showed an important elevation after variable time, CRP enhanced to 3.8  2.1,
p<0.05, and TNF- to 68.3  16, p<0.01. 17 from the 22 studied patients showed CRP
values into the normal range (0.32  0.18 mg/dL), but only two patients showed normal
8levels of TNF- at baseline (range 12-68 pg/mL).Table II, shows the baseline and the
changes in the same analysed parameters.
In regard to nutritional markers (albumin, prealbumin) and fibronolytic capacity
markers (tPA-ratio, high PAI), they showed values lower than normal. In the right
column, the values of these parameters after detecting the elevation of inflammation
markers are shown. Inflammation was accompanied by a decrease in protein intake
(nPNA), serum albumin and t-PA ratio (Table I).
The same schedule is used in Table II which shows the changes in endothelial
function and damage markers. The increase in NO3-pre VOT, trombomodulin, TGF-
and Lp(a) after the appearance of inflammation markers, is remarkable. Other factors
showed elevation in the limit of the statistical significance.
To establish a relationship among these parameters, we performed a matrix of
regression analysis both at baseline and after systemic inflammation (Table III). The
baseline relationship between PDGF with Hcy and TGF- with Lp(a) showed a
narrowing (r=0.4, p<0.05), (0.6, p<0.05). We also found a negative statistically
significant linear correlation between baseline TNF- and NO3-ratio (-0.3, p<0.05, after
SI : -0.5, p<0.05), baseline TNF- and tPA (-0.5, p<0.05), and positive between
baseline TNF- and VCAM-1 (0.5, p<0.05).
In relation to residual renal function (RRF), the mean CCr was 2.2 ± 2.1 ml/min
at baseline. From 17 studied patients, 12 were anuric and eight showed RRF (CCr= 3.4
 2.1 ml/min). Anuric patients showed some baseline differences in analyzed
parameters:
TNF- and CCr showed a negative statistically significant linear correlation (-
0.4, p<0.05). RRF seemed to represent a special protection in these patients with RRF.
9Although, they showed similar changes in C-RP (1.1  2 vs. 2.2  1.27 mg/dL, p<0.05),
TNF- (31  11 vs. 38.8  7.8 pg/ml, p<0.05), NO3-ratio (1.18  0.21 vs. 1.48  0.25,
p<0.05), tPA (1.9  1.4 vs. 1.55  1.5, p<0.05) than that showed by anuric patients. TM
showed no significant changes (263  42 vs. 276  38 ng/mL, NS). Nutritional markers,
represented by serum albumin was higher in patients with RRF than anurics (3.8  0.38
vs. 3.6  0.4 mg/dL, p<0.05).
Finally, table IV shows the different markers measured in the control group. We
did not find differences in all measured markers.
Discussion
The most important finding of this study is the establishment of a clear and real
link between cyclic or constant episodes of SI with endothelial dysfunction, malnutrition
and CV risk in PD patients.
Defining systemic inflammation (SI) in renal patients is very difficult because
there is not a gold standard marker. One may suggest the CRP, the most used in clinical
trials, but we consider this marker as a molecule appearing in late periods. IL-6 and
TNF- are retained by the lack of renal function in dialysis patients. For instance, in our
series, 17 from 22 patients showed normal levels of CRP and only two showed normal
TNF-α plasma levels. Are these patients suffering SI?. High levels of TNF-α may be the
expression of only a mild grade of renal retention and it is difficult to give it a
representative value of inflammation. We do not know which are the toxic levels of
TNF-α in renal patients?. In a previous study we suggested that a value of TNF-α lower
than 65 pg/ml defined the limit of tolerance, based in clinical manifestations (12).
Therefore, any definition of SI in dialysis patients may be discussed. Finally, we have
adopted the coincidental elevation of CRP and a pro-inflammatory cytokine plasma
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level as definition of SI. This methodology has been used by others (9, 10), who used
the elevation of CRP, IL-6 and MMP-9.
In fact, factors such as the contact of leucocytes with hemodialysis membrane are
able to stimulate the cytokine production with deleterious effects (13). However, in
many cases the elevation of these cytokines are not associated to symptoms and their
tolerance level is not well known (12). CRP is the inflammatory marker mostly used in
clinical trials, but this is at the end of inflammatory molecule cascade (13) and many
early inflammatory presses may by infra-diagnosed.
On the other hand, we have confirmed the baseline existence of endothelial
dysfunction in PD patients, characterized by a low fibrinolytic capacity, disorders in
endothelial vasoactive function and elevated plasma markers of endothelial injury. All
these features were associated with SI, ED and poor nutritional status (Table I-II, IV).
These findings confirm the results of other investigators (5-7).
Low fibrinolytic capacity is characterized by tissue-type plasminogen activator
(t-PA) deficiency. This is an endothelium-derived fibrinolytic glycoprotein released by
exercise, VOT and stimulation with desmopresin. tPA values after stimulation by VOT
(expressed as tPA-ratio), indicate an adequate fibrinolytic capacity (3, 8). It has been
demonstrated that patients suffering severe atherosclerosis or unstable angina show low
tPA levels after stimulation (14). Uremia per se is associated with poor tPA response for
unknown causes (3, 4, 8). Recently, we have found that r-HuEPO treatment in PD
patients is associated with a dramatic decrease in tPA-ratio post-VOT, causing a
theoretical worsening of the uremia prothrombotic status (8). Importantly, we have
found a clear association between elevated pro-inflammatory molecules (TNF-) and a
decrease in tPA-ratio (table I).
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Experimentally, the stimulation of human endothelial cells from umbilical vein
endothelial culture with IL-1 and TNF-, reduces tPA synthesis (15). Since tPA can also
be considered as a pro-inflammatory molecule (15, 16), the spontaneous or post-VOT
elevation of tPA may result in a decrease of tPA-ratio and an increase in PAI levels,
predisposing to coagulant phenomena (3, 4, 8). Effectively, we have found that patients
who suffered SI showed an important decrease of tPA-ratio, although, both tPA-post
and pre VOT showed an increase (Table I). Chia S et al (16), found an increase in
spontaneous tPA after SI and concluded, that SI invokes a protective response mediated
by enhancing endothelial fibrinolytic capacity. However, they did not measure tPA-post
endothelial stimuli (i,e. VOT) which could be a better method to measure tPA-activity
(8).
Another important fibrinolytic inhibitor, the PAI, resulted augmented by
inflammation. It has been demonstrated in vivo and in vitro that cytokines (IL-1 and
TNF-) induce elevation of PAI (4, 6, 17). Moreover, malnourishment and patients with
inflammation, show hepatic acute hyperproduction of half-life proteins such as C-
reactant protein, prealbumin, fibronectin, PAI and others (5-7). Finally, and according to
our results and those shown by longer series (18), the elevation of PAI associated with
inflammation should be considered as a CV risk factor due to the predisposition to
thrombotic events.
Endothelial damage as consequence of injuries is followed by vWF, TM and NO
release (9, 18, 19). The vWF release causes stimulation of platelet aggregation and
thrombus formation (2, 8, 17). In dialysis patients, elevated vWF plasma levels have
been found spontaneously (8, 17). However, the kidneys do not remove vWF, and the
lack of renal excretion should not affect plasma levels (19). vWF is also an acute phase
reactant whose synthesis is increased by cytokines (20). In our study, no changes were
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found in vWF levels after SI (table II), suggesting that other uremia-related factors
(thrombin levels, fibrin monomers, endotoxins, complement, or some renal disease as
glomerulonephritis), regulate vWF plasma concentration (19). TM is a structural protein
from the endothelial cells membrane, released in injury conditions, which represents the
dead cells burden (17). Due to its renal excretion, high plasma levels are found in
uremia (8, 19). TM released in plasma activates protein-C to inhibit fibrin formation
(17). TM plasma levels are also affected by inflammatory molecules, proteolysis and
oxidative stress. In culture cells, the stimulation with high doses of TNF- induces a
dramatic increase in TM (4). Our results confirm that SI induces an increase in TM,
representing endothelial damage. NO is the most potent vasodilator synthesized by
endothelial cells, able to inhibit platelet adhesion, releases mitogenic factors, and causes
proliferation of muscle vessel cells (21). Deficient NO production and early
atherosclerosis (22) have been found after administration of recombinant TNF- (23).
Moreover, in endothelial cell culture, TNF- administration reduces the half-life of
mRNA encoding for NO-synthase (24), predisposing to NO-depend vasoconstriction
(25). Effectively, after suffering SI, patients showed spontaneous elevation of NO3-pre
VOT with a low response capacity demonstrated by NO3-post VOT, and in consequence
a decrease in NO3-ratio (VOT, NO3-post/-pre) (Table II).
Endothelial remodeling, there is growing evidence about the implication of
growth factors in endothelial dysfunction and atherosclerosis pathway. These show an
important proliferating activity and are responsible of collateral circulation development
(26). TGF- is a double edge sword growth factor because in normal conditions it
operates as anti-inflammatory, but in pathologic situations it acts as a profibrotic agent.
In advanced atherosclerosis TGF- plasma levels are characteristically diminished (26).
Consistent with low growth factor plasma levels found in atherosclerosis is the concept
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that atherosclerosis is a low-remodeling status. We have found an increase of TGF-
plasma levels (table II) after SI and a positive correlation between TGF- and PAI
(Table III). TGF- stimulates PAI production especially under inflammation situations
(27, 28) and decreases fibrinolytic capacity (26). One of the mechanisms by which TGF-
 induces endothelial damage is by increasing PAI. The elevation of TGF- could
represent an acute anti-inflammatory counter balance. Moreover the inflammatory
response syndrome induces synthesis and releases pro and anti-inflammatory cytokines
including TGF- (28).
Lipoprotein(a) and homocysteine are recognized CV risk factors (29) frequently
elevated in dialysis patients (4, 7, 29). Inflammation causes an increase in the hepatic
synthesis of acute phase reactants. Lp(a) is one of these proteins able to induce
procoagulable status (30). Halper et al (31), in non-uremic population described that the
negative association of TGF- and Lp(a) is very proatherogenic. We found a
spontaneous tendency to a positive linear correlation between both molecules in our
series. Moreover, after inflammation this relationship increased in significance (table
III), suggesting that acute TGF- rise differentiates from what happens in chronic
processes such as atherosclerosis where TGF- plasma levels decreased and Lp(a)
maintained elevated levels although patients showed inflammatory signs (32). In
addition, it has been demonstrated that persistent high Lp(a) level is able to inhibit TGF-
 generation in smooth muscle cells (31, 32).
Homocysteine may also be affected by inflammation (4, 17, 29). However, we
did not find differences in Hcy plasma levels after SI (table II). Hcy is able to induce ED
and atherosclerosis by several mechanisms, stimulating the vessel smooth cell
proliferation and mitogenesis, and platelet adhesion and through its relationship with
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PDGF (33). Our results showed a significant linear correlation between Hcy and PDGF
(r= 0.56, p<0.05) (table III) after suffering SI, supporting this mechanism.
Importantly, we did not find any change in the control group (table IV),
indicating the inflammation is the specific factor responsible of triggering cachexia and
pro-atherogenic mechanisms in uremia.
The role of RRF in the elimination of the excess of pro-inflammatory molecules
has not provoked much attention (34). Moreover, the current dialysis methods do not
eliminate adequately the cytokine overproduction. On the contrary, peritoneal membrane
or hemodialysis filters are important sources of cytokine production (13). Other
important sources are silent infections, virus, Chlamydia pneumonie, Helicobacter
pylori, dental infections, vascular access with thrombosis and native kidneys (13, 35).
Our findings support the idea that RRF protects dialysis patients from the excess of pro-
inflammatory molecules, at least partially. Effectively, in our patients without RRF, the
changes in endothelial damage and function markers caused by SI were more severe
than in those with RRF.
In conclusion, systemic inflammation induces endothelial dysfunction
increasing procogulable and proatherosclerotic mediators and endothelial damage
markers in peritoneal dialysis patients. The present research confirms the link between
the different parts of MIA syndrome and remarks the importance of systemic
inflammation as a starting process of endothelial dysfunction, malnutrition and
cardiovascular risk in uremia.
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Table I. Changes in Nutritional and Endothelial Function Markers During SI.
Parameter Normal range Prior SI During SI P
CCr (ml/min) 90-110 2.18  2 1.9  2.4 NS
Weekly-Kt/V-urea >2 2.2  0.38 2.22  0.4 NS
nPNA (g/kg) >1.1 1.25  0.29 1.09  0.34 <0.05
Albumin (mg/dL) >4 3.89  0.4 3.66  0.44 <0.05
Prealbumin (mg/dL) >30 32.8  10 32  12.5 NS
Urea-MTC (ml/min) variable 17  3.1 21.1  5.8 NS
Cr-MTC (ml/min) 7-11 8.8  1.9 10.6  2.9 0.07(NS)
UF 3.86% (ml)* variable 740  253.3 766.4  227 NS
PAI (ng/mL) <10 9  4.01 11.5  3.5 NS
tPA-pre VOT (ng/mL) 1-12 8.8  6.1 12.4  5.1 0.05
tPA-post VOT (ng/mL) variable 17.9  7.2 16  2.5 NS
tPA-ratio >2 2.03  1.18 1.29  0.5 <0.05
CCr: creatinine clearance. C-RP: C-reactive protein. nPNA: normalized protein nitrogen
appearance. *UF: peritoneal ultrafiltration with a 4h 3.86% dextrose. PAI: plasminogen
activation inhibitor. t-PA: tissue-type plasminogen activator.
20
Table II. Changes in Endothelial Damage, Cardiovascular Risk Markers and
Growth Factors During SI.
Parameter Normal range Prior SI During SI P
NO3-pre VOT (mol/L) 40-60 32.1  16 52.8  12.4 <0.05
NO3-post VOT (mol/L) variable 52  33 56  37.1 NS
NO3-ratio variable 1.6  2 1.06  3 <0.05
vWF-pre VOT (%) 60-150 223  41 227  72 NS
TM (ng/mL) 14-55 279  63 289  47 <0.08(NS)
VCAM-1 (ng/mL) 395-714 1297  409 1548  198 <0.05
VEGF (pg/mL) 62-707 317  153 400.3  156 NS
TGF- (pg/mL) 34-64 25.4  8.4 34.7  10.8 <0.05
PDGF (pg/mL) 750-1100 1500  655 1617  577 NS
Lp(a) (ng/mL) <20 38.5  9.9 56  14.1 <0.05
Fbrinogen (mg/dL) 150-350 463  111 485  100.7 NS
Hcy (ng/mL) 5-10 32.3  11.5 36.3  18.1 NS
NO3: nitrate. vWF: von Willebrand factor. TM: thrombomodulin. VCAM-1:Vascular
cell adhesion molecule-1. VEGF: vascular endothelial growth factor. TGF-:
transforming growth factor betta. PDGF: platelet-derived growth factor. Lp(a): liprotein
(a). Hcy: homocysteine
Table III. Matrix of Linear Correlations at Prior and During SI
Marker tPA-ratio Lp(a) Hcy NO3-ratio CRP Fibri-
nogen
Albu
-min
PAI VCAM-
1
Pre-
SI
After
SI
Pre-
SI
After
SI
Pre-
SI
After
SI
Pre-
SI
After
SI
Pre-
SI
Pre-SI Pre-
SI
Pre-
SI
Pre-SI
TNF- -0.5
*
-0.57
*
0.3
**
0.34
**
-0.3
*
-0.5
*
0.5
*
0.36
**
-0.48
*
0.5
*
PDGF 0.4
**
0.6
*
0.22
**
TGF- 0.34
**
0.5
*
0.36
*
0.66
*
*: p<0.05. **: NS but near to statistical significance.
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Table IV. Nutritional, Endothelial Function, cardiovascular and growth Factors in
the Control Group.
Parameter Baseline 1-3 months P
CCr (ml/min) 3  2.7 2.3  3.1 NS
Weekly-Kt/V-urea 2.31  0.31 2.3  0.39 NS
nPNA (g/kg) 1.22  0.28 1.23  0.24 NS
Albumin (mg/dL) 3.77  0.3 3.81  0.32 NS
Prealbumin (mg/dL) 33  8 31  11.5 NS
Urea-MTC (ml/min) 18.2  4.1 19.1  6.1 NS
Cr-MTC (ml/min) 8  2.1 9.1  3.2 NS
C-reactive protein (mg/dL) 0.33  0.1 0.25  0.2 NS
TNF-α (pg/mL) 31.8  12 28.1  14 NS
PAI (ng/mL) 8.1  3 7.8  4.5 NS
tPA-ratio 1.88  3 2.2  1.1 NS
NO3-ratio 1  0.8 1.7  1.2 0.07 (NS)
vWF-pre VOT (%) 331  123 278  156 NS
TM (ng/mL) 301  112 331  79 NS
VCAM-1 (ng/mL) 1341  487 1409  501 NS
VEGF (pg/mL) 505  398 663  407 NS
TGF- (pg/mL) 38.2  12.8 42  15.1 NS
PDGF (pg/mL) 999  591 1204  661 NS
Lp(a) (ng/mL) 41  12.1 33.5  9 0.09 (NS)
Fbrinogen (mg/dL) 413  89 366  97 NS
Hcy (ng/mL) 28.1  9.1 34  12.1 NS
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CCr: creatinine clearance. TNF-: tumor necrosis factor alpha. PAI: plasminogen
activation inhibitor. t-PA: tissue-type plasminogen activator. NO3: nitrate. vWF: von
Willebrand factor. TM: thrombomodulin. VCAM-1:Vascular cell adhesion molecule-1.
VEGF: vascular endothelial growth factor. TGF-: transforming growth factor betta.
PDGF: platelet-derived growth factor. Lp(a): liprotein (a). Hcy: homocysteine
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Figure legend.
Figure 1. Study design, we study 68 clinically stable peritoneal dialysis patients. We
performed baseline endothelial function test in all of them. 46 patients were excluded of
the follow-up because these did not show elevation of C-reactive protein (CRP) or pro-
inflammatory cytokines. 22 patients showed elevation of inflammatory markers. Five of
22 them initiated the study with CRP mildly elevated therefore were excluded. Finally,
17 patients were included and follow-up during 15 months. When we detected elevation
of CRP we repeated endothelial function test. Control group 12 patients whom did not
suffered elevation of inflammatory markers. We determined inflammatory, endothelial
function, growth factors and nutritional markers baseline and between 1 and 3 months
later.
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Helicobacter pylori Eradication  Improves the Malnutrition, Inflammation
and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
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Abstract: Background. Helicobacter pylori (Hp) infection has frequently been detected in dialysis patients.
Chronic infection induces cytokine production which is poorly cleared by inefficient kidneys. These cytokines
have systemic and catabolic effects. We studied the effects of Hp infection-eradication on serum cytokine levels,
nutrition and endothelial function (EF) markers in peritoneal dialysis (PD) patients.
Methods. Hp-infection was diagnosed by breath test. Prior and post eradication we measured, nutritional markers:
biochemical, daily food-intake and appetite modulator (orexigen neuropeptide-Y, NPY, anorexigen cholecystoki-
nin, CCK). Stomach acid secretion: pepsinogen-I and II, and inflammatory markers: C-reactive protein (CRP), plasma
TNF-a  and IL-6. And EF markers which were taken pre- and post-venous occlusion test (VOT) in the right-arm for 10
min: tissue-type plasminogen activator (tPA), NO3 (representing nitric oxide) and plasminogen activator inhibitor
(PAI).
Forty-eight clinically stable PD patients divided into four groups according to Hp- infection and food intake were
studied: I, Hp(+) and low food-intake (<30 kcal/kg/day, DOQI-guidelines), n=12; II, Hp(+) and normal food intake,
n=4, III Hp(-) and low food intake, n=5, IV, Hp(-) and normal food intake, n=27.
Group-I showed the highest cytokines and the lowest residual renal function (RRF). TNF-a : group-I 127±85.5*
pg/ml; group-II 70.5±25; group-III 60.5±10* and group-IV 43.4±5.4*, *p<0.05. IL-6: group-I 34.2±18* pg/ml,
group-II 3.4±7*, *p<0.05,  group-III 11.1±7.9*, *p<0.05 and group-IV 1.02±0.65*, *p<0.05.  RRF was significantly
higher in group-IV (4.8±1.6 ml/min*) than group-I (2.7±2.3*, *p<0.05). After Hp-eradication in group-I, nutritional
markers and NPY increased. Inflammatory, gastric acid-secretion parameters decreased. EF markers also improved.
Control group included 10  volunteers, non-renal subjects infected by  Hp who followed similar process, including
eradication treatment. Hp-eradication was associated to improvement in inflammatory and stomach acid-secretion
markers.
Conclusions. Hp-infection induces cytokine overproduction associated with malnutrition, inflammation and athe-
rosclerosis syndrome in PD patients. Hp-eradication normalizes stomach acid secretion, decreases inflammation and
improves nutritional status and EF.
Keywords: Peritoneal dialysis, MIA syndrome, Helicobacter pylori, systemic inflammation, cytokines.
INTRODUCTION
The role of inflammation in the genesis of uremic
cachexia and atherosclerosis has recently been emphasized
[1]. This hypothesis, so-called as Malnutrition, inflamma-
tion and atherosclerosis syndrome (MIA) include a complex
syndrome that meets malnutrition, high circulating levels of
inflammatory molecules and atherosclerosis, and divide the
patients in two specific groups, MIA-type I, with normal or
low albumin, co-morbidity uncommon, absence of inflam-
matory markers, low food intake, normal resting energy ex-
penditure (REE), increased oxidative stress, decrease in pro
*Address correspondence to this author at the Servicio de Nefrología,
Hospital Universitario de la Princesa, Diego de León, 62, E-28006 Madrid
Spain; Tel: (+34) 91/ 520-2243; Fax: (+34) 91/ 309-3104;
E-mail: aguileraa@terra.es
tein catabolism, which is possibly reversible with dialysis
and nutritional support.
MIA-type II shows low albumin, high co-morbidity,
high inflammation markers, low or normal food intake, ele-
vated REE, markedly elevated oxidative stress, increase in
protein catabolism and non-reversible with dialysis or nutri-
tional support. In the latter case, inflammation, alone or in
combination with low protein intake, would play the major
role.
MIA syndrome [2] adds to the traditional Cardiovascular
(CV) risk factors (hypertension, dyslipidemia, smoking,
obesity and sedentary), the inflammation as a central and
crucial part [3]. Although considerable information exists as
to the relationship between inflammation, endothelial dys-
function, atherosclerosis and CV complications in renal [3]
and non-renal patients [4], the essential or triggering factor in
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the pathogenesis of MIA syndrome remains undefined. Sev-
eral questions that need an answer include whether inflamma-
tion is the key and initiating factor responsible for stimulat-
ing factors implicated in the atherosclerosis cascade, whether
inflammation is a cause or consequence and whether inflam-
mation is a silent, constant or intermittent pathologic proc-
ess.
Hp is a chronic, often silent infection that induces
chronic overproduction of IL-1, IL-6 and TNF- a  in the non-
uremic population [5-7]. Recently, it has been suggested an
association between Hp-chronic infection, systemic and vas-
cular inflammation, endothelial dysfunction [8], hyperten-
sion [9] and an increase in arterial stiffness (atherosclerosis)
in a healthy population [8, 10].
In end stage renal disease, renal retention together with
cytokine overproduction may be responsible for high plasma
levels of cytokines [11-13]. Concurring with this hypothesis,
the best model of renal-derived cachexia would be a silent
infectious process operating in anuric patients.
The hypothesis of this study was that chronic silent Hp
infection causes overproduction of pro-inflammatory cytoki-
nes which is exacerbated by the lack of renal elimination in
uremic subjects. These extended periods of inflammation
have cachectic and endothelial effects and lead to MIA syn-
drome in dialysis patients.
PATIENTS AND METHODS
This is a cross-sectional study including 48 non-selected
peritoneal dialysis (PD) patients, 24 on continuous ambula-
tory peritoneal dialysis (CAPD) and 24 on automatic perito-
neal dialysis (APD), 22 male and 26 female, ranging in age
from 22 to 79 years (mean 56.9 ± 14). Patients with recog-
nized endothelial diseases (vasculitis, scleroderma, malignant
hypertension), active systemic disease and those under im-
munosuppression were excluded. The causes of renal failure
were glomerulonephritis in nine cases, diabetes in eight,
chronic pyelonephritis in ten, polycystic kidney disease in
six, nephrosclerosis in ten, unknown etiology in four, and
others in one. No recognizable acute or chronic active disor-
ders were present in the three months prior to the study. The
mean period on PD was 17.5 ± 13.2 months (range 3-63).
Hp infection was diagnosed by breath test (Taukit test;
Isomed, Madrid, Spain). This method is based on oral intake
of 100 mg of 13C urea. In the presence of Hp, urease hydro-
lyzes 13C urea, releasing 13CO2 , which is detected by mass
spirometry in a breath sample. Patients were fasting and then
drank half a glass of citric solution (200 cc). After 10 min,
the baseline breath sample (exhalation) was obtained. A solu-
tion of Taukit plus water was ingested immediately and the
second breath sample obtained 309 min later. The breath test
for Hp infection diagnosis is a highly sensitive and specific
method, currently the diagnostic method of choice [7].
Food intake was estimated using a three-day diet assess-
ment (carbohydrates, lipid and proteins per day), including a
weekend day (Wander; Sandoz Nutrición, 1990, Barcelona,
Spain). Results are expressed in kcal/kg/day. According to
DOQI guidelines for dialysis patients [14], a lower food in-
take is considered when daily food take is less than 30
kcal/kg/day.
Four groups of patients were constituted according to daily
food intake and the presence or absence of Hp infection; group
I, Hp positive with low daily food intake, (n = 12). Group
II, Hp positive with normal food intake (n = 4). Group III,
Hp negative with lower food intake (n = 5) and group IV,
Hp negative with normal food intake (n=27).
Other GI symptoms included pyrosis (gastrointestinal
reflux) and dyspepsia in 6 and 8 patients, respectively. Four
patients from group I showed pyrosis and five dyspepsia. In
the group II, two patients suffered dyspepsia. In the group
III, two patient suffered pyrosis, and finally, two patients
from group IV showed dyspepsia.
Groups I and II were treated to eradicate Hp. Two breath
tests, at baseline and after treatment, were used for confirma-
tion. Cytokine levels from patients in whom treatment was
ineffective were not included in this part of the study. The
therapeutic regime included omeprozole (40 mg/day),
clarithromycin (1 g/day) and amoxocillin (1 g/day) with cla-
vulanic acid (250 mg/day) for 10 days.
Gastro duodenal endoscopy addressed by GI symptoms
was performed in ten patients. None of patients included in
this study showed gastric or duodenal lesions (ulcer or gas-
tritis).
A control group was included (10 volunteers, non-renal
population) infected by Hp who followed similar process,
including eradication treatment.
Dialysis adequacy was assessed by weekly urea-KT/V
(urea-kinetic) and nPNA (normalized nitrogen-protein equiva-
lence appearing) [15]. Creatinine renal clearance (Ccr) was
also calculated.
Nutritional markers were determined by measuring se-
rum albumin by the colorimetric method (Hitachi 704),
transferrin, and prealbumin by the immunonephelometric
method (Boehring, Nephelometer-Terminal, Spain. Normal
range was 10-40 mg/dl). IGF-I was measured by radioimmu-
noassay (RIA) (Nichols Institute Diagnostics, San Juan Cap-
istrano, CA), with a normal range of 83-450 ng/ml for per-
sons <40 years and from 54-389 ng/ml for >40 years. Cho-
lesterol and triglycerides were measured by a colorimetric
method and Hitachi 704, respectively. The normal range for
cholesterol was 150-250 mg/dl and triglycerides, 50-175
mg/dl. Ferritin and iron were also determined using a Hi-
tachi 911.
Appetite Modulators
Neuropeptide Y (NPY) is the most potent orexigen
known. NPY was measured in fasting conditions by RIA
method (Peninsula Lab., Belmont, CA) sensitivity of IC50:
23 pg/tube; specificity for human, porcine and rat NPY was
100%. No cross-reactivity was detected for pancreatic poly-
peptide, vasoactive intestinal peptide (VIP), amylin or hu-
man pre-pro-NPY. Normal values were 20-80 pg/ml.
Leptin is an anorexigen agent and inflammatory marker
and representing the quantity fat body store. Leptin was
measured by radio-immuno assay (RIA) using a rabbit poly-
clonal antibody raised against purified recombinant human
leptin (Linco Research, St. Louis, MO). The sensitivity
limit is 0.5 ng/ml and linearity is 100 m g/l. Inter- and intra-
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assay variation were 7.2 ± 0.4 and 25.6 ±  0.9 ng/ml, respec-
tively; normal range is 1-7.8 ng/ml.
Gastrointestinal Peptides
The following peptides responsible for control of gastric
acid secretion were measured by RIA.
GammmaDab [125] gastrin was determined with a precipi-
tating antiserum reagent to separate antibody-bound tracer
from unbound tracer (INCSTAR Corp., Stillwater, MN).
The sensitivity standard curve is defined as the smallest
value that can be distinguished from zero. This value was
calculated from the 95% confidence limit for 30 replicates at
the zero point of the standard curve; calculated sensitivity is
6 pg/ml. Specificity is expressed as the ratio of gastrin con-
centration to the cross-reacting compound concentration at
50% inhibition of maximum binding (cross reactivity of
gastrin G-17-I is 100%, gastrin G-17-II 64%, gastrin G-34-I
22%, gastrin G-13-I 29%, CCK 0.3% and secretin 0.3%).
Normal range values were from 25-115 pg/ml.
CCK is an appetite modulator with orexigenic action.
The 26-33 unsulfated cholecystokinin CCK fragment was
determined (Peninsula, Belmont, CA,). Sensitivity is IC50:
35 pg/100?l, specificity to CCK 26-33 and CCK 33 has
100% cross reactivity. Normal values were 12-20 pg/ml.
Pepsinogen I (Sorin Biomedica Diagnostics, Vercelli,
Italy). Sensitivity is <1 ng/ml at 95% confidence limit. No
significant cross reactions have been described at the highest
concentrations present in serum samples for human- follicle
stimulating hormone (hFSH), luteinizing hormone and thy-
roid-stimulating hormone, human gastrin, porcine glucagon,
human-growth hormone (hGH), proinsulin, insulin, C-
peptide or prolactin. Normal values were 20-80 ng/ml.
Pepsinogen II (Sorin Biomedica Diagnostics). Specificity
is 100%, and assay sensitivity is 0.3 ng/ml at 95% confi-
dence limit. Normal values were 3-20 ng/ml. The pepsino-
gen I/pepsinogen II ratio is a non-invasive method to evalu-
ate peptic secretion and functional gastric mucosal status. A
high ratio (>6) indicates gastric hypersecretion [16].
Inflammatory Markers
C-reactive protein (CRP) was tested by nephelometric
analysis (Boehring Dade., Germany), with a normal range
<0.6 mg/dl.
TNF-a  was measured using enzyme-amplified sensitive
immunoassay (oligoclonal system with monoclonal antibod-
ies, EASIA Medgenix Diagnostics, Belgium). The mini-
mum detectable concentration (MDC) was estimated to be 3
pg/ml and was defined as the TNF- a  concentration corre-
sponding to the mean of 20 replicates of the zero standard ±
2 standard deviations. This method did not show cross-react
with interleukin (IL), IL-1, IL-2 or interferon-a . Normal
values ranged from 3-20 pg/ml. TNF- a  has an anorexigenic
effect.
IL-6 was measured using Easia (Medgenix Diagnostics),
with a normal range of <0.5 pg/ml.
Venous occlusion test (VOT) was performed to stimu-
late endothelium, by inducing stasis in the right arm during
10 min by applying a sphygmomanometer cuff inflated to a
pressure midway between systolic and diastolic values [ mean
arterial pressure = (systolic pressure + diastolic pressure)/2 ]
[11].
Endothelial factors associated with endothelial fibri-
nolytic capacity included tissue-type plasminogen activator
(t-PA) pre-VOT and post-VOT, (ELISA-plasma-t-PA anti-
genic coaliza t-PA: chromogenix, Mölndal, Sweden), and
PAI (plasminogen activator inhibitor) levels determined by a
commercial monoclonal ELISA (Tintelize, PAI Biopool,
Umea, Sweden). We also calculated t-PA ratio (t-PA post-
VOT/pre-VOT).
Endothelial damage markers were trombomodulin
(Asserachrom TM: Diagnostica Stago, Asnières, France),
endothelial relaxing factor nitric oxide (NO) measured as
nitrate (NO3) concentration pre-VOT and post-VOT by capil-
lary electrophoresis. We also calculate NO3-ratio: (post-
VOT/pre-VOT).
Other cardiovascular (CV) risk markers included se-
rum or plasma levels of fibrinogen (inflammatory and pro-
coagulant marker) (thrombin time method described by
Clauss), lipoprotein-a (Lp(a)) (sandwich-type enzyme-linked
immunoassay, TintElize Lp(a); Biopool, Umea Swede), and
homocysteine (Hcy) (high pressure liquid chromatography).
Blood samples were drawn in resting and fasting condi-
tions, between 09:00h and 11:00h and collected into Vacu-
tainer tubes (Becton Dickinson) containing 0.129 mol/L
sodium citrate. The samples were centrifuged and tested im-
mediately or stored at –70ºC until assayed.
Statistical analysis. Results are expressed as median and
range values. Comparisons between data groups were per-
formed using the non-parametric Mann-Whitney rank sum U
test. Spearman's regression analysis and Student's t test were
used for paired and non-paired data. A p<0.05 was consid-
ered statistically significant.
For security reasons, each variable was determined twice
in groups II, III and controls. As results did not differ, we
used and show the first value for comparisons.
RESULTS
Table 1 shows the values of the parameters and their dif-
ferences among the four groups at baseline. Patients from
group I showed significantly lower lymphocyte counts, pre-
albumin, IGF-I, transferrin, serum albumin, nPNA and Ccr
than the remaining groups. These patients also showed
higher TNF- a , IL-6 and CRP levels. CCK and pepsinogen
I/II ratio were both higher in group I than group IV. These
findings suggest an unusual situation of the Hp-infected pa-
tients with respect to the others. Renal creatinine clearance
was significantly higher in group IV relative to group I (4.8
±  1.6 vs. 2.7 ±  2.3 ml/min, p<0.05). The differences in the
other two groups (4.7 ±  1.2 and 2.8 ±  0.9, respectively, for
groups II and III) were not statistically significant. Serum Hb
levels did not differ among groups (average 10.4-11.4 g/dl).
Table 2 shows changes in nutritional, inflammatory, ap-
petite and GI markers in group I before and after Hp eradica-
tion. A significant increase was evident in nutritional mark-
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Table 1. Nutritional, Inflammatory Markers and GI Peptides at Baseline
Parameters Group I Group II Group III Group IV
Diet assessment
(kcal/kg/day)
22.9 ± 3.7
(a,b)
28.2 ± 4.7 24.8 ± 4.6
(a)
31.3 ± 1.8
(b)
Lymphocyte count(/mm3) 1105 ± 259
(a,b)
1225 ± 230 1350 ± 62
(a)
1525±184
(b)
Prealbumin (mg/dl) 26.7 ± 6.4
(c,d)
32.7 ± 9.9
(c)
31.7 ± 0.5 36.1± 2.5
(d)
IGF-I (ng/ml) 151.8 ± 46
(e,f)
259 ± 91 216 ± 12
(e)
243 ± 40
(f)
Transferrin (mg/dl) 177.6 ± 27
(g,h)
242 ± 15
(g)
210 ± 47.7 233.4 ± 35
(h)
Cholesterol (mg/dl) 202 ± 45 227 ± 15.8 193 ± 8.8 215 ± 37
Serum albumin (g/dl) 3.4 ± 0.25
(i,j)
3.7 ± 0.13 3.7 ± 0.3
(i)
3.9 ± 0.15
(j)
Serum creatinine (mg/dl) 7.7 ± 2.3
(k)
7.78 ± 1.3 6.3 ± 1.4 6 ± 0.5
(k)
nPNA (g/kg/day) 0.9 ± 0.16
(i)
1.03 ± 0.1 0.89 ± 0.14 1.08 ± 0.1
(i)
C-reactive protein (mg/dl) 1.16 ± 1.14
(*)
0.7 ± 0.23 0.9 ± 0.6 0.6 ± 0.23
(*)
TNF- a  (pg/ml) 127 ± 85.5
(m,n)
70.5 ± 25 60.5 ± 10
(m)
43.4 ± 5.4
(n)
IL-6 (pg/ml) 34.2 ± 18
(o,p,q)
13.4 ± 7
(o)
11.1 ± 7.9
(p)
1.02 ± 0.65
(q)
Leptin (ng/ml) 40.7 ± 23 35.2 ± 19 35.6 ± 14 43.4 ± 17
Gastrin (pg/ml) 206 ± 156 149 ± 59 136 ± 71 189 ± 36
Cholecystokinin (pg/ml) 47.8 ± 22
(r)
32.5 ± 17 36 ± 7.3 30.5 ± 6.2
(r)
Pepsinogen I (pg/ml) 183.5 ± 67 300 ± 90 196 ± 38.6
(s)
190.8 ± 41
(s)
Pepsinogen II (pg/ml) 25.4 ± 17
(t)
42.7 ± 19 42.1 ± 23 44.9 ± 12
(t)
Pepsinogen I/II ratio 7.3 ± 3.9
(v,w)
7.1 ± 4.7 4.6 ± 1.7
(v)
4.2 ± 3.4
(w)
Neuropeptide Y (pg/ml) 65.1 ± 27.1 66.3 ± 33 58.1 ± 9 69.2 ± 6.8
GI: gastrointestinal. IGF-I: Insulin growth factor type I. nPNA: normalized nitrogen-protein equivalence appearance TNF- a : tumor necrosis factor-alpha. IL-6: interleukin-6.
Letters (a-w): statistically significant differences (p<0.05). (*): p=0.054.
ers, with decrease in acid GI hormone regulators and cytoki-
nes. In contrast, the four patients from group II showed no
changes in nutritional markers (except a small increase in
albumin; 3.7 ± 0.13 ± 3.9 ± 0.3 g/dl, p<0.01) after Hp
eradication. Daily food intake, lymphocyte count, prealbu-
min, IGF-I and transferrin showed no significant changes.
These results may be influenced by the small size of this
series. As a result of Hp treatment, however, cytokine levels
except CRP (0.7 ± 0.23 vs. 0.6 ± 0.3 mg/dl, NS) showed a
significant decrease after Hp eradication (TNF-a , 70.5 ± 25.3
vs. 41.3 ± 8.6 pg/ml, p<0.01 and IL-6, 13.4 ± 7 vs. 3.9 ±
4.6 pg/ml, p<0.01). Relative to appetite modulator peptide
changes, NPY also increased (66.3 ± 34 vs. 83.4 ± 43 pg/ml,
p<0.05), although CCK and leptin did not show modifica-
tions (32.5 ± 17.2 vs. 25.7 ± 8 pg/ml and 35.2 ±
19.7 vs. 25 ± 13 ng/ml, NS, respectively). Similarly, GI
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Table 2. Changes in Nutritional, Inflammatory Markers and GI Peptides Prior and Post -Hp Eradication (Group I)
Parameters Pre- eradication Post- eradication p
Diet assessment (kcal/kg/day) 22.9 ± 3.7 29.4 ± 4.4 <0.01
Lymphocyte count (/mm3) 1105 ± 259.4 1330.8 ± 316 <0.05
nPNA (g/kg/day) 0.9 ± 0.16 1.07 ± 0.3 <0.05
Prealbumin (mg/dl) 26.7 ± 6.5 33.9 ± 56.6 <0.01
IGF-I (ng/ml) 151.8 ± 46 225 ± 111.4 <0.05
Albumin (g/dl) 3.48 ± 0.3 3.67 ± 0.35 <0.05
C-reactive protein (mg/dl) 1.16 ± 1.14 0.88 ± 1.2 <0.1(NS)
TNF- a  (pg/ml) 127 ± 85.5 44.4 ± 29.3 <0.01
IL-6 (pg/ml) 34.2 ± 18.4 11.3 ± 9.8 <0.001
Leptin (ng/ml) 40.7 ± 23 27 ± 14.5 <0.01
Neuropeptide Y (pg/ml) 65 ± 27.5 91.3 ± 25.7 <0.01
Cholecystokinin (pg/ml) 47.8 ± 22.4 25.7 ± 11.5 <0.01
Gastrin (pg/ml) 206 ± 156 153 ±45 <0.1(NS)
Pepsinogen I/II ratio 7.3 ± 3.9 4.1 ± 2.2 <0.05
GI: gastrointestinal. nPNA: normalized nitrogen-protein equivalence appearing. IGF-I: insulin growth factor. TNF- a : tumor necrosis factor. IL-6: interleukin-6.
Table 3. Changes in Endothelial Function and Damage Markers Before and After Hp Eradication (Group I)
Parameters Normal range Prior-eradication Post- eradication p
CCr (ml/min) 90-110 2.7 ±  2.3 2 ±  2.4 NS
PAI (ng/mL) <10 13.2 ±  2.8 9 ±  3.2 <0.05
tPA-pre VOT (ng/mL) 1-12 10.7 ±  6.1 9.1 ±  5.2 NS
tPA-post VOT (ng/mL) variable 16.4 ±  3.3 18.6 ±  5.4 <0.05
tPA-ratio >2 1.5 ±  0.5 2 ±  1 <0.05
NO3-pre VOT ( m mol/L) 40-60 54.3 ±  11.1 42.2 ±  14.1 =0.07(NS)
NO3-post VOT ( m mol/L) variable 55 ±  18.4 58.1 ±  17 NS
NO3-ratio variable 1.01 ±  1.6 1.38 ±  1.2 <0.05
TM (ng/mL) 14-55 313.1 ±  51 270 ±  38 <0.05
Lp(a) (ng/mL) <20 38.4 ±  18 29 ±  9.4 <0.05
Hcy (ng/mL) 5-10 33 ±  17.6 28 ±  11.2 NS
PAI: plasminogen activation inhibitor. tPA: tissue-type plasminogen activator. NO3: nitrate. TM: Thrombomodulin. Lp(a): lipoprotein (a). Hcy: homocysteine. Ccr: creatinine
clearance. VOT: Venous occlusion test.
peptides, gastrin, CCK, pepsinogen I and II and the pepsi-
nogen I/II ratio showed no changes. The Hp breath test none-
theless is superior in accuracy to all of these tests in confirm-
ing Hp eradication.
Table 3 shows changes in endothelial function and dam-
age markers prior and after Hp-eradication. We found an in-
crease in tPA-ratio and NO3-ratio, and decrease in PAI, Lp(a)
and TM.
The pre- and post-Hp eradication results in healthy con-
trol individuals are shown in Table 4. A remarkably lower
effect was registered in inflammatory values, which did not
reach statistical significance, except for IL-6. In contrast, GI
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parameters had similar effects (decrease in CCK, gastrin and
pepsinogen I/II-ratio), demonstrating the positive effect of
the treatment. The lack of effect on nutritional parameters
establishes differences with similarly infected and treated
uremic subjects. No patients from the control group suffered
anorexia, but five experienced dyspepsia. In regard to endo-
thelial function, PAI decreased after Hp-eradication.
Table 5 shows the different statistically significant linear
correlation coefficients among the parameters studied at base-
line.
DISCUSSION
The most important finding in this study is that Hp in-
fection is associated with anorexia and malnutrition in PD
patients, and that its eradication has effects on both condi-
tions. The mechanism through which Hp induces these com-
plications may be cytokine overproduction, with cachectic
action accentuated by retention due to uremic status. Resid-
ual renal function (RRF) appears to play a crucial role in the
preservation of appetite. Hp eradication was associated with
nutritional status and appetite improvement. Hp infection
increased gastric acid secretion, as estimated by GI peptide
serum levels.
Hp infection association with cytokine overproduc-
tion. High plasma levels of TNF- a , IL-1, IL-6 and other
pro-inflammatory substances have been described in the non-
uremic population infected by Hp [5, 6, 17]. A high serum
concentration of cytokines has been found in dialysis pa-
tients [11, 12, 18). In patients from group I, the higher cyto-
kine concentration thus appears to be due to simultaneous
Hp infection and uremia.
Deleterious effects of cytokines in uremic and non-
uremic subjects. We reported an association between high
TNF-a  plasma levels and anorexia in PD patients [11]. Lev-
els of TNF- a  greater than 65 pg/ml were related to deleteri-
ous effects including anorexia, acidosis, hypertriglyceride-
mia, malnutrition, anemia (recombinant human erythro-
poietin resistance) and uremic neuropathy [12]. Other inves-
tigators found pathogenic association between TNF-a  and
muscular structural protein breakdown via the ubiquin-
proteases system, inhibition of hepatic albumin synthesis
and renal amyloidosis [3, 4]. We therefore propose that TNF-
a  should be considered a uremic toxin.
The results showing a negative association between TNF-
a  and IL-6 with nutritional markers including daily food
intake support these findings. Experiments in animals dem-
Table 4. Changes in Nutritional, Inflammatory Markers and GI Peptides in the Non-uremic Patients (Control Group), Prior and
Post Hp-Eradication
Parameters Prior-eradication Post-eradication p
Lymphocyte count (/mm3) 2105 ± 178 2231 ± 323 NS
Prealbumin (mg/dl) 39 ± 5.4 41 ± 3.3 NS
IGF-I (ng/ml) 232 ± 24 245 ± 41 NS
Albumin (g/dl) 4.3 ± 0.8 4.41 ± 0.5 NS
C-reactive protein (mg/dl) 1.11 ± 0.75 0.44 ± 0.26 <0.1(NS)
TNF- a  (pg/ml) 17.6 ± 7.3 12 ± 6.5 <0.1(NS)
IL-6 (pg/ml) 3.8 ± 2.01 1.71 ± 1.16 <0.05
Leptin (ng/ml) 5.38 ± 2.3 6 ± 2.5 NS
NPY (pg/ml) 48 ± 22.4 56 ± 32.2 NS
CCK (pg/ml) 25.7 ± 8.4 13.7 ± 6.3 <0.05
Gastrin (pg/ml) 153 ± 38 98 ± 22.1 <0.01
Pepsinogen I/II ratio 7.7 ± 2.2 4.3 ± 1.5 <0.05
PAI (ng/mL) 10.1 ± 2.3 7.8 ± 2.4 <0.05
tPA-ratio 2.8 ± 1.1 3 ± 1.5 NS
NO3-ratio 1.2 ± 0.3 1.34 ± 0.5 NS
TM (ng/mL) 46 ± 8.8 36 ± 12 NS
Lp(a) (ng/mL) 14 ± 6.1 10.7 ± 4.6 =0.07(NS)
Hcy (ng/mL) 7.7 ± 3.1 6 ± 2.1 NS
GI: gastrointestinal, IGF-I: insulin growth factor. TNF- a : tumor necrosis factor. IL-6: interleukin 6. NPY: neuropeptide Y. CCK: cholecystokinin. PAI: plasminogen activa-
tion inhibitor. tPA: tissue-type plasminogen activator. NO3: nitrate. TM: Thrombomodulin. Lp(a): lipoprotein (a). Hcy: homocysteine.
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onstrated that intracerebral r-mTNF-a  injection induces ano-
rexia, loss weight and cachexia [19, 20].
The results in Table 1 show clear clinical evidence for the
participation of TNF- a  and IL-6 in decreased food intake
(uremic anorexia pathogenic factor). We recently proposed a
"tryptophan-serotonin” hypothesis [21] to explain appetite
loss in dialysis patients, in which inflammatory mediators
play an important pathogenic role.
In the same study [11], patients with GI symptoms
showed high TNF- a  plasma levels, and evidence was found
for RRF participation in protection and preservation of appe-
tite; the present results confirm these observations (Table 1).
Moreover, RRF appears more important than peritoneal urea-
weekly-KT/V in the preservation of normal food intake. We
speculate that patients with RRF are protected from the ef-
fects of chronic and silent infections such as Hp. Low
creatinine clearance may be sufficient to eliminate an impor-
tant part of low molecular weight pro-inflammatory cytoki-
nes such as TNF- a  (55 KD) [22]. The CANUSA study [23]
showed that RRF protects dialysis patients from morbidity
and mortality. The decrease in cytokine levels and the paral-
lel increase in nutritional markers after Hp eradication was
associated to a greater RRF.
Our findings support to the inflammatory hypothesis as a
cause of malnutrition [1]. It may be that dialysis patients
suffer these inflammatory processes in a cyclic manner, in
direct proportion to time on dialysis and in inverse propor-
tion to RRF. Silent inflammation of organs such as heart,
GI tract, liver or blood vessels [11, 17] could be a source of
cytokine overproduction; in such cases, an increase in dialy-
sis dose would not improve the situation.
Another mechanism by which Hp infection may induce
loss of appetite is by decreasing GI motility [24], possibly
also mediated by TNF- a  [22, 25]. Low GI motility is a fre-
quent finding in dialysis patients [26].
CCK and leptin, both anorexigenic substances, and NPY,
the most potent orexigen known, are important biological
appetite modulators that are also affected by uremia [11, 27];
association between inflammatory mediators and leptin has
been described [27]. After Hp eradication in group I, CCK
and leptin decrease and NPY increases (Table 2). A simulta-
neous increase appeared in daily food intake and improve-
ment in nutritional markers. The key factor to understanding
Table 5. Linear Regression Coefficients for Studied Variables at Baseline
Variable Albumin Pre-albumin Transferrin Cholesterol Daily food in-
take
TNF- a Gastrin
Albumin 0.43 ** 0.38 * 0.39 * -0.4 *
Prealbumin 0.43 ** 0.39 * -0.46 **
Cholesterol 0.38 *
nPNA 0.35 *
IGF-I 0.4 * -0.38 *
Daily food intake 0.39 * 0.39 * -0.55 **
IL-6 -0.36 * -0.34* -0.38 * -0.48 ** 0.44 *
C-PR -0.35 * -0.36 * 0.68***
NPY 0.41 * 0.48 ** 0.53 ** -0.6 ***
CCK -0.38 * -0.35 * -0.48** -0.43 **
Pep-I 0.41 *
Pep I/II 0.33* 0.48 **
PAI -0.5**
tPA-ratio 0.46*
NO3-ratio 0.36
TM 0.41* 0.33*
Lp(a) 0.4*
Hcy 0.38*
IGF-I: insulin growth factor. TNF- a : tumor necrosis factor. IL-6: interleukin 6. NPY: neuropeptide Y. CCK: cholecystokinin. Pep.: Pepsinogen. PAI: plasminogen activation
inhibitor. tPA: tissue-type plasminogen activator. NO3: nitrate. TM: Thrombomodulin. Lp(a): lipoprotein (a). Hcy: homocysteine.
*: <0.05. **: <0.01. ***: <0.001. The non-expressed coefficients are not statistically significant.
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the decrease in CCK plasma levels after treatment may be
inherent to a gastric acid-stimulating hormone cycle disorder,
frequently found in non-uremic Hp infected patients [28, 29].
Gastrin and pepsinogen levels decreased in our patients after
Hp eradication (Table 2).
In normal conditions, dietary proteins stimulate antral G
cells to release gastrin to blood; released gastrin stimulates
stomach parietal cells, increasing the intraluminal acid secre-
tion mediated by gastrin releasing factor. The low antral pH
results in negative feedback regulated by somatostatin (D
cells) and CCK, both neutralizing the pH of the alimentary
bolus and protecting the duodenum from low pH [29]. In the
presence of Hp this feedback is broken, however, and CCK,
gastrin, somatostatin and pepsinogens show parallelism,
increasing or decreasing simultaneously [30]. Moreover,
these hormones are markedly elevated in dialysis patients
and normal feedback may be lost. The increase in stomach
acid secretion may contribute to anatomical abnormalities in
the GI tract.
One of the most important markers of gastric acid secre-
tion is the pepsinogen I/II ratio. High pepsinogen I/II ratio is
associated to high acid secretion [16]. Hp eradication de-
creased all gastric acid mediators in all affected patients (Ta-
bles II, IV). In Hp-infected control patients, we found a de-
crease in gastric acid mediators (gastrin, pepsinogens and
CCK) (Table 4), which were previously described after Hp
eradication [28, 29].
Cytokines also participate in gastric acid secretion. The
antral of IL-1 and TNF- a  concentrations are thus inversely
related to somatostatin concentration [31]. One could specu-
late on a similar effect on CCK and pepsinogen levels.
The changes in NPY after Hp  eradication (Table 2) can
not be explained by the gastric acid secretion cycle. How-
ever, an influence of TNF-a  on NPY could not be discarded.
Recently, an inhibitory effect of TNF- a  on a neuropeptide
with a structure similar to that of NPY was described [32].
Supporting this idea are the results showed here and in other
study performed by our group [11], where we found a nega-
tive linear correlation between both substances. Moreover,
the decrease in inflammatory markers was proportionally
inverse to the increase in NPY levels (Table 2).
According to these results, the strong inverse correlation
between TNF- a  and IL-6 levels with nutritional markers
including daily food intake may indicate that these cytokines
are better inflammatory markers than CRP. Furthermore, IL-
6 is a stimulator of CRP synthesis [33].
Endothelial Function, Inflammation and Hp-Eradi-
cation
tPA is an endothelium-derived fibrinolytic glycoprotein
released by exercise, VOT and stimulation with desmo-
presin. tPA values after stimulation by VOT (expressed as
tPA-ratio), indicates an adequate fibrinolytic capacity [34-
36]. It has been demonstrated that patients suffering severe
atherosclerosis or unstable angina show low tPA levels after
stimulation [37]. Uremia per se  is associated with poor tPA
response for unknown causes [34, 35]. Importantly, we have
found a clear association between elevated pro-inflammatory
molecules (TNF-a ) and a decrease in tPA-ratio (Table 5).
Experimentally, the stimulation of human endothelial
cells from umbilical vein endothelial culture with IL-1 and
TNF-a , reduces tPA synthesis [38]. Since tPA can also be
considered as a pro-inflammatory molecule [36], the sponta-
neous or post-VOT elevation of tPA may result in decrease
of tPA-ratio and increase in PAI levels, predisposing to co-
agulant phenomena [34-36]. Effectively, we have found that
Hp-eradication with decrease in inflammatory markers was
associated with increase in tPA-ratio (Table 3). Chia S, et al.
[39], found an increase in spontaneous tPA after systemic
inflammation and concluded, that SI invoke a protective
response mediated by enhancing endothelial fibrinolytic ca-
pacity.
Another important fibrinolytic inhibitor, the PAI, was
augmented by inflammation. It has been demonstrated in
vivo and in vitro that cytokines (IL-1 and TNF- a ) induce
elevation of PAI [40, 41]. Moreover, malnourished and in-
flamed patients, show hepatic acute hyperproduction of half-
life proteins such as C-reactant protein, prealbumin, fi-
bronectin, PAI and others [36]. Finally, and according with
our results and shown by a longer series [42], the elevation
of PAI associated with inflammation should be considered as
a cardiovascular risk factor due to predisposition to throm-
botic events.
Endothelial damage as a consequence of injuries is fol-
lowed by TM and NO release [35, 41-44]. TM is a structural
protein from the endothelial cells membrane, released in in-
jury conditions, which represents the dead cells burden [36,
41]. Due to its renal excretion, high plasma levels are found
in uremia [35, 44]. TM released in plasma activates protein-
C to inhibit fibrin formation [41]. TM plasma levels are also
affected by inflammatory molecules, proteolysis and oxida-
tive stress. In culture cells, the stimulation with high doses
of TNF- a  induces a dramatic increase in TM [36, 40]. Our
results confirm that after Hp-eradication TM decreased, repre-
senting and improving in endothelial structure. NO is the
most potent vasodilator synthesized by endothelial cells,
able to inhibit platelet adhesion, release mitogenic factors,
and cause proliferation of muscle vessel cells [45]. Deficient
NO production and early atherosclerosis [46] have been
found after administration of recombinant TNF-a . Moreover,
in endothelial cell culture, TNF- a  administration reduces the
half-life of mRNA encoding for NO-synthase [47, 48], pre-
disposing to NO-depend vasoconstriction [49]. Effectively,
after Hp-eradication, patients showed spontaneous decrease in
NO3-pre VOT and in consequence a decrease in NO3-ratio
(VOT, NO3-post/-pre) (Table 3).
Lipoprotein(a), Fibrinogen and homocysteine are recog-
nized CV risk factors [50] frequently elevated in dialysis
patients [40, 50]. Inflammation causes increase in the hepatic
synthesis acute phase reactants. Lp(a) is one of these proteins
able to induce procoagulable status [51]. Fibrinogen and Hcy
may also be affected by inflammation [40, 41, 50]. However,
we did not find differences in both parameters after HP-
eradication (Table 3). Fibrinogen showed a not statistically
significant mild decrease. Recently, it has been described
that fibrinogen and other pro-inflammatory parameters were
important predictor of cardiac ischemic attack in patients
infected by HP (78.3% vs. controls 56.2%, p<0.05) [52].
The same association was found by Pellicano R et al. [53].
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They investigated the association between unstable angina
and anti-HP seropositivity in 32 patients, which was
matched with control group (n=62). Again 81% of studied
patients showed HP IgG antibodies vs. 53%, supporting the
hypothesis that a chronic and silent inflammation is able to
triggering pro-coagulant, vasoconstrictor and possibly vessel
proliferating phenomena.
Finally, diagnosis of Hp-infection acquires new impor-
tance in the evaluation of dialysis patients with MIA syn-
drome, since Hp eradication may be a key in the manage-
ment of malnourished patients. We believe that diagnosis
and treatment of Hp infection should precede other ap-
proaches to malnutrition.
In conclusion, Hp infection in peritoneal dialysis pa-
tients causes cytokine overproduction, which is further exac-
erbated by poor renal elimination. Cytokines induce ano-
rexia, cachexia, malnutrition and endothelial dysfunction. In
consequence, residual renal function plays a critical role in
protection from extending the period of high cytokine levels
and may thus contribute to the preservation of the nutrition
status and vascular integrity in PD patients. The changes
associated with Hp eradication supports the role of the MIA
syndrome pathway in dialysis patients.
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Atherosclerosis is an important cause of morbidity and
mortality in peritoneal dialysis (PD) patients.
Oxidative stress plays a role in the pathogenesis of
uremic atherosclerosis. Although antioxidant
substances (vitamins˚A and E) are elevated in the
plasma of dialysis patients, intracellular and clinical
signs of hypovitaminosis are frequently found.
Recently, the importance of vitamin/carrier complexes
as a marker of vitamin bioavailability has been
demonstrated. In the present study, we analyzed
vitamin˚A and E bioavailability, measured as vitamin/
carrier complexes, and the relationship of those
measurements with clinical atherosclerosis status in
PD patients.
We studied 45˚patients (15˚men, 30˚women), who
were divided into four groups according to clinical
atherosclerotic score (CAS). Five cases were scored
as CAS grade˚1 (low CAS); 9 as CAS-2; 18 as CAS-3;
and 13 as CAS-4. Vitamins˚A and E and their carriers
[prealbumin and retinol binding protein (vitamin˚A),
and cholesterol and triglycerides (vitamin˚E)] were
determined.
Plasma levels of vitamin˚A were low in 5˚patients,
normal in 7˚patients, and high in 33˚patients. By
correcting the values for the carrier levels, we created
three groups: 24˚patients showed low vitamin˚A/
carrier complex (5 from the low plasma vitamin˚A
group, 6 from the normal-value group, and 13 from
the high-value group); 11 patients were in the group
with normal vitamin˚A/carrier (1 from the normal
plasma vitamin˚A group, and 10 from the high-value
group); and 10˚patients were in the group with high
vitamin˚A/carrier. The vitamin˚A/carrier complex
showed a statistically significant, negative linear
correlation with CAS and with serum iron.
Low vitamin˚E plasma levels were found in
1˚patient, normal levels in 28˚patients, and high levels
in 16˚patients. When those values were corrected using
the carrier values, three groups were also created. The
group with low vitamin˚E/carrier complex contained
24˚patients (1 from the low-value group, 22˚from the
normal-value group, and 1 from the high-value group).
The group with normal vitamin˚E/carrier complex
contained 21˚patients (15˚from the group with high
vitamin˚E values, and 6 from the normal-value group).
By univariate logistic regression analysis, significant
associations between CAS and vitamin˚E plasma
levels, vitamin˚E/carrier, age, and serum albumin were
found. In the multiple logistic regression analysis, we
confirmed that vitamin˚E/carrier complex, age, and
serum albumin showed independent associations with
CAS, but not with vitamin-only plasma levels.
Our results in PD patients show a vitamin/carrier
complex disorder that results in elevated vitamin
mobilization from pool and target cells. Our results
and the findings of other researchers about
intracellular vitamin˚A and E deficiencies may change
the traditional concept of hypervitaminosis˚A and E
in uremic patients.
Key words
Vitamin˚A, vitamin˚E, vitamin/carrier complex,
antioxidants, atherosclerosis
Introduction
Reactive oxygen species are factors commonly im-
plicated in the development of tissue injury in renal
disorders and in dialysis patients. Antioxidant vita-
mins decrease tissue damage by trapping organic free
radicals and inhibiting lipid peroxidation. Neverthe-
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less, supplementation therapy with vitamin˚A and E
is not recommended in such patients, owing to in-
creased serum vitamin levels.
Vitamin˚A and E deficiencies have been implicated
in premature development of atherosclerosis (1).
Accelerated atherosclerosis and cardiovascular (CV)
complications are recognized as major survival-
determining factors for long-term maintenance dialysis
patients (2,3). In peritoneal dialysis (PD) patients, the
complexity of the situation is increased, because the
atherosclerotic process includes specific factors such
as hyperglycemia, hyperlipidemia, hyperinsulinemia,
obesity, and hypoalbuminemia. In addition, signs of
endothelial dysfunction are frequently found in uremic
patients (3,4). The adoption of strategies to avoid
endothelial injury are therefore relevant.
Increasing plasma levels of antioxidative agents
should improve the hyperoxidative status of uremia.
Nonetheless, disorders in vitamin˚A and E intra-
cellular metabolism, bioavailability, membrane re-
ceptor, and vitamin/carrier complex have been
suggested in uremic patients (1). For instance, plasma
levels of vitamin˚A and its carrier are both increased
with respect to skin content of vitamin˚A. In spite of
the increased plasma levels, the vitamin˚A pool in
the skin is not increased, and cutaneous lesions re-
sembling the abnormalities found in hypovita-
minosis˚A (xerosis) are present in uremia. It has
therefore been suggested that, in uremia, an alter-
ation occurs in cutaneous vitamin˚A receptor or in
the vitamin˚A/carrier complex, with reduction of vi-
tamin entry into cells (1,5).
A similar situation may arise with vitamin˚E sta-
tus in dialysis patients, induced by an increase in the
vitamin˚E carrier (cholesterol and triglycerides) level.
Vitamin˚E is a scavenger, largely localized within
membranes. Because of its high lipid solubility, it
plays a special role with regard to the critical mem-
brane lipid targets of free radicals (6). Uremic hyper-
lipidemia and antioxidant deficiency favoring
oxidative stress is an added factor favoring develop-
ment of atherosclerosis (7). In addition, recent re-
search demonstrates the importance of measuring
vitamin/carrier complex as a marker of vitamin bio-
availability (8).
Our aim was to study vitamin˚A and E bio-
availability, measured as vitamin/carrier complex, and
the relationship of those measurements with clinical
atherosclerosis status in PD patients.
Patients and methods
We studied 45˚clinically stable PD patients. The group
included 15˚men and 30˚women, ranging in age from
27˚to 86˚years (mean: 51.8 ±˚ 13.9˚years); 26 on
continuous ambulatory peritoneal dialysis (CAPD),
and 19˚on automated peritoneal dialysis (APD) [14˚on
continuous cycling peritoneal dialysis (CCPD), and
5 on nightly peritoneal dialysis (NPD)]. The mean
period on PD was 33.5˚± 37˚months (range: 1˚—
179˚months). No acute or chronic active disorders
were present during the 6˚months prior to the study.
The causes of renal failure were glomerulonephritis
(10˚cases), diabetes (8˚cases), polycystic kidney
disease (7˚cases), chronic pyelonephritis (5˚cases),
nephrosclerosis (5˚cases), unknown etiology
(4˚cases), systemic disease (presently inactive,
4˚cases), and other causes (2˚cases). Patients with
cirrhosis, thyroid disease, and familiar dyslipidemias
were excluded.
The patients were divided into four groups accord-
ing to clinical atherosclerosis score (CAS) (9). Five
cases were scored CAS grade˚1 (lowest atheroscle-
rotic status); 9 were scored CAS-2; 18 were scored
CAS-3; and 13 were scored CAS-4.
Prior to starting PD, 32˚patients were diagnosed
with high blood pressure (HBP); however, only 28
had HBP when the present study was performed. Of
the 28, 7 were using angiotensin-converting enzyme
inhibitors; 4, calcium-channel blockers; 7, other drugs
(α and β adrenergic blockers, direct vasodilators, and
angiotensin˚II—receptor blockers); and 10, combina-
tions of antihypertensive drugs. Lipid-lowering agents
were withdrawn 15˚days before the study. By
echocardiogram, 38˚patients showed left ventricular
hypertrophy, 6 in severe grade. Low-dose aspirin was
used by 8˚patients; 36˚patients were physically active;
and 5˚patients were active smokers.
Dialysis adequacy
Dialysis adequacy was assessed by weekly urea Kt/V
and normalized protein catabolic rate (nPCR).
Antioxidants
Antioxidant levels were determined in fasting condi-
tions. Serum albumin was measured by the colorimet-
ric method (Hitachi 704: Boehringer Mannheim,
Mannheim, Germany); transferrin, ceruloplasmin, and
vitamin˚A carriers [prealbumin and retinol binding pro-
tein (RBP)] by the immunonephelometric method
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(Behring Nephelometer Terminal S.A.: Behringwerte
AG, Marbus, Germany); and bilirubin, glucose, and uric
acid by Hitachi 704. Vitamin˚A and E plasma levels
were analyzed using high-performance liquid chroma-
tography (HPLC). The HPLC instrument used was from
Waters Associates, Inc. (Milford, MA, U.S.A.), and
consisted of a 600E solvent delivery system, an auto-
matic sample injector model 712˚WISP, and a model
481˚Lambda Max spectrophotometer programmable
multi-wavelength detector injector with a Millennium
data station. Vitamins were separated on a 3.9↔150˚mm
resolve C18˚column (Waters Associates) packed with
5 µ˚ particles. The solvent was methanol:water (95:5)
at a flow rate of 1.2˚mL/min. Vitamins were detected at
290˚mm. For the analysis, a 100 µ˚L blood serum sample
and 100 µ˚L of an internal standard retinol acetate solu-
tion in ethanol (1 µ˚/mL) were mixed on a vortex mixer
for 10˚seconds. For lipid extraction, 200 µ˚L of spectro-
grade hexane was added, and the contents were mixed
for 60˚seconds. Tubes were centrifuged (2000g for
5˚minutes) to separate the phases, and then the solvents
were transferred to another tube and evaluated in an
automatic environment (Speed-Vac: Savant Instru-
ments, Farmingdale, NY, U.S.A.). The lipids were dis-
solved in 200 µ˚L methanol, and approximately 50 µ˚L
of the solution was injected into the chromatograph.
Normal values in healthy populations are 8˚— 21µ˚g/mL
α-tocopherol (vitamin˚E plasma levels) and 0.4˚—
0.8 µ˚g/mL retinol (vitamin˚A plasma levels).
Vitamin˚A carrier
Prealbumin and RBP were determined by an
immunonephelometric method (BN-100: Behring-
werke, Marburg, Germany). Reference values in
healthy populations are 10˚— 40˚mg/dL for prealbumin
and 3˚— 6˚mg/dL for RBP.
Vitamin˚E carrier
Cholesterol was measured by the colorimetric method,
and triglycerides by the Hitachi 704. Normal ranges
are 150˚— 250˚mg/dL for cholesterol and 50˚—
175˚mg/dL for triglycerides.
Vitamin/carrier complexes
Vitamin˚A/carrier and vitamin˚E/carrier complexes
(µg/mg) were calculated using these equations:
vitamin˚A serum levels (µg/mL)˚/ [˚RBP (µg/mL)˚↔
7.342]
vitamin˚E serum levels (µg/mL)˚/ [cholesterol
(mg/mL)˚+ triglycerides (mg/mL)]
Normal values for vitamin/carrier complexes were
obtained from a selected group of healthy individuals
(without dyslipidemias): 30˚women and 40˚men,
ranging in age from 25˚— 50˚years. The normal range
for vitamin˚A/carrier complex was 0.8˚— 1.2µ˚g/mg;
for vitamin˚E/carrier complex, it was 6˚— 16µ˚g/mg.
Statistical analysis
Comparisons between groups of data were performed
using the Student t-test and the Mann—Whitney U-test.
We also used the linear Spearman regression analysis.
A p˚value less than 0.05 was considered statistically
significant. A multivariate analysis (logistic
regression) was performed to analyze the association
between the dependent variable (severity of CAS,
high or low) and the independent variables, vitamin˚E/
carrier (continuous), age (continuous), and serum
albumin (continuous). All variables were analyzed
individually against the dependent variable, and
multiple regression analysis was then performed. For
CAS and multivariate analysis, all patients were
grouped as low score (CAS-1 and -2) or high score
(CAS-3 and -4). Results are given as median and
range.
Results
Table˚I shows the general analytical data.
Vitamin˚A plasma levels were low in 5˚patients,
normal in 7˚patients, and high in 33˚patients. By
correcting for carrier levels, we created three groups:
24˚patients showed low vitamin˚A/carrier complex
(5 f˚rom the low plasma vitamin˚A group, 6 from the
normal-value group, and 13˚from the high-value group).
The group with normal values of vitamin˚A/carrier
contained 11 patients (1 from the normal-value vitamin˚A
group, and 10 from the high-value group). Finally, 10
patients were in the group with high vitamin˚A/carrier
levels, all from the high plasma value group.
The vitamin˚A/carrier complex showed a
statistically significant, negative linear correlation with
CAS (r˚= —0.36, p˚< 0.05) and with serum iron (r˚=
—0.34, p˚< 0.05).
With respect to vitamin˚E plasma levels, we found
low values in 1˚patient, normal values in 28˚patients,
and high values in 16˚patients. When those values were
corrected for the carrier values, three groups also
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emerged. The group with low vitamin˚E/carrier
complex contained 24˚patients (1 from the low plasma
level group, 22˚from the normal-value group, and 1
from the high-value group). The group with normal
vitamin˚E/carrier complex had 21˚patients (15˚from
the group with high vitamin˚E plasma levels, and 6
from the normal-value group). No patient showed high
vitamin˚E/carrier complex values. Vitamin˚E/carrier
complex showed an inverse correlation with CAS (r˚=
—0.49, p˚< 0.01) and with age (r˚= —0.34, p˚< 0.05).
Women showed significantly higher vitamin˚E plasma
levels than did men [6.9 ±˚ 3.2 µ˚g/mL (n˚=30) vs. 5.5 ±˚
1.6˚µg/mL (n˚= 6), p˚< 0.05].
Vitamin˚A and E plasma levels showed significant
linear correlation with other antioxidant substances.
Vitamin˚A was correlated with transferrin (r˚= 0.36,
p˚< 0.05), ceruloplasmin (r˚= 0.3, p˚< 0.05), uric acid
(r˚= 0.4, p˚< 0.01), total bilirubin (r˚= 0.35, p˚< 0.05),
glucose (r˚= 0.38, p˚< 0.05), vitamin˚E (r˚= 0.36, p˚<
0.05), vitamin˚E/carrier (r˚= 0.74, p˚< 0.01), and
albumin [r˚= 0.28, p˚= 0.054 (NS)]. Vitamin˚E was
correlated with transferrin (r˚= 0.4, p˚< 0.05),
ceruloplasmin (r˚= 0.38, p˚< 0.05), uric acid (r˚= 0.38,
p˚< 0.05), and albumin (r˚= 0.33, p˚< 0.05).
Using multivariate analysis, no significant
associations were found between plasma levels of
vitamin˚A or vitamin˚A/carrier complex and the
remaining variables studied.
By univariate logistic regression analysis,
significant associations were found between CAS and
vitamin˚E plasma levels [odds ratio (OR): 0.86; 95%
confidence interval (CI): 0.77˚to 0.95; p˚= 0.04],
vitamin˚E/carrier (OR: 0.67; 95% CI: 0.5˚to 0.9; p˚=
0.01), age (OR: 1.13; 95% CI: 1.04˚to 1.23; p˚< 0.05),
and serum albumin (OR: 0.086; 95% CI: 0.013˚to 0.54;
p˚= 0.01).
By multiple logistic regression analysis, we
confirmed that vitamin˚E/carrier complex (OR: —0.63;
95% CI: 0.52˚— 0.8; p˚= 0.04), age (OR: 1.38; 95%
CI: 1.14˚— 1.5; p˚= 0.04), and serum albumin showed
an independent association with CAS (OR: —0.4; 95%
CI: 0.018˚— 0.82; p˚= 0.01).
Discussion
High plasma levels of vitamins˚A and E have
traditionally been found in uremic patients (1). This
apparent hypervitaminosis is caused by uremic
retention (1,2,10). Evidence is increasing that, due to
their antioxidant effects, those vitamins and vitamin˚C
protect against a number degenerative disorders,
including CV disease, cataracts, and certain types of
cancer (11,12).
Uremia is considered a pro-oxidative state (8),
manifested in part by accelerated atherosclerosis,
which determines survival in long-term maintenance
dialysis patients (1,2). Oxidative stress is a complex
process implicated in endothelial cell injury and
dysfunction (3,4). Several longitudinal and cohort
studies have examined the relationship between
antioxidant intake and risk of CV events. Patients
with angina pectoris showed lower plasma vitamin˚E
concentrations than did normal subjects (13).
Hypervitaminosis˚A in hemodialysis (HD) patients
has been associated with anemia and hypercalcemia.
Some cases of true vitamin˚A toxicity have also been
reported in such patients (14). Because adequate
vitamin˚A intake is covered by the renal diet, no
additional supplementation is recommended;
supplementation is, in fact, contraindicated.
Nonetheless, clinical signs of vitamin˚A and E
deficiency, with lower tissue levels, have been
described in uremic patients (1,5,6). Vitamin/carrier
complexes have recently been described as powerful
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TABLE I General analytical parameters
Parameters Measured valuea Normal range
Hemoglobin (g/dL) 10.9±1.4 10—15
Urea (mg/L) 144.8±37 Variable
Albumin (g/dL) 3.79±0.49 3.8—4.5
Prealbumin (mg/dL) 32.3±9.3 >30b
RBP (mg/dL) 12±4.6 3—6
Cholesterol (mg/dL) 226±47.8 150—250
Triglycerides (mg/dL) 153±74 50—175
Creatinine (mg/dL) 9.4±2.2 Variable
CCr (mL/min) 2±2.2 Variable
Weekly urea Kt/V 2.2±0.46 >2
nPCR (g/kg daily) 1±0.24 >1
Iron (µg/dL) 62±22.7 50—145
Ferritin (ng/mL) 267±224 50—250
Transferrin (mg/dL) 251±50 209—389
Uric acid (mg/dL) 5.8±3.6 5—8
Total bilirubin (mg/dL) 0.8±0.3 <1.5
Vitamin˚A (µg/mL) 1.36±0.77 0.4—0.8
Vitamin˚E (µg/mL) 20.3±8.1 8—21
Vitamin˚A/carrier (µg/mg) 0.86±0.44 0.8—1.2
Vitamin˚E/carrier (µg/mg) 6.44±2.8 6—16
a All values mean ±˚ standard deviation.
b Accepted value in uremic status.
RBP˚= retinol binding protein; CCr˚= creatinine clearance; nPCR˚=
normalized protein catabolic rate.
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indicators of intracellular vitamin deficiency in
children with cystic fibrosis (8).
Our results showed that 13 of 33˚patients with
elevated vitamin˚A plasma levels (39.4%) showed
lower levels after correction for transport. In addition,
15 of 16˚patients with high vitamin˚E plasma levels
(93.7%) showed normal corrected values, and none
showed high corrected values. Those data confirm that
dialysis patients with normal or high vitamin plasma
levels may have a real deficiency, as demonstrated by
measurement of the carrier complex. That situation
could increase the oxidative stress that is frequently
elevated in uremic patients. Our findings also support
that hypothesis, because CAS was negatively
associated with vitamin/carrier complex levels,
reinforcing the importance of determining the vitamin/
carrier complex rather than the vitamin plasma levels.
In uremic patients, the increase in vitamin/carrier
levels could induce a higher mobilization of the intra-
cellular vitamin pool, with subsequent poorer vitamin
utilization by target cells, as has been demonstrated
in children with cystic fibrosis (8). Supporting our
hypothesis of lower bioavailability of vitamins˚A and
E in uremic patients owing to high carrier mobiliza-
tion are the lower concentrations of those vitamins in
mucosal and membrane cells (for example, red cells)
(1,2,5,6), and the recognized oxidative stress suffered
by uremic individuals (3,7). Because abnormalities in
cutaneous vitamin˚A receptors have been hypoth-
esized, but not identified (1), we propose that dialysis
patients may suffer high vitamin mobilization, with
subsequent pool and target-cell depletion.
By multivariate logistic regression analysis, we
found that vitamin˚E/carrier complex, age, and serum
albumin are associated, as independent factors, with
atherosclerosis (CAS). Age, hypoalbuminemia,
hypertension, and diabetes are recognized risk factors
for increased oxidative stress (12).
Finally, to improve the real vitamin deficiency, it
may be advisable to use oral supplements to increase
vitamin˚A and E plasma levels and achieve normal
vitamin/carrier complex levels. Although many reports
exist of hepatotoxicity associated with high doses of
vitamin˚A supplement (15), we believe, on the basis
of the Peters and Kelly study (8), that, in maintaining
a normal range of vitamin/carrier complex levels, he-
patic toxicity is improbable. Moreover, if we intend
to improve the nutritional status of dialysis patients
with a subsequent increase in prealbumin, RBP, and
other proteins (given the strong relationship between
vitamins and other antioxidant substances), it would
be necessary to give vitamin supplements to maintain
adequate levels of vitamin/carrier complex. In addi-
tion, malnutrition may modulate the reactive oxygen
species that mediate cellular damage through an in-
ability to provide adequate defense if endogenous an-
tioxidants are depleted (16,17). It is also important to
control vitamin carrier levels, especially plasma lip-
ids, because hyperlipidemia is present in 70% of di-
alysis patients (1,2). Moreover, hypercholesterolemia
per se increases oxidative stress (12), providing an-
other argument for maintaining an adequately con-
trolled lipid profile in PD patients.
Conclusions
Our findings in PD patients suggest intracellular
vitamin˚A and E deficiencies, in accordance with
measurements of vitamin/carrier complex levels.
Elevated vitamin mobilization from pool and target
cells is indicated, with risk of subsequent inadequate
bioavailability. The determination of vitamin/carrier
complexes appears to be more important than that of
vitamin plasma levels alone. Vitamin supplementation
to achieve adequate vitamin/carrier complex levels
may be advisable, especially in hyperlipidemic or
malnourished patients.
Our results, and the intracellular vitamin˚A and E
deficiencies described by others, may change the
traditional concept of hypervitaminosis˚A and E status
in uremic patients.
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Anorexia and protein malnutrition, occasionally
associated with obesity, are frequently observed in
peritoneal dialysis (PD) patients. Both are recognized
risk factors for cardiovascular (CV) morbidity and
mortality. Leptin is produced by adipocytes and
regulates body-fat mass through a satiety central
effect. Leptin accumulates in the uremic state. We
analyzed the relationship between plasma leptin levels,
nutritional status, obesity, CV risk factors, and
atherosclerosis in PD patients.
Leptin was determined using a polyclonal antibody
[radioimmunoassay: Linco Research, St.˚Louis, MO,
U.S.A.]. The normal range was 1˚— 7.8˚ng/mL. We
studied 38 PD patients. Mean leptin levels were 59.1 ±˚
57.5˚ng/mL (elevated in 32˚patients). Women (n˚= 21)
showed higher leptin levels than did men (80.4˚±
60˚ng/mL vs. 32.3 ±˚ 43.3˚ng/mL, p˚< 0.01), in spite of
both groups having a similar body mass index (BMI).
A statistically significant direct correlation was found
between leptin and BMI (r˚= 0.7, p˚< 0.01) and triceps
skin-fold measurement (r˚= 0.77, p˚< 0.01). Leptin
levels and renal creatinine clearance (CCr) showed
no significant correlation. Independent of BMI, higher
leptin levels were associated with parameters
considered to be CV risk factors (Framingham study),
such as serum triglycerides˚< 150˚mg/dL (n˚= 29) as
compared with˚> 150˚mg/dL (44.2˚± 53.2˚ng/mL vs.
80 ±˚ 58.4˚ng/mL, p˚< 0.05), cholesterol˚< 250˚mg/dL
(n˚= 28) as compared with˚> 250˚mg/dL, (50 ±˚
55.6˚mg/dL vs. 84.7 ±˚ 57.7˚mg/dL, p˚< 0.05), uric
acid˚< 7˚mg/dL (n˚= 28) as compared with˚> 7˚mg/dL
(47˚± 53.7˚mg/dL vs. 93.1 ±˚ 56.6˚mg/dL, p˚< 0.05),
and the presence or lack of presence of left ventricular
hypertrophy [68.8˚± 60 (n˚= 30) vs. 29.5˚± 23.7
(n˚=˚5), p˚< 0.05].
The patients were classified into two groups
according to a clinical atherosclerosis score (CAS).
Nineteen patients had low CAS scores, and they
showed higher plasma leptin values than did the other
patients (82.4 ±˚ 65.7˚ng/mL vs 35.8 ±˚ 36.6˚ng/mL, p˚<
0.05). Twelve patients with anorexia had lower leptin
values than did patients with normal appetite (19.2 ±˚
15.8˚ng/mL vs. 91.3 ±˚ 58.8˚ng/mL, p˚< 0.001). In non
obese patients (BMI˚< 25 and CCr˚< 3˚mL/min, n˚=
14), leptin had a statistically significant direct linear
correlation with markers of nutrition, including
albumin (r˚= 0.63, p˚< 0.05), transferrin (r˚= 0.4, p˚<
0.05), cholesterol (r˚= 0.65, p˚< 0.05), and
triglycerides (r˚= 0.6, p˚< 0.05). Finally, plasma leptin
levels were notably increased in the PD population,
indicating increased production (possibly by chronic
hyperinsulinism), or uremic retention, or both. By
multivariate analysis, we confirmed the association
between leptin levels and sex, leptin and BMI, and
leptin levels˚> 40˚ng/mL and sex and LVH.
All of those features suggest that plasma leptin
levels could be considered a marker of CV risk and
food intake in non obese PD patients without
inflammation.
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Introduction
Leptin, a hormone produced by adipocytes (1),
regulates body-fat mass through a central satiety effect
via neuropeptide˚Y (NPY) (2). The hormone appears
to be cleared by the kidneys, and data on plasma levels
are now available for chronic renal failure and for
hemodialysis and peritoneal dialysis (PD) patients (3).
Some have speculated that leptin accumulation due
to renal failure may be involved in the pathogenesis
of uremic anorexia and, in consequence, poor
nutritional intake (4,5). Protein malnutrition,
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sometimes associated with obesity, is often observed
in PD patients (4). Inadequate protein intake and high
peritoneal glucose absorption have been involved in
the genesis of those nutritional deficits (4,5). Protein
malnutrition and obesity (5) are both recognized risk
factors for cardiovascular (CV) morbidity and mortality.
Obesity is a poorly studied problem in PD patients and
is usually associated with insulin resistance,
dyslipidemia, CV disease, hypertension, left ventricular
hypertrophy (LVH), and diabetes mellitus type˚2 (6).
Hyperinsulinemia has been implicated as a primary
cause of stimulation of obesity, increased sympathetic
nerve activity, and hypertension (7). Obesity and
hyperinsulinemia are major stimulators of leptin
production, which is positively correlated with fat-mass
index (8). Visceral fat mass is associated with early CV
morbidity and mortality (6).
Recently, leptin action in the regulation of fat
distribution has been demonstrated (9). Interestingly,
Dunbar et al (10) have demonstrated that leptin
injection induces hypertension through renal
sympathetic stimulation. We evaluate here the
relationship between plasma leptin levels, CV risk
factors, atherosclerosis, and nutritional status in PD
patients.
Patients and methods
Thirty-eight clinically stable PD patients [32 on
continuous ambulatory peritoneal dialysis (CAPD) and
6 on automated peritoneal dialysis (APD)] participated
in the study. They included 21˚women and 17˚men
ranging in age from 26˚to 85˚years. The mean length of
time on PD was 34.5˚± 29.2˚months (range: 3˚—
126˚months). Causes of chronic renal failure were
chronic glomerulonephritis (9˚cases), pyelonephritis
(8˚cases), nephrosclerosis (7˚cases), polycystic kidney
disease (5˚cases), systemic disease (3˚cases), and
unknown etiology (6˚cases). Candidates taking thyroid
hormones or steroids (including estrogens, contra-
ception, or hormone replacement therapy) were
excluded from the study. The presence of anorexia and
gastrointestinal symptoms during the preceding
months˚was analyzed. Anorexia was estimated by an
interview that guided the patient through a survey of
3-day food intake. Six patients presented anorexia, and
6˚patients had anorexia with dyspepsia, nausea, or
epigastric pain. Isolated dyspepsia was present in
3˚patients, and epigastric pain in 2˚patients. Twenty-
one patients were asymptomatic.
We used a trans-thoracic 2-D Doppler echo-
cardiogram (HP˚Sonos˚1500, 2.25-MHz transducer:
Hewlett-Packard, Andover, MA, U.S.A.) to determine
LVH [defined as an indexed left ventricular mass
(ILVM) greater than 134 g/m2 in men and 110 g/m2 in
women]. Severe LVH was defined as an ILVM greater
than 175 g/m2 in men and 150 g/m2 in women (Penn
convention).
Severe LVH was present in 5˚patients; medium-
to-mild LVH was present in 25˚patients; no LVH was
present in 5˚patients; and, for 3˚patients, no data were
available. Hypertension was defined as blood pres-
sure˚> 135/85˚mmHg (2˚patients), or a need for anti-
hypertensive drugs (28˚patients). Our patients were
also classified according to a clinical atherosclero-
sis score (CAS) (11). For purposes of multivariate
analysis, all patients were grouped into two scores:
low CAS (CAS-1 and -2) and high CAS (CAS-3 and
-4). We also measured certain CV risk parameters
(cholesterol, triglycerides, and uric acid). In accord
with Framingham and other longitudinal studies, the
values considered to be CV risk levels were
250˚mg/dL for cholesterol, 150˚mg/dL for triglycer-
ides, and 7˚mg/dL for uric acid (12,13).
Obesity was considered to be present when body
mass index (BMI) [weight (kg)˚/ height (m2)] was
greater than 25. Obesity grade˚I was between 25 and
30; obesity grade˚II, between 30 and 40; and obesity
grade˚III, greater than 40 (14). Extracellular volume
status was evaluated by physical examination, blood
pressure, peritoneal fluid balances and weight daily
follow-up, and anthropometrical assessment [triceps
skin fold (TSF) and mid-arm muscle circumference
(MAMC)].
Leptin measurement
We used a polyclonal antibody raised in rabbits against
highly purified recombinant human leptin (radioim-
munoassay: Linco Research, St.˚Louis, MO, U.S.A.).
At the sample size, the sensitivity limit was 0.5˚ng/mL,
and the linearity was 100˚µg/L. Intra- and inter-assay
variation was determined on 5˚human serum samples
containing varying leptin concentrations, yielding
variations of 7.2 ±˚ 0.4˚ng/mL (intra-assay) and 25.6 ±˚
0.9˚ng/mL (inter-assay). The intra-assay coefficient
was 4.8%, and inter-assay coefficient was 3.5%. Leptin
normal range among 115˚healthy subjects (61˚men and
54˚women, aged 15˚— 57˚years, BMI 25.4˚± 3.2) was
1˚— 7.8˚ng/mL.
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Statistical analysis
Linear and Spearman regression analysis were
performed. The Student t-test for paired and non paired
data and the nonparametric comparisons test (Mann—
Whitney) were also performed. A p˚value less than
0.05 was considered statistically significant. Results
are expressed as mean ±˚ standard deviation throughout
the paper.
Univariate and multivariate logistic regression
analyses were also performed. The dependent
variable (leptin level lower and higher than
40˚ng/mL) was analyzed as a dichotomous entry. The
independent continuous variables were serum
cholesterol, triglycerides, albumin, uric acid, BMI,
creatinine clearance (CCr), Kt/V, and age. The other
independent variables analyzed were LVH (yes/no),
sex (male/female), and CAS (CAS-1 and -2, CAS-3
and -4).
Results
At baseline, our patients showed these results:
hemoglobin, 11.7˚± 1.5˚g/dL; lymphocyte count,
1764.2˚± 1124˚cells/mm3; creatinine, 10.3˚±
2.77˚mg/dL; urea, 154.3 ±˚ 42.6˚mg/dL; total body
protein, 6.8 ±˚ 0.52˚g/dL; albumin, 4.04 ±˚ 0.34˚mg/dL;
transferrin, 253.4˚± 50˚mg/dL; cholesterol, 206.6 ±˚
47.8˚mg/dL; triglycerides, 151.2 ±˚ 68.1˚mg/dL;
ferritin 352˚± 360.6˚ng/mL; BMI, 27.2 ±˚ 6.4; TSF,
18.6 ±˚ 10.2˚cm; MAMC, 23.47 ±˚ 5.4˚cm; leptin, 59.1 ±˚
57.5˚ng/mL; normalized protein catabolic rate (nPCR),
1˚± 0.2˚g/kg daily; and weekly urea Kt/V, 2.1˚± 0.37.
Plasma leptin levels were elevated (>˚7.8˚ng/mL)
in 32˚patients (84.2%). Values between 7.9˚ng/mL and
100˚ng/mL were seen in 22˚patients; values between
100˚ng/mL and 200˚ng/mL were seen in 8˚patients;
and 2˚patients showed levels higher than 201˚ng/mL.
Leptin levels were higher in women than in men
[80.4˚± 59.6˚ng/mL (n˚= 21) vs. 32.3 ±˚ 43.3˚ng/mL
(n˚= 17), p˚< 0.01]. The mean BMI did not differ
between those groups [28 ±˚ 8 (21˚women) vs. 26.3 ±˚
3.8 (17˚men), nonsignificant].
Leptin and renal function
A statistically significant, negative linear correlation
was found between CCr and plasma leptin levels when
those levels exceeded 13˚ng/mL (n˚= 28: r˚= —0.37,
p˚< 0.05). A even stronger correlation was found when
plasma leptin levels exceeded 25˚ng/mL (n˚= 25: r˚=
—0.5, p˚< 0.01). In both cases, we found no relationship
between BMI and CCr (r˚= —0.2 and r˚= —0.29, both
nonsignificant) or BMI and length of time on dialysis
(r˚= —0.19 and r˚= —0.28, both nonsignificant).
However, a significant linear correlation was found
between length of time on dialysis and CCr (r˚= —0.41,
p˚< 0.01).
Leptin and BMI
According to the scale in a World Health Organization
report (14), 8˚patients had a below-normal BMI value
(lower than 22.5); 7˚patients, a normal BMI (between
22.5 and 25); 14˚patients, grade˚I obesity (BMI
between 25 and 30); and 9˚patients, grade˚II obesity
(BMI over 30). Overall, a statistically significant direct
linear correlation between plasma leptin and BMI
appeared (n˚= 38: r˚= 0.7, p˚< 0.01). Obese patients
(BMI˚> 25) showed the strongest correlation (r˚= 0.72,
p˚< 0.01). In addition, higher plasma leptin levels were
found in that group (79.5˚± 57.1˚ng/mL vs. 27.9 ±˚
43.6˚ng/mL, p˚< 0.01). No difference in CCr was found
between those two groups (1.7˚± 2.09˚mL/min vs.
1.06 ±˚ 1.73˚mL/min, nonsignificant), nor was the time
on PD significantly different (29.2˚± 21˚months vs.
42.7˚± 37.9˚months, nonsignificant). Furthermore, in
all patients, actual dry weight (r˚= 0.53, p˚< 0.01),
serum triglycerides (r˚= —0.36, p˚< 0.05), and weight
gained in the last year (n˚= 24: 2.4 ±˚ 3˚kg, r˚= 0.44,
p˚< 0.05) showed significant linear correlations with
leptin levels. Similarly, leptin and TSF and MAMC
had significant direct correlations at r˚= 0.77, p˚< 0.01,
and r˚= 0.44, p˚< 0.01, respectively.
Leptin and CV risk factors and CAS
Table˚I shows direct relationships between some CV
risk markers and plasma leptin levels. Differences in
those results (cholesterol and triglycerides) were
similar among patients who received lipid-lowering
agents, who had a lower CCr (<˚3˚mL/min), and who
were in the group that excluded patients with anorexia.
Higher plasma leptin levels were found in patients with
LVH, a relationship that could not be explained by
differences in BMI (Table˚I), CCr (1.49 ±˚ 2.12˚mL/
min vs. 1.45 ±˚ 1.1˚mL/min, nonsignificant) or length
of time on PD (20.2˚± 13.3˚months vs. 39.5 ±˚
30.5˚months, nonsignificant).
Similarly, patients with hypertension showed high
leptin values (Table˚I). Ten patients were scored as
CAS-1; 9 as CAS-2; 11 as CAS-3; and 8 as CAS-4.
Therefore, 19 were assigned to the low CAS group,
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and 19 to the high CAS group. High plasma leptin
levels were associated with a high CAS (82.4˚±
65.7˚ng/mL vs. 35.8 ±˚ 36.6˚ng/mL, p˚< 0.05).
However, the BMI was also different (29.7 ±˚ 7.6 vs.
24.6˚± 3.8, p˚< 0.05).
By univariate logistic analysis, significant
associations were seen between leptin levels and BMI
[odds ratio (OR): 1.36; 95% confidence interval (CI):
1.09˚to 1.71; p˚< 0.009], sex (OR: 11.58; 95% CI:
2.43˚to 55.88; p˚< 0.003), serum triglycerides (OR:
1.01; 95% CI: 1.0002˚to 1.025; p˚= 0.05), and albumin
(OR: 9.29; 95% CI: 1.004˚to 86.5; p˚= 0.05). By
multiple logistic regression analysis, we confirmed
the˚association between leptin levels, sex (OR: 80.87;
95% CI: 4.005˚to 1633.06; p˚= 0.007) and BMI [OR:
1.76; 95% CI: 1.19˚to 2.59; p˚= 0.007 (likelihood ratios
model: 29.16; p˚< 0.0001)], and leptin levels, sex (OR:
19.17; 95% CI: 3.29˚to 111.64; p˚= 0.002) and LVH
[OR: 14.87; 95% CI: 1.17˚to 187.72; p˚= 0.04
(likelihood ratios model: 17.15; p˚< 0.001)].
Leptin and uremic anorexia
Patients with anorexia (n˚= 6) or anorexia with other
gastrointestinal symptoms (n˚= 6) showed lower
plasma leptin levels than did asymptomatic patients
[19.2˚± 15.8˚ng/mL (n˚= 12) vs. 91.3 ±˚ 58.8˚ng/mL
(n˚= 21), p˚< 0.001]. Patients with isolated anorexia
showed similar differences [15.8 ±˚ 13.4˚ng/mL (n˚=˚6)
vs. 91.3 ±˚ 58.8˚ng/mL (n˚= 21), p˚< 0.001]. A lower
BMI value was present in patients with anorexia
(23.8 ±˚ 3.3) than in asymptomatic patients (29.5 ±˚ 7.4,
p˚< 0.01). Patients with anorexia had lower serum
albumin levels than did asymptomatic patients (3.76 ±˚
0.33˚mg/dL vs. 4.13 ±˚ 0.37˚mg/dL, p˚< 0.05).
Leptin and nutritional status
Leptin plasma levels showed significant, positive
linear correlations with markers of nutrition in patients
with BMI˚< 25 and CCr˚< 3˚mL/min (n˚= 14): albumin
(r =˚ 0.63, p˚< 0.05), transferrin (r =˚ 0.4, p˚< 0.05),
cholesterol (r =˚ 0.65, p˚< 0.05), and triglycerides (r =˚
0.6, p˚< 0.05). Lymphocyte count, iron, and nPCR did
not show linear correlations. Patients with BMI˚< 25
showed no correlations.
Discussion
Leptin is a 16-kDa protein that regulates body weight
(1). Several receptors have been isolated from various
tissues, including liver, kidney, and brain (2,3). Under
experimental conditions, intraventricular leptin
injection demonstrated high-affinity binding to
receptors in hypothalamic tissue, where it inhibits
hunger and subsequent food intake through NPY
secretion (3).
Patients on PD show high plasma leptin levels with
respect to normal subjects, as has been described for
hemodialysis patients. Excess production and
accumulation owing to lack of renal excretion have
been suggested as possible causes (3).
Among our PD patients, leptin levels higher than
13˚ng/mL were associated with lower residual renal
function. The high plasma leptin value may repre-
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TABLE I Relationship between plasma leptin levels and cardiovascular risk factors
Risk factors Patients (n) Value Leptin (ng/mL) p˚Value BMI p˚Value
Uric acid (mg/dL) 28 <7 47±53.7 <0.05 27±7.4 NS
10 >7 93.1±56.6 28.5±2.5
Cholesterol (mg/dL) 28 <250 50±55.6 <0.05 27.3±6.9 NS
10 >250 84.7±57.7 29.8±4.5
Triglycerides (mg/dL) 29 <150 44.2±53.2 <0.05 27.4±7.6 NS
9 >150 80±58.4 28.5±4.5
Hypertension (mmHg) 30 Yes 69.4±59.7 <0.01 27.8±6.9 NS
8 No 20.4±23.7 26.8±4
LVH 30 Yes 68.8±60 <0.05 28.3±6.7 NS
5 No 29.5±23.7 26±3.3
Albumin (g/dL) 15 <4 44.8±51.7 NS 26.8±5.8 NS
23 >4 48.4±60.3 27.5±6.9
BMI 25 <25 35.6±38.3 <0.01
13 >25 104.3±62.5
BMI˚= body mass index; NS˚= nonsignificant; LVH˚= left ventricular hypertrophy.
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sent the correction in the uremic state of the normal
leptin level (7.8˚ng/mL for normal renal function).
Similarly, a leptin value lower than 4˚ng/mL in nor-
mal subjects represents anorexia nervosa (15). That
level is not expected among uremic patients, even in
intense malnutrition conditions, owing to accumula-
tion of leptin in plasma. In consequence, the accepted
normal level must be incremented to interpret cor-
rectly the relationship between leptin and nutrition
parameters.
Other factors, such as peritoneal glucose absorp-
tion could contribute, via insulin release [which in-
crements leptin production (8)], to the higher plasma
leptin levels found in PD patients. In fact, ob gene
expression has been described to increase after food
ingestion in rats, perhaps through direct insulin ac-
tion on adipocytes (9). Peritoneal dialysis may be
considered a model for continuous glucose intake
and chronic hyperinsulinism. That could be the
mechanism that predisposes to obesity, hyperlep-
tinemia, insulin resistance, and de novo diabetes in
PD patients.
Our obese patients showed strongly positive
correlations between BMI and plasma leptin levels.
Other investigators also reported that relationship in
obese non uremic patients, suggesting a central
disorder in the leptin receptor or a post receptor signal
transduction defect (16). However, such a relationship
was not observed in our non obese patients.
Other uremic factors may possibly influence leptin
production or release (17). The greater insulin
resistance usually associated with obesity might also
be involved (16). Obesity is associated with increased
morbidity and mortality. Longitudinal studies have
shown significant incidence of hypertension, high
cholesterol levels, hypertriglyceridemia with
proportional BMI increment, and hyperuricemia, all
related to atherosclerosis progression. Obesity and
LVH also represent, per se, a independent coronary
risk factor (13). Regardless of BMI, we found higher
plasma leptin levels in patients with elevated values
of those CV risk factors (Table˚I). A significant direct
linear correlation between triglycerides and leptin was
also seen. The hydrolysis of triglycerides stored in
adipose tissue produces free fatty acids, which can
inhibit glucose utilization by peripheral tissues. That
situation could add to the insulin resistance status
found in uremic patients (6). Left ventricular
hypertrophy is another known effect of hypertension
that increases morbidity and mortality in obese patients
(13). In patients with LVH, we found high plasma
leptin levels that could not be explained by BMI
values.
Sympathetic hyperactivity and hyperinsulinism are
commonly associated with obesity (7). Experimen-
tally, intracerebroventricular leptin administration in-
creased sympathetic lumbar and renal nerve activity,
elevating mean arterial pressure (10). That finding
establishes for the first time a relationship between
leptin and CV modulation. Also supporting that hy-
pothesis is the observation that leptin decreases brain
NPY levels (2), and that NPY intracerebral injection
lowers blood pressure (18). On the other hand, sym-
pathetic stimulation or catecholamines may inhibit
leptin production, thus creating a negative feedback
loop. In chronic renal failure and dialysis patients, clear
evidence exists of sympathetic hyperactivity (19),
which may be a product of uremic leptin accumula-
tion. Hyperleptinemia could induce hypertension, CV
changes (7,8), and dyslipidemia via adrenal hyperac-
tivity (7), increasing atherosclerosis risk in uremic
patients. Furthermore, leptin has been found to stimu-
late the proliferation of glomerular endothelial cells
of the rat (20). The endothelial and metabolic effects
of hyperleptinemic states, such as uremia, should be
studied.
Leptin is a marker of white fat tissue, and
interesting studies have associated the central fat-
mass distribution with high coronary risk in non
uremic (9) and uremic patients (17). High visceral
fat mass has been also associated with coronary
disease (9,14). Recent experimental studies have
shown that leptin is implicated in the distribution of
visceral or intra-abdominal fat (9). We thus wonder
if leptin could be a marker of visceral fat.
Importantly, in multifactorial analysis, we found a
relationship between hyperleptinemia, sex (female),
and LVH. In patients with a high CAS score, we
found an association between high BMI and worse
atherosclerosis status, which supports the hypothesis
that leptin could contribute to peripheral insulin
resistance, hypertension (through increase in
sympathetic activity), dyslipidemia, and CV disease
in obese PD patients.
In non obese patients, plasma leptin levels
nonetheless showed significant direct linear
correlation with the studied markers of nutrition. In
our study group, leptin could therefore be considered
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a marker of nutrition and food intake. With respect to
patients with anorexia, we found leptin values lower
than those exhibited by the rest of the PD population,
probably in relation to their low fat mass.
Finally, we suggest that uremic patients with
anorexia might have integrity of their hypothalamic
leptin receptor. Their increased leptin values might
therefore give rise to an upregulation of the hunger—
satiety center.
Conclusion
Hyperleptinemia in PD patients may be considered a
CV risk marker. In non obese patients without inflam-
mation, leptin may be a marker of food intake.
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Summary
BACKGROUND Hypothalamic cholinergic neuro-
transmission plays a major role in the regulation of
GH secretion. Pyridostigmine, a cholinesterase inhibi-
tor, is able to decrease hypothalamic somatostatiner-
gic tone and release GH in normal subjects. Blockade
of muscarinic receptor with pirenzepine blunts the GH
release in several clinical situations. However, little
information is available on the role played by central
cholinergic pathways in GH regulation in uraemic
patients.
OBJECTIVE We aimed to assess GH responses to
GHRH after pretreatment with pyridostigmine and
pirenzepine in a group of uraemic patients under-
going peritoneal dialysis (PD). GH responses of the
patients treated with recombinant human erythropeitin
(rhEPO) were compared to patients without treatment.
DESIGN We studied 14 male patients on PD and nine
control subjects. All subjects underwent three endo-
crine test in random order after an overnight fast.
Each subject received GHRH (100 mg, i.v. in bolus at
0 minutes). Sixty minutes before the injection of
GHRH subjects were given oral placebo, pyridostig-
mine (120 mg), or pirenzepine (100 mg).
MEASUREMENTS Blood samples for GH were collected
at ÿ60, 0, 15, 30, 45, 60 and 90 minutes The hormonal
secretory responses were studied by a time-averaged
(area under the curves, AUC) and time-independent
(peak values) analysis.
RESULTS Baseline GH concentrations were similar in
patients and controls. GH responses to placebo plus
GHRH were also comparable in patients and controls
(peak 26´6 6 3´8 vs. 33´2 6 4´4 mU/l, AUC 28´2 6 3´4 vs.
27´8 6 4´6mU/h/l).Pyridostigmine administration induced
a signi®cant potentiation of GH responses to GHRH both
in patients (peak 43´26 5´2mU/l, AUC 47´6 6 6´0mU/h/l;
P<0´01) and in control subjects (peak 79´2 6 8´6mU/l,
AUC 78´0 6 9´4mU/h/l; P< 0´01). However, the increment
in GH peak and AUC was signi®cantly (P<0´05) greater in
controls in relation to values found in patients. Pirenze-
pine administration induced an abolishment of GH
release after GHRH stimulation both in PD patients
(peak 5´4 6 2´6mU/l, AUC 6´0 6 2´4mU/h/l; P<0´01) and
inhealthy controls (peak3´8 6 0´6mU/l,AUC4´0 6 0´4mU/
h/l; P<0´05). Responses to pyridostigmine plus GHRH
and pirenzepine plus GHRH were similar in patients on
chronic therapy with recombinant human erythropeitin
and in patients without rhEPO therapy.
CONCLUSION These results suggest that the choli-
nergic regulation of GH release is preserved in uraemic
patients on peritoneal dialysis. The signi®cantly lower
increase in GH response to GHRH induced by pyridos-
tigmine suggests that cholinergic stimulatory tone is
attenuated in patients in relation to control subjects.
Long-term therapy with rhEPO seems not to affect GH
responses to cholinergic stimulation or blockade.
The importance of hypothalamic cholinergic pathways in the
neuroregulation of growth hormone (GH) secretion in man has
been fully established. In normal subjects, central cholinergic
stimulation gives rise to an increase in pituitary GH release,
whereas cholinergic blockade is followed by a blunting in GH
secretion (Dieguez et al., 1988). Pyridostigmine is an inhibitor
of acetylcholinesterase and, hence, an indirect activator of
cholinergic neurotransmission. This drug has been employed to
increase cholinergic tone in different clinical settings. It
reduces the release of somatostatin at hypothalamic level,
thus increasing spontaneous GH secretion (Friend et al., 1997;
Coiro et al., 1998) and potentiating GH responses to GH-
releasing hormone (GHRH) in normal subjects (Massara et al.,
1986a; PenÄalva et al., 1990b; Kelijman & Frohman, 1991;
Arvat et al., 1993; Arvat et al., 1997). Conversely, adminis-
tration of cholinergic receptor antagonist drugs reduces
spontaneous GH release as well as GH responses to GHRH,
sleep, exercise, L-dopa, glucagon, arginine and clonidine
(Massara et al., 1986a; Delitala et al., 1982; Massara et al.,
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1984; Valcavi et al., 1991). Since atropine (Casanueva et al.,
1983) and pirenzepine (Delitala et al., 1982; Massara et al.,
1984), but not nicotine, have shown to attenuate basal and
stimulated GH release, a muscarinic receptor is thought to be
involved.
Patients with chronic renal failure are known to have several
alterations in the regulation of GH secretion. Basal GH
concentrations have been found to be increased (RamõÂrez
et al., 1978), and abnormal responses to several stimuli such as
insulin (Rodger et al., 1986), L-dopa (RamõÂrez et al., 1978),
arginine (Marumoto et al., 1979), thyrotrophin-releasing
hormone (RamõÂrez et al., 1978) or glucose (RamõÂrez et al.,
1978) have been reported. GH responses to direct pituitary
stimulation with GHRH have been found to be normal
(Cantalamessa et al., 1991) or exaggerated (RamõÂrez et al.,
1990) in patients on haemodialysis. Derangements in GH
neuroregulation in uraemia have been advocated to account for
these ®ndings. However, little information is available on the
role played by central somatostatinergic tone in patients with
end-stage renal disease, and the effects of pharmacological
manipulation of cholinergic activity have not been character-
ized in this clinical setting. In a previous study we found that
oral pirenzepine administration was followed by a blunting in
GH responses to GHRH in a small number of patients with end-
stage renal disease treated by peritoneal dialysis (PD) (DõÂez
et al., 1999a). Based on this background, the present study was
performed with the aims of establishing the effects of
enhancement and diminution of cholinergic tone by means of
the oral administration of pyridostigmine and pirenzepine,
respectively, on GH responses to its releasing hormone in a
group of uraemic patients undergoing PD, and of assessing
whether cholinergic modulation is preserved in these patients
or, on the contrary, it could be responsible of some of the
reported uraemia-associated derangements in GH secretion. A
secondary objective has been to compare the responses
obtained in patients treated with recombinant human erythro-
poietin (rhEPO) with those obtained in patients without this
treatment.
Patients and methods
Patients
We studied the cholinergic modulation of GH secretion in 14
uraemic male patients on PD (mean age [ 6 SEM] 44´2 6 3´4
years; mean duration of dialysis, 11´4 6 2´1 months) and nine
healthy volunteers with normal renal function (mean age,
43´1 6 4´8 years). The study was approved by the local ethical
committee, and informed consent was obtained from all
participants before testing. Six patients had end-stage renal
disease due to chronic glomerulonephritis, four had interstitial
nephropathy, two had polycystic kidney disease, one chronic
pyelonephritis and a further one had renal failure of unknown
aetiology. There were no signi®cant differences between
patients and controls with regard to age and body mass index
(24´2 6 0´7 vs. 25´9 6 0´9 kg/m2). All patients were found to be
stable clinically and adequately dialysed (weekly urea Kt/V,
2´04 6 0´34). None had diabetes mellitus, severe secondary
hyperparathyroidism or other endocrine disorder. Five patients
were treated with subcutaneously administered rhEPO (mean
dose, 88´0 6 23´6 U/kg/week; mean duration, 11´2 6 1´4 months),
whereas the remaining nine patients had not received rhEPO
therapy. Patients on rhEPO therapy exhibited blood haemoglo-
bin concentrations (11´3 6 0´4 g/dl) similar than those found in
patients without rhEPO therapy (11´2 6 0´5 g/dl).
Study design
In every patient and control subject, three endocrine tests were
performed in random order, on 3 separate days, after an
overnight fast. Tests began at 0900 hours with the subject
recumbent. An indwelling catheter was placed in a forearm vein
and kept patent with a slow infusion of 0´9% NaCl. Each
subject received GHRH (GHRH-1±29, Geref; Serono, Spain),
100 mg, i.v. in bolus at 0 minutes Blood samples were collected
60 minutes and immediately before the injection of GHRH and
then 15, 30, 45, 60 and 90 minutes after the stimulation. At
ÿ60 minutes patients and controls received either oral placebo,
or pyridostigmine (Mestinon; Hoffmann-La Roche; Basel,
Switzerland), 120 mg p.o., or pirenzepine (Gastrozepin; Boehringer
Ingelheim, Germany), 100 mg p.o. All uraemic patients were
tested with placebo, pyridostigmine and pirenzepine; nine
healthy subjects received placebo and pyridostigmine, and
pirenzepine test was performed only in eight controls. In all
blood samples plasma GH concentration was assessed. Blood
haemoglobin concentration and serum concentration of insulin-
like growth factor type I (IGF I), free thyroxine and
thyrotrophin were also determined at time 0 in one of the
experiments.
Hormone assays
Blood samples were centrifuged immediately and the plasma
stored at ÿ20 8C until assayed. Human plasma GH concentra-
tions were determined by using an automated immunoenzy-
matic assay (AIA 1200, Tosoh Corporation, Tokyo, Japan).
Maximal intra-assay and interassay coef®cients of variation for
the GH assay were 5´4 and 3´3%, respectively. The sensitivity
of the GH assay was 0´2 mU/l. IGF-I concentrations were
determined using commercially available radioimmunoassay
kits (Nichols Institute, San Juan Capistrano, CA, USA) after
extraction by acid-ethanol precipitation. Maximal intra- and
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interassay coef®cients of variation were 3´0 and 8´4%, respec-
tively, and the sensitivity of the assay was 13´5 mg/l. Plasma
thyrotrophin concentration was also determined by using the
Tosoh immunoenzymatic assay. A heterogeneous competitive
immunoassay (Immuno 1 System; Miles, Tarrytown, NY,
USA) was used to quantify free thyroxine concentrations.
Statistical analysis
Results are expressed as mean 6 SEM. The hormonal responses
were studied by a time-averaged (area under the curves, AUC)
and time-independent (peak values) analysis. Peak hormonal
concentration was considered in each test as the maximum level
reached by GH, regardless of the time taken to do so. The AUC
for GH was calculated between 0 and 90 minutes by a
trapezoidal method. The changes in peak and AUC induced
by pyridostigmine plus GHRH and pirenzepine plus GHRH in
relation to placebo plus GHRH stimulation were considered in
absolute value and in per cent values. For each subject the
following parameters were calculated: Dpeak GH after P plus
GHRH (mU/l), %Dpeak GH after P plus GHRH, DAUC GH
after P plus GHRH (mU/h/l), and percentage DAUC GH after P
plus GHRH; where P is pyridostigmine or pirenzepine, and D is
increment in relation to placebo plus GHRH.
The statistical evaluation of the GH responses after
pyridostigmine plus GHRH and pirenzepine plus GHRH in
relation to those obtained after placebo plus GHRH within each
group of studied subjects (patients and volunteers) was
performed by means of the Friedman analysis of variance by
ranks, and the Wilcoxon signed-rank test with the Bonferroni
correction was used to determine which pairs of data differed
when the Friedman test was signi®cant. For comparisons
between patients and controls, the Mann±Whitney test was
employed. The Kuskal±Wallis analysis of variance by ranks
was used to detect differences between three groups (controls,
patients on rhEPO therapy and patients without rhEPO
therapy), and the Mann±Whitney test with Bonferroni correc-
tion was then used to determine which pairs of groups differed
when the Kruskal±Wallis test was signi®cant. The differences
were considered to be signi®cant at a P value less than 0´05.
Results
Responses to placebo plus GHRH
Baseline GH concentrations were similar in patients and
controls (3´2 6 0´6 vs. 2´0 6 0´2 mU/l). We did not ®nd any
signi®cant differences between the two groups of studied
subjects in serum concentrations of IGF I (368´1 6 46´5 vs.
230´2 6 18´3 mg/l), free thyroxine (1´33 6 0´10 vs. 1´22 6
0´07 ng/dl) or thyrotrophin (1´44 6 0´25 vs. 1´34 6 0´17 mU/l).
Stimulation with placebo plus GHRH in uraemic patients was
followed by an increase in GH levels that reached a maximum
of 26´6 6 3´8 mU/l at 30±60 minutes (Figs 1a, 2a). This
maximum did not differ from that found in controls
(33´2 6 4´4 mU/l) at 30±45 minutes (Fig. 1b). The AUC of
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Fig. 1 GH responses to GHRH (100 mg, i.v., arrow) administered
60 minutes after the oral intake (P, arrow) of placebo (X),
pyridostigmine (W) or pirenzepine (B) in (a) a group of 14 uraemic
patients on peritoneal dialysis and (b) in nine healthy volunteers.
Each point represent the mean 6 SEM. Responses after pirenzepine
plus GHRH were studied in eight controls. *P < 0´016; ²P < 0´01
(responses after pyridostigmine or pirenzepine vs. responses after
placebo).
GH was also similar in uraemic patients (28´2 6 3´4 mU.h/l)
and control subjects (27´8 6 4´6 mU.h/l) (Fig. 2b).
Responses to pyridostigmine plus GHRH
When GHRH was injected 60 minutes after oral administration
of pyridostigmine a signi®cant potentiation of GH responses
was observed both in uraemic patients (peak 43´2 6 3´2 mU/l,
P < 0´01; AUC 47´6 6 6´0 mU.h/l, P < 0´01 vs. values after
placebo plus GHRH) and healthy volunteers (peak 79´2 6 8´6,
P < 0´01; AUC 78´0 6 9´4 mU.h/l, P < 0´01 vs. values after
placebo plus GHRH). This potentiation reached statistically
signi®cant values at 15±90 minutes in patients (Fig. 1A) and at
0±90 minutes in controls (Fig. 1B).
Absolute values for GH peak and GH AUC were signi®-
cantly higher in healthy volunteers than in uraemic patients
(P < 0´01 for GH peak, and P < 0´05 for GH AUC, Fig. 2).
Moreover, the increment in GH peak after pyridostigmine plus
GHRH was 16´4 6 4´0 mU/l (76´1 6 18´7%) in patients and
46´0 6 6´0 mU/l (150´5 6 20´4%, P < 0´01) in controls. On the
other hand, the increment in GH AUC was 19´4 6 4´4 mU.h/l
(77´8 6 19´4%) in patients, and 50´2 6 6´0 mU.h/l (203´9 6
28´3%, P < 0´01) in controls. In summary, increments in GH
peak and AUC after pyridostigmine plus GHRH were
signi®cantly higher in healthy volunteers with respect to
values found in uraemic patients (Fig. 2).
Responses to pirenzepine plus GHRH
Pirenzepine administration induced an abolishment of GH
release after GHRH stimulation in both groups of studied
subjects (Fig. 1). In patients, a signi®cant reduction was observed
both in GH peak (5´4 6 2´6 mU/l, P < 0´01 vs. peak after
placebo plus GHRH) and in GH AUC (6´0 6 2´4 mU.h/l,
P < 0´01 vs. AUC after placebo plus GHRH). A similar
reduction was found in control subjects (Fig. 2).
The decrement in GH peak and GH AUC were ÿ21´2 6
2´2 mU/l (ÿ 83´6 6 3´4%) and ÿ22´2 6 2´2 mU.h/l (ÿ 75´2 6
6´9%), respectively, in uraemic patients, and ÿ30´2 6 4´6 mU/l
(ÿ 87´2 6 2´6%) and ÿ24´4 6 4´8 mU.h/l (ÿ 83´8 6 2´4%),
respectively, in controls. That is, there were no statistically
signi®cant differences between patients and controls in the
decrement in GH responses induced by pretreatment with
pirenzepine.
Effect of rhEPO therapy on growth hormone responses
We have also studied the maximum concentrations and AUC of
GH secretion in the three endocrine tests in control subjects and
in patients classi®ed according to the presence or absence of
rhEPO therapy. We could not ®nd any signi®cant difference
among these groups of subjects in responses after placebo plus
GHRH and after pirenzepine plus GHRH. However, Kruskal±
Wallis test demonstrated signi®cant differences in peak
(P < 0´05), Dpeak (P < 0´01), AUC (P < 0´05), and DAUC
(P < 0´01) after pyridostigmine plus GHRH in the three group
of subjects. Nonetheless, when studying differences between
pairs of groups (i.e. by using the Mann±Whitney test with
Bonferroni correction), we could not ®nd any signi®cant
difference between patient treated and not-treated with rhEPO
concerning GH responses to pyridostigmine plus GHRH. That
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Fig. 2 (a) Maximum GH concentrations and (b) AUC of GH
secretion in 14 uraemic patients (B) and nine control subjects (A) in
response to GHRH injection 60 minutes after the oral administration
of placebo, pyridostigmine and pirenzepine. Each column represents
the mean 6 SEM. Responses after pirenzepine plus GHRH were
studied in eight controls. Comparisons between patients and controls
(Mann±Whitney test): ³P < 0´05; §P < 0´01. Comparisons within each
group (Wilcoxon test with Bonferroni correction): *P < 0´016;
²P < 0´01.
is, although peak, Dpeak, AUC and DAUC for GH release after
pyridostigmine plus GHRH were higher in patients without
rhEPO (peak 48´0 6 7´4 mU/l; Dpeak 20´8 6 5´8 mU/l; AUC
53´0 6 8´8 mU.h/l, DAUC 24´8 6 6´4 mU.h/l) than in patients
on chronic rhEPO therapy (peak 34´4 6 3´6 mU/l; Dpeak 2´6 6
1´4 mU/l; AUC 38´0 6 4´0 mU.h/l, DAUC 10´0 6 1´8 mU.h/l),
these differences were not statistically signi®cant (P > 0´05 in
all cases). In other words, we identi®ed a trend to higher
responses to pyridostigmine plus GHRH in untreated patients.
Three patients complained of transient dry mouth after
pirenzepine. Pyridostigmine caused, borborygmi in one patient,
transient abdominal pain in ®ve patients and diarrhoea in three
patients. Pyridostigmine and pirenzepine did not cause overt
side-effects in any control subject.
Discussion
The group of uraemic patients here studied exhibited normal
baseline concentrations of GH and IGF-I, as well as a GHRH-
induced GH release similar to that found in controls. Only male
patients were selected, as there is sex related difference in the
neuroregulation of GH secretion that may be related to altered
cholinergic tone (De Marinis et al., 1997). We also selected
euthyroid, well-nourished and nondiabetic patients in order to
avoid variability in GH values derived from conditions such as
thyroid dysfunction, malnutrition, obesity or diabetes (Dieguez
et al., 1988). Our results show that enhancement of cholinergic
activity by pyridostigmine induced a striking increment in GH
responses to GHRH in both controls and patients. Previous
investigations have shown that pyridostigmine potentiates the
somatotrope response to GHRH normal subjects (PenÄalva et al.,
1990b), and in different clinical situations with disrupted GH
regulation such as acromegaly (Massara et al., 1986a), obesity
(Scacchi et al., 1999), Cushing's disease (Giustina et al., 1991),
hypothyroidism (Valcavi et al., 1993) or insulin-dependent
diabetes mellitus (Martina et al., 1997). Moreover, pyrido-
stigmine counteracts the inhibitory effect exerted on GH release
by exogenous GH infusion (Kelijman & Frohman, 1991), oral
glucose (PenÄalva et al., 1989), intravenous glucose (Delitala
et al., 1990), oral dexamethasone (Del Balzo et al., 1990), free
faty acids elevation by lipid-heparin infusion (PenÄalva et al.,
1990a), or repeated GHRH administration (Massara et al.,
1986b). Experimental studies have shown that the action of
pyridostigmine is mediated by a decrease in the hypothalamic
release of somatostatin (Locatelli et al., 1986), and it has been
demonstrated that, in man, pyridostigmine enhances GH
secretory burst mass, without altering GH half-life or GH
secretory burst duration or frequency (Friend et al., 1997).
The observed increment in GH release in PD patients was
lower than that found in normal controls. This ®nding suggests
that cholinergic mechanisms of GH regulation are preserved in
uraemia, although at a lower level than that present in healthy
subjects. In fact, GH peak and GH AUC were increased by
150´5% and 203´9%, respectively, in controls, but only by
76´1% and 77´8%, respectively, in PD patients. There are no
previous data on the effect of pyridostigmine on GH secretion
in uraemic adult patients. Cappa et al. (1991) reported that
pyridostigmine increased GHRH-induced GH release in a
group of uraemic children with baseline blunted GH responses
to GHRH, but failed to potentiate these responses in another
group of children with normal GHRH responsiveness. Our data
might be accounted for by a decrease in somatostatinergic tone
in stable PD patients, and a subsequent lower GH releasing
capacity after inhibition of somatostatin secretion. Since
pyridostigmine requires endogenous acetylcholine release, our
data also seem to indicate that uraemic patients have a reduced
central cholinergic tone or a lower acetylcholine releasing
capacity than controls.
Results here reported con®rm that cholinergic muscarinic
blockade with pirenzepine greatly suppresses GH responses in
both normal subjects and uraemic patients as previously shown
(DõÂez et al., 1999a), suggesting that sensitivity to muscarinic
cholinergic receptor blockade is preserved in uraemia. This
®nding agrees with reports from other investigators who
reported that pirenzepine signi®cantly reduced GHRH-induced
GH secretion in clinical situations characterized by an altered
GH neuroregulation, such as diabetes (GonÄi et al., 1997),
obesity (Maccario et al., 1995), anorexia nervosa (MuÈller &
Rolla, 1996), acromegaly (Massara et al., 1986a), hyper-
thyroidism (Valcavi et al., 1991) or dementia (Murialdo et al.,
1990±91). The mechanism by which pirenzepine induces GH
suppression is believed to be based on stimulation of
endogenous somatostatin release (Casanueva et al., 1986).
Therefore, our results suggest that GH secretion in uraemia is
modulated, at least in part, by acetylcholine-dependent changes
in somatostatinergic tone. However, pirenzepine, as well as
pyridostigmine, is mainly eliminated by the renal route, and the
actions of these drugs might actually be prolonged by their
longer elimination half-life in uraemia.
The results also suggest that chronic therapy with rhEPO do
not affect GH responses to pharmacological manipulation of
cholinergic neurotransmission. We could not ®nd differences
between patients treated and not treated with rhEPO in GH
responses. We have previously shown that long-term treatment
with rhEPO in PD patients potentiates GH responses to GHRH,
although this effect did not persist beyond 6 months of therapy
(DõÂez et al., 1999b). Interestingly, mean duration of rhEPO
therapy in our group of PD patients was 11´2 months, i.e. a time
in which no EPO-induced changes in GH response to GHRH
were expected according to our previous data.
In conclusion, we have found that male patients on PD
exhibited normal GH responses to direct pituitary stimulation
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with GHRH. In these patients the increase in cholinergic tone
by pyridostigmine induced a clear-cut enhancement in GHRH-
induced GH release. Muscarinic blockade with pirenzepine
blunted GH responses to its releasing hormone. The potentia-
tion of GH secretion induced by pyridostigmine was found to be
lower than that of normal volunteers. These data imply that the
cholinergic regulation of GH release is preserved in uraemic
patients. The signi®cant lower increase in GH response to
GHRH induced by pyridostigmine suggests that cholinergic
stimulatory tone is attenuated in patients on PD.
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2Abstract
Malnutrition is a severe and frequent complication in peritoneal dialysis patients (PD).
Eating behavior disorders are deep implicated in the pathogenesis of malnutrition. Anorexia
induces a deficit of several nutrients and obesity in PD is frequently associated to protein
malnutrition. The present research analyzed the eating behavior disorders in 18 PD patients
(twelve with anorexia, twelve obese with high food intake, and eighteen without eating behavior
disorders) and a control group with ten heath volunteers. We determined in serum appetite
modulator substances at baseline and after a standard food stimuli (Fresubin, Fresenius,
Spain, with 750 Kcal), 30, 60 and 90 minutes. Eating motivation was evaluated a visual analogue
scale (VAS) from Hill J et al.
Patients with anorexia showed high satiety before and after to eat, and low desire and
pleasure to eat. Neuropeptide Y (NPY) the most potent orexigen known, and cholecystokinin
(CCK) a potent anorexigen showed linear correlation with VAS, NPY was associated with more
appetite and CCK with lower. Baseline, anorexic patients showed high levels of anorexigen
substances, peptide–C, CCK, IL-1, TNF- and gastric inhibitory peptide gastric inhibitory peptide
GIP, and low of NPY. On the contrary, obese group showed higher NPY plasma levels and lower
of anorexigens than the remains. Very well defined disorders in the peptide release were found
in the different groups.
Patients with anorexia showed a highest and early CCK peak explaining the early satiety
sensation measured by VAS. Moreover, NPY stimulation curve was flat with levels decreasing to
values lower than baseline at 90 minutes in association with less appetite.
Obese group showed 2 NPY peaks (at 30 and 90 minutes). This explain the great and
repeated food intake and the hunger sensation (VAS) showed after 90 minutes from the food
stimuli. Insulin and NPY curves were always parallel. IL-1 showed a linear correlation with insulin
and GIP, possibly because both are stimulation of insulin secretion. IL-1 and CCK showed also
linear correlation and synergic action inducing anorexia. Both IL-1 and TNF- are pro-
inflammatory cytokines that induce insulin resistance and central anorexia. These findings
support the inflammatory hypothesis.
Leptin and low nitric oxide (NO3) values are also anorexigen agents. Leptin participated
as anorexigen only at baseline because this not changed with food stimuli. In all studied patients
3NO3 showed a decrease in relation with controls. Abdominal subcutaneous adipose tissue were
obtained from elective surgeries and catheter replacement. TNF-, leptin and adiponectin
mRNA expression was measured by real-time RT-PCR. TNF- was over-expressed in uremic
patients, mainly in patients with anorexia. The patron of leptin was very similar, the obese group
showed the lowest expression. Adiponectin expression was lower in uremic patients than CG
and the obese showed the lowest.
Conclusion, in PD patients, the eating behavior disorders are abnormally modulate by
appetite peptides witch are baseline elevated in plasma and are abnormally released. This
disorder may be due to renal peptide retention and abnormal inter-relationship between peptide,
insulin and cytokines. Uremic carbohydrate intolerance and pro-inflammatory substances
appears as novel and important appetite modulator in dialysis patents. Cytokines induces
anorexia acting directly in different phases of hunger-satiety cycle.
Introduction
Malnutrition in dialysis patients is definitely associated with high morbidity and mortality
(1, 2). This complication is present in near 20-40% of the cases. In peritoneal dialysis (PD)
patients, malnutrition is particularly dramatic because peritoneal loss of proteins induces a
Kwashiorkor-like syndrome (1).
In PD patients, the lack of appetite is the main obstacle to get an adequate nutritional
status (3). Several factors have been described as responsible of uremic anorexia.
One of the most attractive ideas is that in renal disease several endogenous agents
modify hunger-satiety cycle by renal retention. These substances normally regulate the appetite
as well: cholecystokinin (CCK), leptin, neuropeptide Y (NPY), nitric oxide (NO), gastrin-releasing
peptide (GRP) and gastric inhibitory polypeptide (GIP). Overproduction with retention of others
molecules that are usually not involved in appetite control might be other explanation, cytokines
(tumor necrosis factor alpha (TNF-) and interleukin-1 (IL-1)), is the most classic example (3).
Both ideas give support to uremic toxin’s hypothesis as responsible of uremic anorexia (4). In
fact, the hypothesis of anorectic effect by middle molecules isolated from dialysis ultrafiltrate has
not been proved (5, 6). The common practice of attributing appetite disorders to insufficient
4dialysis dose is not longer sustained. Furthermore, all that endogenous agents are scantly
eliminated by dialysis.
Other interesting hypothesis to explain malnutrition and atherosclerosis of dialysis
patients as a common pathway, is the inflammatory hypothesis (MIA syndrome or malnutrition,
inflammation and atherosclerosis). This suggests that dialysis patients suffer two forms of
malnutrition, the type I showed maximal expression of inflammatory mediators with catabolic
action, one of this symptom is anorexia (7). However, in the uremic anorexia pathway is only not
implicated cytokines as well suggested (3).
The diversity of responses to common situations derived from all these processes is
remarkable and has not been clarified. Not all dialysis patients suffer anorexia under similar
apparent conditions. This condition points to disorders partially independent of dialysis
clearance. Metabolic disorders in the peripheral via of hunger-satiety cycle control, have been
suggested by our group (8). The peripheral via of hunger-satiety cycle control include appetite
modulators produced by adipose tissue, stomach, liver and pancreas and the biochemical sing
transmitted to brain by blood and vagus nerve.
In the present paper, we hypothesized that disorders in peptide release associated with
insulin resistance, inflammatory processes and peptide accumulation by renal insufficiency,
induce a variable combination of eating behavior disorders, resulting in anorexia and obesity.
Therefore, with the aim of demonstrate this hypothesis, we performed this study dividing
our PD population in three groups based in appetite disorders. We explored the peripheral via of
hunger-satiety cycle control through the interrelationship among peptide appetite regulators,
insulin resistance and inflammatory markers after standardized food intake.
Patients
We included forty-two (20 males and 22 females) clinically stable PD patients. Twenty
were on continuous ambulatory peritoneal dialysis (CAPD) and twenty-two in automated
peritoneal dialysis (four in CCPD and eighteen on OCPD). The mean age was 56.5  12.8 years,
and the mean period on PD was 35.6  33.9 months. No acute disorders were present during
the two months prior to the study. The causes of chronic renal failure were nephrosclerosis in
fifteen, glomerulonephritis in eleven, polycystic kidney disease in eight, unknown in four and
systemic disease in four.
5Five patients had been diagnosed of hiatus hernia and two of acid pylori disease. Three
referred mild occasional gastrointestinal symptoms (pyrosis in three and dyspepsia in two).
We expressly excluded diabetics, patients suffering neoplasia, chronic or acute
infections, liver and rheumatoid diseases.
Fourteen patients were ingesting calcium carbonate, twelve aluminum-based phosphate
binders, ten oral vitamin D3 supplements and six, anti-H2 inhibitors of stomach acid secretion.
Methods
We determined the following parameters:
1.- Dialysis adequacy: urea-KT/V and normalized equivalent of protein-nitrogen appearance
(nPNA) (9).
2.- Nutritional markers:
a) Long-term: plasma creatinine, albumin, cholesterol (colorimetric method, Hitachi 704)
and transferrin by immunonephelometric method (Boering Nephelometric-Terminal S.A., Spain),
serum iron (Hitachi 911), vitamin B12 and folic acid (radioimmunoassay).
b) Anthropometric parameters were measured using the recommendations by Frisancho
(10), including tricep skin-fold (TSH), midarm circumference (MAC), and midarm muscle
circumference (MAMC (cm) = MAC (cm) –3.14 x TSF (cm)). TSF was determined using a
caliper (Holtain LTD. , Cross-well, Crymych, Dyfed SA41 3UF. UK).
c) Body composition was determined through bioelectric impedance (BI) (a multi-
frequency, Maltron BF 905, USA). Anthropometric data, gender, weight and height were
considered. Four electrodes were allocated, two in the non-dominant hand and two in feet, with
a separation of 5 cm between electrodes. The decrease in the voltage after the administration of
one micro-ampere of electricity, give the impedance or resistance. The software calculates intra
and extra cellular body water (liters and %), fat and water-free fat mass (indirect measured of
mass muscle), in kg and percentage
d) Medium-term nutritional markers: short half-life proteins, plasma prealbumin, retinal-
binding protein (RBP) and anti-thrombin-III (immunonephelometric method). Serum growth
hormone (GH) was determined by immunoenzymatic assay (AIA 1200; Tosoh Corporation,
Tokio, Japan). Maximal intra- and interassay coefficients of variation were 5.4% and 3.3%,
respectively. The sensitivity of GH assay was 0.1 ng/ml (Normal < 5 ng/ml). Serum IGF-I was
determined by radioimmunoassay after acid-ethanol extraction (Nichols Institute Diagnostics,
6San Juan Capastrano, CA). Maximal intra- and inter-assay coefficients of variation were 2.9 %
and 11.4 %, respectively. The sensitivity was 12.9 ng/ml. Normal range was 83-450 ng/ml for
younger than 40 years and 54-389 ng/ml for older than 40 years.
e) Short-term nutritional markers: urea nitrogen, serum phosphate and potassium. Mean
daily dietary intake was determined from individual 24-hour food records during a 3-day period.
Daily calories, carbohydrate, lipid, and protein intake were calculated for each patient using a
commercially available computer software (Wander, Sandoz Nutrición, 1990, Barcelona, Spain).
3.- Eating motivation was evaluated through eating motivation scale (visual analogue
scale or VAS) by Hill & Blundell (11). VAS included five questions that should be answered
before and after eating: desire, hunger and fullness filling, prospective consumption and
palatability. The results were giving in a horizontal scale (0-100).
The evaluation of appetite peptide modulator included basaline samples (fasting
condition), 30, 60 and 90 minutes after the ingestion of a standard supplement (Fresubin,
Fresenius, Medical Care. Germany) with 750 cc, 750 kcal, 17 g of carbohydrates, 7.5 g of
proteins, 5.8 g of fat and 79 ml of water.
Anorexia was defined by a low eating motivation (personal interview and VAS), low food
intake (nPNA <1 g/kg/day, daily dietary assessment <30 kcal/kg/day) and low nutritional markers
(DOQI clinical practice guideline of nutrition) (12).
Obesity with high food intake was considered when BMI was higher than 30 kg/m2
(grade I), 30-40 kg/m2 (II) and > 40 kg/m2 (III) (WHO criteria) (13), high eating motivation (VAS),
high daily food intake or bulimia criteria (DSM-IV) (14).
Normal eating behavior was considered in absence of anorexia and bulimia, normal BMI
(18.5-25 kg/m2) and normal nutritional markers (12).
According to these parameters our patients were divided in three groups: those suffering
anorexia (n=5), obesity (n=6) with high food intake and those without eating behavior disorders
(n=7). Finally, we include a control group with seven health volunteers.
4.- Plasma or serum peptide appetite modulator were determined by ELISA (enzyme-
amplified sensitive immunoassay).
a.- Glucose by hexoquinase reaction (Boehringer Mannhein, Alemania). Fasting normal
range 90 y 120 mg/dl.
7b.- Insulin (Sorin; Biomedica, Saluggia, Italy). The intra and interassay coefficients of
variation were 6.6 % and 6.2 %, respectively. The sensitivity of insulin assay was 3 mIU/ml.
c.- Glucagon (ICN Biomedicals, California, USA). The sensitivity <10 pmol/l, without
cross-reaction with enteroglucagon. Normal values 70-90 mg/dL.
d.- C-peptide (Medigenix; Diagnostics Fleurus, Belgium). Maximal intra- and interassay
were 7.6 % and 8.8 %, respectively. The sensitivity was 0.1 ng/ml and the normal range was 0.5
to 3 ng/ml.
e.- Neuropeptide Y (NPY) (Peninsula Laboratories, Inc. Belmont, CA, USA).
Radioassay. The IC50 was 23 pg/100l (normal range 220-370 pg/ml).
f.- Cholecystokinin (CCK) the 26-33 unsulfated fragment was determined (Peninsula
Laboratories, Inc. Belmont, CA, USA). The IC50 was 35 pg/100l (normal values 12-20 pg/ml).
g.- Leptin (Linco Research, St. Louis, MO, USA). The sensitivity was 0.5 ng/ml and
linearity of 100 g/l. The normal range in our laboratory is 3-7.8 ng/ml.
h.- Gastric inhibitory Peptide (GIP) (Peninsula Laboratories, Inc. Belmont, CA, USA).
The IC50 was 92.88 pg/tube (normal range 35-52 pg/ml).
i.- Ghrelin (RIA, 125-Ighrelin, Linco, research, Inc, Missouri USA), Sensibility 100 pg/ml.
The normal range: 900-2500 pg/ml.
j.- Nitric oxide. We measured serum nitrate concentrations (NO3), a final metabolite of
NO, by capillary electrophoresis. Normal values were considered between 90-110 mol/l (21).
k.- Cytokines with recognized action on hunger-satiety cycle were studied. Baseline
levels of tumor necrosis factor (TNF-) and interleukin 1 (IL-1) were determined by ELISA
(enzyme-amplified sensitive immunoassay, Easia Medigenix Diagnostics S.A. Belgium). Values
considered normal were 3-20 pg/ml and <15 pg/ml, respectively.
L.- Ghrelin was determined by RIA, 125-Ighrelin: Linco research; sensitivity, 100 ng/ml,
normal range in 28 healthy volunteers from our hospital (900-2500 pg/mL).
Adipose tissue cytokine gene expression, abdominal subcutaneous adipose tissue was
obtained from elective surgeries and catheter replacement. The sample were put in warm saline
and washed twice with saline to eliminate blood and connective tissue. Samples were snap
frozen in liquid nitrogen to -80 ºC. Total RNA was isolated with the RNeasy lipid tissue kit
(Qiagen, Valencia, CA). The RNA was quantified by measurement of absorbency at 260-280
8nm. Cytokine mRNA expression was measured by real-time RT-PCR. The RT-for-PCR Kit
(Clontech, Palo alto, CA). We used -actin to correct the cytokine values.
Statistical Analysis.
Results are given as mean  SD and range. Comparisons between groups were
performed using a non-parametric test, the Mann-Whitney rank-sum U-test. Spearman
regression analysis and “t” student tests were used for paired and non-paired data. A “p” value
less than 0.05 was considered statistically significant.
To express the statistical differences on the tables, letters “a” through “i” represent
significant differences in horizontal sense and symbols in vertical sense.
Results
Demographic and hematological characteristics at baseline are shown in table I.
Anorectic patients (group I) were older and showed lower nPNA, albumin, prealbumin, RBP,
IGF-I, albumin, TSF, BSF, AMMC, BMI, daily food intake, lean, fat and water body masses by BI
and higher plasma levels of TNF- and IL-1 than the other groups.
Table II shows the data of visual analogue scale (VAS). Anorectic patients also show
differences before and after eating than other patients, indicating a poor appetite state. An
opposite eating behavior was present in obese group. Table III shows significant linear
correlation, positive and negative respectively, between CCK and NPY plasma levels and VAS.
Importantly, this dynamic feature confirms a cause-effect relationship between these two
endogenous peptides and appetite in PD patients.
Table IV shows the variations in plasma glucose concentration after Fresubin intake.
All uremic patients show higher baseline glucose, insulin (Table V), glucagon (Table VI) and C-
peptide (table VII) levels than control group. Obese patients (Group II) show also higher values
of insulin and C-peptide, throughout the whole curve. Group III exhibited a very similar glucose
curve than obese patients. In contrast, Group I showed a flat insulin curve until 90 minutes.
Regarding the glucagon curve, no differences were found between groups I and II.
Table VIII and Figure 1, show the changes in CCK curve after Fresubin intake. At
baseline, group I showed high CCK plasma levels than remaining groups. Moreover, anorectic
patients increased 3.8-fold CCK levels at 30 minutes after food stimuli. The increment in group II
was clearly lesser and retarded (1.3-fold their baseline value, after 60 minutes of food stimuli)
9(19.9  4.1 vs. 27.2  6.2 pg/ml, p<0.05). In contrast, non-anorectic non-obese uremic patients
(Group III) showed an intermediate CCK peak (2.2-fold). In healthy controls the peak was 3.4-
fold at minute 90.
NPY curve under food intake stimuli (Table IX, Figure 2) showed that anorectic patients
had lower baseline levels, although into the normal range. The maximal reached value was at 30
minutes but this was non statistically significant (369  26, vs. 405.4  44.2 pg/ml, NS).
Importantly, a significant decrease occurred at minute 90 after the stimuli. Obese showed higher
baseline NPY values than the others and showed significant increase at minute 30 (463.5 
61.6, vs. 605.5  65.7 pg/ml, p<0.05), maintaining stable at minute 90. Controls showed a NPY
peak after 30 minutes and decreased at minute 90. The NPY curve from group III was very
similar to controls.
Gastrointestinal inhibitory peptide (GIP) plasma levels were higher in uremic patients
than in controls (Table X). After food stimuli, groups I, II and control showed GIP peaks at
minute 60, whereas obese patients did not show changes.
The leptin levels curve (Table XI) showed baseline differences between the groups but
did not change after food stimuli.
Table XII shows the post-prandrial changes in NO3 plasma values. PD patients showed
higher levels than controls (172.2  42.5 vs 92.1  8 mol/l, p<0.001). All patients showed an
important decrease in NO3 concentration 30 minutes after eating. At 60 minutes, NO3 increased
in all except in obese where this increase occurred at minute 90. Control group showed a
progressive NO3 increase, starting at minute 60.
PD patients showed significant linear correlation between baseline insulin and glucose
(r= 0.74, p<0.01), glucose-30´(0.73, p<0.01), glucose-60´, glucose-90´ (0.71, p<0.01), baseline
GIP (0.45, p<0.05), GIP-30´ (0.6, p<0.01), GIP-60´ (0.7, p<0.01) and GIP-90´ (0.58, p<0.05).
Insulin-60´ levels showed linear correlation with C-peptide-60´ (0.74, p<0.01), C-peptide-
90´(0.79, p<0.01), leptin-60´ (0.67, p<0.01), leptin-90´ (0.56, p<0.05), NPY-30´ (0.62, p<0.01)
and NPY-90´ (0.58, p<0.01).
Insulin-90´ showed linear correlation with C-peptide-90´ (0.7, p<0.01), baseline leptin
(0.62, p<0.01) and NPY-90´ (0.59, p<0.01) levels.
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Serum Leptin at baseline showed negative linear correlation with CCK (-0.51, p<0.05),
positive with baseline NPY (0.51, p<0.05), BMI (0.6, p<0.01), fat mass (by BI) (0.67, p<0.01) and
baseline NO3 (0.51, p<0.05). Leptin-30´ and 60´ showed also linear correlation with NO3-60´
(0.51, p<0.05 and 0.56, p<0.01, respectively).
Baseline NPY showed negative linear correlation with baseline IL-1 (-0.52, p<0.05) and
TNF- (-0.51, p<0.05). NPY-30´ and 90´ was negatively correlated with baseline IL-1 (-0.64,
p<0.01 y -0.61, p<0.01, respectively). NPY-90´showed positive linear with all points of leptin
curve (baseline, 30, 60, 90 minutes), (0.51, p<0.05, 0.67, p<0.01, 0.67, p<0.01, 0.63, p<0.01,
respectively).
TNF- and IL-1 showed a positive linear correlation (0.85, p<0.005), both with baseline IL-1 and
CCK (0.45, p<0.05) and IL-1 and GIP (0.46, p<0.05).
Table XIII shows the post-prandrial changes in Ghrelin plasma values. CG showed an
important decrease in ghrelin values after food intake. Ghrelin recover its baseline values 90
minutes after eat. Dialysis patients showed a fat ghrelin curve. Obese showed a fat curve with a
very slow decrease at 90 minutes after food intake.
In regard to adipose tissue cytokine gene expression, TNF- was over-expressed in
uremic patients, mainly in patients with anorexia. The patron of leptin was very similar, the obese
group showed the lowest expression. Adiponectin expression was lower in uremic patients than
CG and the obese showed the lowest (fig. 1a, 1b, 1c).
Figure 1. represent the gene expression of TNF-α, leptin and adiponectin in abdominal
fats samples from PD patients getting during peritoneal catheter replacement.
Discussion
Four important findings arise from this study:
1/ the existence of well-defined eating behavior disorders in dialysis patients,
2/ the presence of appetite-related peptide releasing disorders, both spontaneous and after
food-intake,
3/ the close relationship between these peptide disorders and the eating behavior in PD patients
and,
4/ the strong relationship between peptide disorders and uremic carbohydrate intolerance.
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The characterization of appetite disorders is difficult due to the participation of social,
cultural, religious and personal conditions (3). Methodologically, Barkeling et al. (11) used a
visual analogue scale (VAS) developed by Hill J (15), to measure the eating motivation.
Recently, VAS has been successfully used and validated in PD, HD and renal transplanted
patients (16, 17). Our results employing this scale demonstrate that all patients show greater
fullness before and after lunch and lower palatability sensations. To explain these findings,
abdominal discomfort with increase in stomach external pressure by PD fluids and constant
peritoneal glucose absorption have been suggested on PD patients (16). The maximal
expression of lesser hunger, lower palatability and eating desire, joining with a greater fullness
sensation, were found in the anorectic group. Opposite features were found in obese patients
(Table II). Curiously, in non-uremic obese patients the eating motivation measured by VAS was
not so strongly intense regarding uremics (11). The high plasma levels of NPY (orexigen) and
low of CCK (anorexigen agent) (tables I, IV, VII y X), may be responsible of this eating behavior.
Other important point is that our patients showed diet preference for carbohydrates, results quite
similar to that of Hylander et al (16, 17).
Uremic PD patients confirmed the presence of spontaneous high plasma levels of
anorexigen peptides and cytokines, inlcuding glucose, TNF-, IL-1, insulin, glucagon, CCK,
leptin, C-peptide and GIP. These last two with anorexigen effect mediated by insulin.
Importantly, anorectic patients showed the highest plasma levels of anorexigen such as TNF-,
IL-1, glucagon, C-peptide and CCK, with the lowest NPY levels (Tables I and IX). Recently, we
have found high TNF- and relatively low NPY plasma levels in a group of PD patients suffering
anorexia (18). Experimentally, parenteral or intracerebral administration of TNF- induces loss
of appetite (19, 20). Clinically, TNF- has been associated with nervous and cancer anorexia,
wasting syndrome and rheumatic cachexia (20-23). In uremics, the source of TNF- is over-
production and renal retention. Moreover, the current dialysis technique is not able to eliminate
cytokine and, even HD membranes stimulate TNF- production. Also, peritoneal membrane
may result irritated by plastics and PD fluids (24, 25). Inflammed organs are important sources
of TNF-. We recently have shown indirect evidence of excessive TNF- production in uremic
patients with acid peptic disease (18). In other study, the eradication treatment for Helicobacter
pylori improved serum albumin and anorexia (26). TNF- has also been associated to uremic
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anemia, acidosis, hypertriglyceridemia, uremic neuropathy and cardiopathy (18, 27). As a
consequence, we have proposed that TNF- should be included in the list of uremic toxins (27).
IL-1 is other cytokine associated with many inflammatory diseases (28). Experimentally,
the administration of rIL-1 to animals induces loss of appetite (29). Similar to TNF-, IL-1
exhibits uremic retention (9). According with our results, patients with anorexia showed the
lowest residual renal function (RRF) and the highest cytokine concentration (table I). This invites
to speculate about the relevance of RRF as more important determinant of appetite than urea-
KT/V. These results give also support to the recently postulated hypothesis about the
inflammation as cause of malnutrition and atherosclerosis in dialysis patients (30).
Several data support the association between cytokine excess, GI peptides and
carbohydrate metabolism abnormalities. High levels of serum cytokines induce peripheral insulin
resistance (31, 32). Many GI peptides are stimulated or inhibited by cytokines or insulin.
Examples for this, is the synergic action of CCK and IL-1 inducing anorexia (33), and the
regulation of GIP, leptin, and NPY by insulin (34-36). In addition, acidosis induced by TNF- is a
diabetogenic factor as well (3, 18). Finally, leptin, a powerful anorexigen and pro-inflammatory
molecule, also regulates the appetite and induces insulin resistance. All these relatioships point
to the role of insulin resistance in the regulation of hunger-satiety cycle. Our results, showing the
paralellism between high insulin, cytokine and peptide plasma levels, agree with the dependence
between carbohydrate metabolism and hunger-satiety regulation in PD patients.
In summary, the link between cytokine and peptide appetite modulators could be
dependent on the insulin resistance in muscle and fat.
On the dynamic stimulation by food intake
One of the most important findings of this study is the well defined disorder in peptide
release after food intake stimuli in the different eating behavior disorders in dialysis patients. In
PD patients with anorexia, the plasma levels of CCK were frankly elevated. CCK is a potent
anorexigen with peripheral and central actions (37, 38), implicated in the pathogenesis of
anorexia nervosa (39), cancer (40), senile (41) and alcoholic (42). CCK is also retained in
dialysis patients and not modified by PD or HD (43, 44). However, in a previous study, we have
not found high CCK plasma levels in anorectic patients prior to the food stimuli (18). As it is
shown in Table VIII and Figure 1, a “peak” of plasma CCK, 30 minutes after eating appeared.
This “peak” may be responsible of early fullness sensation (table II and VIII). This CCK “peak”
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has also been found in patients with anorexia nervosa (45). Although, in this disorder the exact
cause is unknown, the phenomenon is potentially reversible when the nutritional status is
recovered (45, 46). This points to some reversible disorder of insulin peripheral action. On the
contrary, our obese patients showed a delayed CCK “peak” (table VIII). Again, this abnormality
may be found in non-uremic patients with bulimia nervosa, where the CCK “peak” appears later
and 50% lower than controls (47),
Importantly, we found linear correlation between CCK and IL-1, IL-1 and GIP,
and GIP and insulin. Recently, a synergic effect between IL-1 and CCK inducing anorexia, has
been described (33). IL-1 and GIP are stimulating factors to release insulin by the pancreas (34).
Therefore, one may speculate that elevated levels of these substances might induce the
pseudo-diabetes in uremics. Effectively, in patients with type II diabetes or suffering chronic
pancreatitis, GIP are important regulators of insulin secretion. In both cases, high plasma levels
are found (35, 48).
Regarding to NPY (table IX, figure 2), patients with anorexia showed prior intake plasma
lower levels than the remaining, except the control group. In normal conditions the “peak” of
NPY appears 15-30 minutes after the food stimuli. Our results in control group are similar to that
of other authors in non-uremic population (49) and we believe that this “peak” is responsible of
hunger persistence and increase of gastric emptiness sensation. This explains the popular
knowledge that small snakes (tapas) before the main mail are appetite stimulators. Importantly,
patients with anorexia did not show this NPY-peak. On the contrary, NPY showed significant
decrease at 90 minutes to values lower than baseline, explaining the early and late lack of
appetite measured by VAS (table II and III). Obese group showed NPY-peaks at 30 and 90
minutes after food stimuli that could explain the early, late and great quantity of food ingested. In
bulimic patients this post-prandrial rebound has been previously described (50). Obese showed
NPY levels into the normal range, although higher relative to non-obese. In non-uremic obese
population, recent studies suggest disorders in hunger-hypothalamic receptor sensibility (49,
50). In Zuker (Ob/Ob) rats, NPY and leptin levels are significantly increased, inducing repeated
and compulsive food intakes, due to the lack of inhibition of NPY release by leptin (51). In
uremic status, both hypothalamic leptin-receptor and metabolic disorders similar to Zuker rats
have not been discarded yet. In other words, since insulin is the main stimulating factor for NPY
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release (see parallel curves of insulin and NPY in tables V and IX), and obese showed the
highest plasma insulin levels, that would be the reason for high NPY plasma levels found.
But not only the carbohydrate intolerance appears as a regulator of hunger-satiety
disorders in uremia. Recently, we have published an inverse relationship between TNF- and
NPY in PD patients (18). We have speculated that TNF- is an inhibitor for NPY in uremia.
Recently, Xu et al, (52) have shown the association between a cytokine called “hypothalamic
ciliary neurotropic factor” (CNF) and NPY. CNF has a very similar chemical structure to TNF-
and has anorexigen properties mediated by hypothalamic inhibition of NPY release. In a similar
sense, and representing inflammation status, we have found a negative correlation between
NPY and IL-1 supporting the MIA hypothesis (7).
Leptin is a hormone released by adipose tissue which is retained in dialysis patients and
has been associated with malnutrition, via induction of anorexia by decreasing hypothalamic
NPY (53, 54). In addition, leptin modulates insulin activity in target cells inducing insulin
resistance (55, 56). Therefore, we speculate that baseline high plasma leptin levels found in
uremics (both normal and control group) could be another responsible of uremic carbohydrate
intolerance. However, in our study plasma leptin did not change 90 minutes after food intake,
pointing that leptin-diabetogenic effect can be modulated by the food intake itself. In fact, other
authors have published that in normal population plasma leptin increases after 4 hours of food
intake (56). We have no data at this term.
Nitric oxide (NO) is another important appetite stimulator (3, 8). Decrease in NO
production induces appetite inhibition (57). Moncada’s group have described a potent NO
inhibitor which accumulates in uremic patients (58). In consequence, one might expect that
dialysis patients showed lower NO3 plasma values than controls. However, we did not found
significant differences in these levels. This apparent contradiction may be explained by the
uremic retention of inactive forms of NO, represented by NO3 (59). Anyway, NO3 is a good
marker of NO production in clinic practice (60). Both groups of patients in dialysis showed a
decrease in NO production after food stimuli. When we compared obesity and anorexia
conditions, the intergroup differences did not reach statistical significance, being all NO3 values
lower than controls. Possibly, NO maintains transcendental and more important relationship
with other factors of endothelial origin (58, 60). The relationship between NO and insulin
metabolism is determined by the effects of NO on insulin release by pancreas (3, 61, 62) and
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the equilibrium with endothelin-1 released by endothelium which induces insulin resistance (61-
63). High endothelin-1 plasma levels has been reported in uremics (63). In consequence, the
decrease in NO plasma levels 30 minutes after food stimuli that we found, might worse the
uremic carbohydrate intolerance. These data remarks the role of insulin on hunger-satiety
control.
In regard to fat gene expression, we found an over-expression of TNF-α in anorectic
patients, representing a cytokine over-production which is released to the blood inducing
systemic effects. Adiponectin showed a down expression which has been described in obeses
and severe atherosclerotics.
Finally, table III shows different interesting relationship between eating behavior and
peptide appetite modulators. These results are important because demonstrate the importance
of using eating behavior surveys and appetite peptide modulators measurements in daily clinical
practice. Importantly, several of these peptides participate in mental and physiologic sensations
more than gastric fullness (3, 36). According with this idea, NPY increases the desire and the
quantity of prospective food intake before eating, but does not participate in the post-prandrial
sensation like CCK. Furthermore, CCK does not participate in fullness sensation after eating
(table III).
Conclusion. In PD patients, eating behavior disorders are modulated by appetite
peptides with peripheral and central action, that are elevated in plasma and abnormally released
at baseline conditions. This disorder may be due to renal peptide retention, alterations in their
inter-relationship, carbohydrate intolerance and presence of excessive pro-inflammatory
cytokines. Cytokines are able to alter the regulation of appetite through direct and indirect
mechanisms on the different phases of hunger-satiety cycle.
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Table I. Baseline Differences Between Groups
Parameter Anoretic
(PD) patients
Obeses
(PD) pateints
Asymptomatic
(PD) pateints
Controls P
Age (years) 66.4 10(a,d) 56.3  7.1(b) 49.7  14(a,c) 33  3.7(b,d) (a,b,c)<0.05,
(d)<0.001
DP duration (m) 36.8  32.3 23  11.5 45.5  46.7 NS
CCr (ml/min) 0.5  0.45(a) 1.42 1.01(b) 1.38  1.39(c) 101  7(a,b,c) (a,b,c)<0.001
nPNA (g/kg/día) 0.87 0.21(a) 1.1  0.25 1.14 0.11(a) (a)<0.05
KT/V de urea 2  0.25 1.98  0.33 2.17  0.33 NS
Serum Urea (mg/dl) 152  21(a) 159  45(b) 146  51(c) 28.6 4(a,b,c) (a,b,c)<0.001
Cr (mg/dl) 10.4  2(a) 11.3  2(b) 10.5  3(c) 1  0.7(a,b,c) (a,b,c)<0.001
Cholesterol (mg/dl) 174  57.4 211  55.6 188  56 184  30 NS
Albumin (g/dl) 3.70.08(a,b) 4  0.2(a) 3.9  0.4 5  0.4(b) (a,b)<0.05
Transferrin (mg/dl) 209  36 262  47 205  50.7 303  57.2 NS
Prealbumin (mg/dl) 26  7(a,b) 31  2.9(a) 31  7.5 34  3(b) (a,b)<0.05
RBP (mg/dl) 8.4  3(a,b) 11.5  3(a) 13  2(b) 5.3  1.2 (a,b)<0.05
Lymph. cc/mm3 1298  444 1452  613 1727  480 1877  592 NS
Vitamin B12 (pg/ml) 779.3  372.8 973  323.7 893  207.6 516.5  181.6 NS
Folic acid (ng/ml) 5.4  1.5 4.5  1.2 5.5  1.9 7  4.8 NS
Iron (g/dl) 72  26.7 70.2  16.6 65.8  27 81  27 NS
IGF-I (ng/ml) 257.5 122(a) 370 142.7(a) 365  224.6 205  91.2 (a)<0.05
GH (ng/ml) 3.4  3.8 4  4.8 2.2  1.4 1.7  1.7 NS
TSF (cm) 9.5  4(a,b) 24.2 11.4(a) 22.3  9.4(b) 19.9  10.1 (a,b)<0.05
BSF (cm) 4  0.6(a,b,c) 18.6  7.3(a) 11.4  8.6(b) 13.7  9.5(c) (a,b,c)<0.05
AMMC (cm) 24.21.4(a,b) 27.4  2(a,c) 23.9  13(c) 36.8  13(b) (a,b,c)<0.05
Diet Survey (kcal/d) 1277  467.4
(a,b,c)
2320  179.4
(a)
2006  351
(b)
2089  339
(c)
(a)<0.01
(b,c)<0.05
Fat (kcal/d) 60.4  28.9
(a,b)
102  23.2
(a,c)
98  22
(b)
74.7  15
(c)
(a,b,c)<0.05
Proteins (kcal/d) 63  18(a) 85.7 16.6(a) 83.8  13.7 74.5  21.8 (a)<0.05
Carbohydra (kcal/d) 98  41(a,b,c) 227  71(a) 155.5  27(b) 248.867.2(c) (a,b,c)<0.01
BIP. BMI (kg/m2) 23  2(a) 31.1  3(a,b) 25  2 24  1.5(b) (a,b)<0.05
BIP. Lean (kg) 22.83.7(a,b 30.4  4.5(a) 25.4  2.8 28.6  5.7(b) (a,b)<0.05
BIP. Fat (kg) 18  5.4(a) 25  8.8(a,b) 13.5  5.3(b) 18.7 4.2 (a,b)<0.05
IPB. Water (l) 35.7  5.3(a) 43.7  7.7(a) 37.7  5.4 36.6  5.8 (a,b)<0.05
TNF- (pg/ml) 12143.8(a,b) 40  11.6(a) 38.2  16(b) 18  4 (a, b)<0.01
IL-1 (pg/ml) 6.120.8(a,b) 2.1  0.43(a) 2.2  1.34(b) 1  0.8 (a,b)<0.001
CCr: creatinin clereance. Cr: serum creatinin. RBP: retinol protein binding. IGF-I: Insulin growth
factor type I. GH: growth hormone. TSF: trycipital skin fold. BSF: bicipital skin fold. AMMC: arm
muscular mean circunference. BIP: bioelectric impidance. d: day. BMI: body mass index.
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Table II. Eating Motivation Measured Through Visual Analogue Scale (VAS) in
Peritoneal Dialysis Patients Suffering Eating Behavior Disorders.
VAS Patients Anorectic
(n=12)
Obese
(n=12)
Asymptomatic
(n=18)
Controls
(n=10)
P
Diet survey
(kcal/day)
1277  467.4
(a,b,c)
2320  179.4
(a)
2006  351
(b)
2089  339
(c)
(a)<0.01
(b,c)<0.05
Proteins (kcal/day) 63  18(d) 85.7 16.6(d) 83.8  13.7 74.5  21.8 (d)<0.05
Desire to eat before
lunch
60  6.1
(e,f)
76.6  6
(e)
67.8  6.9 72.8  3.9
(f)
(e,f)<0.01
Desire to eat after
lunch
8.6  2.2
(g)
21.6  4
(g)
13.2  5 13.5  8.5 (g)<0.05
Hunger before
lunch
60  6.1
(h,i,j)
78.3  6
(h)
68.6  4.7
(i)
74.3  4.5
(c,j)
(h)<0.001
(i,j)<0.01
Hunger after lunch 8  4.4
(k,l)
21.6  4
(k)
12.8  5.5 17.1  4.8
(l)
(k,l)<0.01
Fullness before
lunch
28  8.4
(m,n)
18.8  2.5 12.5  4.2
(m)
11.8  4.1
(n)
(m,n)<0.01
Fullness after lunch 81  5.4
(o)
59.1  19.6
(o,p)
77  5.6 77  5.6
(p)
(o,p)<0.05
Prospective
consumption before
lunch
59  5.5
(q,r)
78.3  4
(s)
71.4  3.7
(q,s)
75.7  4.5
(r)
(q,r)
<0.001
(s)<0.01
Prospective
consumption after
lunch
6  2.2
(t,u,v)
25  5.4
(t,w)
12.3  2.7
(u,w)
13.5  4.7
(v)
(t)<0.001
(u,v)<0.01
Palatability 60  7
(x,y,z)
75  5.4
(x)
71.4  4.7
(y)
74.3  5.3
(z)
(x,y,z)<0.01
VAS is measured in a horizontal scale, maxim value 100 mm.
(a-x): statistic differences (read in horizontal).
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Table III. Relationship between NPY and CCK Release Response and Visual Analogue
Scale
VAS / Peptide CCK 0 CCK 30 CCK 60 CCK 90 NPY 0 NPY 30 NPY 60 NPY 90
Desire to eat before
lunch
-0.6** -0.52** -0.4* 0.55** 0.43* 0.55**
Desire to eat after
lunch
-0.43* -0.38* 0.46* 0.54** 0.55**
Hunger before
lunch
-0.41* -0.66** -0.6** -0.5* 0.51** 0.45*
Hunger before
lunch
-0.55** -0.52** -0.53** 0.42* 0.43*
Fullness after lunch -0.46* -0.6** -0.57**
Prospective
consumption before
lunch
-0.74** -0.6** -0.48* 0.48* 0.5** 0.47*
Prospective
consumption before
lunch
-0.6** -0.57** -0.51** 0.8** 0.44* 0.75**
Palatability -0.5* -0.63** -0.75** -0.5* 0.42* 0.42*
Hunger 2 hous
before lunch
-0.74** -0.6** -0.6** 0.71** 0.45* 0.63**
Saciety 2 hours
after lunch
0.53** 0.42*
*: p<0.05, **: p<0.01
Note: the results of this table has interest by the capacity of these peptide to modulate the
appetite in post-prandrial periodo. Look table VIII (CCK) and IX (NPY) in the diferent groups.
These peptides are modulated by insulin secretion, the uremics suffer a diabetes tipe II like
fenomenum, therefore the uremic hydrocarbonade intolerance could play a role in the peptide
appetite modulator and in consequence induce loss of appetite or obesity.
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Table IV. Changes in the Glucose Concentration (mg/dl) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
96.5  33
(a,b)
102.5  41 106.7  68
(a)
81.5  4.3
(b)
(a,b ) <0.05
Baseline
(0 min)
93.6  33
(c,d,)
101.3  40.5
(e,,$,#)
105 69
(d,,,*)
81  5
(c,e,,+)
(c,d,e) <0.05
30 min 119.4  33
()
144.5  45.5
(f,g,)
131  70
(f,)
102  17
(g,)
(f,g) <0.05
60 min 119  68 156.5  56
(h,$)
156  66.4
(h,)
81  14.6
(+)
(h) <0.05
90 min 129  76.6 157  80
(i,#)
161.3  82
(*)
75.8  9
(i)
(i) <0.05
post prandial
changes (p)
()<0.05 (,$,#) <0.05 (,,*) <0.05 (,+)<0.05
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Table V. Changes in the Insulin (mIU/ml) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
34  23
(a,b)
36  34.6 14.3  6
(a)
12.3  4.8
(b)
(a,b ) <0.05
Baseline
(0 min)
34  24
(c,d)
41.3  50.7
(e,)
13.84.9
(d,,,*)
12.4 3.2
(c,e,,+)
(c,d,e) <0.05
30 min 55.2  35 135.8  52
(f,g,)
62.2  48.2
(f,)
71.4  3.4
(g,)
(f,g) <0.05
60 min 80  51.8 158.8  81.7
(h,)
78.2  43.2
(h,)
94  52.8
(+)
(h) <0.05
90 min 89  56.5 155  111
(i,)
79.6  47.1
(*)
58.5  16.8
(i)
(i) <0.05
post prandial
changes (p)
NS () <0.05 (,,*) <0.05 (,+)<0.01
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Table VI. Changes in the Glucagon Concentration (pg/mg) After Fresubin Intake.
Time Anorectic
(PD)
Obesos (PD) No síntomas
(PD)
Controles (p) entre grupos
Baseline
(-15 min)
173.8  77
(a,b)
147.3  41 131.1  32
(a)
76  9.2
(b)
(a,b ) <0.05
Baseline
(0 min)
170  35.7
(c,d,)
145  35.9
()
130.7  23
(c)
76.4  9.7
(d,)
(c,d) <0.05
30 min 181  34
e,)
168.7  33.3
(f,)
122.8  29
(g)
75  11
(e,f,g)
(e,f,g) <0.01
60 min 190.6  37.7
(h,)
160.8  18(i) 133.8  27 83  16.5
(h,i,)
(h,i) <0.01
90 min 178.4  30(j,k) 151.5  15 133  29
(k)
80.8  16
(j)
(j) <0.001,
(k) <0.05
post prandial
changes (p)
(,)<0.05 () <0.05 NS ()<0.01
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Tabla VII. Changes in the C-peptide Concentration (ng/ml) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
18.7  8.6
(a)
17 6.3
(b)
11.9  4.7
(c)
2.7  0.9
(a,b,c)
(a,b,c ) <0.05
Baseline
(0 min)
18.2  8
(d)
16.8  6.3
(e,,$,&)
11.3  4.2
(f,,,*)
2.50.6
(d,e,f,,+)
(d,e,f) <0.05
30 min 19.3  11.2 23.5  7.9
(g,)
15.9  7
(h,)
6.9  1.9
(g,h,)
(g,h) <0.05
60 min 22.9  14.7 30.7  12.7
(i,$)
21.2  6.4
(j, ,)
10.3 3.5
(i,j, ,+)
(i,j) <0.05
90 min 26.5 14.6 34.9  14.3
(k,i,&)
23.4  9.7
(l, ,*)
8.4  1.8
(k,l,,+)
(k,l) <0.05
post prandial
changes (p)
NS (,$,&) <0.05 (,,*) <0.05 (,+) <0.01
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Table VIII. Changes in the CCK Concentration (pg/mg) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
26.5  3.9
(a,b)
18.7  5.5
(a)
20.7  7.5 11.7  2.9
(b)
(a,b) <0.05
Baseline
(0 mim)
25.8  3.7
(c,d,,, )
19.9  4.1
(c,)
21.6  8
(d,,,*)
10.9  1.8
(d,e,,+,)
(c,d) <0.05
30 min 95  21.9
(e,f,g,)
26.5  11.4
(e)
35.1  12.6
(f,)
29.7  7.8
(g,)
(e,g) <0.001
(f) <0.01
60 min 74.8  28
(h,i,j,)
27.2  6.2
(h,)
47.6  14
(i,)
33.4  4.5
(j,+)
(h,i,j) <0.05
90 min 68.9  32
(k,l,m,)
20.8  8.4
(k)
35  12.4
(l,*)
37.7  10
(m,)
(k,l,m) <0.05
post prandial
changes (p)
() <0.01,
(,) <0.05
() <0.05 (,*) <0.01
() <0.001
(,+,) <0.001
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Table IX. Changes in the NPY Concentration (pg/mg) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
367  30.5
(a,b,c)
466.7  76.2
(a)
445.8  60.7
(b)
270.2  29.9
(c)
(a,b,c) <0.05
Baseline
(0 min)
369  260
(d,e,f,)
463.5  61.6
(d,, )
433.7  60.7
(e,,*)
320.5  47.9
(f,,+)
(d,e,f) <0.05
30 min 405.4  44.2
(g,h)
605.5  65.7
(g,i,, )
492.8  34.5
(h,)
441  34.3
(g,i,, )
(g,i) <0.001
(h) <0.01
60 min 358  80 470.7  67
(j,)
407  84 340.8  52.2
(j, ,)
(j) <0.05
90 min 230.4  73
(k,)
563  80.7
(k,l,m,,)
377  68.7
(l,*)
256.8  77.4
(i,m,+)
(j) <0.001
(k,l,m) <0.01
post prandial
changes (p)
() <0.01 () <0.01,
(,) <0.05
(,*) <0.05 (,) <0.001
(+ ,) <0.05
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Table X. Changes in the GIP Concentration (pg/mg) After Fresubin Intake.
Tiempo Anorectic
(PD)
Obeses
(PD)
Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
106.8  23.5
(a)
143.3  82.6
(b)
131.6  25.3
(c)
50.6  11.6
(a,b,c)
(a,b,c)<0.01
Baseline
(0 min)
101.2  22
(d,,)
111.8  27.7
(e,)
132.6  25
(f,)
47.1  7.3
(a,e,f,,+,)
(d,e,f)<0.01
30 min 130.4  38.5
(g)
145.9  29.2
(h,)
140.5  42.2
(i)
84.7  9.6
(g,h,i,)
(g,h,i) <0.01
60 min 142.2  24.1
(j,)
159.6  44.1
(k,)
196.3  90.7
(f)
100.8  13
(j,k,+)
(j,k) <0.05
90 min 136.8  33.8
()
188.6  80.4
(i,)
190.5  68.4
(l,)
94  6.3
(l,)
(l) <0.05
post prandial
changes (p)
() <0.01,
() <0.05
() <0.05 () <0.05 (,) <0.05
(+)<0.01
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Table XI. Changes in the Leptin Concentration (ng/ml) After Fresubin Intake.
Time Anorectic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls
Baseline
(-15 min)
43  46 134  66 36.8  29 10.7  7
Baseline
(0 min)
44.545(a,d) 110  45(a,b,c) 35  28(b,e) 11.8  8(c,d,e)
30 min 39.7  40 125  67 33  26.2 9.6  7.2
60 min 41  42 111  50 31  19.7 11.9  9.3
90 min 37.6  39 117  56.6 29.7  23 12.5  10
p: (a,b,c,d,e)<0.01
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Table XII. Changes in the NO3 Concentration (mol/l) After Fresubin Intake.
Time Anoretic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
174.2  60
(a)
190  36
(b)
153.9  25.4
(c)
92.1  8
(a,b,c)
(a,c)<0.001
(b)<0.05
Baseline
(0 min)
175  59.9
(d,)
190  35.9
(e,,)
152  26.6
(f,,)
92.7  7.5
(d,e,f,,$)
(d,f) <0.001
(e)<0.05
30 min 113.4  31.8
(g,,)
109.2  39.5
()
103.1  31.6
()
87.1  6.8
(g)
(g) <0.05
60 min 148.7  21.3
()
159.3  58.4
(#)
80  57
()
125.5  39
() NS
90 min 155.4  55 106.7  42.6
(,#)
119.2  95 138.2  52.4
($)
NS
Post prandial
changes (p)
()<0.01
()<0.05
(,)<0.01
(#)<0.05
()<0.01
() <0.05
(,$)<0.05
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Table XIII. Changes in the Ghrelin Concentration (pg/mL) After Fresubin Intake.
Time Anoretic
(PD)
Obeses (PD) Asymptomatics
(PD)
Controls (p) between
groups
Baseline
(-15 min)
174.2  60
(a)
190  36
(b)
153.9  25.4
(c)
92.1  8
(a,b,c)
(a,c)<0.001
(b)<0.05
Baseline
(0 min)
175  59.9
(d,)
190  35.9
(e,,)
152  26.6
(f,,)
92.7  7.5
(d,e,f,,$)
(d,f) <0.001
(e)<0.05
30 min 113.4  31.8
(g,,)
109.2  39.5
()
103.1  31.6
()
87.1  6.8
(g)
(g) <0.05
60 min 148.7  21.3
()
159.3  58.4
(#)
80  57
()
125.5  39
() NS
90 min 155.4  55 106.7  42.6
(,#)
119.2  95 138.2  52.4
($)
NS
Post prandial
changes (p)
()<0.01
()<0.05
(,)<0.01
(#)<0.05
()<0.01
() <0.05
(,$)<0.05
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Figure 1.- Gene expression of TNF-α, leptin and adiponectin in abdominal fats samples from
PD patients getting during peritoneal catheter replacement.
Advances in Peritoneal Dialysis, Vol. 20, 2004
Anorexia and malnutrition are common complications
and powerful predictors of morbidity and mortality in
peritoneal dialysis (PD) patients. Megestrol acetate
(MA) is a progestogen that has been demonstrated to
increase appetite and weight in patients with cancer or
acquired immunodeficiency syndrome. To determine
whether MA might benefit PD patients, we treated 32
patients with 160 mg MA daily.
Treatment lasted a mean of 5.93 ± 5.12 months
(range: 1 – 23 months). In 68.8% of the patients, appe-
tite improved. Weight gain was statistically significant
starting in the third month (initial weight: 66.5 ± 11.4 kg;
weight at third month: 68 ± 10.4 kg; p < 0.05). We ob-
served a nonsignificant increase in serum albumin at
the third treatment month (initial serum albumin: 3.44 ±
0.27 g/L; serum albumin at third month: 3.54 ± 0.27 g/L;
p = 0.45). No side effects were observed.
Our experience suggests that treatment with 160 mg
MA daily in PD patients leads to an increase in appe-
tite, serum albumin, and weight gain in most patients,
with no negative side effects.
Key words
Megestrol acetate, malnutrition, anorexia
Introduction
Anorexia and malnutrition are common complications
and powerful predictors of morbidity and mortality in
peritoneal dialysis (PD) patients (1,2). Treatment modi-
fications that can help to prevent or treat malnutrition
are adequate dialysis dose, avoidance of acidemia, and
addition of food supplements. More experimental forms
of nutrition therapy (3,4) include dialytic nutrition, ap-
petite stimulants [for example, megestrol acetate (MA)],
and growth factors (anabolic recombinant human growth
hormone or insulin-like growth factor I).
The appetite stimulant MA is a semi-synthetic ste-
roid progestogen that was originally used as therapy
in metastatic breast and endometrial cancer. What was
originally considered the most frequent side effect of
MA treatment—increased appetite and body
weight—has gradually become an established treat-
ment for malnutrition in patients with acquired im-
munodeficiency syndrome or non hormonal–
responsive cancer (5,6).
The four published studies that evaluated MA in
end-stage renal disease (ESRD) populations (3,7,8,9)
had varying results and conclusions. Our purpose in
the present study was to (A) determine whether MA
increases appetite and improves parameters of nutri-
tion in PD patients and (B) explore the required dose
and MA side effects.
Patients and methods
Between January 1995 and March 2001, we retrospec-
tively recruited 163 PD patients from our PD unit.
Within that cohort, we treated 32 patients who had
anorexia and malnutrition with 160 mg MA daily.
We evaluated whether MA increased appetite and
weight, and whether it improved these parameters of
nutrition: serum albumin, cholesterol, triglycerides,
lymphocyte count, transferrin, and protein catabolic
rate (PCR). We also recorded the appearance of any
side effects.
Table I shows demographic information, Kt/V, and
causes of ESRD for the 32 study patients (19 men,
13 women; 19 on continuous ambulatory PD, 13 on
automated PD). Median age of the patients was 64.19 ±
13.8 years. The initial Kt/V for the group was 2.14 ±
0.56. Twenty patients were receiving erythropoietin
treatment.
Statistical analysis
Results for normally distributed continuous variables
are expressed as mean ± standard deviation, and p <
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0.05 was considered statistically significant. Continu-
ous variables were analyzed using the paired Student
t-test and the Wilcoxon t-test as appropriate.
Results
The mean duration of MA treatment was 5.93 ±
5.12 months (range: 1 – 23 months). Appetite in-
creased in 22 of the 32 patients (68.8%). Megestrol
acetate was stopped in 27 patients for these reasons:
because appetite increased (n = 10); because the pa-
tients died from causes unrelated to MA therapy
(n = 7); because appetite failed to increase (n = 8); and
because the patients underwent renal transplantation
(n = 2).
Weight gain during the first 2 months was statisti-
cally nonsignificant (initial weight: 66.5 ± 11.4 kg;
weight at first month: 67.2 ± 11.8 kg; p = 0.82), but
weight gain became statistically significant starting
at the third month (weight at third month: 68 ± 10.4 kg;
p < 0.05). We observed a nonsignificant increase in
serum albumin from the third treatment month (ini-
tial serum albumin: 3.44 ± 0.27 g/L; serum albumin
at third month: 3.5 ± 0.27 g/L; p = 0.45). The patients’
PCR increased significantly from the third treatment
month (initial PCR: 0.95 ± 0.3 2 g/kg/day; PCR at
third month: 1.13 ± 0.45 g/kg/day; p = 0.032). Except
for cholesterol, the other parameters of nutrition (tri-
glycerides, lymphocyte count, transferrin) increased
beginning in the first month; however, the increase
did not become statistically significant (Table II). No
patients presented with side effects during treatment
with 160 mg MA daily.
Discussion
Malnutrition is a common complication associated
with high mortality and morbidity in dialysis patients
(1,2,8). Malnutrition in dialysis patients has multifac-
torial causes.
Anorexia is probably the most important cause of
inadequate dietary energy and protein intake in long-
term dialysis patients (1,3). Loss of appetite may be
related to several factors, including drug–nutrient in-
teractions, cytokine effects on the central nervous sys-
tem, depression, poverty, and loneliness (3,10).
Interventions to treat malnutrition in dialysis pa-
tients include both dialytic and nutritional approaches
(3). The first step should always be an evaluation of
the dialysis dose. Underdialysis has been associated
with increased morbidity and mortality in dialysis
patients and may induce anorexia and nausea (11). To
date, nutritional interventions have encouraged supple-
mentation by the enteral or parenteral route or both
(3). A potential new therapy for treating malnutrition
in dialysis patients is the use of appetite stimulants, in
particular MA (3,5), a semi-synthetic steroid progesto-
gen. It is an orally active derivative of the naturally
occurring hormone progesterone.
Oncologists observed that MA, used in the therapy
of patients with metastatic breast and endometrial can-
cers, was associated with appetite stimulation and body
weight gain. The exact mechanism by which MA
stimulates appetite is still largely unknown. The ef-
fect has been postulated to be at least partly mediated
by neuropeptide Y, a potent central appetite stimulant
that also inhibits the in vitro production of cytokines,
including tumor necrosis factor alpha, interleukin-1,
and interleukin-6 (5). Most of the weight gain came
from increased adipose tissue. Karcic et al. demon-
strated that, in vitro, MA is a potent inducer of lipo-
cyte differentiation (5,8).
Several studies on MA as treatment for malnutri-
tion in patients with cancer or acquired immunodefi-
ciency syndrome have been published (12–16). In the
study by Loprinzi et al. (13), 133 patients with cancer
were randomly assigned to receive 800 mg MA daily
or a placebo. Patients assigned to MA more frequently
reported improved appetite (p = 0.003) and food in-
take (p = 0.009) as compared with patients receiving
placebo. Von Roenn et al. (12) studied 271 cachectic
patients with acquired immunodeficiency syndrome,
randomly assigning them to receive placebo or
100 mg, 400 mg, or 800 mg MA daily for 12 weeks.
Costero et al.
TABLE I Characteristics of the study patients
Patients (n) 32
Mean age (years) 64.1±13.8
Sex (M/F) 19/13
Mean dialysis duration (years) 3.93±3.25
Mean weekly Kt/V 2.14±0.56
Time on MA treatment (months) 5.93±5.12
Cause of end-stage renal disease (n)
Diabetes 9
Glomerulonephritis 5
Nephrosclerosis 5
Unknown 5
Interstitial nephritis 3
Systemic lupus erythematosus 2
Polycystic kidney disease 2
Vasculitis 1
M/F = male/female; MA = megestrol acetate.
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The MA stimulated appetite, food intake, and body
weight gain and improved the patients’ overall sense
of well-being.
However, there are several problems with the in-
formation found in the literature about MA. The prin-
cipal problem is that of appropriate dosing. Most
studies used a dose of 800 mg daily (6,12,13). One of
the studies also employed a range of doses from as
low as 160 mg daily to as high as 1280 mg daily (13).
Between those extremes, other studies have used dos-
ing levels of 160 mg daily (13,14), 320 mg daily (14),
and 480 mg daily (15). Our study used the low, 160 mg
daily dose.
The second problem has to do with the contradic-
tory findings about the toxicity of MA. Some investi-
gators found only limited or no side effects (6,13,15).
Others (6,12) reported significant side effects, includ-
ing encephalopathy, depression, hypervolemia, impo-
tence, irregular menses, rash, fluid retention, and
diarrhea. In our study population, no side effects were
observed at the 160 mg daily dose.
The third problem is the nature of the measured
benefit from MA. Lien and Ruffenach (8) found an
increase in serum albumin. Tchekmedyian (16) found
no increase in survival. We found a nonsignificant in-
crease in serum albumin and in other parameters of
nutrition, except for cholesterol (Table II).
We are aware of four small studies to date that
examine the effect of MA in dialysis patients. Lien
and Ruffenach (8) studied the effect of a low MA dose
(40 mg daily) in 16 malnourished dialysis patients.
Serum albumin increased in 75% of the patients, and
all of the responders reported an increase in food in-
take because of improved appetite. However, no sig-
nificant weight gain occurred, and 1 patient stopped
MA because of vaginal bleeding. Williams et al. (9)
found that a low dose of MA (160 mg daily) was not
effective in increasing serum albumin level or lean
body mass in a small group of malnourished hemodi-
alysis patients.
Burrowes et al. (3) reported on a hemodialysis
patient with hypoalbuminemia who received MA for
24 weeks. That patient was started on a moderate dose
of MA (320 mg daily) that was increased to 440 mg
daily at week 13, and to 560 mg daily at week 20. The
patient’s serum albumin level was maintained, but fat
increased by 163%. The patient did not experience
any other side effects.
Boccanfuso et al. (7) studied the effect of 400 mg
MA twice daily in 17 dialysis patients. Those patients
reported improved appetite and showed an increase
in dry weight, but no increase in serum albumin. How-
ever, reported side effects included diarrhea, confu-
sion, hyperglycemia, headaches, dizziness, and
elevated lactate dehydrogenase.
In our study, 32 peritoneal dialysis patients re-
ceived 160 mg MA daily over a median period of
5.93 ± 5.12 months. Appetite improved in 68.8% of
the patients. We observed statistically nonsignificant
increases in serum albumin and statistically signifi-
cant weight gain from the third month. No side ef-
fects were observed.
Conclusions
Megestrol acetate is a well-established treatment for
anorexia and cachexia associated with cancers and
acquired immunodeficiency syndrome. Our experi-
ence suggests that, in PD patients, treatment with
160 mg MA daily increases appetite significantly and
serum albumin nonsignificantly, and produces sig-
nificant weight gain in most treated patients without
producing side effects. However, a few small, contro-
versial studies of anorexia in dialysis patients treated
with MA also exist. Further studies are needed to fully
Megestrol Acetate in PD Patients
TABLE II Body weight and parameters of nutrition at initiation of megestrol acetate treatment and at 3 months
Month 0 Month 3 p Value
Body weight (kg) 66.5±11.4 68±10.4 <0.05
Serum albumin (g/L) 3.44±0.27 3.54±0.27 NS
Protein catabolic rate (g/kg/day) 0.95±0.32 1.13±0.45 <0.05
Cholesterol (mg/dL) 190.8±47.1 187.87±50.4 NS
Triglycerides (mg/dL) 144.1±86.1 147.1±73.1 NS
Lymphocyte count (cells/mL) 1457.92±813.7 1667.3±579.26 NS
Transferrin (mg/dL) 212.81±58.3 223.4±52.04 NS
NS = nonsignificant.
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evaluate the role of MA in the treatment of anorexia
and cachexia in dialysis patients.
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The minute-to-minute effect on blood glucose levels
of high-dextrose peritoneal dialysate is not known.
We arranged for 7 patients with diabetes, treated by
peritoneal dialysis (PD), to wear a continuous glu-
cose monitoring system (CGMS: Medtronic MiniMed,
Northridge, CA, U.S.A.). A sensor was inserted sub-
cutaneously into the skin of the patient’s abdomen or
back to measure glucose in the interstitial fluid. Read-
ings were recorded every 5 minutes for up to 72 hours.
The portion of the day during which the patient’s
blood glucose levels were greater than 180 mg/dL
(calculated as a percentage of time) was recorded.
Most of the patients participating in the study had
elevated levels of glycohemoglobin and hemoglobin
A1c, and, for a large percentage of the day, showed
blood glucose tracings well above the recommended
standards of control. Representative CGMS tracings
from patients with type 1 and type 2 diabetes are
shown.
Key words
Continuous blood glucose monitor
Introduction
Good glycemic control is often difficult to obtain in
diabetic patients treated by peritoneal dialysis (PD).
The minute-to-minute effect on blood glucose levels
of peritoneal dialysate containing high concentrations
of glucose is not known. Current practice is to teach
patients to monitor blood glucose levels at home by
applying finger-stick blood to a home glucose moni-
tor. To determine overall control of blood glucose,
hemoglobin A1c (HbA1c) values are measured at
regular intervals in the clinic.
However, uremia and treatment with PD may al-
ter the relationships between blood glucose patterns
and HbA1c. To understand those interactions, we com-
pared standard measures with the blood glucose pat-
tern obtained using a continuous glucose monitoring
system [CGMS: Medtronic MiniMed, Northridge, CA.
U.S.A. (1)].
Patients and methods
We arranged for 7 patients with diabetes, treated by
PD, to wear a CGMS. A sensor inserted subcutane-
ously into the skin of the patient’s abdomen or back
sends signals to a recording device every 5 minutes,
yielding approximately 288 readings in 24 hours. To
calibrate the CGMS readings, each patient was also
asked to perform finger-stick blood-sugar measure-
ments using a traditional blood glucose meter at least
4 times daily. The patients were asked to keep a log of
diet, insulin (or oral hypoglycemic medication), ex-
ercise, and PD exchanges and treatments. The CGMS
monitoring was repeated at 1- to 3-month intervals,
after dietary or medical interventions.
Readings by the CGMS were not visible in real
time, but only after the sensor was removed, and the
data downloaded to a computer. The portion of the
day during which the wearer’s blood glucose levels
exceeded 180 mg/dL (as a percentage of time) was
calculated.
Each study was conducted over 3 consecutive
days.
• On day 1 the Medtronic MiniMed CGMS was ap-
plied to the patient, and the patient was educated
in the use of the monitor.
• On day 2 the patient returned for a fasting blood
draw in the morning. Blood was drawn to mea-
sure HbA1c and glycohemoglobin.
• On day 3 the CGMS was removed, and the results
were analyzed and reviewed with the patient.
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At the time of the study, patients were being treated
with several hypoglycemic regimens, including oral
agents or insulin combinations [glargine and lispro,
or neutral protamine hagedorn (NPH) and regular in-
sulin]. Results of the CGMS readings were shared with
study participants as a tool to attempt to improve gly-
cemic control. In addition, participants received coun-
seling in nutrition and diabetes management from a
registered dietician and other medical professionals.
Results
Most of the patients participating in the study had el-
evated levels of glycohemoglobin or HbA1c, or both.
Table I summarizes the percentage of time the patients’
blood glucose levels exceeded 180 mg/dL, as com-
pared with more standard measures.
A general concordance between measures is noted
in this preliminary, observational study. Two repre-
sentative CGMS tracings are shown (Figures 1 and 2).
Meals, exercise, dialysis exchanges, and medication
can be seen to have a direct temporal impact on blood
glucose values.
Discussion
Blood glucose levels are well above the recommended
standards of control for a large portion of the day in
diabetic patients treated by PD. In some patients, a
clear increase in blood glucose occurs after a perito-
neal exchange or in response to initiating cycler ex-
changes. One important observation is that finger-stick
blood glucose determinations are accurate. However,
because finger-stick glucose levels are performed in-
termittently, they may miss many hours of markedly
higher or lower readings. In Figure 2, the effect of
intraperitoneal insulin is particularly rapid, but a
marked rebound occurs after meals or dialysis ex-
changes. Because the role of PD solution with its
soluble glucose is incompletely understood, more
study is needed.
Schwing et al.
TABLE I Markers of hyperglycemia in the study patients
>180 mg/dL GHb HbA1c
Date (% time) (%) (%)
Patient 1 April 2003 1 7.3 7.5
May 2003 56 7.4 8.0
June 2003 51 7.4 8.9
July 2003 52 9.8 8.3
September 2003 38 9.0
November 2003 23 8.5
Patient 2 January 2003 32 9.1 7.9
March 2003 26 8.1 7.3
Patient 3 February 2003 42 7.5
March 2003 21 7.9 7.3
June 2003 66 7.9 8.1
Patient 4 February 2003 39 9.3 7.9
Patient 5 September 2003 67 7.1
Patient 6 September 2003 43
October 2003 48 6.4 7.0
Patient 7 January 2004 11 6.4
GHb = glycohemoglobin; HbA1c = hemoglobin A1c.
FIGURE 1 Continuous blood glucose monitor (CGMS) pattern in 74-year-old man with type 2 diabetes, treated with oral hypoglycemic
agent. 1 = meal; 2 = snack; 3 = exercise; 4 = oral agent; 5 = short-acting insulin; 6 = PD exchange; 7 = initiation of cycler exchanges.
Note glycemic response to meals (code number 1), and effect of exercise (code number 3) to lower blood glucose.
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